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Glossary of Terms 
90-90-90: An ambitious treatment target to help end the HIV epidemic. By 2020, 90% of all people living 
with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained 
antiretroviral therapy (ART); and 90% of all people receiving ART will have viral load (VL) suppression 
(VLS). 
 
95-95-95: By 2030, 95% of all people living with HIV will know their HIV status; 95% of all people 
diagnosed with HIV will receive sustained ART; and 95% of all people receiving ART will have VLS. 
 
Acquired Immunodeficiency Syndrome (AIDS): AIDS is a disease that can develop after HIV infection 
causes severe damage to the immune system, leaving the body vulnerable to life-threatening 
conditions, such as infections and cancers. 
 
Adults: Defined in this survey as the population of individuals 15 years of age and older.  
 
Antiretroviral (ARV): A type of medication used to treat HIV.  
 
Antiretroviral Therapy (ART): Treatment with ARVs that inhibit the ability of HIV to multiply in the body, 
leading to improved health and survival among people living with HIV. 
 
ARV-adjusted Diagnosed: When participants had reported being aware of their HIV-positive status 
before receipt of HIV rapid testing in SHIMS2 or their prior diagnosis was identified by presence of 
detectable ARVs in their blood sample.  
 
ARV-adjusted on Treatment: When participants reported currently taking ART or their treatment status 
was identified by presence of detectable ARVs in their blood sample.  
 
Awareness of HIV Status: When participants who tested HIV positive in the survey reported knowing 
their HIV-positive status. Participants who tested HIV positive in the survey and reported a previous HIV-
negative or indeterminate result, or never testing for HIV were classified as unaware of their HIV status.   
 
CD4+ T-Cells: Cluster of Differentiation4+ T-cells (CD4) are white blood cells that are an essential part of 
the human immune system. These cells are often referred to as T-helper cells. HIV attacks and kills CD4 
cells, leaving the body vulnerable to a wide range of infections. The CD4 count is used to determine the 
degree of weakness of the immune system from HIV infection and has been used to determine the need 
for and response to ART. 
 
Child with Special Circumstances: An emancipated minor; a child aged 12-17 years who is married, has a 
child of his/her own and is not currently living with parents, or is the decision maker in a household with 
no identified adult head of household. 
 
Children: Defined in this survey as the population of individuals 0-14 years of age. 
GLOSSARY OF TERMS 
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Elite Controllers: A small subset of people living with HIV whose immune systems are able to maintain 
viral load suppression for years without treatment. 
 
Enumeration Area (EA): A limited geographic area defined by the national statistical authority and the 
primary sampling unit for the Population-based HIV Impact Assessment (PHIA) surveys.  
 
Human Immunodeficiency Virus (HIV): The virus that causes AIDS. The virus is passed from person to 
person through blood, semen, vaginal fluids, and breast milk. HIV attacks CD4 cells in the body, leaving 
the person living with HIV vulnerable to illnesses that a healthy immune system would have eliminated. 
 
HIV Incidence: A measure of the frequency with which new cases of HIV occur in a population over a 
period of time. The denominator is the population at risk; the numerator is the number of new cases 
occurring during a given time period. 
 
HIV Prevalence: The proportion of persons in a population who are living with HIV at a specific point in 
time.  
 
HIV Viral Load (VL): The concentration of HIV in the blood, usually expressed as copies per milliliter (mL) 
of blood. 
 
HIV Viral Load Suppression (VLS): An HIV VL of less than 1,000 copies per mL of blood. 
 
Household: A person or group of persons (related or unrelated to each other) who live in the same 
compound (fenced or unfenced), share the same cooking arrangements, and have one person whom 
they identify as head of that household.  
 
Informed Consent: A legal condition whereby a person can give permission based upon a clear 
understanding of the facts, implications, and future consequences of an action. In order to give 
informed consent, the individual concerned must have adequate reasoning faculties and be in 
possession of all relevant facts at the time he or she gives consent. 
 
Intimate Partner Violence (IPV): Defined in this survey as physical or sexual violence by a current or 
former male intimate partner. An intimate partner is defined as a cohabitating partner, regardless of 
marital status. 
 
Male Circumcision (MC): The removal of some or the entire foreskin (prepuce) from the penis. 
Medically supervised adult MC is a scientifically proven method for reducing a man’s risk of acquiring 
HIV through heterosexual intercourse. 
 
Prevention of Mother-to-Child-Transmission (PMTCT): Activities to prevent an HIV-positive woman 
passing HIV to her baby during pregnancy, labor and delivery, or breastfeeding. The United Nations 
recommends effective PMTCT to include a four-fold approach: (1) primary prevention of HIV infection 
among women of childbearing age; (2) preventing unintended pregnancies among women living with 
HIV; (3) preventing HIV transmission of women living with HIV to their infants; and (4) providing 
appropriate treatment, care, and support to mothers living with HIV and their children and families.  
 
Elimination of Mother-to-Child Transmission of HIV: A reduction in mother-to-child-transmission of HIV 
to such a low level that it no longer constitutes a public health problem. This is defined as ≤50 new 
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pediatric infections per 100,000 live births and a transmission rate of either <5% in breastfeeding 
populations or <2% in nonbreastfeeding populations.  
 
Tuberculosis: A contagious bacterial disease that spreads through the air and is a leading cause of death 
among people living with HIV in Africa.  
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The Government of the Kingdom of Eswatini, formerly known as Swaziland, is pleased to present the 
second Swaziland HIV Incidence Measurement Survey 2016-2017 (SHIMS2) report. Following SHIMS 
conducted in 2011, SHIMS2 provides the first measure of the impact of HIV program scale-up in 
response to the HIV epidemic. It further provides useful information for policy direction and strategic 
planning for the HIV response in Eswatini and ensures adoption of new approaches toward achieving the 
country’s goal of ending AIDS by 2022. SHIMS2 reflects the nation’s journey in the fight against HIV and 
encourages policy makers to use this as a tool to mobilize financial, technical, and logistical resources to 
strengthen the national HIV response.  
 
SHIMS2 results show a significant reduction in new infections by nearly half and doubling in the 
proportion of HIV-positive people with suppressed viral loads since 2011. SHIMS2 results also show 
significant achievements toward the 90-90-90 goals, with Eswatini at 87-89-91. These important data 
contribute to the national and global body of HIV knowledge to achieve an AIDS-free generation by 2022 
in Eswatini and by 2030 globally. The findings indicate that the country is on the right path to end the 
epidemic despite its devastating effects over past decades.  
 
SHIMS2 was led by the Government of the Kingdom of Eswatini (GKOE) Central Statistical Office, 
Ministry of Health, and National Emergency Response Council on HIV/AIDS (NERCHA) and implemented 
in partnership with ICAP at Columbia University (in Eswatini and New York). Technical and funding 
support were provided by the United States Centers for Disease Control and Prevention (CDC) through 
the President’s Emergency Fund for AIDS Relief (PEPFAR).  
 
The GKOE wishes to acknowledge the expert contributions of the SHIMS2 Core Leadership Group, 
Project Implementation Task Team, Technical Steering Committee, and the many stakeholders who 
contributed to and supported the survey. Sincere appreciation goes to all participating households for 
their time and cooperation, without which the survey would not have been a success.  
 
On behalf of His Majesty’s Government, I therefore call upon all sectors, agencies, policy makers, 
partners, and relevant stakeholders to use the scientific information in this document fully to improve 
the health and well-being of the people of the Kingdom of Eswatini.   
 
 
Mr. Ambrose Mandvulo Dlamini 
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Summary of Key Findings 
Survey Household Characteristics 
▪ Close to half (46.0%) of households in Eswatini had at least one HIV-positive household member. 
▪ The percentage of households with two or more HIV-positive members (among households with at 
least one HIV-positive household member) was greater in rural areas (31.8%) compared with urban 
areas (21.3%).  
▪ About one in three (35.3%) households had an HIV-positive head of household. 
 
Survey Respondent Characteristics 
▪ Nearly a tenth (9.9%) of females were widowed compared with only 1.7% of males.  
▪ More than a tenth (12.3%) of children aged 0-14 years lived in households from the highest wealth 
quintile, but nearly double that percentage (26.2%) lived in households from the lowest wealth 
quintile. 
▪ Nearly all (99.4%) young adolescents aged 10-14 years currently attended school. 
 
HIV Incidence 
▪ Using the limiting antigen (LAg) avidity assay and viral load testing algorithm, annual HIV incidence 
among adults aged 15 years and older was 1.36% (1.02% males, 1.70% females). This corresponds to 
approximately 7,300 new cases of HIV infection annually among adults aged 15 years and older.    
▪ Using an antiretroviral (ARV)-adjusted LAg avidity testing algorithm, annual HIV incidence among 
adults aged 15 years and older was 1.13% (0.85% males, 1.41% females). This corresponds to 
approximately 6,000 new cases of HIV infection annually among adults aged 15 years and older. 
▪ Using an ARV-adjusted LAg avidity testing algorithm, annual HIV incidence among males was highest 




▪ HIV prevalence in adults aged 15 years and older was 27.0% (20.4% males, 32.5% females). This 
corresponds to approximately 197,000 adults aged 15 years and older living with HIV. 
▪ HIV prevalence peaked in males aged 45-49 years (48.8%) and in females aged 35-39 years (54.2%).  
▪ More than half of females aged 30-44 years were living with HIV: ages 30-34 years (50.7%), ages 35-
39 years (54.2%), and ages 40-44 years (51.9%).  
▪ Three-quarters (74.6%) of widowed females aged 15-49 years were living with HIV.  
▪ HIV prevalence was 10.9% among adults aged 65 years and older.  
 
HIV Testing 
▪ A large majority (87.1%) of adults aged 15 years and older had ever tested for HIV and received their 
test results (81.9% males, 91.4% females).  
▪ Lifetime testing among males was lower in ages 15-19 years (61.9%) and ages 20-24 years (77.7%) 
and peaked in ages 45-49 years at 91.0%. Among females, lifetime testing was 90% or higher in ages 
20-64 years and peaked at 99.4% in ages 30-34 years.  
SUMMARY OF KEY FINDINGS 
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▪ One in two (51.6%) adults aged 15 years and older had tested for HIV and received their test result 
in the prior 12 months. 
▪ Testing in the prior 12 months among adults aged 15 years and older was lowest in ages 15-19 years 
(40.6%), and highest in ages 20-24 years (63.1%) and 25-29 years (63.1%). 
 
HIV Diagnosis and Treatment 
▪ A majority (84.7%) of HIV-positive adults aged 15 years and older reported being aware of their HIV-
positive status (77.5% males, 88.6% females).  
▪ About three-quarters (74.1%) of adults living with HIV aged 15 years and older reported awareness 
of their HIV-positive status and currently being on antiretroviral therapy (ART) (68.7% males, 77.0% 
females). 
▪ A large majority (95.9%) of HIV-positive adults aged 15 years and older who reported current ART 
use had detectable ARVs in their blood. Among those who reported as not previously diagnosed, 
14.8% had detectable ARVs in their blood; 8.3% of adults who reported as previously diagnosed and 
not on ART had detectable ARVs in their blood. 
 
Viral Load Suppression 
▪ Prevalence of viral load suppression (VLS) among all HIV-positive adults aged 15 years and older was 
73.1% (67.6% males, 76.0% females). 
▪ Prevalence of VLS among HIV-positive adults aged 15 years and older who report being on ART was 
91.9% (91.3% males, 92.2% females). 
▪ VLS prevalence among all HIV-positive adults aged 15 years and older was lowest (50.6%) among 
those aged 15-24 years (32.9% males, 55.5% females). 
 
90-90-90 Targets 
▪ Based on self-report and presence of detectable ARVs, 87.0% of adults living with HIV aged 15 years 
and older knew their HIV status (80.1% males, 90.7% females). 
▪ Based on self-report and presence of detectable ARVs, 88.8% of HIV-positive adults aged 15 years 
and older were on ART (90.2% males, 88.1% females). 
▪ Based on self-report and presence of detectable ARVs, 91.4% of adults living with HIV aged 15 years 
and older had suppressed viral loads (90.5% males, 91.8% females). 
 
Clinical Characteristics of People Living with HIV 
▪ Less than half (44.7%) of HIV-positive adults aged 15 years and older were immunosuppressed with 
a CD4+ T-cell (CD4) count of less than 500 cells/microliter (μL). Severe immunosuppression with a 
CD4 count of less than 100 cells/μL was uncommon (2.2%). 
▪ About two-fifths (38.9%) of adults living with HIV aged 15 years and older who reported as unaware 
of their HIV-positive status had a late HIV diagnosis with CD4 count less than 350 cells/μL (42.4% 
males, 35.0% females). 
▪ All HIV-positive adults aged 15 years and older who initiated ART within 12 months of the survey 
and virtually all people living with HIV who ever initiated ART reported currently being on ART at the 
time of the survey (100% and 99.1%, respectively). 
▪ Five of 28 samples (17.9%) from recently infected HIV-positive adults aged 15 years and older in the 





Prevention of Mother-to-Child Transmission 
▪ Nearly all (99.4%) mothers aged 15-49 years, who delivered in the three years prior to the survey, 
attended at least one antenatal care (ANC) visit during their pregnancy. 
▪ Among mothers aged 15-49 years who gave birth within the prior three years, the percentage of 
mothers who never breastfed and tested HIV positive (11.5%) was almost three times higher than in 
mothers who never breastfed and tested HIV negative (4.3%). 
▪ Among mothers aged 15-49 years who gave birth during the 12 months prior to the survey, 98.4% 
reported knowing their HIV status before delivery: 30.2% were diagnosed as HIV positive before 
ANC, 6.4% were newly diagnosed as HIV positive in ANC, and 61.8% tested HIV negative in ANC. 
▪ Among HIV-positive mothers aged 15-49 years who gave birth during the 12 months prior to the 
survey, 56.1% were on ARVs prior to pregnancy, and 34.0% were newly initiated onto ARVs during 
pregnancy, labor, or delivery. 
▪ More than a tenth (12.8%) of infants aged 0-17 months, born to HIV-positive mothers aged 15-49 
years in the 17 months prior to the survey, were confirmed HIV positive by virologic testing. 
 
Young People 
▪ Among young people aged 15-24 years, 3.5% had sex before the age of 15 years (4.5% males, 2.5% 
females).  
▪ Using an ARV-adjusted LAg avidity testing algorithm, estimated annual incidence was 1.07% (95% 
confidence interval (CI): 0.46%-1.69%) among young people aged 15-24 years: 0.52% (95% CI: 
0.00%-1.14%) males, 1.67% (95% CI: 0.62%-2.71%) females.   
▪ HIV prevalence in young people aged 15-24 years was higher in ages 20-24 years (4.2% males, 20.9% 
females) than in ages 15-19 years (3.9% males, 7.2% females). 
▪ Testing in the prior 12 months was significantly higher in ages 15-19 years in females than in males 
(47.9% and 33.0%, respectively) and significantly higher in ages 20-24 years in females than in males 
(74.2% and 51.1%, respectively).  
▪ Among HIV-positive young people aged 15-24 years, about one-third (33.9%) were unaware of their 
HIV-positive status (48.5% males, 29.8% females).  
▪ Among young people aged 15-24 years who are living with HIV, over half (54.1%) were aware of 
their HIV-positive status and on ART (46.8% males, 56.1% females).  
▪ Among HIV-positive young people aged 15-24 years, half (50.6%) had suppressed viral loads (32.9% 
males, 55.5% females).  
▪ Based on self-reported prior HIV diagnosis, self-reported ART use, and ARV biomarker detection in 
HIV-positive young people aged 15-24 years, 72.1% were classified as ARV-adjusted diagnosed; 
among them, 85.3% were classified as ARV-adjusted on treatment, of which 76.5% had VLS. 
 
Children 
▪ HIV prevalence among children aged 0-14 years was 2.8% and peaked in ages 10-14 years at 4.1%. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 77.5% of HIV-
positive children aged 0-14 years had a known HIV-positive status. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 100.0% of HIV-
positive children aged 0-14 years were on ART. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 73.9% of HIV-




HIV Risk Behaviors 
▪ Among adults aged 15 years and older who had sexual debut before the age of 15 years, less than a 
fifth (18.7%) of males were HIV positive, compared to about half (50.6%) of females. 
▪ Among adults aged 15 years and older with two or more sexual partners in the prior 12 months, HIV 
prevalence was nearly double in females (45.3%) than in males (22.8%). 
▪ Among adults aged 15 years and older who did not use a condom at last sexual intercourse in the 
prior 12 months, about a fifth (20.9%) were HIV positive (16.8% males, 24.1% females). 
▪ Among adults aged 15 years and older who were living with their sexual partner and who had sex 
with a non-marital, non-cohabitating partner in the prior 12 months, more than half (54.5%) used a 
condom at last sexual intercourse. Condom use at last sexual intercourse with a non-marital, non-
cohabitating partner was comparatively higher in married adults (63.7%). 
▪ Among adult males aged 15 years and older, 70.7% reported as uncircumcised and 26.7% had 
received medical male circumcision. One-third (34.8%) of adult males aged 15-24 years self-reported 
as medically circumcised. 
 
Intimate Partner Violence 
▪ Among ever married or partnered (i.e. having a cohabitating partner) females aged 15 years and 
older, 3.6% reported intimate partner violence (IPV) in the 12 months prior to the survey. IPV 
peaked at 9.8% among those aged 20-24 years. 
▪ Among ever married or partnered females aged 15-24 years, over a tenth (11.2%) experienced IPV in 
the 12 months prior to the survey. 
▪ IPV was higher among ever married or partnered females aged 15 years and older testing HIV 
positive in the survey (5.9%), compared to those testing HIV negative in the survey (2.3%). 
▪ Among females aged 15 years and older, 5.2% had experienced physical violence in their lifetime. 
Lifetime physical violence was highest among those aged 20-24 years (9.2%). 
 
Tuberculosis 
▪ One-third (34.8%) of self-reported adults living with HIV aged 15 years and older attended a health 
facility for tuberculosis (TB) services. 
▪ A large majority (97.9%) of self-reported HIV-positive adults aged 15 years and older, who report 
attending TB services and a TB diagnosis, reported receipt of TB treatment.  
 
Food and Water Security 
▪ Across the four regions, food insecurity in the four weeks prior to the survey was higher in 
Shiselweni region (39.6%) and Lubombo region (35.5%). 
▪ The percentage of households experiencing water insecurity for hygiene was more than twice as 
high in rural areas (15.5%) than in urban areas (6.1%). 
▪ Food shortages occurred in more than a third (34.7%) of female-headed households compared with 




Chapter 1   Introduction 
1.1 Background 
The Population-based HIV Impact Assessment (PHIA) Project is a multicountry initiative funded by the 
United States President’s Emergency Plan for AIDS Relief (PEPFAR) to conduct national HIV-focused 
surveys that describe the status of the HIV epidemic. The surveys measure important national and 
regional HIV-related parameters, including progress toward the achievement of the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 90-90-90 targets (UNAIDS, 2014), and will guide policy and funding 
priorities. 
 
The Swaziland HIV Incidence Measurement Survey 2 2016-2017 (SHIMS2) was led by the Government of 
the Kingdom of Eswatini (GKOE) through the Ministry of Health (MOH) and the Central Statistical Office 
(CSO) and was conducted with funding from PEPFAR and technical assistance from the U.S. Centers for 
Disease Control and Prevention (CDC). The survey was implemented by ICAP at Columbia University in 
collaboration with local developmental and implementing partners. SHIMS2 2016-2017 received ethical 
approvals from the Eswatini National Health Research Review Board, Westat Institutional Review Board, 
the CDC Institutional Review Board, and the Columbia University Medical Center Institutional Review 
Board. SHIMS2 was a follow-on survey to the Swaziland HIV Incidence Measurement Survey (SHIMS) 
conducted in 2011.  
 
1.2 Overview of SHIMS2 2016-2017 
SHIMS2 2016-2017, a household-based national survey under the multicountry PHIA Project, was 
conducted between August 2016 and March 2017 to measure the status of Eswatini’s national HIV 
response. SHIMS2 offered home-based testing and counseling (HBTC) with return of results and 
collected information about uptake of HIV care and treatment services. This survey is the second in 
Eswatini to measure national HIV incidence, viral load suppression (VLS) prevalence, CD4 count 
distribution, and transmitted HIV drug resistance. It is the first to measure pediatric HIV prevalence and 
presence of ARV drugs in blood. The survey also collected information on selected behaviors associated 
with HIV acquisition and transmission, and common HIV co-morbidities and other health conditions. 
 
Although HIV facility-based sentinel surveillance and previously conducted population-based surveys, 
such as SHIMS 2011, provided useful knowledge regarding Eswatini’s HIV epidemic and HIV-control 
efforts, information critical to understand the current status of the epidemic and guide future 
interventions was needed. With its focus on measuring key biological endpoints in a nationally 
representative sample of the population, SHIMS2 provides direct estimates of HIV-infection risk and 
burden; the effectiveness and population-level impact of HIV-related prevention, care, and treatment 
interventions implemented in the country; and progress toward the achievement of the UNAIDS 90-90-
90 targets. 
 
1.3 Specific Objectives 
The goal of the survey was to examine the distribution of HIV disease in Eswatini, to assess the coverage 
and impact of HIV services at the population level, and to measure HIV-related risk behaviors using a 
nationally representative sample of adults (defined in this survey as those aged 15 years and older, 
1 INTRODUCTION 
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unless otherwise noted) and children (defined in this survey as those aged 0-14 years, unless otherwise 
noted).  
 
Primary objectives  
▪ To estimate the national HIV incidence rate in a household-based, nationally representative sample 
of adults aged 15 years and older in Eswatini in 2016-2017.  
▪ To estimate the sub-national prevalence of HIV VLS in a household-based, nationally representative 
sample of adults aged 15 years and older in Eswatini in 2016-2017.  
▪ To estimate national HIV prevalence in a household-based, nationally representative sample of 
children aged 0 to 14 years in Eswatini in 2016-2017. 
 
Secondary objectives 
Among adults aged 15 years and older: 
▪ To estimate national HIV prevalence in 2016-2017. 
▪ To compare national HIV incidence estimates among those aged 18-49 years in 2011 versus 2016-
2017. 
▪ To compare national HIV incidence estimates among young women aged 18-24 years in 2011 versus 
2016-2017. 
▪ To examine correlates of incident HIV infection.  
▪ To estimate mean population viral load (VL) among adults living with HIV.  
▪ To compare national prevalence VLS in 2011 versus 2016-2017. 
▪ To compare regional estimates VLS in 2011 versus 2016-2017.   
▪ To describe the national CD4 count distribution of adults living with HIV.   
▪ To estimate enrollment in HIV care among those with prevalent HIV infection.  
▪ To measure the prevalence of ART use among those with prevalent HIV infection. 
▪ To measure uptake of HIV testing and ART use among women recently pregnant or breastfeeding. 
▪ To measure the prevalence of transmitted ARV drug resistance among those with recent HIV 
infection. 
▪ To examine correlates of VLS on ART. 
▪ To describe reported sexual behavior associated with HIV transmission risk.  
▪ To estimate prior testing and knowledge of HIV status.  
▪ To estimate the prevalence of MC among men.  
▪ To measure the uptake of TB services.  
▪ To measure the acceptability of early ART use among those who test HIV seropositive and self-
report no current ART use. 
 
Among children aged 0-14 years: 
▪ To examine correlates of prevalent HIV infection.  
▪ To estimate enrollment in HIV care among children living with HIV.  
▪ To describe the national CD4 count distribution of children living with HIV. 
▪ To describe sub-national VLS among children living with HIV.  
▪ To measure the prevalence of ART use among those with prevalent HIV infection.  
▪ To measure the prevalence of transmitted ARV drug resistance among those with recent HIV 
infection. 
▪ To assess correlates of VLS among those on ART.  
▪ To describe sexual debut and prevalence of sexual behavior associated with HIV transmission risk 
among children aged 10-14 years. 
▪ To estimate the prevalence of MC among male children.   
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Chapter 2   Survey Design, Methods, and Response Rates 
SHIMS2 2016-2017 was a nationally representative, cross-sectional, population-based survey of 
households across Eswatini. Its target population corresponded to children (defined as those aged 0-14 
years) and adults (defined as those aged 15 years and older, unless otherwise noted). The survey 
population excluded institutionalized children and adults. 
 
2.1 Sample Frame and Design 
 
SHIMS2 used a two-stage, stratified cluster sample design. The sampling frame was comprised of all 
households in the country based on the 2007 Swaziland Population and Housing Census, which includes 
2,064 enumeration areas (EA), containing an estimated 212,195 households.1 The first stage selected 
286 EA (clusters) using a probability proportional to size method. The 286 EAs were stratified by four 
geographical regions (Hhohho, Manzini, Shiselweni, and Lubombo), with each EA defined by rural and 
urban status. During the second stage, a sample of households was randomly selected within each EA, 
or cluster, using an equal probability method, where the average number of households selected per 
cluster was 20 and the actual number of households selected per cluster ranged from 15 to 43 (Figure 
2.1.A and Table 2.1.A). 
 
The sample size was calculated to provide a representative national estimate of HIV incidence among 
adults aged 15-49 years with a relative standard error less than or equal to 20.0%. Representative 
regional estimates of VLS prevalence, among HIV-positive adults aged 15-49 years with 95% confidence 
intervals (CI) with ±10% bounds around the point estimates, were also used. One-half of the households 
were randomly selected for inclusion of children, which was designed to provide a representative 
national estimate of pediatric HIV prevalence with a relative standard error less than or equal to 15.0%. 
The target sample size was 12,042 for adults, and 3,361 for children. Appendix A, Sample Design and 
Weighting provides detailed explanations of the sampling and weighting processes. 
 
 
Table 2.1.A Distribution of sampled enumeration areas and households, by region,  
SHIMS2 2016-2017 
 Enumeration areas  Households 
Region Urban Rural Total  Urban Rural Total 
Hhohho 19 63 82  425 1,409 1,834 
Manzini 22 72 94  492 1,610 2,102 
Shiselweni 12 41 53  268 917 1,185 
Lubombo 14 44 58  313 984 1,297 
Total 67 220 287  1,498 4,920 6,418 
 
  




2.2 Eligibility Criteria, Recruitment, and Consent Procedures 
The eligible survey population included: 
▪ Women and men aged 18 years and older living in the selected households and visitors who slept in 
the household the night before the survey, who were willing and able to provide written consent in 
either siSwati or English. 
▪ Adolescents aged 10-17 years living in the selected households, and visitors who slept in the 
household the night before the survey, who were willing and able to provide written assent in either 
siSwati or English, and whose parents or guardians were willing and able to provide written 
permission for their participation in either siSwati or English.  
▪ Children aged 0-9 years living in the selected households, and child visitors who slept in the 
household the night before the survey, whose parents or guardians were willing and able to provide 
written consent for their participation in either siSwati or English. 
 
An electronic informed consent form was administered using a tablet computer (Appendix H). At each 
stage of the consent process, consent was indicated by signing or making a mark on the consent form on 
the tablet and on a printed copy, which was retained by the participant. A designated head of household 
provided written consent for household members to participate in the survey, after which individual 
members were rostered during a household interview. Adults and children with special circumstances 
(e.g., emancipated minors) provided written consent on the tablet for an interview. After completing the 
interview, they provided written consent for participation in the biomarker component of the survey, 
including HBTC, with return of HIV-testing results and CD4 counts during the household visit. Receipt of 
tests results was a requirement for participation in the biomarker component. If an individual did not 
want to receive his or her HIV test result, this was considered a refusal for the biomarker component. 
Adults were also asked for written consent to store their blood samples in a repository to perform 
additional tests in the future. 
 
Participants aged 10-17 years were asked for assent to the interview and biomarker components after 
permission was granted by their parents or guardians. Parents provided consent for biomarker testing 
for minors below the age of assent (ages 0-9 years). Procedures with illiterate participants or 
participants with a sight disability involved the use of an impartial witness, chosen by the potential 
participant, who also signed or made a mark on the consent form on the tablet and the printed copy. If 
no witness could be identified, the potential participant or household (if the head of household was 
sight disabled or illiterate) was deemed ineligible. 
 
2.3 Survey Implementation 
 
Survey Governance Structure   
A national Core Leadership Group (CLG) including Directors within MOH, CSO, CDC/PEPFAR and ICAP 
was established to provide high-level technical oversight for SHIMS2. In addition, a Technical Steering 
Committee (TSC) was formed to guide the process of planning and implementing this survey and to 
provide technical input as needed. The TSC includes representatives from the MOH, CSO, ICAP, 
CDC/PEPFAR, Eswatini Health Laboratory Services (EHLS), National Emergency Response Council on 
HIV/AIDS (NERCHA), country representation from World Health Organization (WHO), Joint United 
Nations Programme on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA), United Nations 
Children’s Fund (UNICEF), and local partners including University Research Co (URC), Elizabeth Glaser 
Pediatric AIDS Foundation (EGPAF), Médecins Sans Frontières (MSF), Populations Services International 
(PSI), Pact, Baylor, and Clinton Health Access Initiative (CHAI). A smaller operations group called the 
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Project Implementation Task Team (PITT) met weekly to discuss the pre-implementation, 
implementation, and post-implementation of data collection activities and ensure CLG and TSC direction 
was followed. The PITT included the Principal Investigators from MOH, CDC/PEPFAR, and ICAP in 
Eswatini, and members of the MOH, CDC/PEPFAR, and ICAP Project Implementation Team. ICAP 
partnered with Westat in the implementation of the survey to support data management.   
 
Training of Field and Laboratory Staff  
▪ Survey staff received training on both the contents of the data collection instruments and tablet use. 
The training curriculum included: 
▪ Scientific objectives of the survey 
▪ Survey design and methods 
▪ Completion of survey forms 
▪ Data collection 
▪ Staff responsibilities 
▪ Recruitment of participants 
▪ Informed consent procedures, including human subjects’ protection, privacy, and confidentiality 
▪ Blood collection for children and adults, including venipuncture and finger/heel-stick 
▪ Home-based HIV testing and counseling 
▪ CD4 count measurement using point-of-care Pima™ analyzer 
▪ Referral of participants to health and social services 
▪ Management and transportation of blood specimens 
▪ Biosafety and waste management 
▪ Communication skills 
▪ Protocol deviations, adverse events, and reporting of events  
 
Laboratory staff were trained in specimen management, including sample processing, labeling, and 
quality assurance (QA). Central laboratory staff were trained in VL measurement, early infant diagnosis, 
HIV confirmatory testing, and HIV recency testing using the LAg-Avidity enzyme immunoassay (EIA).  
 
Survey Staff 
Fieldwork started on August 30, 2016 and completed on March 31, 2017. Fieldwork was conducted by 
16 locally hired field teams composed of a supervisor, six health workers, and a driver. Field teams 
included both male and female staff and members spoke both siSwati and English. A total of 163 
regional coordinators, team supervisors, field health workers, community-mobilization coordinators, 
and drivers participated in data collection. Survey personnel were selected based on their qualifications 
and areas of expertise. The field health workers obtained consent, administered the interview, 
conducted phlebotomy, performed CD4 counts using a point-of-care instrument, and delivered HIV 
testing services (HTS) for adults and children. The field teams were managed by four regional 
coordinators and supervised by sixteen team supervisors, who guided and oversaw data collection 
activities, performed quality checks, and provided technical support. 
 
In addition, 15 laboratory technicians processed samples and performed additional procedures for HIV-1 
VL, infant virologic HIV testing, and quality control (QC) and QA. National and international monitors 
periodically conducted direct observation of data collection activities in the field and in the laboratories 




Community Sensitization and Mobilization 
Community mobilization was conducted prior to data collection to maximize community support and 
participation in the survey at the national, regional, inkhundla (i.e., local administrative structure in 
Eswatini), and chiefdom levels. The mobilization began before fieldwork commenced with a high-level 
national launch meeting that included key national and regional leaders, mass media, and other 
stakeholders. Community mobilization teams visited each EA prior to initiation of data collection and 
partnered with community health workers to meet key gatekeepers in the communities (chiefs, local 
government officials, and religious and community leaders). The mobilization teams consulted 
community leaders, held community sensitization meetings, disseminated informational materials such 
as brochures and posters, and held discussions with selected households and other community 




Data-collection teams were continuously overseen by field-based supervisors and regional coordinators, 
as well as periodically monitored by national and international teams with representation from 
collaborating institutions. Monitoring teams visited field and laboratory sites at least monthly and 
provided direct supervision as well as verification of results by household revisits. Daily monitoring 
forms for household and individual outcome tracking were also reviewed by monitors for completeness. 
Field-based supervisors also supported teams by organizing supplies and transport of blood samples, 
coordinating community-mobilization efforts, providing technical troubleshooting, and checking the 
quality of household procedures and data collected.  
 
The national and international monitoring teams observed and assessed the quality of survey 
procedures, including adherence to protocol and standard operating procedures, and identified and 
responded to challenges with data collection. Regular debriefing sessions were held between field-
based supervisors and monitoring teams. Monitoring reports were circulated to collaborating 
institutions and the SHIMS2 PITT to respond to any issues. 
 
Electronic monitoring system 
An electronic dashboard system was established to monitor the progression of the survey. The 
dashboard summarized data uploaded to the PHIA server daily. The dashboard tracked coverage and 
completion of EAs, sampled households, household response, eligible household members providing 
consent to the interview, biomarker components of the survey, blood draws, response rates, and overall 
progress toward the achievement of the target sample.  
 
Questionnaire Data Collection 
Questionnaire and field laboratory data were collected on mobile tablet devices using an application 
programmed in Open Data Kit, an open-source mobile data collection application. The household 
interview collected information on household residents, assets, economic support, and recent deaths 
(Appendix E). The adult interview was administered to participants aged 15 years and older and included 
modules on demographic characteristics, sexual and reproductive health, marriage, MC, sexual activity, 
HIV testing and treatment history, TB and other diseases, alcohol use, and gender norms (Appendix F). 
The young adolescent interview was administered to participants aged 10-14 years and included 
modules on demographic characteristics, HIV stigma, HIV knowledge and risk perception, exposure to 
HIV prevention interventions, sexual activity, social norms, HIV testing and treatment history, alcohol 
and drug use, parental support, and violence (Appendix G). Participants who self-reported their HIV-
positive status were asked questions about their HIV care experience. Parents also answered questions 
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about their children’s (ages 0-14 years) health and participation in HTS services. In each household, one 
adult woman was also randomly selected to answer questions about her experiences with violence. 
Participants of any age who reported being victims of violence and minors who reported being victims of 
sexual exploitation were provided with referrals to social services. Female participants were interviewed 
by female staff, and male participants by male staff, whenever possible. The questionnaire was 
administered in the two languages most commonly used in Eswatini. The English and siSwati versions of 
the questionnaires were reviewed and tested thoroughly for acceptability, feasibility, and flow of 
questions. 
 
2.4 Field-Based Biomarker Testing 
 
Blood Collection 
Blood was collected by qualified survey staff from consenting participants. Fourteen milliliter (mL) of 
venous blood was collected from adults, while six mL was collected from persons aged 2-14 years. One 
mL of capillary blood was collected from children aged 0-2 years, using finger-stick for children aged 6-
24 months and heel-stick for children aged 6 months and under. 
 
Blood samples were labeled with a unique bar-coded participant identification number and stored in 
temperature-controlled cooler boxes. At the end of each day, samples were transported to a regional 
hub or central laboratory for processing into plasma aliquots and dried blood spots (DBS), and were 
frozen within 24 hours of blood collection. 
 
HIV Home-Based Testing and Counseling 
HIV HBTC was conducted in each household based on national guidelines (Figure 2.4.A). The survey used 
a sequential rapid-testing algorithm in the field: Determine™ HIV-1/2 (Abbott Molecular Inc., Chicago, 
Illinois, United States) as a screening test, Uni-Gold™ HIV-1/2 (Trinity Biotech, Co. Wicklow, Ireland) as a 
confirmatory test, and Clearview™ Complete HIV-1/2 (Chembio, Medford, New York, United States) as a 
tiebreaker test. Individuals with a nonreactive result on the screening test were reported as HIV 
negative. Individuals with a reactive screening test underwent confirmatory testing. Those with reactive 
results on both the screening and confirmatory tests were classified as HIV positive. Individuals with a 
reactive screening test result, followed by a nonreactive confirmatory test result, underwent tiebreaker 
testing. Individuals with a reactive tiebreaker test result were classified as HIV positive. Those with a 




Figure 2.4.A Household-based HIV-testing algorithm, SHIMS2 2016-2017 
 
 
HIV-seropositive participants who reported not being on ART were referred to HIV care and treatment 
services at a health facility of their choice. For children, results were returned to a parent or guardian. 
Participants with a nonreactive tiebreaker test result were advised to attend a facility in two weeks for 
repeated testing, as per national guidelines. 
 
For children aged 18 months or less, only the screening test (Determine™) was performed in the field. If 
the test was reactive, HIV total nucleic acid (TNA) polymerase chain reaction (PCR) for virologic testing of 
HIV infection was performed in the reference laboratory, as described below (Section 2.5). 
 
For participants who reported being HIV positive, but who tested HIV negative at the time of the survey, 
additional laboratory-based testing was conducted using HIV TNA PCR for confirmation of the status. In 
conjunction with the MOH, survey staff revisited these participants and health providers to provide 
counseling and guidance on next steps to confirm these results, particularly for those on ART.  
 
QC, using a panel of positive and negative dried tube specimens, was performed on a weekly basis by 
field staff performing HIV testing. In addition, QA proficiency testing was conducted twice in the course 
of the survey, using a panel of masked HIV-positive and negative dried tube specimens. Proficiency in 




CD4 T-Cell Count Measurement 
All participants who tested HIV positive during HBTC, and a random sample of 2.0% of those who tested 
HIV negative, received a CD4 count measurement in the field by qualified survey staff. The 
measurement was performed using the Pima™ CD4 Analyzer (Abbott Molecular Inc., Chicago, Illinois, 
United States, formerly Alere). 
 
HIV linkage to care 
Participants were eligible for linkage to care (LTC) services if they tested HIV positive during HBTC at the 
time of their interview and reported as either: newly diagnosed with HIV, having initiated ART but had 
not visited a clinic in the prior three months, or having never initiated ART. 
 
LTC teams visited facilities selected by the participant for referral to HIV care. Jointly working with 
health facility staff, LTC teams identified LTC-eligible participants by the facility copy of the referral form 
and supported facility staff to telephone participants to encourage attendance at the clinic. When 
referral forms did not indicate consent for future contact or no phone number, a call was not placed to 
the participant. If a participant was not reachable by phone and had consented to contact by home visit, 
a home visit was conducted.  
 
Once contacted, participants were asked a series of questions to identify their prior experience with 
linkage to HIV services. If a participant had not yet linked to care, they were encouraged to do so with 
additional counseling messages and the facility staff or SHIMS2 LTC staff would schedule an 
appointment with the participant. Those who had linked prior to contact by the LTC team were also 
encouraged to make an appointment to receive their HIV VL results at the facility. 
 
2.5 Laboratory-Based Biomarker Testing 
 
Central Laboratory Procedures 
A central laboratory for the survey was established within the existing national reference laboratory. 
Trained technicians performed processing of whole blood specimens into plasma aliquots and DBS cards 
for storage at -20°C, testing for QA, and HIV confirmatory testing. For QA of the HIV rapid testing 
conducted in the field, the first 50 samples tested by each field tester, and subsequently a random 
sample of 5.0% of all specimens, were retested in the laboratory using the national HIV rapid-testing 
algorithm. All specimens that received confirmatory testing and tested nonreactive during HBTC 
underwent a second confirmatory test using Geenius HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, 
California, United States). A positive Geenius result defined HIV-positive status. Central laboratory 
procedures included HIV VL testing, HIV TNA PCR for infant virologic testing and to confirm the status of 
those who self-reported an HIV-positive status but tested negative in HBTC, HIV recency testing, and 
long-term storage of samples at -80°C. 
 
Survey staff conducted household revisits for investigation of discrepancies between the results of 
testing in the field and in the laboratory. The specimens collected during the revisit underwent 
comprehensive retesting in the laboratory. For each case, an analysis of the nature of the discrepancy, 
and potential sources of error, was performed to define the definitive HIV status for analytical purposes. 
 
Viral Load Testing 
The HIV-1 VL (HIV Ribonucleic acid (RNA) copies per mL) of confirmed HIV-positive participants was 
measured at the central laboratory using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, 
version 2.0 (Roche Molecular Diagnostics, Indianapolis, Indiana, United States). The open-mode protocol 
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for the Roche COBAS Ampliprep/TaqMan HIV-1 Assay was used to prepare samples for amplification. 
The Abbott m2000 System (Abbott Molecular Inc., Chicago, Illinois, United States) was used to conduct 
DBS VL testing at the National Institute for Communicable Diseases (NICD) in Johannesburg, South 
Africa, when testing was unavailable at the central laboratory. The Abbott m2000 System consists of two 
separate instruments, the m2000sp (which carries out automated extraction, purification, and 
preparation of HIV-1 RNA), and the m2000rt (which amplifies, detects, and measures the HIV-1 RNA 
load). For plasma, the 0.6 mL protocol was used, while the open-mode protocol for the Abbott RealTime 
HIV-1 assay was used to measure VL from DBS samples from children and adults with insufficient volume 
of plasma. 
 
VL results were returned within six to eight weeks to the health facility chosen by each HIV-positive 
participant. The duration and completion for returning results was monitored through internal quality 
assurance systems and managed by designated study staff. Participants were provided with a referral 
form during HBTC for subsequent retrieval of their results. Survey staff also contacted each participant 
via Short Message Service (SMS) to inform them that their VL results were available at the chosen facility 
and to further advise them to seek care and treatment. 
 
Infant HIV Virological Testing 
For infants aged 18 months and under who screened positive for HIV during HBTC, virologic testing was 
conducted via HIV TNA PCR using the COBAS® AmpliPrep/COBAS® TaqMan® 96 analyzer using the 
COBAS® Ampliprep/COBAS TaqMan® HIV-1 Qualitative Test, version 2.0 (Roche Molecular Diagnostics, 
Branchburg, New Jersey, United States). Results were returned to the health facility selected by the 
infant’s parent or guardian within six to eight weeks, and survey staff also contacted the parent or 
guardian via telephone to inform them that the infant’s results were available at the facility. 
 
HIV Recent Infection Testing Algorithm 
To distinguish recent from long-term HIV infections, the survey used two different laboratory-based 
testing algorithms. Each algorithm employed a combination of assays: 1) HIV-1 LAg-Avidity EIA (Sedia 
Biosciences Corporation, Portland, Oregon, United States) and VL (Figure 2.5.A) and 2) HIV-1 LAg-Avidity 
EIA, VL, and ARV detection (Figure 2.5.B), as described in Appendix B. 
 
Specimens with median normalized optical density ≤1.5 were classified as potential recent infections, 
and their VL results were assessed. Specimens with VL < 1,000 copies/mL were classified as long-term 
infections, while those with VL ≥ 1,000 copies/mL were classified as recent infections (Figure 2.5.A). In 
the ARV-adjusted algorithm, specimens with VL ≥ 1,000 copies/mL and with detectable ARVs were 
classified as long-term infections. Specimens with VL ≥ 1,000 copies/mL and without detectable ARVs 
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Figure 2.5.B HIV-1 recent infection testing algorithm (LAg/viral load/ARV), aged 18 months and 




Detection of Antiretroviral Drug Resistance   
HIV resistance to ARVs was assessed for all those HIV-positive participants 18 months and older, 
classified as recent HIV infections, and a small subset of confirmed long-term infections. In addition, all 
infants less than the age of 18 months with confirmed infection were evaluated to determine vertical 
transmission of ARV-resistant HIV. Mutations in the HIV protease and reverse transcriptase genes that 
confer ARV drug resistance (according to the Stanford drug resistance database) were detected 
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Specimens were sent to CDC in the United States where testing was performed at the International 
Laboratory Branch, a WHO-accredited laboratory for drug resistance testing.   
 
Detection of Antiretrovirals  
Qualitative screening for detectable concentrations of ARVs was conducted on DBS specimens from all 
HIV-positive adults and children, by means of high-resolution liquid chromatography coupled with 
tandem mass spectrometry. The method used for ARV detection was a modified version of the 
methodology described by Koal et al.2 This qualitative assay was highly specific, as it separates the 
parent compound from the fragments, and highly sensitive, with a limit of detection of 0.02 microgram 
(μg)/mL for each drug, and a signal-to-noise ratio of at least 5:1 for all drugs. As detection of all ARVs in 
use at the time of the survey was cost-prohibitive, three ARVs were selected as markers for the most 
commonly prescribed first and second line regimens: efavirenz, lopinavir, and nevirapine. These ARVs 
were also selected based on their relatively long half-lives, allowing for a longer period of detection 
following intake.  
 
Detection of ARVs is considered indicative of participant use of a given drug at the time of blood 
collection. Results below the limit of detection among individuals who reported ARV use indicate that 
there was no recent exposure to the regimen or that adherence to a prescribed regimen is sub-optimal, 
but cannot be interpreted as “not on ART.” In addition, given the limited number of ARVs selected for 
detection, their absence could not rule out the use of other ART regimens that do not include them.   
 
ARV detection was performed by the Division of Clinical Pharmacology of the Department of Medicine at 
the University of Cape Town in South Africa. 
 
2.6 Data Processing and Analysis 
All field data were collected on tablets, transmitted to a central server using a secure virtual private 
network, and stored in a secure PostgreSQL database. Data cleaning was conducted using SAS 9.4 (SAS 
Institute Inc., Cary, North Carolina, United States). Laboratory data were cleaned and merged with the 
final questionnaire database using unique specimen barcodes and study identification numbers. 
 
All results presented in the report are based on weighted estimates unless otherwise noted. Analysis 
weights account for sample selection probabilities and are adjusted for nonresponse and noncoverage. 
Nonresponse adjusted weights were calculated for households, individual interviews, and individual 
blood draws in a hierarchical form. Adjustment for nonresponse for initial individual and blood-level 
weights was based on the development of weighting adjustment cells, defined by a combination of 
variables that are potential predictors of response and HIV status. The nonresponse adjustment cells 
were constructed using chi-square automatic interaction detection algorithm. The cells were defined 
based on data from the household interview for the adjustment of individual-level weights, and from 
both the household and individual interviews for the adjustment of blood sample-level weights. Post-
stratification adjustments were implemented to compensate for noncoverage in the sampling process. 
This final adjustment calibrated the nonresponse-adjusted individual and blood weights to make the 
sum of each set of weights conform to national population totals by sex and five-year age groups. 
 
Descriptive analyses of response rates, characteristics of respondents, HIV prevalence, CD4 count 
distribution, HIV testing, self-reported HIV status, self-reported ART, VLS, prevention of mother-to-child 
transmission (PMTCT) indicators, and sexual behavior were conducted using SAS 9.4. 
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Incidence estimates were based on the number of HIV infections identified as recent with the HIV-1 LAg 
avidity plus VL algorithm or with the HIV-1 LAg avidity plus VL and ARV algorithm, and obtained using 
the CDC Incidence Calculator, which uses the formula recommended by the WHO Technical Working 
Group on HIV Incidence Assays and the Consortium for the Evaluation and Performance of HIV Incidence 
Assays, with time cutoff (T) = 1.0 year and residual proportion false recent (PFR) = 0.00. For the purposes 
of this analysis, HIV incidence is expressed as the cumulative incidence or risk of new infections in a 12-
month period, which is a close approximation to the instantaneous incidence rate. It is important to 
note that SHIMS2 was not powered to estimate incidence at the regional level or across different sub-
groups. 
 
2.7 Response Rates 
Using the American Association for Public Opinion Research Response Rate 4 method,3 household 
response rates were calculated using the number of complete and incomplete household interviews 
among all eligible households and the number estimated to be eligible among households with unknown 
eligibility (households not located, not attempted, or unreachable). Vacant and destroyed households, 
nonresidential units, and household units with no eligible respondents were considered not eligible and 
excluded from the calculation.  
 
Individual interview response rates were calculated as the number of individuals who were interviewed 
divided by the number of individuals eligible to participate in the survey. Blood draw response rates for 
adults were calculated as the number of individuals who provided blood, divided by the number of 
individuals who were interviewed. Blood draw response rates for children were calculated as the 
number of individuals who provided blood, divided by the number of individuals eligible to participate in 
the biomarker component of the survey. 
 
Of the 6,417 selected households, 6,056 and 5,185 were occupied and interviewed, respectively. The 
overall household response rate (unweighted) was 84.9% (79.3% in urban areas and 87.2% in rural 
areas). After adjusting for differential sampling probabilities and nonresponse, the overall weighted 
household response rate was 84.5% (79.1% in urban areas and 87.1% in rural areas) (Table 2.7.A). 
 
A total of 12,857 adults (5,648 males and 7,209 females) were eligible to participate in the survey. 
Interview response rates (unweighted) were 86.8% for males and 93.9% for females. Among those 
adults who were interviewed, 91.9% of males and 95.0% of females (unweighted) also had their blood 
drawn. 
 
Children in half of the selected households were eligible for blood draw. Of the 2,697 eligible children 
aged 0-9 years, 82.7% of males and 81.8% of females (unweighted) had their blood drawn. Of the 1,300 
eligible children aged 10-14 years, interview response rates (unweighted) were 88.9% of males and 
92.5% of females. Among 10-14-year-olds interviewed, 98.3% of males and 97.5% of females 




Table 2.7.A Household response rates 
Number of households selected, occupied, and interviewed and household response rates (unweighted and 
weighted), by residence, SHIMS2 2016-2017 
  Residence 
Total 
Result Urban Rural 
    
Household interviews    
Households selected 1,863 4,554 6,417 
Households occupied 1,757 4,299 6,056 
Households interviewed 1,408 3,777 5,185 
    
Household response rate1 (unweighted) 79.3 87.2 84.9 
Household response rate1 (weighted) 79.1 87.1 84.5 





Table 2.7.B Interviews and blood draw response rates  
Number of eligible individuals and response rates for individual interviews1 and blood draws2 (unweighted and 
weighted), by residence and sex, SHIMS2 2016-2017 
 Residence    
 Urban  Rural  Total 
Result Males Females  Males Females  Males Females 
Eligible individuals, aged 0-9 years         
Number of eligible individuals 199 200  1,139 1,159  1,338 1,359 
Blood draw response rate (unweighted) 74.4 73.0  84.1 83.3  82.7 81.8 
Blood draw response rate (weighted) 74.3 75.4  83.8 82.8  82.0 81.4          
Eligible individuals, aged 10-14 years         
Number of eligible individuals 79 78  580 563  659 641 
Interview response rate (unweighted) 82.3 87.2  89.8 93.3  88.9 92.5 
Interview response rate (weighted) 83.5 88.4  89.7 92.7  88.7 92.0 
Blood draw response rate (unweighted) 100.0 92.6  98.1 98.1  98.3 97.5 
Blood draw response rate (weighted) 100.0 92.1  97.9 97.9  98.2 97.0          
Eligible individuals, aged 15-24 years         
Number of eligible individuals 332 434  1,721 1,735  2,053 2,169 
Interview response rate (unweighted) 88.0 92.4  86.6 93.0  86.8 92.9 
Interview response rate (weighted) 88.2 93.0  86.6 92.8  86.9 92.8 
Blood draw response rate (unweighted) 89.0 93.3  94.9 96.2  93.9 95.6 
Blood draw response rate (weighted) 89.6 93.4  95.0 96.1  94.0 95.4          
Eligible individuals, aged 15-49 years         
Number of eligible individuals 1,090 1,301  3,549 4,224  4,639 5,525 
Interview response rate (unweighted) 87.3 92.2  85.5 93.7  86.0 93.4 
Interview response rate (weighted) 87.3 92.5  85.4 93.6  85.9 93.3 
Blood draw response rate (unweighted) 88.4 91.7  92.7 95.4  91.6 94.6 
Blood draw response rate (weighted) 88.2 92.0  92.6 95.3  91.4 94.3 
         
Eligible individuals, aged 15 years and older         
Number of eligible individuals 1,255 1,536  4,393 5,673  5,648 7,209 
Interview response rate (unweighted) 87.6 92.3  86.6 94.3  86.8 93.9 
Interview response rate (weighted) 87.6 92.5  86.4 94.2  86.7 93.7 
Blood draw response rate (unweighted) 88.2 91.3  93.0 95.9  91.9 95.0 
Blood draw response rate (weighted) 87.9 91.7  92.9 95.8  91.6 94.7 
1Interview response rate = number of individuals interviewed/number of eligible individuals 
2Blood draw response rate = number of individuals who provided blood/number of individuals interviewed 
 
2.8 References 
1. Central Statistical Office (CSO). 2007 Population and Housing Census Volume 6. Mbabane, Swaziland: 
CSO; 2007. 
 
2. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in 
dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid 
Commun Mass Spectrom. 2005;19(21):2995-3001. 
 
3. American Association for Public Opinion Research (AAPOR). Standard Definitions: Final Dispositions of 
Case Codes and Outcome Rates for Surveys. 9th edition. AAPOR; 2016.  
http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf. 
Accessed March 21, 2019. 
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Chapter 3   Survey Household Characteristics 
3.1 Key Findings 
 
3.2 Background 
This chapter describes the characteristics of households surveyed in SHIMS2. Household composition is 
described in terms of sex of the head of household, as well as the size of the household. The age 
structure of the de facto household population (i.e., persons who slept in the household the night 
before) is described by sex as well as urban/rural residence. This chapter also describes the prevalence 
and composition of households impacted by HIV, which are households with one or more HIV-positive 
members. 
 
3.3 Household Composition 
More than half (54.5%) of households in Eswatini were female-headed (48.9% in urban areas and 57.2% 
in rural areas). The median household size was four persons (interquartile range (IQR): 2-6), with a 
median of two persons (IQR: 1-4) in urban households and four persons (IQR: 2-6) in rural households. 
The median number of children under 18 years of age in the household was one (IQR: 0-3), with a 
median of zero (IQR: 0-2) in urban households and two (IQR: 0-3) in rural households (Table 3.3.A).  
 
Children under the age of 15 years comprised 36.6% (18.2% males and 18.4% females) of the de facto 
household population, those aged 15-49 years constituted 50.5% (22.9% males and 27.6% females), and 
those aged 50 years and older constituted 12.9% (4.7% males and 8.2% females; Table 3.3.B; Figure 
3.3.A). 
 
The population in rural areas was younger than in urban areas (39.4% of the rural population was aged 
0-14 years compared with 27.6% of the urban population). In urban areas, 62.2% of the population was 
aged 15-49 years versus 46.9% of the population in rural areas. Adults aged 50 years and older 
comprised a similar percentage of the population in rural areas (13.7%) and urban areas (10.2%; Table 
3.3.C; Figure 3.3.B). 
 
 
3 SURVEY HOUSEHOLD CHARACTERISTICS 
 
▪ Close to half (46.0%) of households in Eswatini had at least one HIV-positive household member. 
▪ The percentage of households with two or more HIV-positive members (among households with 
at least one HIV-positive household member) was greater in rural areas (31.8%) compared with 
urban areas (21.3%).  







Table 3.3.A Household composition 
Percent distribution of households by sex of head of household; median size of household and median (Q11, Q32) 
number of children 18 years of age, by residence, SHIMS2 2016-2017 
 Residence    
 Urban  Rural  Total 
Characteristic Percent Number  Percent Number  Percent Number 
Household headship         
Male 51.1 737  42.8 1,619  45.5 2,356 
Female 48.9 671  57.2 2,158  54.5 2,829 
         
Total 100.0 1,408  100.0 3,777  100.0 5,185 
         
 Residence   
 Urban  Rural  Total 
Characteristic Median Q1, Q3  Median Q1, Q3  Median Q1, Q3 
Size of households 2 (1, 4)  4 (2, 6)  4 (2, 6) 
Number of children below 18 years of age 0 (0, 2)  2 (0, 3)  1 (0, 3) 
1 Q1: quartile one 
2 Q3: quartile three         
                 
Table 3.3.B Population pyramid 
Distribution of the de facto household population, by five-year age groups and sex, SHIMS2 2016-2017 
 Males  Females  Total 
Age Percent Number   Percent Number   Percent Number 
0-4 6.1 1,250  6.2 1,277  12.3 2,527 
5-9 6.1 1,284  6.4 1,346  12.5 2,630 
10-14 6.0 1,257  5.8 1,224  11.8 2,481 
15-19 5.8 1,218  5.6 1,148  11.4 2,366 
20-24 4.1 839  5.1 1,025  9.2 1,864 
25-29 3.8 754  4.7 922  8.4 1,676 
30-34 3.3 650  4.3 867  7.6 1,517 
35-39 2.7 536  3.3 646  6.0 1,182 
40-44 1.8 366  2.4 479  4.3 845 
45-49 1.4 286  2.2 445  3.6 731 
50-54 1.1 234  2.0 397  3.1 631 
55-59 1.0 211  1.6 323  2.6 534 
60-64 0.9 194  1.5 316  2.4 510 
65-69 0.7 147  1.0 203  1.7 350 
70-74 0.5 94  1.0 203  1.4 297 
75-79 0.3 74  0.5 112  0.9 186 
≥80 0.2 55  0.6 130  0.8 185 
 
        
Total 45.9 9,449  54.1 11,063  100.0 20,512 
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Table 3.3.C Distribution of de facto household population by age, sex, and residence 








































          
Total 100.0 1,777 
 












































          








Figure 3.3.B Household population by age, sex, and residence, SHIMS2 2016-2017 
 
 
3.4 Prevalence of HIV-Affected Households 
In Eswatini, 46.0% of households had at least one HIV-positive member. The distribution was similar for 
urban households (45.1%) and rural households (46.5%; Table 3.4.A; Figure 3.4.A). Among these HIV-
affected households, 71.4% had one HIV-positive member, 23.1% had two HIV-positive members, and 
4.3% had three HIV-positive members. The distribution of the number of HIV-positive household 
members varied by urban and rural residence. Among households with at least one HIV-positive 
member, the percentage of households with one HIV-positive member was greater in urban areas 
(78.7%) than in rural areas (68.2%). In contrast, the percentage of households with at least two HIV-
positive members was larger in rural areas (25.5% with two HIV-positive members and 6.3% with three 
or more HIV-positive members) than in urban areas (17.8% with two HIV-positive members and 3.5% 
with three or more HIV-positive members; Table 3.4.B; Figure 3.4.B).  
 
About one in three (35.3%) households in the country had an HIV-positive head of household. A greater 
percentage of female-headed households than of male-headed households have the head of the 
household living with HIV (37.8% of female household heads were HIV-positive versus 31.9% of male 
household heads; Table 3.4.C).  
 
Table 3.4.A Prevalence of HIV-affected households 
Percentage of households with at least one household member who tested HIV-positive, by residence,  
SHIMS2 2016-2017 
Residence Percent Number 
Urban 45.1 1,283 
Rural 46.5 3,640 
   
Total 46.0 4,923 
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Figure 3.4.A Prevalence of HIV-affected households by residence, SHIMS2 2016-2017 
 
 
Table 3.4.B HIV-affected households by number of HIV-positive members  
Among households with at least one HIV-positive household member, percent distribution of households by 
number of HIV-positive household members, by residence, SHIMS2 2016-2017  
Residence 







Number of HIV-positive 
household members 












































Figure 3.4.B HIV-affected households by number of HIV-positive members and residence,  
SHIMS2 2016-2017 
 





Table 3.4.C Prevalence of households with an HIV-positive head of household 
Percentage of households with an HIV-positive head of household, by sex of head of household, 
SHIMS2 2016-2017 
Sex of head of household Percent Number 
Male 31.9 1,925 
Female 37.8 2,593    











Chapter 4   Survey Respondent Characteristics 
4.1 Key Findings 
 
4.2 Background 
SHIMS2 assessed key indicators and outcomes for children, adolescents, and adults. To provide context 
for these outcomes, this chapter summarizes the basic demographic and socioeconomic characteristics of 
survey respondents. In this report, most key indicators are stratified according to these characteristics. 
 
4.3 Demographic Characteristics of the Adult Population 
In Eswatini, almost three-quarters (73.0%) of adults (defined in this survey as those aged 15 years and 
older, unless otherwise noted) lived in rural areas. About half (51.8%) of adults had never married. 
Never being married was more common among males (58.3%) than females (46.4%). In contrast, 
females were more likely to be widowed (9.9% of females versus 1.7% of males). A third of the 
population (34.8%) lived in Manzini, compared to roughly half of that in Lubombo (18.7%) and 
Shiselweni (16.7%). Only 2.9% of the adult population was in a polygynous union. Nearly equal 
proportions of the population had attended primary (27.5%), secondary (28.5%), and high school 
(28.1%) levels of education, while only 5.5% of the population had no education. Wealth quintile was 
similarly distributed across the male, female, and total adult population (Table 4.3.A). 
 
  
4 SURVEY RESPONDENT CHARACTERISTICS 4 SURVEY RESPONDE T CHARACTERISTICS 
 
 
▪ Nearly a tenth (9.9%) of females were widowed compared with only 1.7% of males.  
▪ More than a tenth (12.3%) of children aged 0-14 years lived in households from the highest 
wealth quintile, but nearly double that percentage (26.2%) lived in households from the lowest 
wealth quintile. 
▪ Nearly all (99.4%) young adolescents aged 10-14 years currently attended school. 
▪  
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Table 4.3.A Demographic characteristics of the adult population 
Percent distribution of the population aged 15 years and older by sex and other selected demographic characteristics, 
SHIMS2 2016-2017 
 Males 
 Females  Total 
Characteristic Percent Number  Percent Number  Percent Number 
Residence         
Urban 26.9 1,100  27.1 1,418  27.0 2,518 
Rural 73.1 3,804  72.9 5,351  73.0 9,155 
Region         
Hhohho 30.7 1,536  29.0 1,998  29.8 3,534 
Lubombo 19.5 1,017  18.1 1,314  18.7 2,331 
Manzini 33.7 1,497  35.6 2,161  34.8 3,658 
Shiselweni 16.1 854  17.3 1,296  16.7 2,150 
Marital status         
Never married 58.3 2,772  46.4 2,925  51.8 5,697 
Married 31.3 1,596  34.3 2,334  32.9 3,930 
Living together 5.1 228  4.9 301  5.0 529 
Divorced/separated 3.6 181  4.5 290  4.1 471 
Widowed 1.7 99  9.9 885  6.1 984 




    
In polygynous union 1.9 110  3.8 293  2.9 403 
Not in polygynous union 33.3 1,672  32.6 2,176  32.9 3,848 
Not currently in union 63.3 3,052  60.5 4,100  61.7 7,152 





    
No education 4.8 276  6.0 539  5.5 815 
Primary 28.7 1,496  26.4 1,985  27.5 3,481 
Secondary 25.9 1,294  30.7 2,005  28.5 3,299 
High school 29.9 1,373  26.7 1,625  28.1 2,998 
Tertiary 10.7 458  10.2 600  10.4 1,058 
Wealth quintile         
Lowest 20.7 1,093  21.0 1,590  20.9 2,683 
Second 20.3 1,042  20.2 1,433  20.2 2,475 
Middle 23.2 1,153  22.7 1,598  23.0 2,751 
Fourth  17.3 797  17.6 1,070  17.4 1,867 





    
15-19 19.0 1,074  16.2 1,064  17.5 2,138 
20-24 17.8 709  15.8 950  16.7 1,659 
25-29 15.1 642  14.2 861  14.6 1,503 
30-34 11.7 541  12.4 811  12.1 1,352 
35-39 8.9 453  10.5 602  9.8 1,055 
40-44 6.5 323  8.1 450  7.4 773 
45-49 5.2 246  6.4 420  5.9 666 
50-54 4.1 214  4.8 379  4.5 593 
55-59 3.3 188  3.7 309  3.5 497 
60-64 2.8 176  2.6 304  2.7 480 
65+ 5.4 338  5.2 619  5.3 957 
         
Total 15-24 36.9 1,783  31.9 2,014  34.2 3,797 
Total 15-49 84.3 3,988  83.6 5,158  83.9 9,146 
Total 15+ 100.0 4,904  100.0 6,769  100.0 11,673 
Note: Education categories refer to the highest level of education attended, whether or not that level was completed. 






4.4 Demographic Characteristics of the Pediatric Population 
Among children (defined in this survey as those aged 0-14 years, unless otherwise noted), 9.8% were 
under the age of 18 months. More than a third (36.5%) were 0-4 years of age. The majority (81.8%) of 
children lived in rural areas. Nearly a third (31.9%) lived in Manzini, while close to a fifth (19.3%) lived in 
Shiselweni. Lower wealth is more common among children: A quarter (26.2%) lived in households from 
the lowest wealth quintile, while less than half that percentage (12.3%) lived in households from the 
highest wealth quintile (Table 4.4.A). Differences in distribution between males and females were 
minimal across age, residence, region, and wealth quintile. Among adolescents aged 10-14 years, nearly 
all (99.4%) currently attended school. Over three-quarters (77.4%) currently attended higher primary 
school (73.6% of males and 81.2% of females). About a tenth (11.1%) currently attended lower primary 
school. Current lower primary school attendance was more frequent among males (16.1%) compared to 
females (6.0%; Table 4.4.B).   
 
Table 4.4.A Demographic characteristics of the pediatric population 
Percent distribution of population aged 0-14 years by sex and selected demographic characteristics,  
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Table 4.4.B Demographic characteristics of the adolescent population 
Percent distribution of the population aged 10-14 years, by sex and selected demographic characteristics,  
SHIMS2 2016-2017 
 Males  Females  Total 
Characteristic Percent Number  Percent Number  Percent Number 
Residence         
Urban 15.6 65  16.1 68  15.8 133 
Rural 84.4 521  83.9 525  84.2 1,046 
         
Region         
Hhohho 29.7 173  27.0 161  28.4 334 
Lubombo 23.8 147  18.5 114  21.2 261 
Manzini 30.7 166  31.9 174  31.3 340 
Shiselweni 15.8 100  22.6 144  19.2 244 
    
 
    
Education    
 
    
Currently in lower primary 16.1 94  (6.0) 35  11.1 129 
Currently in higher primary 73.6 412  81.2 470  77.4 882 
Currently in secondary (9.2) 48  12.6 70  10.9 118 
Not currently attending school * 6  * 1  * 7 
         
Total 10-14 100.0 586  100.0 593  100.0 1,179 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 




Chapter 5   HIV Incidence 
5.1 Key Findings 
 
5.2 Background 
HIV incidence is the measure of new HIV infections in a population during a specified time period. It can 
provide important information on the status of the HIV epidemic and can be used for effective, targeted 
HIV prevention planning for groups that are most vulnerable to recent infection and for measuring the 
impact of HIV prevention programs. This chapter presents annual estimates of HIV incidence among 
adults (defined in this survey as those aged 15 years and older, unless otherwise noted) at the national 
level. Two sets of estimates are presented, each determined through a unique laboratory-based testing 
algorithm that distinguishes recent from long-term infections (Appendix B). SHIMS2 was not powered to 
estimate incidence at the regional level or across different sub-groups. 
 
Incidence estimation was based on first identifying potential recent infections among all HIV-positive 
samples in the survey using the LAg avidity assay.1,2 The first testing algorithm (i.e., HIV-1 LAg avidity 
plus VL) uses VL testing to exclude specimens with low VL and limit misclassification of persons as recent 
infections who are elite controllers or on effective ART. The second algorithm (i.e., HIV-1 LAg avidity plus 
VL and ARV detection) uses ARV detection to exclude specimens with high VL and limit misclassification 
of persons as recent infections who are on ART but have drug resistance or poor treatment adherence. 
 
5.3 HIV Incidence Among Adults 
 
HIV incidence estimates using LAg avidity and HIV viral load 
Using the LAg avidity assay and VL testing algorithm, estimated incidence was 1.36% (95% CI: 0.92%-
1.80%) among adults (1.02% among males and 1.70% among females). This corresponds to 
approximately 7,300 new cases of HIV infection annually among adults. Annual incidence peaked among 
males aged 25-34 years (1.50%), and females aged 35-49 years (2.40%). HIV incidence for adults aged 
15-49 years was estimated at 1.48% (95% CI: 0.93%-2.03%; 0.99% in males, 1.99% in females). Estimates 
are not statistically significantly different; SHIMS2 was not designed to compare incidence estimates 
across demographic sub-groups (Table 5.3.A). 
▪ Using the limiting antigen (LAg) avidity assay and viral load testing algorithm, annual HIV 
incidence among adults aged 15 years and older was 1.36% (1.02% males, 1.70% females). This 
corresponds to approximately 7,300 new cases of HIV infection annually among adults aged 15 
years and older.    
▪ Using an antiretroviral (ARV)-adjusted LAg avidity testing algorithm, annual HIV incidence among 
adults aged 15 years and older was 1.13% (0.85% males, 1.41% females). This corresponds to 
approximately 6,000 new cases of HIV infection annually among adults aged 15 years and older. 
▪ Using an ARV-adjusted LAg avidity testing algorithm, annual HIV incidence among males was 
highest in those aged 25-34 years (1.50%) and among females was highest in those aged 35-49 
years (2.09%). 




HIV incidence estimates using LAg avidity, HIV viral load, and ARV detection 
Using the ARV-adjusted LAg avidity testing algorithm, estimated incidence was 1.13% (95% CI: 0.73%-
1.53%) among adults (0.85% in males and 1.41% in females). This corresponds to approximately 6,000 
new cases of HIV infection annually among adults. Annual incidence peaked among males aged 25-34 
years (1.50%), and among females aged 35-49 years (2.09%). HIV incidence for adults aged 15-49 years 
was estimated at 1.28% (95% CI: 0.77%-1.79%; 0.85% among males and 1.73% among females). 
Estimates are not statistically significantly different; SHIMS2 was not designed to compare incidence 
estimates across demographic sub-groups (Table 5.3.B). 
 
Table 5.3.A Annual HIV incidence using limiting antigen/viral load testing algorithm  
Annual incidence of HIV among persons aged 15-49 and 15 years and older using the limiting antigen/viral load 
testing algorithm, by sex and age, SHIMS2 2016-2017 


















15-24 0.79 (0.07, 1.50) 
 
1.87 (0.76, 2.98) 
 
1.31 (0.66, 1.96) 
25-34 1.50 (0.00, 3.06) 
 
1.84 (0.17, 3.48) 
 
1.65 (0.49, 2.80) 
35-49 0.68 (0.00, 1.85) 
 
2.40 (0.45, 4.33) 
 
1.65 (0.44, 2.85) 
15-49 0.99 (0.32, 1.66) 
 
1.99 (1.09, 2.88) 
 
1.48 (0.93, 2.03) 
15+ 1.02 (0.47, 1.57) 
 
1.70 (0.96, 2.44) 
 
1.36 (0.92, 1.80) 
1 Relates to Global AIDS Monitoring indicator 3.1: HIV incidence 
2 CI (confidence interval) indicates the interval that is expected to include the true population parameter 95% of the time  
 
Table 5.3.B Annual HIV incidence using limiting antigen/viral load/antiretroviral testing 
algorithm 
Annual incidence of HIV among persons aged 15-49 and 15 years and older, by sex and age, using LAg/VL/ARV 




















15-24 0.52 (0.00, 1.14) 
 
1.67 (0.62, 2.71) 
 
1.07 (0.46, 1.69) 
25-34 1.50 (0.00, 3.06) 
 
1.54 (0.00, 3.09) 
 
1.52 (0.39, 2.64) 
35-49 0.68 (0.00, 1.85) 
 
2.09 (0.23, 3.92) 
 
1.47 (0.31, 2.63) 
15-49 0.85 (0.21, 1.49) 
 
1.73 (0.96, 2.50) 
 
1.28 (0.77, 1.79) 
15+ 0.85 (0.34, 1.35) 
 
1.41 (0.78, 2.04) 
 
1.13 (0.73, 1.53) 
1 Relates to Global AIDS Monitoring indicator 3.1: HIV incidence 




5.4 Gaps and Unmet Needs 
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▪ New HIV infections continue at high rates among males aged 25-34 years and females aged 35-49 
years. 
▪ Prevention interventions that target both gender groups could more effectively control the 
epidemic. 
▪ Incidence estimates of geographic micro-epidemics and population sub-groups, such as among 
key populations, would be useful to more precisely target intervention efforts. 
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Chapter 6   HIV Prevalence 
6.1 Key Findings 
 
6.2 Background 
This chapter presents representative estimates of prevalence of HIV infection among adults (defined in 
this survey as those aged 15 years and older, unless otherwise noted) at the national and regional levels 
by selected demographic and behavioral characteristics. It also presents HIV prevalence estimates 
among children (defined in this survey as those aged 0-14 years, unless otherwise noted) at the national 
level and estimates of the number of people living with HIV in Eswatini. HIV prevalence testing was 
conducted in each household using a serological rapid diagnostic testing algorithm based on Eswatini’s 
national guidelines. Appendix A describes the sample design and Appendix C provides estimates of 
sampling errors. Appendix B describes the HIV testing methodology. 
 
6.3 Adult HIV Prevalence by Select Demographic Characteristics 
National HIV prevalence among adults was 27.0%. This corresponds to approximately 197,000 adults 
who are living with HIV. HIV prevalence was higher among females (32.5%) than males (20.4%). Nearly 
half (47.7%) of divorced/separated adults were living with HIV, compared with less than a fifth (18.4%) 
of those never married. About a third (34.1%) of adults in polygynous union were living with HIV. HIV 
prevalence among adults was higher among those with no education (31.6%) and those who completed 
only primary level education (32.5%), which was double the HIV prevalence among those with tertiary 
level education (16.0%; Table 6.3.A; Figure 6.3.A). 
 
Among adults aged 15-49 years, HIV prevalence was 27.2% (18.9% in males and 34.3% in females). 
Almost three-quarters (74.6%) of widowed females aged 15-49 years were living with HIV. This group 
accounted for the majority of HIV prevalence among all widowed adults aged 15-49 years (73.1%). HIV 
prevalence was highest among those in polygynous union (43.7%). Over two-fifths (42.9%) of adults 
aged 15-49 years with no education were living with HIV. HIV prevalence was comparable between 
women aged 15-49 years who reported being currently pregnant (35.4%) versus those who reported not 
being currently pregnant (34.3%; Table 6.3.B).   
  
6 HIV PREVALENCE  
 
▪ HIV prevalence in adults aged 15 years and older was 27.0% (20.4% males, 32.5% females). This 
corresponds to approximately 197,000 adults aged 15 years and older living with HIV. 
▪ HIV prevalence peaked in males aged 45-49 years (48.8%) and in females aged 35-39 years 
(54.2%).  
▪ More than half of females aged 30-44 years were living with HIV: ages 30-34 years (50.7%), ages 
35-39 years (54.2%), and ages 40-44 years (51.9%).  
▪ Three-quarters (74.6%) of widowed females aged 15-49 years were living with HIV.  
▪ HIV prevalence was 10.9% among adults aged 65 years and older.  
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Table 6.3.A HIV prevalence by demographic characteristics: Ages 15 years and older  
Prevalence of HIV among persons aged 15 years and older, by sex and selected demographic characteristics,  
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Table 6.3.B HIV prevalence by demographic characteristics: Ages 15-49 years 
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Type of union 
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23.0 1,368          
Pregnancy status 
        









NA NA          





The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 




6.4 Adult HIV Prevalence by Age and Sex 
HIV prevalence among adults aged 15-24 years was 9.1% and was over three times as prevalent in 
females (13.9%) than in males (4.1%). Over one in three (36.3%) adults aged 25 years and older was 
living with HIV. HIV prevalence among adults aged 25 years and older was 41.2% in females and 29.9% in 
males (Table 6.4.A). 
 
Among adults, HIV prevalence peaked at 49.1% in those aged 35-39 years. HIV prevalence was highest in 
females aged 35-39 years (54.2%) and in males aged 45-49 years (48.8%). In fact, more than half of 
females aged 30-34 years (50.7%), 35-39 years (54.2%), and 40-44 years (51.9%) were living with HIV. 
HIV prevalence, when estimated across five-year age groups from ages 20-39 years, was significantly 
higher in females than in males (ages 20-24 years: 20.9% vs 4.2%; ages 25-29 years: 37.5% vs 13.3%; 
ages 30-34 years: 50.7% vs 28.1%; ages 35-39 years: 54.2% vs 41.9%; Figure 6.4.A). 
 
A tenth (10.9%) of adults aged 65 years and older were living with HIV. HIV prevalence was double the 
percentage in males (14.9%) than in females (7.4%) in this age bracket. 
 
Table 6.4.A HIV prevalence by age and sex 
Prevalence of HIV among persons in Eswatini, by sex and age, SHIMS2 2016-2017 











0-17 months 4.3 142  4.0 124  4.2 266 
18-59 months 0.5 377  1.0 388  0.8 765 
5-9 3.1 587  2.7 600  2.9 1,187 
10-14 4.7 576  3.4 578  4.1 1,154 
         
Total 0-4 1.6 519  1.8 512  1.7 1,031 
Total 0-14 3.0 1,682  2.6 1,690  2.8 3,372 
         
15-19 3.9 1,028  7.2 1,031  5.6 2,059 
20-24 4.2 647  20.9 895  12.8 1,542 
25-29 13.3 572  37.5 811  26.1 1,383 
30-34 28.1 474  50.7 744  40.8 1,218 
35-39 41.9 410  54.2 568  49.1 978 
40-44 43.3 292  51.9 430  48.4 722 
45-49 48.8 232  42.3 399  44.9 631 
50-54 41.9 192  36.1 360  38.5 552 
55-59 31.8 176  29.5 298  30.5 474 
60-64 31.9 163  22.3 294  26.8 457 
65+ 14.9 320  7.4 598  10.9 918 
         
15-29  6.7 2,247  21.2 2,737  14.2 4,984 
20-39 18.3 2,103  39.0 3,018  29.5 5,121 
25+ 29.9 2,831  41.2 4,502  36.3 7,333 
         
Total 15-24 4.1 1,675  13.9 1,926  9.1 3,601 
Total 15-49 18.9 3,655  34.3 4,878  27.2 8,533 
Total 15+ 20.4 4,506  32.5 6,428  27.0 10,934 
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6.5 Adult HIV Prevalence by Region 
In Eswatini, HIV prevalence among adults did not vary substantially across regions. HIV prevalence was 




Figure 6.5.A HIV prevalence (map) among adults aged 15 years and older, by region,  
SHIMS2 2016-2017  
  
 56 
Figure 6.5.B HIV prevalence (bar graph) among adults aged 15 years and older, by region,  
SHIMS2 2016-2017  
 






▪ Targeting high prevalence populations for testing, treatment, and care will help the country 
reach the 90-90-90 goals. 
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Chapter 7   HIV Testing 
7.1 Key Findings 
 
7.2 Background 
HIV testing is necessary for awareness of HIV status and a critical component of HIV epidemic control 
targets. Awareness of HIV-positive status is the first step for engagement with HIV care and treatment 
services, accessing ART, prevention counseling for HIV-positive and HIV-negative individuals to reduce 
risk of HIV transmission or acquisition, and access to screening services for other co-morbidities. 
 
Data presented in this section pertain to adults (defined in this survey as those aged 15 years and older, 
unless otherwise noted), who reported ever testing for HIV and receiving the test results. Results on HIV 
testing in the 12 months before the survey and receipt of the test results are also presented to 
understand frequent or recent testing. 
 
7.3 Self-Reported HIV Testing Among Adults 
Among adults, 87.1% had ever tested for HIV and received their test results (i.e., lifetime testing). Half 
(51.6%) had received HIV testing and their test results in the 12 months prior to the survey. Lifetime 
testing and testing in the prior 12 months were higher in those with tertiary education (91.0% and 
56.8%, respectively) and lower in those not currently in a union (82.5% and 49.7%, respectively). HIV 
testing uptake was generally comparable across residence, region, and wealth quintile (Table 7.3.C).  
 
Among adults aged 15-24 years, about three-quarters (75.4%) had ever tested for HIV and received their 
test results. Lifetime testing was lower in ages 15-19 years (65.2%) than in ages 20-24 years (86.1%). In 
contrast, the majority (93.2%) of those aged 25 years and older had ever tested for HIV. Among adults 
aged 15-24 years, about half (51.6%) had received HIV testing and their test results in the 12 months 
prior to the survey. Among adults, testing in the prior 12 months was lowest in ages 15-19 years (40.6%) 
and highest in ages 20-24 years (63.1%) and 25-29 years (63.1%; Table 7.3.C).  
 
Lifetime testing and testing in the prior 12 months were higher among females (91.4% and 55.3%, 
respectively) than males (81.9% and 47.2%, respectively). Among females, lifetime testing was lower in 
ages 15-19 years (68.3%) and ages 65 years and older (81.9%). Lifetime testing was 90% or higher in ages 
7 HIV TESTING  
  
▪ A large majority (87.1%) of adults aged 15 years and older had ever tested for HIV and received 
their test results (81.9% males, 91.4% females).  
▪ Lifetime testing among males was lower in ages 15-19 years (61.9%) and ages 20-24 years 
(77.7%) and peaked in ages 45-49 years at 91.0%. Among females, lifetime testing was 90% or 
higher in ages 20-64 years and peaked at 99.4% in ages 30-34 years.  
▪ One in two (51.6%) adults aged 15 years and older had tested for HIV and received their test 
result in the prior 12 months. 
▪ Testing in the prior 12 months among adults aged 15 years and older was lowest in ages 15-19 
years (40.6%), and highest in ages 20-24 years (63.1%) and 25-29 years (63.1%). 
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20-64 years and peaked at 99.4% in ages 30-34 years. Among males, lifetime testing was lower in ages 
15-19 years (61.9%) and ages 20-24 years (77.7%) and peaked in ages 45-49 years at 91.0%. Testing in 
the prior 12 months was significantly higher in ages 15-19 years in females (47.9%) than males (33.0%) 
and significantly higher in ages 20-24 years in females (74.2%) than males (51.1%; Tables 7.3.A and 
7.3.B, Figure 7.3.A). 
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Table 7.3.A Self-reported HIV testing: Males  
Percentage of men, defined as the male population aged 15 years and older, who ever received HIV testing and received their test results, 
and percentage who received HIV testing and received their test results in the past 12 months, by result of PHIA survey HIV test and selected 
demographic characteristics, SHIMS2 2016-2017 
Characteristic Percentage who ever received HIV 
testing and received results1 
Percentage who received HIV testing in the 
past 12 months and received results1 
Number 
Result of PHIA survey HIV test 
   
HIV positive 92.6 32.5 966 
HIV negative 79.9 51.0 3,494 
Not tested 74.9 48.1 392     
Residence 
   
Urban 82.9 48.9 1,085 
Rural 81.6 46.6 3,767     
Region 
   
Hhohho 80.5 45.0 1,522 
Lubombo 84.6 49.3 1,009 
Manzini 82.1 48.6 1,472 
Shiselweni 81.1 45.6 849     
Marital status 
   
Never married 76.1 46.7 2,741 
Married 90.9 49.5 1,581 
Living together 87.2 47.8 227 
Divorced/separated 90.1 39.1 178 
Widowed 84.5 37.6 98     
Type of union 
   
In polygynous union 93.2 51.6 109 
Not in polygynous union 90.2 48.5 1,659 
Not currently in union 77.1 46.0 3,017 
Don't know/missing 86.0 61.7 67     
Education 
   
No education 85.5 46.1 274 
Primary 81.6 44.9 1,479 
Secondary 78.4 44.3 1,279 
High school 82.7 49.0 1,359 
Tertiary 87.2 56.0 454     
Wealth quintile 
   
Lowest 80.8 47.1 1,085 
Second 83.1 46.4 1,029 
Middle 82.8 48.4 1,145 
Fourth  79.5 46.9 789 
Highest 83.0 46.8 803     
Age 
   
15-19 61.9 33.0 1,059 
20-24 77.7 51.1 698 
25-29 88.1 60.9 635 
30-34 90.8 53.7 539 
35-39 89.3 47.4 451 
40-44 90.6 44.9 321 
45-49 91.0 43.5 245 
50-54 87.0 38.9 213 
55-59 88.3 40.9 184 
60-64 89.1 43.5 174 
65+ 85.9 49.2 333 
15-29 75.0 47.3 2,392 
20-39 85.5 53.8 2,323 
25+ 89.1 50.3 3,095     
Total 15-24 69.5 41.8 1,757 
Total 15-49 80.9 47.8 3,948 
Total 15+ 81.9 47.2 4,852 
1Relates to PEPFAR indicator DIAGNOSED_NAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 7.3.B Self-reported HIV testing: Females  
Percentage of women, defined as the female population aged 15 years and older, who ever received HIV testing and received their test 
results, and percentage who received HIV testing and received their test results in the past 12 months, by result of survey HIV test and 
selected demographic characteristics, SHIMS2 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results1 
Percentage who received HIV testing in the 
past 12 months and received results1 
Number 
Result of PHIA survey HIV test    
HIV positive 99.0 31.5 2,027 
HIV negative 87.7 67.0 4,366 
Not tested 90.8 56.1 325 
    
Residence    
Urban 90.8 55.0 1,400 
Rural 91.7 55.4 5,318 
    
Region    
Hhohho 90.4 53.9 1,980 
Lubombo 92.5 56.5 1,308 
Manzini 91.8 55.4 2,147 
Shiselweni 91.2 56.2 1,283 
    
Marital status    
Never married 85.6 55.5 2,898 
Married 97.9 58.8 2,322 
Living together 99.3 61.4 301 
Divorced/separated 95.7 52.5 289 
Widowed 90.5 41.4 875 
    
Type of union    
In polygynous union 97.3 61.0 291 
Not in polygynous union 98.2 58.6 2,167 
Not currently in union 87.2 53.0 4,062 
Don't know/missing 96.4 58.8 198 
    
Education    
No education 90.7 50.9 535 
Primary 92.3 49.7 1,976 
Secondary 90.1 55.2 1,990 
High school 91.1 61.1 1,613 
Tertiary 94.4 57.4 592 
    
Wealth quintile    
Lowest 92.3 55.3 1,578 
Second 93.0 57.9 1,428 
Middle 91.6 57.8 1,585 
Fourth  91.8 54.3 1,066 
Highest 88.2 50.2 1,059 
    
Age    
15-19 68.3 47.9 1,050 
20-24 93.9 74.2 949 
25-29 98.1 65.0 860 
30-34 99.4 55.2 804 
35-39 98.8 48.6 599 
40-44 99.2 45.5 446 
45-49 96.6 52.6 419 
50-54 93.3 47.0 375 
55-59 94.0 50.0 306 
60-64 90.3 45.1 301 
65+ 81.9 42.2 609 
15-29 86.3 62.2 2,859 
20-39 97.3 62.2 3,212 
25+ 96.3 52.6 4,719 
    
Total 15-24 81.0 61.0 1,999 
Total 15-49 91.9 57.1 5,127 
Total 15+ 91.4 55.3 6,718 
1Relates to PEPFAR indicator DIAGNOSED_NAT. 




Table 7.3.C Self-reported HIV testing: Total  
Percentage of adults, those aged 15 years and older, who ever received HIV testing and received their test results, and percentage who 
received HIV testing and received their test results in the past 12 months, by result of PHIA survey HIV test and selected demographic 
characteristics, SHIMS2 2016-2017 
Characteristic Percentage who ever received HIV 
testing and received their results1 
Percentage who received HIV testing in the past 
12 months and received their results1 
Number 
Result of PHIA survey HIV test 
   
HIV positive 96.8 31.9 2,993 
HIV negative 83.9 59.2 7,860 
Not tested 81.6 51.5 717 
Residence 
   
Urban 87.2 52.2 2,485 
Rural 87.1 51.3 9,085 
Region 
   
Hhohho 85.7 49.7 3,502 
Lubombo 88.7 53.1 2,317 
Manzini 87.5 52.4 3,619 
Shiselweni 86.8 51.6 2,132 
Marital status 
   
Never married 80.7 51.0 5,639 
Married 94.9 54.7 3,903 
Living together 93.7 55.1 528 
Divorced/separated 93.5 47.1 467 
Widowed 89.8 40.9 973 
Type of union 
   
In polygynous union 96.1 58.2 400 
Not in polygynous union 94.5 53.9 3,826 
Not currently in union 82.5 49.7 7,079 
Don't know/missing 93.5 59.6 265 
Education 
   
No education 88.6 49.0 809 
Primary 87.2 47.4 3,455 
Secondary 85.3 50.7 3,269 
High school 87.0 55.3 2,972 
Tertiary 91.0 56.8 1,046 
Wealth quintile 
   
Lowest 87.1 51.6 2,663 
Second 88.5 52.6 2,457 
Middle 87.5 53.5 2,730 
Fourth  86.2 50.9 1,855 
Highest 85.8 48.7 1,862 
Age 
   
15-19 65.2 40.6 2,109 
20-24 86.1 63.1 1,647 
25-29 93.4 63.1 1,495 
30-34 95.6 54.5 1,343 
35-39 94.9 48.1 1,050 
40-44 95.7 45.3 767 
45-49 94.4 48.9 664 
50-54 90.6 43.6 588 
55-59 91.6 46.1 490 
60-64 89.7 44.4 475 
65+ 83.7 45.5 942     
15-29 80.8 55.0 5,251 
20-39 91.9 58.4 5,535 
25+ 93.2 51.6 7,814     
    
Total 15-24 75.4 51.6 3,756 
Total 15-49 86.9 52.9 9,075 
Total 15+ 87.1 51.6 11,570 
1Relates to PEPFAR indicator DIAGNOSED_NAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable 
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Figure 7.3.A Proportion of adults aged 15 years and older who reported having received an HIV test 
in the last 12 months, by age and sex, SHIMS2 2016-2017 
 




▪ Lifetime and testing in the prior 12 months were lower among men than women in ages 15 years 
and older. Continued efforts to increase HIV testing uptake among men is needed to remove this 
gender gap.  
▪ HIV testing uptake was lower in ages 15-24 years compared to ages 25 years and older. Among 
adults, HIV testing uptake was lowest in male and female adults aged 15-19 years. Strategies to 
increase testing among young people, aged 15-24 years, is needed with specialized targeting of 
ages 15-19 years. 
▪ Testing in the prior 12 months among ages 15-24 years was significantly higher among women 
than men. Greater focus toward HIV testing among men aged 15-24 years is warranted.  
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Chapter 8   HIV Diagnosis and Treatment  
8.1 Key Findings 
 
8.2 Background 
Recent studies have proven that treating people living with HIV at higher CD4 counts improves immune 
recovery; decreases the incidence of non-AIDS events, comorbidities, and mortality; and reduces sexual 
and vertical transmission. In 2016, after extensive review of evidence of both the clinical and 
population-level benefits of expanding ART, the WHO changed their recommendation to support a 
policy of “Treat All,” regardless of CD4 count.1,2 By November 2017, almost all countries in sub-Saharan 
Africa had adopted this policy, despite the challenges in ensuring uptake and implementation.2 This 
policy was adopted in Eswatini in October 2016. 
 
8.3 Self-Reported Diagnosis and Treatment Status Among HIV-Positive Adults 
Among HIV-positive adults (defined in this survey as those aged 15 years and older, unless otherwise 
noted), 15.3% reported they were unaware of their HIV-positive status. The percentage of HIV-positive 
males reported as unaware of their HIV-positive status was nearly double the percentage of HIV-positive 
females (22.5% in males versus 11.4% in females). Overall, unawareness of one’s HIV-positive status was 
higher in urban areas (20.5%) than in rural areas (13.1%). Being unaware of one’s HIV-positive status 
was highest in those never married (23.0%) and not currently in union (18.4%). Being unaware of one’s 
HIV-positive status was lowest in Shiselweni region (8.7%), among those widowed (4.1%), and among 
those with no education (9.5%; Tables 8.3.A, 8.3.B, and 8.3.C).  
 
Among adults living with HIV aged 15-24 years, 33.9% were unaware of their HIV-positive status. Across 
all adults, being unaware of one’s HIV-positive status was highest in ages 15-19 years (35.6%) and next 
highest in ages 20-24 years (33.1%). About half (48.5%) of HIV-positive males aged 15-24 years were 
unaware of their HIV-positive status compared with less than one-third (29.8%) of HIV-positive females 
aged 15-24 years (Tables 8.3.A, 8.3.B, and 8.3.C). 
 
Among adults living with HIV, nearly three-quarters (74.1%) reported awareness of their HIV-positive 
status and ART use: 68.7% in males and 77.0% in females. Overall, reported awareness of one’s HIV-
positive status and ART use was higher in rural areas (76.7%) than in urban areas (67.9%). Awareness of 
one’s HIV-positive status and ART use was highest in Shiselweni region (82.7%), among those widowed 
8 HIV DIAGNOSIS AND TREATMENT  
  
▪ A majority (84.7%) of HIV-positive adults aged 15 years and older reported being aware of their 
HIV-positive status (77.5% males, 88.6% females).  
▪ About three-quarters (74.1%) of adults living with HIV aged 15 years and older reported 
awareness of their HIV-positive status and currently being on antiretroviral therapy (ART) (68.7% 
males, 77.0% females). 
▪ A large majority (95.9%) of HIV-positive adults aged 15 years and older who reported current ART 
use had detectable ARVs in their blood. Among those who reported as not previously diagnosed, 
14.8% had detectable ARVs in their blood; 8.3% of adults who reported as previously diagnosed 
and not on ART had detectable ARVs in their blood. 
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(86.7%), and among those with no education (85.9%). The percentage of HIV-positive adults reported on 
ART, generally decreased with the increase of education level and wealth quintile (Tables 8.3.A, 8.3.B, 
and 8.3.C).  
 
Among people living with HIV aged 15-24 years, about half (54.1%) reported awareness of their HIV-
positive status and ART use: 46.8% in males and 56.1% in females. Among all adults living with HIV, 
awareness of one’s HIV-positive status and ART use was lowest in ages 20-24 years (53.6%) and in ages 
15-19 years (55.0%). Reported awareness of HIV-positive status and ART use was 80% or greater in 




Figure 8.3.A Proportion of HIV-positive adults aged 15 years and older, reporting awareness of HIV 
status and antiretroviral therapy (ART) status, by age and sex, SHIMS2 2016-2017 
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Table 8.3.A Self-reported HIV diagnosis and treatment status: Males  
Percent distribution of HIV-positive men, those aged 15 years and older, by self-reported antiretroviral therapy (ART) status, by selected 
demographic characteristics, SHIMS2 2016-2017   
Aware of HIV status 
  
Characteristic Unaware of HIV status Not on ART On ART1 Total Number 
Residence 
     
Urban 29.8 10.1 60.1 100.0 256 
Rural 19.4 8.2 72.4 100.0 712 
Region 
     
Hhohho 24.3 6.8 68.9 100.0 294 
Lubombo 17.4 15.1 67.5 100.0 239 
Manzini 28.5 6.3 65.3 100.0 291 
Shiselweni 12.1 8.8 79.1 100.0 144 
Marital status 
     
Never married 36.4 9.0 54.6 100.0 281 
Married 14.8 8.1 77.0 100.0 506 
Living together 30.5 10.8 58.7 100.0 69 
Divorced/separated 16.9 8.2 74.9 100.0 77 
Widowed (10.2) (14.3) (75.5) 100.0 33 
Type of union 
     
In polygynous union (16.9) (14.0) (69.1) 100.0 42 
Not in polygynous union 16.5 8.1 75.4 100.0 520 
Not currently in union 30.7 9.3 60.1 100.0 391 
Don't know/missing * * * * 15 
Education 
     
No education 16.2 3.5 80.2 100.0 73 
Primary 20.3 6.7 73.0 100.0 377 
Secondary 25.3 11.7 63.0 100.0 247 
High school 27.3 9.4 63.4 100.0 220 
Tertiary (13.5) (13.2) (73.3) 100.0 46 
Wealth quintile 
     
Lowest 18.9 5.5 75.6 100.0 235 
Second 25.9 7.1 67.1 100.0 213 
Middle 22.9 9.0 68.0 100.0 203 
Fourth  23.9 9.7 66.4 100.0 169 
Highest 21.2 14.1 64.6 100.0 147 
Age 
     
15-19 (35.0) (5.5) (59.5) 100.0 39 
20-24 (61.5) (3.9) (34.6) 100.0 29 
25-29 48.9 11.2 39.8 100.0 81 
30-34 25.4 12.8 61.8 100.0 139 
35-39 19.8 11.7 68.4 100.0 183 
40-44 18.8 6.1 75.0 100.0 133 
45-49 10.2 11.8 77.9 100.0 122 
50-54 12.8 7.2 80.0 100.0 84 
55-59 11.6 2.4 86.0 100.0 57 
60-64 7.7 0.0 92.3 100.0 53 
65+ (13.2) (1.5) (85.3) 100.0 48 
15-29 48.7 8.5 42.8 100.0 149 
20-39 30.9 11.4 57.7 100.0 432 
25+ 20.5 9.1 70.4 100.0 900       
Total 15-24 48.5 4.7 46.8 100.0 68 
Total 15-49 25.6 10.3 64.1 100.0 726 
Total 15+ 22.5 8.8 68.7 100.0 968 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  




Table 8.3.B Self-reported HIV diagnosis and treatment status: Females  
Percent distribution of HIV-positive women, those aged 15 years and older, by self-reported antiretroviral therapy (ART) status, by selected 
demographic characteristics, SHIMS2 2016-2017   
Aware of HIV status 
  
Characteristic Unaware of HIV status Not on ART On ART1 Total Number 
Residence 
     
Urban 15.3 12.5 72.1 100.0 466 
Rural 9.8 11.2 78.9 100.0 1,558 
Region 
     
Hhohho 15.8 10.0 74.2 100.0 577 
Lubombo 9.3 13.1 77.6 100.0 431 
Manzini 11.2 13.5 75.3 100.0 636 
Shiselweni 7.3 8.6 84.1 100.0 380 
Marital status 
     
Never married 17.4 13.1 69.5 100.0 726 
Married 7.7 11.4 81.0 100.0 748 
Living together 13.9 8.2 77.9 100.0 124 
Divorced/separated 11.6 13.5 74.9 100.0 124 
Widowed 3.3 8.6 88.2 100.0 287 
Type of union 
     
In polygynous union 12.4 8.9 78.7 100.0 82 
Not in polygynous union 8.2 11.1 80.7 100.0 734 
Not currently in union 13.6 12.1 74.2 100.0 1,137 
Don't know/missing 8.4 11.5 80.1 100.0 71 
Education 
     
No education 5.8 5.2 89.0 100.0 151 
Primary 7.7 10.5 81.7 100.0 691 
Secondary 11.4 12.1 76.5 100.0 657 
High school 16.3 13.3 70.4 100.0 414 
Tertiary 17.8 15.0 67.2 100.0 108 
Wealth quintile 
     
Lowest 7.1 10.3 82.5 100.0 514 
Second 9.4 10.1 80.5 100.0 437 
Middle 12.6 13.2 74.1 100.0 453 
Fourth  14.0 12.8 73.2 100.0 355 
Highest 15.7 11.8 72.5 100.0 263 
Age 
     
15-19 35.9 11.4 52.6 100.0 72 
20-24 27.6 15.1 57.3 100.0 196 
25-29 14.6 14.2 71.2 100.0 318 
30-34 8.2 13.7 78.1 100.0 390 
35-39 7.2 10.7 82.2 100.0 318 
40-44 7.1 6.9 86.0 100.0 224 
45-49 4.7 13.5 81.8 100.0 169 
50-54 6.8 7.7 85.4 100.0 135 
55-59 6.1 9.3 84.6 100.0 91 
60-64 10.6 2.5 86.9 100.0 67 
65+ (6.4) (2.3) (91.4) 100.0 44 
15-29 21.5 14.2 64.3 100.0 586 
20-39 12.6 13.2 74.1 100.0 1,222 
25+ 8.5 11.2 80.3 100.0 1,756       
Total 15-24 29.8 14.2 56.1 100.0 268 
Total 15-49 12.0 12.2 75.7 100.0 1,687 
Total 15+ 11.4 11.6 77.0 100.0 2,024 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
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Table 8.3.C Self-reported HIV diagnosis and treatment status: Total  
Percent distribution of HIV-positive adults, those aged 15 years and older by self-reported HIV diagnosis and antiretroviral therapy (ART) 
status, by selected demographic characteristics, SHIMS2 2016-2017   
Aware of HIV status 
  
Characteristic Unaware of HIV status Not on ART On ART1 Total Number 
Residence 
     
Urban 20.5 11.7 67.9 100.0 722 
Rural 13.1 10.2 76.7 100.0 2,270 
Region 
     
Hhohho 18.8 8.9 72.3 100.0 871 
Lubombo 12.4 13.8 73.8 100.0 670 
Manzini 17.0 11.0 71.9 100.0 927 
Shiselweni 8.7 8.7 82.7 100.0 524 
Marital status 
     
Never married 23.0 11.9 65.1 100.0 1,007 
Married 10.7 10.0 79.3 100.0 1,254 
Living together 20.4 9.2 70.4 100.0 193 
Divorced/separated 13.6 11.5 74.9 100.0 201 
Widowed 4.1 9.2 86.7 100.0 320 
Type of union 
     
In polygynous union 13.9 10.7 75.4 100.0 124 
Not in polygynous union 11.8 9.8 78.4 100.0 1,254 
Not currently in union 18.4 11.4 70.3 100.0 1,528 
Don't know/missing 12.5 10.6 76.9 100.0 86 
Education 
     
No education 9.5 4.6 85.9 100.0 224 
Primary 12.5 9.1 78.4 100.0 1,068 
Secondary 15.4 12.0 72.6 100.0 904 
High school 20.3 11.9 67.8 100.0 634 
Tertiary 16.3 14.4 69.3 100.0 154 
Wealth quintile 
     
Lowest 11.1 8.7 80.2 100.0 749 
Second 15.2 9.0 75.8 100.0 650 
Middle 16.1 11.8 72.1 100.0 656 
Fourth  17.3 11.8 70.9 100.0 524 
Highest 17.8 12.7 69.6 100.0 410 
Age 
     
15-19 35.6 9.4 55.0 100.0 111 
20-24 33.1 13.3 53.6 100.0 225 
25-29 22.9 13.5 63.7 100.0 399 
30-34 13.4 13.5 73.1 100.0 529 
35-39 11.6 11.0 77.3 100.0 501 
40-44 11.3 6.6 82.1 100.0 357 
45-49 7.1 12.7 80.1 100.0 291 
50-54 9.5 7.5 83.0 100.0 219 
55-59 8.5 6.3 85.2 100.0 148 
60-64 9.0 1.1 89.9 100.0 120 
65+ 10.7 1.8 87.5 100.0 92 
15-29 27.8 12.8 59.4 100.0 735 
20-39 17.9 12.7 69.4 100.0 1,654 
25+ 12.9 10.5 76.7 100.0 2,656 
      
Total 15-24 33.9 12.1 54.1 100.0 336 
Total 15-49 16.3 11.6 72.1 100.0 2,413 
Total 15+ 15.3 10.6 74.1 100.0 2,992 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT/SUBNAT.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 





8.4 Concordance of Self-Reported Treatment Status Versus Laboratory ARV Data 
ARVs (i.e., efavirenz, lopinavir and nevirapine) were detected in the blood of almost three-quarters 
(74.3%) of HIV-positive adults (69.6% in males and 76.7% in females). Among adults living with HIV 
reporting a prior HIV diagnosis and current ART use, 95.9% had detectable ARVs in their blood (96.1% in 
males and 95.8% in females; Tables 8.4.A, 8.4.B, and 8.4.C).  
 
ARVs were detected in 14.8% of HIV-positive adults reporting no prior diagnosis. Among adults living 
with HIV reporting no prior diagnosis, the percentage with detectable ARVs was higher in females 
(18.3%) than in males (11.5%; Tables 8.4.A, 8.4.B, and 8.4.C).  
 
Among HIV-positive adults reporting a prior diagnosis and no ART use, 8.3% had detectable ARVs in their 
blood. The percentage with detectable ARVs among adults living with HIV reporting a prior diagnosis 
and no ART use was lower in females (7.2%) than in males (11.0%; Tables 8.4.A, 8.4.B, and 8.4.C).  
 
Table 8.4.A Concordance of self-reported treatment status versus presence of antiretrovirals 
(ARVs): Males  
Percent distribution of HIV-positive males aged 15 years and older by presence of detectable ARVs versus self-
reported HIV treatment status, SHIMS2 2016-2017  
ARV status1 
  
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status 
    
Not previously diagnosed 88.5 11.5 100.0 192 
Previously diagnosed, not on ART2 89.0 11.0 100.0 82 
Previously diagnosed, on ART 3.9 96.1 100.0 694      
Total 15-24 54.2 45.8 100.0 68 
Total 15-49 34.9 65.1 100.0 727 
Total 15+ 30.4 69.6 100.0 970 
1Antiretroviral detection assay included only efavirenz, lopinavir, and nevirapine; 2 ART: Antiretroviral therapy. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
Table 8.4.B Concordance of self-reported treatment status versus presence of antiretrovirals 
(ARVs): Females 
Percent distribution of HIV-positive females aged 15 years and older, by presence of detectable ARVs versus 
self-reported HIV treatment status, SHIMS2 2016-2017  
ARV status1 
  
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status 
    
Not previously diagnosed 81.7 18.3 100.0 212 
Previously diagnosed, not on ART2 92.8 7.2 100.0 224 
Previously diagnosed, on ART 4.2 95.8 100.0 1,584      
Total 15-24 43.0 57.0 100.0 268 
Total 15-49 24.5 75.5 100.0 1,686 
Total 15+ 23.3 76.7 100.0 2,023 
1Antiretroviral detection assay included only efavirenz, lopinavir, and nevirapine; 2 ART: Antiretroviral therapy. 




Table 8.4.C Concordance of self-reported treatment status versus presence of antiretrovirals 
(ARVs): Total  
Percent distribution of HIV-positive adults aged 15 years and older by presence of detectable ARVs versus self-
reported HIV treatment status, SHIMS2 2016-2017 
 ARV status1   
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status     
Not previously diagnosed 85.2 14.8 100.0 404 
Previously diagnosed, not on ART2 91.7 8.3 100.0 306 
Previously diagnosed, on ART 4.1 95.9 100.0 2,278 
     
Total 15-24 45.5 54.5 100.0 336 
Total 15-49 27.8 72.2 100.0 2,413 
Total 15+ 25.7 74.3 100.0 2,993 
1 Antiretroviral detection assay included only efavirenz, lopinavir, and nevirapine; 2 ART: Antiretroviral therapy. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
8.5 Gaps and Unmet Needs  
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▪ Awareness of HIV-positive status and current ART use among HIV-positive adults was lower in 
urban areas than in rural areas. Identifying undiagnosed HIV-positive adults and linkage to ART 
services may require tailored strategies unique to urban areas.  
▪ Awareness of HIV-positive status and current ART use was lower among young people aged 15-
24 years and among males. The needs of young males, in particular, are addressed less 
successfully. Specified program strategies are needed to address the distinctive needs of young 
men. 
▪ Discordance between self-reported ART status and presence of detectable ARVs could be due to 
stigma. Programs may benefit from additional focus on stigma-reduction interventions.  
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Chapter 9   Viral Load Suppression 
9.1 Key Findings 
 
9.2 Background 
VLS is a key indicator of treatment success in HIV-positive individuals. For the purposes of SHIMS2, VLS is 
defined as VL less than 1,000 HIV RNA copies/mL of plasma. This chapter describes VLS among the 
population of HIV-positive adults (defined in this survey as those aged 15 years and older, unless 
otherwise noted) by age, sex, region, and other demographic characteristics. 
 
9.3 Adult Viral Load Suppression by Demographic Characteristics 
VLS prevalence among HIV-positive adults was 73.1%: 67.6% in males and 76.0% in females. The 
majority (91.9%) who reported as previously diagnosed and on ART had suppressed viral loads (91.3% in 
males and 92.2% in females), compared with less than a fifth (17.5%) of whom reported as previously 
diagnosed and not on ART. About a fifth (21.2%) of those reported as not previously diagnosed had 
suppressed viral loads. VLS prevalence was highest among widowed adults living with HIV (85.9%) and 
lowest among those never married (64.1%). VLS prevalence was also highest among HIV-positive adults 
with no education (86.1%; Table 9.3.A).  
  
  
9 VIRAL LOAD SUPPRESSION  
  
▪ Prevalence of viral load suppression (VLS) among all HIV-positive adults aged 15 years and older 
was 73.1% (67.6% males, 76.0% females). 
▪ Prevalence of VLS among HIV-positive adults aged 15 years and older who report being on ART 
was 91.9% (91.3% males, 92.2% females). 
▪ VLS prevalence among all HIV-positive adults aged 15 years and older was lowest (50.6%) among 
those aged 15-24 years (32.9% males, 55.5% females). 
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Table 9.3.A Viral load suppression by demographic characteristics  
Among HIV-positive adults aged 15 years and older, percentage with viral load suppression (< 1,000 copies/mL)1, by sex, self-reported HIV 
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1 mL: milliliter; 2 VLS: viral load suppression; 3 Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed 
viral loads and PEPFAR indicator VL_SUPPRESSION_NAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 





9.4 Adult Viral Load Suppression by Age and Sex 
Among HIV-positive adults aged 15-24 years, about half (50.6%) had a suppressed viral load: 32.9% in 
males and 55.5% in females. About three-quarters (76.1%) of people living with HIV aged 25 years and 
older had suppressed viral loads (70.3% in males and 79.3% in females). Among HIV-positive individuals 
aged 15 years and older, VLS prevalence was lowest in ages 15-19 years (49.8%) and highest in ages 60-
64 years (89.8%; Table 9.4.A). 
 
VLS prevalence was 80% or higher in females aged 35 years and older and in males aged 45 years and 
older. Most (85.5%) adults aged 65 years and older had a suppressed viral load with minimal difference 
between males (84.9%) and females (86.6%; Table 9.4.B; Figure 9.4.A).  
 
Table 9.4.A Viral load suppression, by age and sex (5-year age groups)  
Prevalence of viral load suppression (< 1,000 copies/mL)1 among the HIV-positive population in Eswatini, by sex and age, 
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1 mL: milliliter;  2 VLS: viral load suppression; 3 Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed 
viral loads and PEPFAR indicator VL_SUPPRESSION_NAT . 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 




Table 9.4.B Viral load suppression, by age and sex (10-15-year age groups) 
Percentage with viral load suppression (< 1,000 copies/mL)1 among the HIV-positive population in Eswatini, by 
sex and age, SHIMS2 2016-2017 











0–14 58.3 52  (64.9) 44  61.3 96 
15–24 32.9 69  55.5 269  50.6 338 
25–34 54.8 220  73.5 713  68.4 933 
35–44 69.2 317  83.4 543  78.3 860 
45–54 80.0 207  81.5 304  80.8 511 
55-64 89.3 111  87.3 158  88.3 269 
65+ (84.9) 48  (86.6) 44  85.5 92 
1 mL: milliliter; 2VLS: viral load suppression; 3Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed 
viral loads and PEPFAR indicator VL_SUPPRESSION_NAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
 
Figure 9.4.A Proportion of viral load suppression (<1000 copies/mL) among people living with HIV, 
by age and sex, SHIMS2 2016-2017 
 
 
9.5 Adult Viral Load Suppression by Region 
In Eswatini, VLS prevalence among adults living with HIV was comparable across Manzini (71.5%), 
Hhohho (72.1%), and Lubombo (72.6%) regions. Prevalence of VLS was highest in Shiselweni (79.1%), 




Figure 9.5.A Viral load (<1000 copies/mL) among HIV-positive adults aged 15 years and older, by 






Figure 9.5.B Viral load (<1000 copies/mL) among HIV-positive adults aged 15 years and older, by 
region, SHIMS2 2016-2017  
 
 




▪ Although no gender disparity is present among HIV-positive adults with a prior HIV diagnosis and 
on ART, VLS among all adults living with HIV was higher among females than males. The gender 
gap in VLS among all HIV-positive adults may result from gender-based barriers to diagnosis and 
linkage to ART services. Concerted efforts to strengthen linkage to ART services, especially 
among adult males, may balance VLS between males and females. 
▪ Young people living with HIV aged 15-24 years are lagging in HIV VLS. Differentiated services to 
better address the needs of young people need further consideration. 
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Chapter 10   90-90-90 Targets 




To achieve HIV epidemic control, Eswatini adopted the UNAIDS 90-90-90 targets: By 2020, 90% of all 
people living with HIV will know their HIV status; 90% of all persons with diagnosed HIV infection will 
receive sustained ART; and 90% of all people receiving ART will have VLS.1 The 90% target on diagnosis 
of HIV-positive persons measures accessibility and targeted uptake of national HIV testing services. The 
90% target on sustained ART among those diagnosed measures accessibility of national treatment 
services and effectiveness of linkages from HIV testing to treatment. Lastly, the 90% target on VLS 
among those diagnosed and on ART measures treatment retention and adherence. The cumulative 
achievement of 90-90-90 targets results in VLS in at least 73% of all HIV-positive persons.  
 
Previous chapters described the reach of national HIV testing services regardless of HIV status, the 
coverage of HIV treatment among the HIV-positive population nationwide, and the impact of testing and 
treatment services on VLS among people living with HIV in the country. This chapter presents the 90-90-
90 indicators in two ways. First, Table 10.3.A uses self-reported diagnosis and self-reported ART use. 
Adults (defined in this survey as those aged 15 years and older, unless otherwise noted) are classified as 
diagnosed (i.e., knowledge or awareness of HIV-positive status) by a self-reported HIV-positive status 
before receipt of HIV rapid testing in SHIMS2. Adults are classified as on treatment (i.e., on ART) by a 
self-report of current ART use. Second, Table 10.3.B uses self-reported diagnosis, self-reported ART use, 
and ARV biomarker data. Diagnosed and on treatment measures in Table 10.3.A are adjusted to include 
persons with detectable ARVs in their blood, regardless of their self-reported diagnosis or self-reported 
ART use. Adults are classified as ARV-adjusted diagnosed by self-reported HIV-positive status before 
receipt of HIV rapid testing in SHIMS2 or by detectable ARVs in their blood. Adults are classified as ARV-
adjusted on treatment by self-reported current use of ART or by detectable ARVs in their blood. In 
Tables 10.3.A and 10.3.B, adults with VLS who reported being unaware of their HIV-positive status or as 
not currently on treatment are excluded from the numerator of the 90% target on VLS. 
 
10.3 Status of the 90-90-90 Targets 
 
90-90-90 targets per self-reported HIV diagnosis and self-reported ART use 
Among HIV-positive adults, 84.7% reported as diagnosed. Self-reported prior HIV diagnosis in adults was 
higher in females (88.6%) than in males (77.5%). Among self-reported diagnosed HIV-positive adults, 
▪ Based on self-report and presence of detectable ARVs, 87.0% of adults living with HIV aged 15 
years and older knew their HIV status (80.1% males, 90.7% females). 
▪ Based on self-report and presence of detectable ARVs, 88.8% of HIV-positive adults aged 15 years 
and older were on ART (90.2% males, 88.1% females). 
▪ Based on self-report and presence of detectable ARVs, 91.4% of adults living with HIV aged 15 
years and older had suppressed viral loads (90.5% males, 91.8% females). 
10 90-90-90 TARGETS    
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87.4% reported current treatment (88.6% in males and 86.9% in females). In adults reporting current 
treatment, 91.9% had suppressed viral loads: 91.3% in males and 92.2% in females (Table 10.3.A).  
 
Among HIV-positive young people, 66.1% reported as diagnosed. Among self-reported diagnosed young 
people living with HIV, 81.7% reported being on treatment. In HIV-positive young people reporting 
current treatment, 76.4% had VLS. In contrast, among people living with HIV aged 25 years and older, 
the percentages of reported prior HIV diagnosis (87.1%), reported diagnosed and currently on treatment 
(88.0%), and on current treatment with VLS (93.3%) were higher compared with young people (Table 
10.3.A). 
 
90-90-90 targets per self-reported HIV diagnosis, self-reported ART use, and ARV biomarker data 
Among HIV-positive adults, 87.0% reported as diagnosed or had detectable ARVs in their blood (i.e., 
ARV-adjusted diagnosed) and was higher in females (90.7%) than in males (80.1%). Among adults living 
with HIV who were classified as ARV-adjusted diagnosed, 88.8% reported ART use or had detectable 
ARVs in their blood (i.e., ARV-adjusted on treatment; 90.2% in males and 88.1% in females). Among HIV-
positive adults classified as ARV-adjusted on treatment, 91.4% had VLS: 90.5% in males and 91.8% in 
females (Table 10.3.B).  
 
Among young people living with HIV aged 15-24 years, 72.1% were classified as ARV-adjusted diagnosed 
of whom 85.3% were classed as ARV-adjusted on treatment. Among these individuals on ART, 76.5% had 
VLS. Among HIV-positive adults aged 25 years and older, the percentages classified as ARV-adjusted 
diagnosed (88.9%), ARV-adjusted diagnosed and on treatment (89.2%), and ARV-adjusted diagnosed and 





Table 10.3.A Adult 90-90-90, self-reported antiretroviral therapy (ART) data, conditional percentages  
90-90-90 targets among people living with HIV aged 15 years and older, by sex and age, SHIMS2 2016-2017 
Diagnosed1  
 Males  Females  Total 
Age 
Percentage 
who self-reported HIV 
positive 
Number   
Percentage 
who self-reported HIV 
positive 





15-24 51.5 68  70.2 268  66.1 336 
25-34 65.7 220  88.9 708  82.4 928 
35-49 83.1 438  93.4 711  89.5 1,149 
15-29 51.3 149  78.5 586  72.2 735 
20-39 69.1 432  87.4 1,222  82.1 1,654 
25+ 79.5 900  91.5 1,756  87.1 2,656 
15-49 74.4 726  88.0 1,687  83.7 2,413 
15+ 77.5 968  88.6 2,024  84.7 2,992 
 
 On Treatment2 Among Those Diagnosed 
 Males  Females  Total 
Age 
Percentage 
who self-reported on ART 
Number  
Percentage 
who self-reported on ART 
Number  
Percentage 
who self-reported on ART 
Number 
15-24 (90.9) 38  79.9 192  81.7 230 
25-34 81.4 149  84.3 636  83.7 785 
35-49 88.0 374  89.3 668  88.8 1,042 
15-29 83.5 81  82.0 467  82.2 548 
20-39 83.5 311  84.9 1,078  84.5 1,389 
25+ 88.5 738  87.8 1,619  88.0 2,357 
15-49 86.2 561  86.1 1,496  86.1 2,057 
15+ 88.6 776  86.9 1,811  87.4 2,587 
 
 Viral Load Suppression (VLS), Among Those on Treatment 











15-24 (61.3) 35  79.9 157  76.4 192 
25-34 85.6 123  91.6 537  90.3 660 
35-49 92.7 328  94.8 598  94.1 926 
15-29 79.1 70  86.1 383  84.9 453 
20-39 86.7 261  90.9 920  89.9 1,181 
25+ 92.9 659  93.6 1,430  93.3 2,089 
15-49 88.6 486  91.8 1,292  90.9 1,778 
15+ 91.3 694  92.2 1,587  91.9 2,281 
1Relates to Global AIDS Monitoring indicator (GAM) 1.1: People living with HIV who know their HIV status and PEPFAR indicator DIAGNOSED_NAT; 
2Relates to GAM 1.2: People living with HIV on antiretroviral therapy and PEPFAR indicator TX_CURR_NAT; 3Relates to GAM 1.4: People living with HIV 
who have suppressed viral loads and PEPFAR indicator VL_SUPPRESSION_NAT. 





Table 10.3.B Adult 90-90-90, self-reported antiretroviral therapy (ART) status and/or laboratory antiretroviral (ARV) 
data, conditional percentages 
90-90-90 targets among people living with HIV aged 15 years and older, by sex and age, SHIMS2 2016-2017 
Diagnosed1  
 Males  Females  Total 
Age 
Percentage 
who self-reported HIV 
positive AND/OR with 
detectable ARVs 
Number   
Percentage 
who self-reported HIV 
positive AND/OR with 
detectable ARVs 
Number   
Percentage 
who self-reported HIV positive 
AND/OR with detectable ARVs 
Number 
15-24 60.3 68  75.5 268  72.1 336 
25-34 69.2 220  91.1 710  85.0 930 
35-49 84.8 439  94.6 712  90.9 1,151 
15-29 58.3 149  82.5 587  76.9 736 
20-39 72.3 433  89.5 1,225  84.6 1,658 
25+ 81.6 902  93.1 1,759  88.9 2,661 
15-49 77.3 727  90.2 1,690  86.1 2,417 
15+ 80.1 970  90.7 2,027  87.0 2,997 
 
 On Treatment2 Among Those Diagnosed 
 Males  Females  Total 
Age 
Percentage with detectable 
ARVs AND/OR who self-
reported being on ART 
Number  
Percentage with detectable 
ARVs AND/OR who self-
reported being on ART 
Number  
Percentage with detectable 
ARVs AND/OR who self-
reported being on ART 
Number 
15-24 (92.2) 44  83.7 204  85.3 248 
25-34 84.3 156  85.5 651  85.2 807 
35-49 89.9 381  90.4 677  90.2 1,058 
15-29 86.7 91  84.9 488  85.2 579 
20-39 85.8 324  86.3 1,104  86.2 1,428 
25+ 90.1 756  88.7 1,647  89.2 2,403 
15-49 88.4 581  87.5 1,532  87.8 2,113 
15+ 90.2 800  88.1 1,851  88.8 2,651 
 
 Viral Load Suppression (VLS), Among Those on Treatment 











15-24 (57.6) 41  81.2 173  76.5 214 
25-34 85.0 133  91.2 557  89.9 690 
35-49 92.4 342  94.1 612  93.5 954 
15-29 76.3 81  86.3 413  84.5 494 
20-39 85.6 279  90.5 956  89.3 1,235 
25+ 92.5 687  93.0 1,468  92.8 2,155 
15-49 87.6 516  91.4 1,342  90.3 1,858 
15+ 90.5 728  91.8 1,641  91.4 2,369 
1Relates to Global AIDS Monitoring indicator (GAM) 1.1: People living with HIV who know their HIV status and PEPFAR indicator DIAGNOSED_NAT; 
2Relates to GAM 1.2: People living with HIV on antiretroviral therapy and PEPFAR indicator TX_CURR_NAT; 3Relates to GAM 1.4: People living with HIV 
who have suppressed viral loads and PEPFAR indicator VL_SUPPRESSION_NAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  
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Figure 10.3.A Adults aged 15 years and older 90-90-90, adjusted for laboratory antiretroviral data,1 
SHIMS2 2016-2017 
 
1In the antiretroviral (ARV)-adjusted 90-90-90, participants are classified as ‘Aware’ or ‘Diagnosed’ if they reported 
being aware of their HIV-positive status before testing positive in SHIMS2 and/or had detectable ARVs in their 
blood. Participants are classified as ‘On Treatment’ if they reported that they were on treatment and/or if they had 
detectable ARVs in their blood.  
*Inset numbers are conditional proportions. 
 




1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An ambitious treatment target to 
help end the AIDS epidemic. Geneva: UNAIDS; 2014. 
http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf.  Accessed December 20, 
2018.  
▪ Among HIV-positive adults, the percentage of males with a prior HIV diagnosis is notably lower 
than females, yet no comparable gap is shown in current ART use or in VLS. Efforts to target HIV 
testing toward men who are at risk of HIV infection are warranted. 
▪ Young people aged 15-24 years who are living with HIV have notably lower percentages of prior 
HIV diagnosis and VLS. It is key for efforts to target HIV testing toward young people and to 
support ART retention among them.  
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Chapter 11    Characteristics of People Living with HIV 
11.1 Key Findings 
 
11.2 Background 
The quality of HIV care and treatment is based on key principles of accessibility, efficiency, and safety. As 
countries implement treatment for all HIV-positive people, ensuring a sustainable health system that is 
people-centered and innovative requires diligent monitoring and responsiveness.1 Indicators such as 
CD4 count at diagnosis and retention on ART can provide evidence of program coverage, the ability to 
reach vulnerable populations, and quality of care. The distribution of CD4 counts among people living 
with HIV also reflects population health, and the potential impact of HIV on mortality. Finally, the 
measurement of transmitted drug resistance informs optimization of national ART guidelines, including 
second- and third-line therapies. These measures provide a unique opportunity to gauge progress in the 
expansion of HIV clinical services in Eswatini, as well as identify gaps and future challenges. 
 
11.3 CD4 Counts and Immunosuppression 
Among HIV-positive adults (defined in this survey as those aged 15 years and older, unless otherwise 
noted), 44.7% were immunosuppressed with a CD4 count of less than 500 cells/μL. Immunosuppression 
was higher in males (59.2%) than in females (37.1%). The median CD4 count was 534 cells/μL in adults 
living with HIV (438 cells/μL in males and 587 cells/μL in females). The percentage of HIV-positive adults 
with CD4 counts less than 100 cells/μL did not meaningfully vary by demographic characteristics (Tables 
11.3.A and 11.3.B). 
 
Among adults living with HIV who reported a prior HIV diagnosis and ART use, 40.2% had a CD4 count of 
less than 500 cells/μL (56.4% in males and 32.6% in females). The median CD4 count was 560 cells/μL 
(456 cells/μL in males and 616 cells/μL in females). Among HIV-positive adults who reported a prior HIV 
diagnosis and no ART use, 55.8% had a CD4 count of less than 500 cells/μL (67.7% in males and 51.1% in 
11 CLINICAL CHARACTERISTICS OF PEOPLE LIVING 
WITH HIV 
▪ Less than half (44.7%) of HIV-positive adults aged 15 years and older were immunosuppressed 
with a CD4+ T-cell (CD4) count of less than 500 cells/microliter (μL). Severe immunosuppression 
with a CD4 count of less than 100 cells/μL was uncommon (2.2%). 
▪ About two-fifths (38.9%) of adults living with HIV aged 15 years and older who reported as 
unaware of their HIV-positive status had a late HIV diagnosis with CD4 count less than 350 
cells/μL (42.4% males, 35.0% females). 
▪ All HIV-positive adults aged 15 years and older who initiated ART within 12 months of the survey 
and virtually all people living with HIV who ever initiated ART reported currently being on ART at 
the time of the survey (100% and 99.1%, respectively). 
▪ Five of 28 samples (17.9%) from recently infected HIV-positive adults aged 15 years and older in 
the survey had mutations associated with resistance to only one class of ARVs, non-nucleoside 
reverse transcriptase inhibitors. 
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females). The median CD4 count was 452 cells/μL (373 cells/μL in males and 488 cells/μL in females; 
Tables 11.3.A and 11.3.B, Figure 11.3.A).  
 
Among adults living with HIV, 2.2% were severely immunosuppressed with a CD4 count of less than 100 
cells/μL (3.2% in males and 1.7% in females). Severe immunosuppression was highest in adults who 
reported a prior HIV diagnosis and no ART use (5.0%) and lowest in adults who reported a prior HIV 
diagnosis and ART use (1.8%). Among adults who reported a prior HIV diagnosis and no ART use, severe 
immunosuppression was over five times higher in males (11.8%) than in females (2.3%; Table 11.3.A).  
 
Among HIV-positive adults aged 15-24 years, 40.2% were immunosuppressed with a CD4 count of less 
than 500 cells/μL and 2.4% were severely immunosuppressed with a CD4 count of less than 100 cells/μL. 
The median CD4 count was 576 cells/μL (Tables 11.3.A and 11.3.B). 
 
 
Figure 11.3.A CD4 count distribution among HIV-positive adults aged 15 years and older, by 
antiretroviral treatment (ART) status, SHIMS2 2016-2017 
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Table 11.3.A Prevalence of immunosuppression  
Among HIV-positive adults aged 15 years and older, percentage with immunosuppression (< 100 cells/μL1; <200 cells/μL; <500 cells/μL), by sex, self-reported diagnosis and antiretroviral therapy (ART) status, 
and selected demographic characteristics, SHIMS2 2016-2017  



































Self-reported diagnosis and 
treatment status 
              
Not previously diagnosed 1.7 14.1 64.6 192 
 
2.4 12.3 53.2 212 
 
2.1 13.2 59.0 404 
Previously diagnosed, not on 
ART 
11.8 18.9 67.7 82 
 
2.3 10.9 51.1 224 
 
5.0 13.2 55.8 306 
Previously diagnosed, on 
ART 
2.5 9.4 56.4 694 
 
1.4 3.8 32.6 1,586 
 
1.8 5.6 40.2 2,280 
Missing * * * 4 
 
* * * 6 
 
* * * 10                
Residence 
              
Urban 2.1 12.0 58.0 257 
 
2.4 6.5 35.2 467 
 
2.3 8.5 43.3 724 
Rural 3.7 11.1 59.7 715 
 
1.3 5.2 37.8 1,561 
 
2.1 7.2 45.3 2,276                
Region 
              
Hhohho 2.9 10.0 60.2 295 
 
1.4 5.8 36.4 577 
 
1.9 7.3 45.0 872 
Lubombo 3.2 16.3 61.3 240 
 
1.8 4.9 33.4 431 
 
2.4 9.3 44.0 671 
Manzini 3.0 8.9 55.6 292 
 
2.1 5.9 39.3 639 
 
2.4 6.9 44.8 931 
Shiselweni 4.5 12.4 62.3 145 
 
1.0 5.3 37.8 381 
 
2.0 7.3 44.9 526                
Marital status 
              
Never married 3.7 12.1 60.3 282 
 
2.5 7.2 38.5 728 
 
2.9 8.6 44.9 1,010 
Married 2.7 10.2 58.9 508 
 
1.2 4.1 37.0 748 
 
1.8 6.7 46.3 1,256 
Living together 4.8 12.6 54.6 69 
 
1.5 5.9 30.5 125 
 
2.8 8.5 39.9 194 
Divorced/separated 1.7 10.2 56.5 77 
 
1.6 3.2 29.5 124 
 
1.6 5.8 39.7 201 
Widowed (4.2) (20.5) (69.8) 34 
 
0.6 6.2 40.4 287 
 
1.0 7.9 43.9 321                
Type of union 
              
In polygynous union (0.0) (8.4) (69.0) 42 
 
0.8 2.3 35.2 82 
 
0.5 4.4 46.9 124 
Not in polygynous union 3.1 10.6 57.3 522 
 
1.1 4.5 36.2 735 
 
2.0 7.2 45.5 1,257 
Not currently in union 3.3 12.4 60.3 393 
 
2.0 6.5 37.8 1,139 
 
2.4 8.1 44.0 1,532 
Don't know/missing * * * 15 
 
2.7 5.4 36.9 72 
 
4.4 7.6 42.7 87                
Education 
              
No education 2.8 11.3 61.5 74 
 
0.0 2.8 32.1 151 
 
1.0 5.9 42.6 225 
Primary 2.6 9.7 60.0 379 
 
1.1 5.2 35.9 692 
 
1.6 6.9 45.1 1,071 
Secondary 5.1 14.9 60.4 247 
 
2.1 5.7 38.2 658 
 
3.0 8.3 44.6 905 
High school 3.1 11.6 58.2 221 
 
1.9 6.5 38.9 414 
 
2.3 8.3 45.9 635 
Tertiary (0.0) (5.0) (49.6) 46 
 
3.0 6.6 34.1 109 
 




Table 11.3.A Prevalence of immunosuppression (continued) 
Among HIV-positive adults aged 15 years and older, percentage with immunosuppression (< 100 cells/μL1; <200 cells/μL; <500 cells/μL), by sex, self-reported diagnosis and antiretroviral therapy (ART) status, 
and selected demographic characteristics, SHIMS2 2016-2017 

































              
Lowest 3.4 10.9 62.5 235 
 
1.3 6.0 38.2 515 
 
2.0 7.7 46.5 750 
Second 4.0 11.3 60.9 214 
 
1.8 5.2 32.3 437 
 
2.6 7.3 42.3 651 
Middle 2.1 12.5 54.1 205 
 
1.7 5.8 41.6 455 
 
1.8 8.1 45.8 660 
Fourth  4.3 13.0 64.2 169 
 
1.2 5.6 35.6 355 
 
2.2 8.1 45.2 524 
Highest 1.8 8.5 53.0 148 
 
2.4 4.9 37.4 264 
 
2.2 6.2 43.2 412 
               
Age 
              
15-19 (1.6) (8.2) (61.1) 40 
 
2.5 11.4 32.2 72 
 
2.2 10.3 42.3 112 
20-24 (6.3) (14.9) (58.6) 29 
 
1.8 7.7 35.5 197 
 
2.5 8.9 39.2 226 
25-29 2.2 6.9 46.6 81 
 
2.4 5.9 37.1 319 
 
2.4 6.2 39.4 400 
30-34 4.6 13.1 64.9 139 
 
1.5 4.6 38.2 392 
 
2.5 7.2 46.3 531 
35-39 5.5 17.8 62.1 184 
 
1.4 4.5 36.9 319 
 
2.9 9.2 45.8 503 
40-44 2.5 9.2 59.6 133 
 
1.4 6.0 34.4 224 
 
1.8 7.2 43.5 357 
45-49 3.1 8.2 56.1 123 
 
1.0 5.6 42.3 169 
 
2.0 6.8 48.3 292 
50-54 0.7 9.2 63.3 84 
 
2.0 2.8 42.3 135 
 
1.4 5.7 51.8 219 
55-59 1.8 10.8 49.7 58 
 
0.0 3.1 33.2 90 
 
0.8 6.6 40.6 148 
60-64 0.0 11.2 60.6 53 
 
3.9 7.4 38.7 67 
 
1.7 9.5 51.0 120 
65+ (1.6) (7.8) (62.2) 48 
 
(0.0) (8.6) (26.7) 44 
 
1.0 8.1 49.4 92                
15-29 3.0 8.9 52.3 150 
 
2.2 7.2 36.0 588 
 
2.4 7.6 39.8 738 
20-39 4.6 13.8 59.6 433 
 
1.8 5.4 37.1 1,227 
 
2.6 7.8 43.5 1,660 
25+ 3.2 11.3 59.1 903 
 
1.6 5.1 37.5 1,759 
 
2.2 7.3 45.3 2,662                
Total 15-24 4.0 11.6 59.9 69 
 
2.0 8.7 34.7 269 
 
2.4 9.3 40.2 338 
Total 15-49 3.9 11.8 59.1 729 
 
1.7 5.8 37.0 1,692 
 
2.4 7.7 44.0 2,421 
Total 15+ 3.2 11.4 59.2 972 
 
1.7 5.6 37.1 2,028 
 
2.2 7.6 44.7 3,000 
1 μL: microliter 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
The interquartile range (IQR) is a measure of variability, based on dividing a data set into quartiles. Quartiles divide a rank-ordered data set into four equal parts. The values that divide each part are called the 




Table 11.3.B Median CD4 count and prevalence of immunosuppression  
Among HIV-positive adults aged 15 years and older, median (Q1, Q3) CD4 count and percentage with immunosuppression 
(< 100 cells/μL1), by sex, self-reported diagnosis and ART status, and selected demographic characteristics, SHIMS2 2016-2017 





< 100 cells/μL 
Number  Median 
(Q1, Q3) 
Percentage 






< 100 cells/μL 
Number 
Self-reported diagnosis and 
treatment status 
           
Not previously diagnosed 409 (266, 586) 1.7 192 
 
438 (295, 697) 2.4 212 
 
418 (279, 617) 2.1 404 
Previously diagnosed, not on ART 373 (240, 523) 11.8 82 
 
488 (309, 663) 2.3 224 
 
452 (291, 624) 5.0 306 
Previously diagnosed, on ART 456 (324, 630) 2.5 694 
 
616 (447, 804) 1.4 1,586 
 
560 (399, 757) 1.8 2,280 
Missing * * 4 
 
* * 6 
 
* * 10 
            
Residence 
           
Urban 440 (308, 621) 2.1 257 
 
604 (397, 791) 2.4 467 
 
557 (358, 731) 2.3 724 
Rural 437 (308, 596) 3.7 715 
 
576 (414, 780) 1.3 1,561 
 
525 (362, 729) 2.1 2,276             
Region 
           
Hhohho 438 (306, 611) 2.9 295 
 
578 (409, 777) 1.4 577 
 
533 (351, 737) 1.9 872 
Lubombo 409 (287, 567) 3.2 240 
 
592 (440, 768) 1.8 431 
 
524 (357, 711) 2.4 671 
Manzini 457 (326, 632) 3.0 292 
 
590 (385, 790) 2.1 639 
 
539 (362, 729) 2.4 931 
Shiselweni 435 (291, 570) 4.5 145 
 
589 (423, 786) 1.0 381 
 
541 (384, 740) 2.0 526             
Marital status 
           
Never married 422 (281, 578) 3.7 282 
 
586 (387, 782) 2.5 728 
 
539 (351, 716) 2.9 1,010 
Married 448 (319, 627) 2.7 508 
 
590 (412, 776) 1.2 748 
 
520 (358, 722) 1.8 1,256 
Living together 485 (306, 655) 4.8 69 
 
604 (437, 768) 1.5 125 
 
565 (364, 742) 2.8 194 
Divorced/separated 459 (321, 581) 1.7 77 
 
656 (475, 861) 1.6 124 
 
553 (395, 794) 1.6 201 
Widowed 366 (229, 518) (4.2) 34 
 
544 (417, 745) 0.6 287 
 
531 (382, 731) 1.0 321 
            
Type of union 
           
In polygynous union 376 (306, 575) (0.0) 42 
 
623 (361, 802) 0.8 82 
 
532 (323, 726) 0.5 124 
Not in polygynous union 457 (319, 634) 3.1 522 
 
589 (417, 764) 1.1 735 
 
524 (359, 729) 2.0 1,257 
Not currently in union 425 (284, 576) 3.3 393 
 
580 (410, 790) 2.0 1,139 
 
541 (360, 730) 2.4 1,532 
Don't know/missing * * 15 
 
577 (435, 780) 2.7 72 
 
547 (396, 728) 4.4 87             
Education 
           
No education 427 (315, 584) 2.8 74 
 
604 (452, 755) 0.0 151 
 
549 (367, 711) 1.0 225 
Primary 436 (320, 579) 2.6 379 
 
585 (424, 790) 1.1 692 
 
527 (361, 728) 1.6 1,071 
Secondary 435 (254, 601) 5.1 247 
 
589 (411, 784) 2.1 658 
 
540 (362, 734) 3.0 905 
High school 451 (327, 605) 3.1 221 
 
572 (390, 766) 1.9 414 
 
522 (352, 723) 2.3 635 
Tertiary 484 (311, 716) (0.0) 46 
 
621 (412, 810) 3.0 109 
 
579 (380, 763) 2.0 155 
            
Wealth quintile 
           
Lowest 444 (326, 559) 3.4 235 
 
573 (423, 782) 1.3 515 
 
519 (371, 712) 2.0 750 
Second 420 (307, 597) 4.0 214 
 
625 (438, 825) 1.8 437 
 
553 (361, 758) 2.6 651 
Middle 464 (287, 660) 2.1 205 
 
558 (377, 742) 1.7 455 
 
527 (357, 722) 1.8 660 
Fourth  413 (297, 563) 4.3 169 
 
606 (412, 787) 1.2 355 
 
534 (354, 728) 2.2 524 
Highest 478 (308, 703) 1.8 148 
 
560 (414, 739) 2.4 264 
 




Table 11.3.B Median CD4 count and prevalence of immunosuppression (continued) 
Among HIV-positive adults aged 15 years and older, median (Q1, Q3) CD4 count and percentage with immunosuppression 
(< 100 cells/μL1), by sex, self-reported diagnosis and ART status, and selected demographic characteristics, SHIMS2 2016-2017 















< 100 cells/μL 
Number 
Age 
           
15-19 399 (279, 588) (1.6) 40 
 
671 (372, 923) 2.5 72 
 
574 (345, 853) 2.2 112 
20-24 434 (304, 543) (6.3) 29 
 
606 (402, 790) 1.8 197 
 
577 (373, 744) 2.5 226 
25-29 502 (345, 636) 2.2 81 
 
597 (406, 801) 2.4 319 
 
574 (389, 757) 2.4 400 
30-34 405 (297, 564) 4.6 139 
 
582 (400, 753) 1.5 392 
 
533 (360, 716) 2.5 531 
35-39 428 (257, 618) 5.5 184 
 
569 (438, 742) 1.4 319 
 
519 (353, 702) 2.9 503 
40-44 465 (340, 600) 2.5 133 
 
595 (435, 798) 1.4 224 
 
528 (392, 718) 1.8 357 
45-49 452 (331, 579) 3.1 123 
 
552 (352, 758) 1.0 169 
 
507 (344, 698) 2.0 292 
50-54 425 (276, 613) 0.7 84 
 
569 (365, 779) 2.0 135 
 
489 (330, 731) 1.4 219 
55-59 496 (307, 603) 1.8 58 
 
658 (439, 876) 0.0 90 
 
548 (369, 775) 0.8 148 
60-64 398 (284, 660) 0.0 53 
 
546 (368, 759) 3.9 67 
 
493 (312, 683) 1.7 120 
65+ 388 (303, 566) (1.6) 48 
 
561 (484, 688) (0.0) 44 
 
500 (331, 622) 1.0 92 
            
15-29 455 (330, 610) 3.0 150 
 
602 (404, 816) 2.2 588 
 
575 (374, 765) 2.4 738 
20-39 430 (292, 607) 4.6 433 
 
585 (413, 768) 1.8 1,227 
 
543 (366, 732) 2.6 1,660 
25+ 439 (310, 608) 3.2 903 
 
579 (412, 776) 1.6 1,759 
 
527 (360, 722) 2.2 2,662             
Total 15-24 424 (301, 577) 4.0 69 
 
610 (399, 851) 2.0 269 
 
576 (360, 781) 2.4 338 
Total 15-49 437 (314, 600) 3.9 729 
 
585 (412, 781) 1.7 1,692 
 
536 (365, 731) 2.4 2,421 
Total 15+ 438 (309, 603) 3.2 972 
 
587 (412, 782) 1.7 2,028 
 
534 (360, 730) 2.2 3,000 
1 μL: microliter 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 





11.4 Late HIV Diagnosis 
Late HIV diagnosis is defined as having a CD4 count less than 350 cells/μL, tested HIV positive in SHIMS2, 
and self-reported as HIV negative. Among adults who tested HIV positive in SHIMS2 but reported being 
HIV negative, nearly two-fifths (38.9%) had a CD4 count less than 350 cells/μL (42.4% in males and 
35.0% in females) and 13.4% had a CD4 count less than 200 cells/μL (14.0% in males and 12.8% in 
females).  
 
Among adults living with HIV, who reported not being aware of their HIV-positive status, 
immunosuppression with CD4 count less than 350 cells/μL was higher in rural areas (43.3%) than in 
urban areas (31.9%) and immunosuppression with CD4 count less than 200 cells/μL was more 
comparable between rural (12.8%) and urban (14.5%) areas.  
 
Among young people aged 15-24 years who tested HIV positive in SHIMS2 but reported being HIV 
negative, 39.0% had a CD4 count less than 350 cells/μL and 11.9% had a CD4 count less than 200 




Table 11.4.A Late HIV diagnosis  
Among adults aged 15 years and older, who tested HIV positive in the PHIA survey but reported HIV negative, percentage who had  






























           
Urban 14.8 33.9 59 
 
14.0 29.3 52 
 
14.5 31.9 111 
Rural 13.4 48.2 111 
 
12.1 38.1 123 
 
12.8 43.3 234 
Region 
           
Hhohho 14.8 45.6 64 
 
14.0 33.5 66 
 
14.4 39.8 130 
Lubombo (27.4) (54.7) 28 
 
(5.3) (30.4) 32 
 
16.5 42.7 60 
Manzini 6.0 30.7 62 
 
15.6 38.9 52 
 
10.1 34.1 114 
Shiselweni * * 16 
 
(11.5) (34.7) 25 
 
(17.7) (47.9) 41 
Marital status 
           
Never married 11.6 40.8 82 
 
13.9 29.8 95 
 
12.7 35.3 177 
Married 18.7 46.3 59 
 
(6.7) (43.4) 43 
 
13.9 45.2 102 
Living together * * 14 
 
* * 14 
 
(3.4) (29.9) 28 
Divorced/separated * * 12 
 
* * 16 
 
(18.5) (46.6) 28 
Widowed * * 3 
 
* * 6 
 
* * 9 
Type of union 
        
   
In polygynous union * * 6 
 
* * 8 
 
* * 14 
Not in polygynous union 14.8 37.8 62 
 
(9.1) (41.3) 44 
 
12.6 39.1 106 
Not currently in union 14.0 44.1 97 
 
14.9 30.5 117 
 
14.5 37.2 214 
Don't know/missing * * 5 
 
* * 6 
 
* * 11 
Education 
           
No education * * 9 
 
* * 7 
 
* * 16 
Primary 12.2 44.0 58 
 
(15.5) (36.6) 45 
 
13.4 41.3 103 
Secondary (16.5) (42.8) 48 
 
13.4 38.8 56 
 
15.0 40.8 104 
High school (12.1) (40.4) 48 
 
15.6 42.2 53 
 
13.8 41.3 101 
Tertiary * * 7 
 
* * 13 
 
* * 20 
Wealth quintile 
           
Lowest (22.3) (46.1) 37 
 
(11.2) (24.9) 31 
 
18.0 37.8 68 
Second (18.1) (53.3) 37 
 
(12.5) (40.5) 35 
 
15.6 47.5 72 
Middle (10.8) (32.7) 39 
 
12.5 32.9 50 
 
11.7 32.8 89 
Fourth  (5.8) (36.0) 31 
 
(17.5) (42.5) 30 
 
11.1 39.0 61 
Highest (13.1) (44.6) 26 
 
(9.7) (32.1) 29 
 
11.4 38.1 55 
Age            
15-19 * * 9  * * 21  (12.4) (35.8) 30 
20-24 * * 15  (12.4) (39.0) 43  11.7 40.4 58 
25-29 (4.8) (27.9) 34  (3.8) (20.0) 35  4.3 24.2 69 
30-34 (15.5) (38.7) 30  * * 23  9.5 31.2 53 
35-39 (26.3) (50.7) 30  * * 19  (22.3) (48.3) 49 
40-44 * * 18  * * 11  (19.8) (52.1) 29 
45-49 * * 10  * * 5  * * 15 
50-54 * * 9  * * 7  * * 16 
55-59 * * 6  * * 3  * * 9 
60-64 * * 4  * * 5  * * 9 
65+ * * 5  * * 3  * * 8 
            
15-29 5.7 35.1 58  10.3 30.2 99  8.4 32.2 157 
20-39 13.9 38.9 109  8.2 30.7 120  11.1 34.9 229 
25+ 15.2 41.8 146  12.0 34.4 111  13.9 38.9 257 
            
Total 15-24 * * 24  14.0 36.1 64  11.9 39.0 88 
Total 15-49 13.9 41.1 146  12.2 34.8 157  13.1 38.1 303 
Total 15+ 14.0 42.4 170  12.8 35.0 175  13.4 38.9 345 
1 μL: microliter 
2Relates to Global AIDS Monitoring indicator 1.5: Late HIV diagnosis. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 




11.5 Retention on Antiretroviral Therapy 
Among HIV-positive adults who initiated ART less than 12 months prior to the survey, 100% reported 
continued ART use at the time of the survey. All (100.0%) people living with HIV with detectable ARVs 
reported they were still on ART (Table 11.5.A). 
 
Among HIV-positive adults who initiated ART 12 months or more prior to the survey, 99.1% reported 
continued ART at the time of the survey. Nearly all (99.8%) people living with HIV with detectable ARVs 




Table 11.5.A Retention on antiretroviral therapy (ART): HIV-positive adults who reported being on ART less than 12 
months prior to the survey  
Among HIV-positive adults aged 15 years and older who reported initiating ART less than 12 months prior to the survey, percentage who 















still receiving ART1 
Number 
Presence of detectable ARVs         
Detectable 100.0 109  100.0 246  100.0 355 
Not detectable * 7  * 19  (100.0) 26 
Residence 
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100.0 324          















1 Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. The sum of the 
sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 11.5.B Retention on antiretroviral therapy (ART): HIV-positive adults who reported being on ART 12 months 
or more prior to the survey 
Among HIV-positive adults aged 15 years and older who reported initiating ART 12 months or more prior to the survey, percentage who 
reported still receiving ART, by sex and selected demographic characteristics, SHIMS2 2016-2017 
 Males  Females  Total 
Characteristic Percentage 








still receiving ART1 
Number 
Presence of detectable ARVs 
        









81.5 72          
Residence 
        











        



















98.8 366          
Marital status 
        
























99.2 248          
Type of union 
        



















98.4 52          
Education 
        
























100.0 92          
Wealth quintile 
        
























98.5 248          
Age 
        






















































100.0 70          














99.1 1,747          















1Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. Estimates with an asterisk are 
based on a very small number (less than 25) of unweighted cases and have been suppressed. The sum of the sample sizes for a given classification may be less 
than the total sample size because of missing responses to the classification variable.  
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11.6 Transmitted Resistance to Antiretrovirals 
Among 28 samples from recently infected HIV-positive adults, 80.8% were successfully amplified. Among 
the amplified samples, five had evidence of resistance to ARVs. All had mutations associated with 
resistance to non-nucleoside reverse transcriptase inhibitors. None had mutations associated with 
resistance to nucleoside reverse transcriptase inhibitors or to protease inhibitors (Table 11.6.A). Among 
the subset of samples that underwent genotyping, 98.9% were Subtype C. One sample was a 
recombinant genotype (Table 11.6.B). 
 
Table 11.6.A Resistance to antiretrovirals  
Among persons aged 15 years and older who were recently infected with HIV, percentage with resistance to antiretrovirals 
(ARVs), by class of ARV, SHIMS2 2016-2017 
 Percent Number DR Mutations Detected1 
Successfully amplified2 (80.8) 28 
 
Any * 5 G190A, K101KE, K103N, V106M, Y188L 
NRTI * 0 
 
NNRTI * 5 G190A, K101KE, K103N, V106M, Y188L 
PI * 0 
 
NRTI & NNRTI * 0 
 
NRTI, NNRTI & PI * 0 
 
1Based on Stanford Database for HIV Drug Resistance Mutation. https://hivdb.stanford.edu/assets/media/resistance-mutation-handout-
Dec2017.b8f72e32.pdf.  
2Unweighted figures, from a total of 22 cases. 
NRTI: Nucleoside Reverse Transcriptase Inhibitors 
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors 
PI: Protease inhibitor 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
 
Table 11.6.B HIV subtype 
Percent distribution of HIV-positive persons aged 15 years and older who underwent genotyping, by HIV Subtype, SHIMS2 
2016-2017 
  Total 
  Percent Number 
Subtype A * 0 
Subtype B * 0 
Subtype C 98.9 92 
Subtype D * 0 
Subtype G * 0 
Recombinant * 1 
   
Total 100.0 93 





11.7 Gaps and Unmet Needs 
 
11.8 References 
1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection. Geneva: World Health Organization; 2016. 
http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed December 20, 2018. 
 
  
▪ Late HIV diagnosis continues despite achievements in HIV diagnosis among adults living with 
HIV. Strengthening HIV diagnosis and treatment among men who are likely to present late is 
needed. 
▪ Prevalence of drug resistance to non-nucleoside reverse transcriptase inhibitors may exceed the 
WHO recommended threshold of 10% for removing a first-line regimen from the national 
formulary. Further information is needed to determine whether a shift is warranted. 
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Chapter 12   Prevention of Mother-to-Child Transmission 
12.1 Key Findings 
 
12.2 Background 
Pregnant women living with HIV are at high risk of transmitting HIV to their infants during pregnancy, 
during birth, and through breastfeeding. Over 90% of new infections among infants and young children 
occur through mother-to-child transmission of HIV (MTCT). Without any interventions, between 20% 
and 45% of infants may become infected, with an estimated risk of 5-10% during pregnancy, 10-20% 
during labor and delivery, and 5-20% through breastfeeding.1 In 2010, global targets were set to 
decrease new HIV infections in children and reduce mortality among mothers living with HIV, including a 
90% reduction in child HIV infections, a 50% reduction in AIDS-related maternal deaths, and virtual 
elimination of MTCT.2 
 
To prevent MTCT, the United Nations recommends a comprehensive four-pronged approach including: 
(1) primary prevention of HIV infection among women of childbearing age; (2) preventing unintended 
pregnancies among women living with HIV; (3) preventing HIV transmission from women living with HIV 
to their infants; and (4) providing appropriate treatment, care, and support to mothers living with HIV 
and their children and families.2  
 
This chapter describes ANC attendance, breastfeeding practices, awareness of a woman’s HIV status 
prior to or during pregnancy, use of ART during pregnancy in women who were aware of their HIV-
positive status during pregnancy, and infant HIV testing conducted during the survey. 
 
12.3 Antenatal Care Attendance 
Among mothers aged 15-49 years who delivered in the three years preceding the survey, nearly all 
(99.4%) attended at least one ANC visit during their pregnancy. ANC attendance was comparable across 
regions, marital status, wealth quintile, and age. Among mothers aged 15-49 years who delivered in the 
12 PREVENTION OF MOTHER-TO-CHILD 
TRANSMISSION   
  
▪ Nearly all (99.4%) mothers aged 15-49 years, who delivered in the three years prior to the 
survey, attended at least one antenatal care (ANC) visit during their pregnancy. 
▪ Among mothers aged 15-49 years who gave birth within the prior three years, the percentage of 
mothers who never breastfed and tested HIV positive (11.5%) was almost three times higher 
than in mothers who never breastfed and tested HIV negative (4.3%). 
▪ Among mothers aged 15-49 years who gave birth during the 12 months prior to the survey, 
98.4% reported knowing their HIV status before delivery: 30.2% were diagnosed as HIV positive 
before ANC, 6.4% were newly diagnosed as HIV positive in ANC, and 61.8% tested HIV negative in 
ANC. 
▪ Among HIV-positive mothers aged 15-49 years who gave birth during the 12 months prior to the 
survey, 56.1% were on ARVs prior to pregnancy, and 34.0% were newly initiated onto ARVs 
during pregnancy, labor, or delivery. 
▪ More than a tenth (12.8%) of infants aged 0-17 months, born to HIV-positive mothers aged 15-49 
years in the 17 months prior to the survey, were confirmed HIV positive by virologic testing. 
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prior three years, ANC attendance was lowest in polygynous unions (95.9%) and in those with no 
education (95.7%; Table 12.3.A).    
 
Table 12.3.A Antenatal care 
Among women aged 15-49 years who delivered in the three years preceding the survey, percentage who attended at 
least one antenatal care visit for her most recent birth, by selected demographic characteristics, SHIMS2 2016-2017 
Characteristic 
Percentage who attended at  
least one antenatal care visit 
Number 
Residence   
Urban 99.8 246 
Rural 99.2 921 
   
Region   
Hhohho 99.4 313 
Lubombo 99.3 258 
Manzini 99.5 385 
Shiselweni 99.2 211 
   
Marital status   
Never married 99.0 533 
Married 99.8 465 
Living together 100.0 100 
Divorced/separated (98.0) 48 
Widowed * 17 
   
Type of union   
In polygynous union (95.9) 26 
Not in polygynous union 100.0 489 
Not currently in union 98.9 598 
Don't know/missing 100.0 54 
   
Education   
No education (95.7) 25 
Primary 99.4 279 
Secondary 100.0 404 
High school 99.0 358 
Tertiary 99.1 98 
   
Wealth quintile   
Lowest 99.6 279 
Second 99.4 281 
Middle 99.6 276 
Fourth  99.6 176 
Highest 98.3 154 
   
Age   
15-19 99.1 106 
20-24 99.4 348 
25-29 99.7 310 
30-34 98.8 241 
35-39 100.0 116 
40-44 (100.0) 41 
45-49 * 5 
   
Total 15-24 99.4 454 
Total 15-29 99.5 764 
Total 15-49 99.4 1,167 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted 
with caution. Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
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12.4 Breastfeeding 
Among mothers aged 15-49 years who gave birth within the prior three years, current breastfeeding 
was higher in mothers testing HIV negative in the survey (36.4%) compared to mothers testing HIV 
positive (28.5%). Having never breastfed was higher in mothers testing HIV positive (11.5%) than in 
mothers testing HIV negative (4.3%; Table 12.4.A). 
 
Table 12.4.A Breastfeeding status by child's age and mother's HIV status  
Percent distribution of last-born children born to women aged 15-49 years in the three years preceding the survey by 
breastfeeding status, by child's age and mother's HIV status, SHIMS2 2016-2017 
Characteristic Never 
breastfed 





Child's age (months) 
     
0-1 3.1 29.0 67.9 100.0 71 
2-3 7.9 26.0 66.1 100.0 90 
4-5 8.0 27.4 64.6 100.0 65 
6-8 6.9 28.0 65.1 100.0 102 
9-11 9.5 29.8 60.7 100.0 115 
12-17 4.3 57.8 38.0 100.0 186 
18-23 8.5 81.1 10.4 100.0 191 
24-36 6.7 92.5 0.8 100.0 323       
Result of mother's PHIA survey HIV test 
     
HIV positive 11.5 60.0 28.5 100.0 416 
HIV negative 4.3 59.2 36.4 100.0 682 
Not tested (5.3) (72.1) (22.6) 100.0 49       
Total 6.9 60.1 33.0 100.0 1,147 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
 
12.5 Awareness of Mother’s HIV Status 
Among mothers aged 15-49 years who gave birth during the 12 months prior to the survey, 98.4% 
reported knowing their HIV status before delivery: 30.2% were diagnosed as HIV positive before ANC, 
6.4% were newly diagnosed as HIV positive in ANC, and 61.8% tested HIV negative in ANC (Table 12.5.A).  
 
Among mothers aged 15-49 years who gave birth during the 12 months prior to the survey, prior HIV 
diagnosis was higher in urban areas (33.8%) than in rural areas (28.9%) and was highest in Lubombo 
region (36.5%). Prior HIV diagnosis among mothers aged 15-49 years who gave birth in the prior 12 
months was lowest in ages 15-19 years (9.6%) and increased with age to a peak of 55.4% in ages 35-39 
years. Among mothers aged 15-49 years who gave birth during the prior 12 months, receiving a new HIV 
diagnosis in ANC was highest in those aged 30-34 years (16.0%; Table 12.5.A). 
 
Among mothers aged 15-24 years who gave birth during the 12 months prior to the survey, 97.5% 
reported knowing their HIV status before delivery: 16.9% were diagnosed as HIV positive before ANC, 
4.0% were newly diagnosed as HIV positive in ANC, and 76.5% were diagnosed as HIV negative in ANC. 
Prior HIV diagnosis among mothers aged 15-49 years who gave birth in the previous 12 months was over 
twice as high in ages 20-24 years (19.4%) than in ages 15-19 years (9.6%). New HIV diagnosis among 
mothers aged 15-49 years, who gave birth in the prior 12 months, was relatively comparable in ages 15-





Table 12.5.A Prevention of mother-to-child transmission, known HIV status  
Among women aged 15-49 years who gave birth within the past 12 months, percentage who were tested for HIV during antenatal care and 
received their results or who already knew they were HIV positive, by selected demographic characteristics, SHIMS2 2016-2017 




tested HIV positive 
Percentage who 
tested HIV negative 
Percentage who 
already knew they 
were HIV positive 
Total percentage 
with known HIV 
status1 
Number of women who 
delivered within the past 
12 months 
Residence 
     
Urban 7.2 56.9 33.8 98.0 94 
Rural 6.2 63.5 28.9 98.6 354       
Region 
     
Hhohho 7.0 66.0 26.2 99.3 112 
Lubombo 9.0 51.7 36.5 97.2 108 
Manzini 4.9 60.0 33.0 97.9 141 
Shiselweni 5.5 72.3 22.2 100.0 87       
Marital status 
     
Never married 4.6 72.5 20.1 97.2 222 
Married 8.1 49.6 41.8 99.5 155 
Living together (6.5) (59.8) (33.7) (100.0) 48 
Divorced/separated * * * * 16 
Widowed * * * * 5       
Type of union 
     
In polygynous union * * * * 9 
Not in polygynous union 7.1 54.2 38.7 100.0 176 
Not currently in union 5.5 69.5 22.5 97.5 243 
Don't know/missing * * * * 20       
Education 
     
No education * * * * 9 
Primary 8.8 50.7 39.7 99.2 114 
Secondary 5.1 58.1 36.8 100.0 165 
High school 5.8 74.8 14.8 95.4 130 
Tertiary (7.3) (74.0) (18.7) (100.0) 28       
Wealth quintile 
     
Lowest 5.9 62.3 31.9 100.0 115 
Second 8.5 61.3 29.4 99.2 119 
Middle 6.2 65.8 23.6 95.6 101 
Fourth  7.4 51.8 38.6 97.8 67 
Highest (2.3) (70.5) (27.3) (100.0) 45       
Age 
     
15-19 4.9 85.5 9.6 100.0 56 
20-24 3.7 73.5 19.4 96.6 148 
25-29 4.1 58.7 36.2 99.1 117 
30-34 16.0 42.0 41.0 99.0 78 
35-39 (3.2) (41.4) (55.4) (100.0) 36 
40-44 * * * * 13 
45-49 * * * * 0 
  
     
15-29 4.1 69.9 24.1 98.1 321 
25-49 8.4 49.8 41.0 99.2 244       
Total 15-24 4.0 76.5 16.9 97.5 204 
Total 15-49 6.4 61.8 30.2 98.4 448 
1Relates to PEPFAR indicator PMTCT_STAT_NAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
12.6 Antiretroviral Therapy Among HIV-Positive Pregnant Women 
Among HIV-positive mothers aged 15-49 years who gave birth during the 12 months prior to the survey, 
over half (56.1%) were on ARVs prior to pregnancy, and more than a third (34.0%) were newly initiated 
onto ARVs during pregnancy, labor, or delivery (Table 12.6.A).  
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Among HIV-positive mothers aged 15-24 years who gave birth during the 12 months prior to the survey, 
48.0% were on ARVs prior to pregnancy and 40.3% were newly initiated onto ARVs during pregnancy, 
labor, or delivery (Table 12.6.A). 
 
Table 12.6.A Prevention of mother-to-child transmission, HIV-positive pregnant women who received 
antiretrovirals (ARVs) 
Among self-reported HIV-positive women aged 15-49 years who gave birth within the past 12 months, percentage who received ARVs during 
pregnancy to reduce the risk of mother-to-child-transmission, by selected demographic characteristics, SHIMS2 2016-2017 
Characteristic Percentage who were 
already on ARVs prior 
to pregnancy 
Percentage who were newly 
initiated on ARVs during 




Number of HIV-positive 
women who gave birth 
within the past 12 months 
Residence 
    
Urban (59.2) (29.1) (88.3) 36 
Rural 54.8 36.0 90.7 125      
Region 
    
Hhohho (62.4) (32.4) (94.9) 35 
Lubombo (53.7) (35.6) (89.3) 48 
Manzini 50.9 34.7 85.6 53 
Shiselweni (64.6) (31.0) (95.6) 25      
Marital status 
    
Never married 49.3 37.7 87.0 54 
Married 56.7 35.1 91.8 76 
Living together * * * 18 
Divorced/separated * * * 10 
Widowed * * * 3      
Type of union 
    
In polygynous union * * * 6 
Not in polygynous union 63.1 29.5 92.5 79 
Not currently in union 47.9 40.0 88.0 67 
Don't know/missing * * * 9      
Education 
    
No education * * * 6 
Primary 51.8 39.6 91.4 52 
Secondary 63.1 28.0 91.1 67 
High school (39.7) (40.2) (79.9) 28 
Tertiary * * * 7      
Wealth quintile 
    
Lowest (51.6) (36.7) (88.3) 43 
Second (58.3) (35.7) (94.0) 44 
Middle (55.6) (41.2) (96.8) 30 
Fourth  (54.9) (27.7) (82.5) 29 
Highest * * * 14      
Age 
    
15-19 * * * 8 
20-24 (55.1) (35.4) (90.4) 36 
25-29 (55.1) (31.2) (86.3) 44 
30-34 (55.5) (40.3) (95.7) 45 
35-39 * * * 21 
40-44 * * * 7 
45-49 * * * 0 
15-29 51.7 35.6 87.2 88 
25-49 58.9 31.7 90.7 117      
Total 15-24 (48.0) (40.3) (88.3) 44 
Total 15-49 56.1 34.0 90.0 161 
1Relates to Global AIDS Monitoring indicator 2.3: Preventing the mother-to- child transmission of HIV and PEPFAR indicator PMTCT_ARV_NAT.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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12.7 Mother-to-Child Transmission 
Among infants under the age of 18 months born to HIV-positive mothers aged 15-49 years, 12.8% were 
confirmed HIV positive by virologic testing. Among infants between the ages of 0-11 months, 14.7% 
were confirmed HIV positive by virologic testing (Table 12.7.A). (Note: Virological testing was conducted 
only among those infants with a reactive rapid test at screening during the survey.) 
 
Among HIV-positive mothers aged 15-49 years with infants under 18 months of age, 14.5% reported 
ever breastfeeding their infant and 2.4% reported ARV use at the first ANC visit (Table 12.7.A). 
 
Table 12.7.A Mother-to-child transmission of HIV 
Among infants born in the last 17 months to HIV-positive women aged 15-49 years, percentage confirmed positive for HIV 
infection, by mother's self-reported antiretroviral therapy (ART) and breastfeeding status, SHIMS2 2016-2017 
Characteristic 
Percentage of infants 
confirmed HIV positive1,2 
Number of infants born 
to HIV-positive women3,4 
Mother's self-reported ARV status   
Mother unaware of HIV status during pregnancy * 7 
Already on ARVs at first antenatal visit (2.4) 36 
Newly initiated on ARVs during pregnancy or labor and delivery * 20 
Did not receive ARVs during pregnancy * 4 
Missing self-reported ARV status * 22 
    
Mother's self-reported breastfeeding status   
Ever breastfed the infant 14.5 60 
Never breastfed the infant * 7 
Missing self-reported breastfeeding status * 22 
    
Total 0-11 months 14.7 62 
Total 0-17 months 12.8 89 
1Relates to Global AIDS Monitoring indicator 2.2: Mother-to-child transmission of HIV. 
2Infants confirmed as HIV positive by virological testing (virological testing was only conducted among infants who had a reactive screening 
test). 
3Includes only infants who were tested for HIV during the PHIA survey. 
4Women who tested HIV positive during the PHIA survey. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 





12.8 Gaps and Unmet Needs 
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▪ Exclusive breastfeeding in infants aged 0-6 months is standard of care, regardless of the mother’s 
HIV status. Yet, over a tenth of HIV-positive mothers never breastfed their infants. Interventions 
encouraging age-appropriate exclusive breastfeeding and complementary feeding regardless of 
the mother’s HIV status are essential to promote infant health, particularly when combined with 
effective ART in HIV-positive mothers. 
▪ One in ten previously diagnosed HIV-positive mothers self-reported as no ARV use during 
pregnancy, labor, or delivery. Closing this gap in treatment delivery is key to assure reduced 
MTCT and morbidity and mortality among HIV-positive mothers.   
▪ A proportion of infants aged 0-17 months were diagnosed with HIV by virologic testing. Yet 
effective ART provision to HIV-positive mothers can virtually eliminate HIV MTCT. Better 
strategies are critical to assure provision of preventive ARV regimens to all HIV-exposed infants, 
including ART to pregnant and breastfeeding HIV-positive mothers.  
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Chapter 13   Young People 




One-third of the population of sub-Saharan Africa is between the ages of 10-24 years, a phenomenon 
often referred to as the “youth bulge.”1 Young people (defined as older adolescents aged 15-19 years 
and young adults aged 20-24 years) are more likely to engage in risky sexual behaviors than older adults 
and have less frequent contact with the healthcare system. Control of HIV in this demographic is critical 
for long-term epidemic control but is also particularly challenging. This chapter presents the prevalence 
of early sexual debut before the age of 15 years among young people, and also describes HIV incidence, 
prevalence, and the 90-90-90 targets for this age group. 
 
13.3  Sexual Intercourse Before the Age of 15 Years  
Among young people aged 15-24 years, 3.5% had sex before the age of 15 years (4.5% in males and 2.5% 
in females). Early sexual debut among young people was higher in urban areas (4.9%) than in rural areas 
(3.1%) and was highest in Manzini region (4.2%). Sexual debut before the age of 15 years was lowest in 
those never married (3.1%). Early sexual debut was most common in the highest wealth quintile (4.6%) 
and progressively decreased to the lowest wealth quintile (2.2%) (Table 13.3.A).  
 
Among young people, early sexual debut was higher in ages 20-24 years (5.9% in males and 3.6% in 
females) than in ages 15-19 years (3.2% in males and 1.6% in females). Early sexual debut among young 
females was highest in those who attended primary education (4.3%) and lowest in those who attended 
tertiary (0%). In contrast, early sexual debut among young males was lowest in those who attended 
▪ Among young people aged 15-24 years, 3.5% had sex before the age of 15 years (4.5% males, 2.5% 
females).  
▪ Using an ARV-adjusted LAg avidity testing algorithm, estimated annual incidence was 1.07% (95% 
confidence interval (CI): 0.46%-1.69%) among young people aged 15-24 years: 0.52% (95% CI: 
0.00%-1.14%) males, 1.67% (95% CI: 0.62%-2.71%) females.   
▪ HIV prevalence in young people aged 15-24 years was higher in ages 20-24 years (4.2% males, 
20.9% females) than in ages 15-19 years (3.9% males, 7.2% females). 
▪ Testing in the prior 12 months was significantly higher in ages 15-19 years in females than in males 
(47.9% and 33.0%, respectively) and significantly higher in ages 20-24 years in females than in 
males (74.2% and 51.1%, respectively).  
▪ Among HIV-positive young people aged 15-24 years, about one-third (33.9%) were unaware of 
their HIV-positive status (48.5% males, 29.8% females).  
▪ Among young people aged 15-24 years who are living with HIV, over half (54.1%) were aware of 
their HIV-positive status and on ART (46.8% males, 56.1% females).  
▪ Among HIV-positive young people aged 15-24 years, half (50.6%) had suppressed viral loads 
(32.9% males, 55.5% females).  
▪ Based on self-reported prior HIV diagnosis, self-reported ART use, and ARV biomarker detection in 
HIV-positive young people aged 15-24 years, 72.1% were classified as ARV-adjusted diagnosed; 
among them, 85.3% were classified as ARV-adjusted on treatment, of which 76.5% had VLS. 
13 YOUNG PEOPLE 
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primary education (3.9%) and increased to those who attended tertiary (10.8%). Early sexual debut was 
lowest among females who had never married (1.9%), but in contrast was highest among males who 
had never married (4.3%) (Table 13.3.A).      
 
Table 13.3.A Sexual intercourse before 15 years of age  
Percentage of young people aged 15–24 years who had sexual intercourse before 15 years of age; by sex and selected demographic 







Characteristic Percentage who had sex 
before 15 years of age 
Number 
 
Percentage who had sex 
before 15 years of age 
Number 
 
Percentage who had sex 
before 15 years of age 
Number 
Residence 
        









3.1 3,045          
Region 
        



















3.3 725          
Marital status 
        
























* 1          
Type of union 
        



















(10.7) 47          
Education 
        
























4.9 173          
Wealth quintile 
        
























4.6 498          
Age 
        









4.7 1,606          





Estimate in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 




13.4 HIV Incidence and Prevalence 
 
HIV incidence estimates using LAg avidity and HIV viral load 
Using the VL-adjusted LAg avidity testing algorithm, estimated incidence was 1.31% (95% CI: 0.66%-
1.96%) among young people: 0.79% (95% CI: 0.07%-1.50%) in males and 1.87% (95% CI: 0.76%-2.98%) in 
females. Interpretation of estimates is limited since SHIMS2 was designed to estimate incidence in ages 
15-49 years (Table 5.3.A). 
 
HIV incidence estimates using LAg avidity, HIV viral load, and ARV detection 
Using the ARV-adjusted LAg avidity testing algorithm, estimated incidence was 1.07% (95% CI: 0.46%-
1.69%) among young people: 0.52% (95% CI: 0.00%-1.14%) in males and 1.67% (95% CI: 0.62%-2.71%) in 
females. Interpretation of estimates is limited since SHIMS2 was designed to estimate incidence in ages 
15-49 years (Table 5.3.B). 
 
HIV prevalence 
Nearly one-tenth (9.1%) of young people was HIV positive. HIV prevalence in females was more than 
triple the HIV prevalence in males (13.9% and 4.1%, respectively). HIV prevalence was higher in ages 20-
24 years (4.2% in males and 20.9% females) than in ages 15-19 years (3.9% in males and 7.2% in 
females; Table 6.4.A). 
 
13.5 HIV Testing, Treatment, and Viral Load Suppression 
 
HIV testing among young people  
Among young people, three-quarters (75.4%) had ever tested for HIV and received their test results (i.e., 
lifetime testing). Lifetime testing was lower in ages 15-19 years (65.2%) than in ages 20-24 years 
(86.1%). Half (51.6%) had received HIV testing and their test results in the 12 months prior to the survey. 
Testing in the prior 12 months was lower in ages 15-19 years (40.6%) than in ages 20-24 years (63.1%) 
(Table 7.3.C).  
 
Among young people, lifetime testing and testing in the prior 12 months were higher in females (81.0% 
and 61.0%, respectively) than in males (69.5% and 41.8%, respectively). Lifetime testing was lower in 
ages 15-19 years (61.9% in males and 68.3% females) than in ages 20-24 years (77.7% in males and 
93.9% in females). Similarly, testing in the prior 12 months was lower in ages 15-19 years (33.0% in 
males and 47.9% in females) than in ages 20-24 years (51.1% in males and 74.2% in females). Testing in 
the prior 12 months was significantly higher in ages 15-19 years in females (47.9%) than males (33.0%) 
and significantly higher in ages 20-24 years in females (74.2%) than males (51.1%) (Tables 7.3.A and 
7.3.B, Figure 7.3.A). 
 
Self-reported diagnosis and treatment status among HIV-positive young people  
Among young people living with HIV, one-third (33.9%) were unaware of their HIV status: 48.5% in 
males and 29.8% in females. Being unaware of their HIV-positive status was higher in females ages 15-19 
years (35.9%) than those aged 20-24 years (27.6%). In contrast, being unaware of their HIV-positive 
status was less common in males aged 15-19 years (35.0%) than in those aged 20-24 years (61.5%; 
Tables 8.3.A, 8.3.B, and 8.3.C). 
 
Over half (54.1%) of young people living with HIV were aware of their HIV status and on ART: 46.8% in 
males and 56.1% in females. Awareness of one’s HIV-positive status and ART use was lower in females 
aged 15-19 years (52.6%) than in those aged 20-24 years (57.3%). In contrast, awareness of one’s HIV-
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positive status and ART use was higher in males aged 15-19 years (59.5%) than in those aged 20-24 years 
(34.6%; Tables 8.3.A, 8.3.B, and 8.3.C). 
 
Half (50.6%) of young people living with HIV had a suppressed viral load: 32.9% in males and 55.5% in 
females. Viral suppression was comparable between females aged 15-19 years (55.0%) and those aged 
20-24 years (55.7%). In contrast, viral suppression was higher in males aged 15-19 years (40.2%) than in 
those aged 20-24 years (25.8%; Table 9.4.A). 
 
13.6 Status of the 90-90-90 Targets 
 
90-90-90 targets per self-reported HIV diagnosis and self-reported ART use 
In HIV-positive young people, 66.1% reported as diagnosed. Among them, 81.7% reported current 
treatment. In those reporting current treatment, 76.4% had VLS. (Table 10.3.A). 
 
In HIV-positive young females, 70.2% reported as diagnosed; among them, 79.9% reported current 
treatment, of whom 79.9% had suppressed viral loads. In HIV-positive young males, 51.5% reported as 
diagnosed; among them, 90.9% reported current treatment, 61.3% of whom had suppressed viral loads 
(Table 10.3.A). 
 
90-90-90 targets per self-reported HIV diagnosis, self-reported ART use, and ARV biomarker data 
In HIV-positive young people, 72.1% were classified as ARV-adjusted diagnosed. Among those who were 
ARV-adjusted diagnosed, 85.3% were classed as ARV-adjusted on treatment. In young people classified 
as ARV-adjusted on treatment, 76.5% had suppressed viral loads (Table 10.3.B, Figure 13.6.A). 
 
In HIV-positive young females, 75.5% were classified as ARV-adjusted diagnosed. Among them, 83.7% 
were classed as ARV-adjusted on treatment and of these, 81.2% had suppressed viral loads. In HIV-
positive young males, 60.3% were classified as ARV-adjusted diagnosed. Among them, 92.2% were 





Figure 13.6.A Young people, aged 15-24 years, 90-90-90 antiretroviral-adjusted data,1  
SHIMS2 2016-2017 
 
1In the antiretroviral (ARV)-adjusted 90-90-90, participants are classified as ‘Aware’ or ‘Diagnosed’ if they reported knowing 
their HIV-positive status before testing HIV positive in SHIMS2 and/or had detectable ARVs in their blood. Participants are 
classified as ‘On Treatment’ if they reported that they were on treatment and/or if they had detectable ARVs in their blood.  
2Estimates in parentheses are based on a small number (25-49) of unweighted cases and should be interpreted with caution.  
*Inset numbers are conditional proportions. 
 




1. Hervish A, Clifton D. The Status Report on Adolescents and Young People in Sub-Saharan Africa: 
Opportunities and Challenges. Johannesburg and Washington, DC: Population Reference Bureau; 2012.  
  
▪ Well over a third of HIV-positive young people were not diagnosed. Among those previously 
diagnosed with HIV, nearly a sixth were not on ART. Among those on ART, nearly a quarter did not 
have suppressed viral loads. Tailored targeting of programs towards the specific needs of older 
adolescents and young adults may enhance the effectiveness of HIV services.  
▪ Only half of young people living with HIV had viral load suppression—underscoring the need for 
strategic targeting and strong treatment adherence support.  
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Chapter 14   Children 
14.1 Key Findings 
 
14.2 Background 
Estimates of HIV prevalence, number living with HIV, and viral suppression among children are 
commonly derived indirectly from clinic-based data or epidemiologic models. SHIMS2 provides direct 
measurements of these estimates among children (defined in this survey as those aged 0-14 years, 
unless otherwise noted), which are critical for meeting the needs of planning for HIV prevention, care, 
and treatment services for children, evaluating PMTCT programs, and addressing specific needs of 
children. 
 
This chapter presents results on the 90-90-90 targets in children, using parent/guardian-reported data 
(i.e., prior diagnosis of child’s HIV status and ART use) and data on detectable ARVs in the blood. 
Analyses are presented similarly to Chapter 10 UNAIDS 90-90-90 targets on adults aged 15 years and 
older. For this chapter, parents or guardians were asked about a child’s HIV status and ART use. Data on 
detectable ARVs were used in combination with parent/guardian-reported ART use to define the ART 
status of a child. Presence of detectable ARVs in children with parent/guardian-reported undiagnosed 
HIV-positive status were reclassified as diagnosed. Children with viral suppression, but whose parents 
reported them as undiagnosed or not on ART, were excluded from the numerator of the 90% target on 
VLS. 
 
14.3 HIV Prevalence 
Among children, HIV prevalence was 2.8%. The prevalence of HIV in children increases across five-year 
age groups: 1.7% in ages 0-4 years, 2.9% in ages 5-9 years, and 4.1% in ages 10-14 years (Table 6.4.A).  
 
HIV prevalence in children is higher in males (3.0%) than in females (2.6%). Among ages 0-4 years, HIV 
prevalence is higher in females (1.8%) than in males (1.6%). However, HIV prevalence is higher in males 
(3.1%) compared with females (2.7%) in ages 5-9 years and in ages 10-14 years, 4.7% and 3.4% among 





14 CHILDREN   
  
▪ HIV prevalence among children aged 0-14 years was 2.8% and peaked in ages 10-14 years at 
4.1%. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 77.5% of 
HIV-positive children aged 0-14 years had a known HIV-positive status. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 100.0% of 
HIV-positive children aged 0-14 years were on ART. 
▪ Based on parent/guardian-report and presence of detectable ARVs in blood samples, 73.9% of 
HIV-positive children aged 0-14 years had VLS. 
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14.4 Status of the 90-90-90 Targets 
 
90-90-90 targets per parent/guardian-reported HIV diagnosis and parent/guardian-reported ART use 
Among children living with HIV, 71.2% were parent/guardian-reported as diagnosed. Among children 
whose parent/guardian-reported them as diagnosed with HIV, 100.0% were reported being on 
treatment. Among those reported as on treatment, 74.0% had suppressed viral loads (Table 14.4.A).  
 
90-90-90 targets per parent/guardian-reported HIV diagnosis, parent/guardian-reported ART use, and 
ARV biomarker data 
Among children living with HIV, 77.5% were parent/guardian-reported as diagnosed or had detectable 
ARVs in their blood (i.e., ARV-adjusted diagnosed). Among children classified as ARV-adjusted 
diagnosed, 100.0% were reported on treatment or had detectable ARVs in their blood (i.e., ARV-
adjusted on treatment). In HIV-positive children classified as ARV-adjusted on treatment, 73.9% had 
suppressed viral loads (Table 14.4.B, Figure 14.4.A).  
 
Table 14.4.A Pediatric 90-90-90 (parent-reported antiretroviral therapy [ART] data, conditional percentages) 
90-90-90 targets among children living with HIV aged 0-14 years, by age SHIMS2 2016-2017 
 Diagnosed  On Treatment  Viral Load Suppression (VLS) 
 Total  
Among children whose  
parent reported that the  
child is HIV positive 
 
Among children whose 
parent reported that the 
child is on ART 
Age 
Percentage 
whose parent  
reported that  




reported that  






0-17 months * 10 
 
* 3 * 3 

























Estimate in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  




Table 14.4.B Pediatric 90-90-90 (parent-reported antiretroviral therapy [ART] data and laboratory 
antiretroviral [ARV] data; conditional percentages) 
90-90-90 targets among children living with HIV aged 0-14 years, by age SHIMS2 2016-2017 
 Diagnosed  On Treatment  
Viral Load Suppression 
(VLS) 
 Total  
Among children whose parent  
reported that the child is HIV positive 
AND/OR with detectable ARVs 
 
Among children whose parent  
reported the child was on ART  
AND/OR with detectable ARVs 
Age 
Percentage 
whose parent reported 
that the 
 child is HIV positive 
AND/OR  




reported the  
child was on ART 
AND/OR  



































Estimate in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
 
Figure 14.4.A Children, aged 0-14 years, 90-90-90, laboratory antiretroviral-adjusted data,1 SHIMS2 
2016-2017  
 
1In the antiretroviral (ARV)-adjusted 90-90-90, participants are classified as ‘Aware’ or ‘Diagnosed’ if 
they reported being aware of their HIV-positive status before testing HIV positive in SHIMS2 and/or had 
detectable ARVs in their blood. Participants are classified as ‘On Treatment’ if they reported that they 
were on treatment and/or if they had detectable ARVs in their blood.  




14.5 Gaps and Unmet Needs 
 
  
▪ At least one in five HIV-positive children had not been diagnosed with HIV. Identification of these 
children is necessary to assure lower morbidity and mortality in this age group.  
▪ More than one in four HIV-positive children on treatment had uncontrolled HIV VL. It is critical to 
ensure children are on the optimal regimen for their age and weight and that they (or their 
caregivers) receive tailored adherence support. 
▪ With 4.1% of children aged 10-14 years living with HIV, programs to support HIV knowledge, 
including safer sex practices, and HIV treatment to prevent transmission, are key for these early 
adolescents approaching sexual debut.  
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Chapter 15   HIV Risk Behaviors 
15.1 Key Findings 
 
15.2 Background  
This chapter describes the prevalence of sexual behaviors that elevate risk of HIV infection. SHIMS2 
asked questions about high-risk behaviors, including early sexual debut (sexual intercourse before the 
age of 15), recent engagement in multiple sexual partnerships, condom use at last sexual intercourse, 
recent engagement in paid sexual intercourse, and condom use at last sexual intercourse with a non-
marital, non-cohabitating partner. With this information, programs can target those individuals most in 
need of information and most at risk for HIV infection. 
 
The MOH of Eswatini recommends voluntary medical male circumcision (VMMC) as a cost-effective 
strategy to reduce female-to-male sexual transmission of HIV. To inform VMMC programs, men aged 15 
years and older were asked if they had been medically or traditionally circumcised. 
 
15.3 HIV Prevalence by Sexual Behavior 
Among adults (defined in this survey as those aged 15 years and older), HIV prevalence was higher in 
those with early sexual debut (37.2%) compared to those with sexual debut at ages 25 years and older 
(23.7%). Among those who reported early sexual debut, 18.7% of males and 50.6% of females were HIV-
positive. Among adults with two or more sexual partners in the past 12 months, 28.7% were HIV-
positive. HIV prevalence was nearly twice as high in females than in males among adults with two or 
more sexual partners in the prior 12 months (45.3% and 22.8%, respectively; Table 15.3.A).  
 
A fifth (20.9%) of adults who did not use a condom at last sexual intercourse in the prior 12 months 
were HIV positive (16.8% of males and 24.1% of females). However, two-fifths (40.0%) of adults who 
used a condom at last sexual intercourse in the prior 12 months were HIV positive (30.6% of males and 
48.4% of females). Nearly a third (32.4%) of adults who abstained from sexual intercourse in the prior 12 
months were HIV positive (22.6% in males and 36.1% in females; Table 15.3.A). 
15 HIV RISK BEHAVIORS   
▪ Among adults aged 15 years and older who had sexual debut before the age of 15 years, less than 
a fifth (18.7%) of males were HIV positive, compared to about half (50.6%) of females. 
▪ Among adults aged 15 years and older with two or more sexual partners in the prior 12 months, 
HIV prevalence was nearly double in females (45.3%) than in males (22.8%). 
▪ Among adults aged 15 years and older who did not use a condom at last sexual intercourse in the 
prior 12 months, about a fifth (20.9%) were HIV positive (16.8% males, 24.1% females). 
▪ Among adults aged 15 years and older who were living with their sexual partner and who had sex 
with a non-marital, non-cohabitating partner in the prior 12 months, more than half (54.5%) used 
a condom at last sexual intercourse. Condom use at last sexual intercourse with a non-marital, 
non-cohabitating partner was comparatively higher in married adults (63.7%). 
▪ Among adult males aged 15 years and older, 70.7% reported as uncircumcised and 26.7% had 
received medical male circumcision. One-third (34.8%) of adult males aged 15-24 years self-
reported as medically circumcised. 
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HIV prevalence was comparable between adults who did and did not report paid sexual intercourse in 
the 12 months prior to the survey (29.7% and 31.5%, respectively) (Table 15.3.A).  
 
Table 15.3.A HIV prevalence by sexual behavior  

















Age at first sexual intercourse 
        



















23.7 612          
Number of sexual partners in the past 12 
months 
        














28.7 914          
Condom use at last sexual intercourse 
in the past 12 months 
        














32.4 1,723          
Paid sexual intercourse in the past 12 
months 
        





















31.5 7,030          















1Includes persons who paid or received money for sexual intercourse. 
2No paid sexual intercourse or no sexual intercourse in the past 12 months. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable.   
Estimate in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
 
15.4 Condom Use at Last Sex with a Non-Marital, Non-Cohabitating Partner 
Among adults who were sexually active in the 12 months prior to the survey, 48.3% had sex with a non-
marital, non-cohabitating partner (53.6% in males and 43.9% in females). Among sexually active adults, 
sex with a non-marital, non-cohabitating partner was less than half the percentage in those with no 
education (27.1%) than in those completing high school (58.2%). A fifth (20.7%) of sexually active adults 
living with their sexual partner had sex with a non-marital, non-cohabitating partner in the prior 12 
months, in contrast to 5.7% of sexually active married adults. Among sexually active adults in 
polygynous unions, 14.3% had sex with a non-marital, non-cohabitating partner in the prior 12 months. 
Sex with a non-marital, non-cohabitating partner among sexually active adults in polygynous unions was 
higher in males (28.6%) than in females (8.0%; Tables 15.4.A, 15.4.B, and 15.4.C).  
 
Among sexually active adults, sex with a non-marital, non-cohabitating partner was higher at ages 15-24 
years (83.4%) than at ages 25 years and older (37.4%). This disparity was greater in males (95.0% in ages 
15-24 years and 42.1% in ages 25 years and older) than in females (75.1% in ages 15-24 years and 33.1% 
in ages 25 years and older). The percentage of sexually active adults who had sex with a non-marital, 
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non-cohabitating partner was highest in ages 15-19 years (92.5%) and next highest in ages 20-24 years 
(80.4%) and in ages 25-29 years (60.2%). Among sexually active adults aged 30-44 years, the percentage 
who had sex with a non-marital, non-cohabitating partner ranged from 30.2% to 45.6%. The percentage 
of sexually active adults aged 45 years and older who had sex with a non-marital, non-cohabitating 
partner ranged from 8.5% to 18.7% (Tables 15.4.A, 15.4.B, and 15.4.C).   
 
Among adults who had sex with a non-marital, non-cohabitating partner in the 12 months prior to the 
survey, 69.3% used a condom at last sexual intercourse (73.3% in males and 65.1% in females). In adults 
who had sex with a non-marital, non-cohabitating partner in the 12 months prior, three-quarters 
attended tertiary education (74.1%) and three-quarters of the highest wealth quintile (74.7%) used a 
condom at last sexual intercourse. More than half (54.5%) of adults living with their sexual partner, who 
had sex with a non-marital, non-cohabitating partner in the prior 12 months, used a condom at last 
sexual intercourse. Condom use at last sexual intercourse was comparatively higher in married adults 
who had sex with a non-marital, non-cohabitating partner (63.7%). A condom was used at last sexual 
intercourse in 60.6% of adults in polygynous unions, who had sex with a non-marital, non-cohabitating 
partner in the prior 12 months (Tables 15.4.A, 15.4.B, and 15.4.C). 
 
Among adults who had sex with a non-marital, non-cohabitating partner, condom use at last sexual 
intercourse was 71.4% in ages 15-24 years and 67.7% in ages 25 years and older. The percentage of 
condom use at last sexual intercourse among adults who had sex with a non-marital, non-cohabitating 
partner was highest in ages 15-19 years (76.2%) and lowest in ages 65 years and older (52.5%; Table 




Table 15.4.A Condom use at last sex with a non-marital, non-cohabitating partner: Males 
Among males aged 15 years and older who reported having sex in the past 12 months, percentage who reported having a non-marital, non-
cohabitating partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 
months, percentage who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected 
demographic characteristics, SHIMS2 2016-2017  
Among males who reported having sex 
in the past 12 months 
 
Among males who reported having sex 
with a non-marital, non-cohabiting partner 
in the past 12 months 
Characteristic 
Percentage who reported having sex 
with a non-marital, non-cohabitating 
partner in the past 12 months 
Number  
Percentage who reported using 
a condom the last time they had 




     
Urban 53.8 858 
 
74.0 442 
Rural 53.5 2,420 
 
72.9 1,189 
      
Region 
     
Hhohho 51.4 1,035 
 
74.7 499 
Lubombo 52.8 684 
 
69.1 338 
Manzini 55.1 1,025 
 
75.0 529 
Shiselweni 55.7 534 
 
71.6 265 
      
Marital status 
     
Never married 94.8 1,403 
 
75.0 1,294 
Married 9.1 1,479 
 
66.1 127 
Living together 25.6 222 
 
60.3 55 
Divorced/separated 91.6 126 
 
67.6 110 
Widowed (97.1) 35 
 
(71.2) 33 
      
Type of union 
     
In polygynous union 28.6 101 
 
(63.8) 25 
Not in polygynous union 10.5 1,563 
 
63.9 151 
Not currently in union 94.6 1,564 
 
74.4 1,437 
Don't know/missing 34.5 50 
 
* 18 
      
Education 
     
No education 27.3 193 
 
(76.8) 47 
Primary 43.2 971 
 
68.9 375 
Secondary 57.5 757 
 
71.3 412 
High school 64.6 957 
 
74.2 597 
Tertiary 53.2 395 
 
80.5 199 
      
Wealth quintile 
     
Lowest 49.8 642 
 
71.7 293 
Second 55.8 671 
 
73.1 335 
Middle 55.7 763 
 
68.2 394 
Fourth  55.1 574 
 
73.6 303 
Highest 51.2 628 
 
80.4 306 
      
Age 
     
15-19 97.5 190 
 
86.7 179 
20-24 94.2 457 
 
76.1 420 
25-29 75.3 545 
 
74.0 407 
30-34 55.8 481 
 
66.6 264 
35-39 36.3 392 
 
65.7 143 
40-44 28.3 297 
 
65.6 83 
45-49 16.9 216 
 
(82.1) 33 
50-54 19.4 177 
 
(74.4) 34 
55-59 19.1 157 
 
(53.2) 27 
60-64 14.0 149 
 
* 20 
65+ 9.5 217 
 
* 21 
15-29 85.9 1,192 
 
76.7 1,006 
20-39 68.5 1,875 
 
72.5 1,234 
25+ 42.1 2,631 
 
69.9 1,032 
      
Total 15-24 95.0 647 
 
78.6 599 
Total 15-49 61.8 2,578 
 
73.7 1,529 
Total 15+ 53.6 3,278 
 
73.3 1,631 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 15.4.B Condom use at last sex with a non-marital, non-cohabitating partner: Females  
Among females aged 15 years and older who reported having sex in the past 12 months, percentage who reported having a non-marital, non-
cohabitating partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 
months, percentage who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected 
demographic characteristics, SHIMS2 2016-2017  
Among females who reported having sex 
in the past 12 months 
 
Among females who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having 
sex with a non-marital, non-




Percentage who reported using a 
condom the last time they had sex 




     
Urban 51.5 985 
 
67.0 496 




     
Hhohho 42.4 1,303 
 
66.8 521 
Lubombo 43.0 862 
 
59.5 353 
Manzini 45.3 1,379 
 
66.9 591 




     
Never married 90.4 1,608 
 
66.3 1,437 
Married 3.1 2,134 
 
58.1 55 
Living together 16.4 285 
 
(46.7) 42 
Divorced/separated 92.9 153 
 
61.8 135 
Widowed 76.8 141 
 
71.2 99 
Type of union 
     
In polygynous union 8.0 244 
 
* 15 
Not in polygynous union 3.8 2,024 
 
49.4 63 
Not currently in union 89.8 1,902 
 
66.2 1,671 




     
No education 26.9 214 
 
(56.3) 44 
Primary 33.8 1,193 
 
63.2 367 
Secondary 45.6 1,308 
 
63.2 578 
High school 52.4 1,166 
 
67.9 592 




     
Lowest 42.3 954 
 
59.7 376 
Second 43.7 937 
 
68.6 379 
Middle 44.7 1,004 
 
61.6 410 
Fourth  44.0 706 
 
67.5 305 




     
15-19 89.4 306 
 
69.0 268 
20-24 69.9 766 
 
63.1 529 
25-29 47.8 794 
 
63.9 373 
30-34 37.5 727 
 
62.1 259 
35-39 27.9 533 
 
74.1 138 
40-44 31.7 362 
 
65.3 107 
45-49 18.6 283 
 
57.9 52 
50-54 18.0 205 
 
(77.0) 33 
55-59 10.1 149 
 
* 13 
60-64 13.1 99 
 
* 12 
65+ 5.6 119 
 
* 4 
15-29 63.3 1,866 
 
64.6 1,170 
20-39 47.5 2,820 
 
64.4 1,299 
25+ 33.1 3,271 
 
65.2 991       
Total 15-24 75.1 1,072 
 
65.0 797 
Total 15-49 47.0 3,771 
 
64.9 1,726 
Total 15+ 43.9 4,343 
 
65.1 1,788 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 15.4.C Condom use at last sex with a non-marital, non-cohabitating partner: Total  
Among persons aged 15 years and older who reported having sex in the past 12 months, percentage who reported having a non-marital, non-
cohabitating partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 
months, percentage who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected 
demographic characteristics, SHIMS2 2016-2017 
 Among persons who reported having sex 
in the past 12 months 
 
Among persons who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having sex with a 
non-marital, non-cohabitating partner in the 
past 12 months 
Number   
Percentage who reported using a condom 
the last time they had sex with a non-
marital, non-cohabitating partner1 
Number 
Residence      
Urban 52.6 1,843  70.5 938 
Rural 46.6 5,778  68.7 2,481 
Region      
Hhohho 46.7 2,338  70.9 1,020 
Lubombo 47.6 1,546  64.5 691 
Manzini 49.8 2,404  70.9 1,120 
Shiselweni 49.2 1,333  67.9 588 
Marital status      
Never married 92.6 3,011  70.8 2,731 
Married 5.7 3,613  63.7 182 
Living together 20.7 507  54.5 97 
Divorced/separated 92.3 279  64.4 245 
Widowed 81.4 176  71.2 132 
Type of union      
In polygynous union 14.3 345  (60.6) 40 
Not in polygynous union 6.8 3,587  59.6 214 
Not currently in union 92.1 3,466  70.3 3,108 
Don't know/missing 26.8 223  55.6 57 
Education      
No education 27.1 407  66.8 91 
Primary 38.4 2,164  66.3 742 
Secondary 50.3 2,065  66.9 990 
High school 58.2 2,123  71.2 1,189 
Tertiary 50.0 849  74.1 405 
Wealth quintile      
Lowest 45.5 1,596  65.4 669 
Second 49.1 1,608  70.9 714 
Middle 49.9 1,767  65.1 804 
Fourth  49.2 1,280  70.7 608 
Highest 47.8 1,368  74.7 624 
Age      
15-19 92.5 496  76.2 447 
20-24 80.4 1,223  69.7 949 
25-29 60.2 1,339  69.6 780 
30-34 45.6 1,208  64.5 523 
35-39 31.4 925  70.0 281 
40-44 30.2 659  65.4 190 
45-49 17.8 499  68.4 85 
50-54 18.7 382  75.5 67 
55-59 15.3 306  (57.8) 40 
60-64 13.7 248  (71.3) 32 
65+ 8.5 336  (52.5) 25 
15-29 73.1 3,058  70.8 2,176 
20-39 56.7 4,695  68.7 2,533 
25+ 37.4 5,902  67.7 2,023 
Total 15-24 83.4 1,719  71.4 1,396 
Total 15-49 53.4 6,349  69.3 3,255 
Total 15+ 48.3 7,621  69.3 3,419 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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15.5 Male Circumcision 
Among adult males, 70.7% self-reported as uncircumcised; 26.7% had received medical circumcision; 
and few (0.9%) had received nonmedical circumcision. Self-reported medical circumcision was highest in 
adult males who never married (31.7%) and who were in the highest wealth quintile (33.9%). Self-
reported medically circumcised adult males were nearly two times the percentage in those not currently 
in a union (30.6%) compared to those in polygynous union (15.8%) and three times the percentage of 
those attended tertiary education (31.7%) versus those with no education (10.4%; Table 15.5.A). 
 
One-third (34.8%) of adult males aged 15-24 years self-reported as medically circumcised. Self-reported 
medical circumcision among all adult males was highest in ages 15-19 years (38.2%) and decreased by 
age groups to the lowest percentage in ages 65 years and older (7.5%; Table 15.5.A).  
 
Among adult males who tested HIV positive in the survey, 15.2% reported as medically circumcised. Of 





Table 15.5.A Male circumcision 
Percent distribution of males aged 15 years and older by self-reported circumcision status, by result of PHIA survey HIV test and selected 
demographic characteristics, SHIMS2 2016-2017 
 
Circumcised1 






Result of PHIA survey HIV test 
      
HIV positive 15.2 0.9 82.3 1.7 100.0 972 
HIV negative 29.7 0.9 68.0 1.5 100.0 3,534 
Not tested 27.1 1.5 67.8 3.6 100.0 398        
Residence 
      
Urban 29.2 1.2 68.1 1.4 100.0 1,100 
Rural 25.7 0.8 71.7 1.8 100.0 3,804        
Region 
      
Hhohho 26.6 0.9 70.5 1.9 100.0 1,536 
Lubombo 25.7 0.2 72.4 1.7 100.0 1,017 
Manzini 29.0 1.3 68.5 1.2 100.0 1,497 
Shiselweni 22.9 0.9 73.7 2.5 100.0 854        
Marital status 
      
Never married 31.7 0.5 66.5 1.3 100.0 2,772 
Married 19.6 1.2 77.0 2.3 100.0 1,596 
Living together 20.8 2.0 75.3 2.0 100.0 228 
Divorced/separated 22.3 2.5 73.7 1.5 100.0 181 
Widowed 8.0 3.6 83.4 4.9 100.0 99        
Type of union 
      
In polygynous union 15.8 0.9 80.2 3.1 100.0 110 
Not in polygynous union 19.9 1.3 76.6 2.2 100.0 1,672 
Not currently in union 30.6 0.7 67.3 1.4 100.0 3,052 
Don't know/missing 26.0 1.5 69.5 3.0 100.0 70        
Education 
      
No education 10.4 2.3 81.4 5.8 100.0 276 
Primary 23.3 1.1 73.5 2.0 100.0 1,496 
Secondary 28.2 0.5 70.2 1.0 100.0 1,294 
High school 29.4 0.6 68.7 1.3 100.0 1,373 
Tertiary 31.7 1.5 65.0 1.8 100.0 458        
Wealth quintile 
      
Lowest 23.7 0.8 72.8 2.8 100.0 1,093 
Second 25.4 0.6 72.5 1.5 100.0 1,042 
Middle 24.5 0.5 73.5 1.4 100.0 1,153 
Fourth  26.8 1.7 70.0 1.5 100.0 797 
Highest 33.9 1.2 63.5 1.4 100.0 818        
Age 
      
15-19 38.2 0.1 60.4 1.3 100.0 1,074 
20-24 31.2 0.4 67.4 1.0 100.0 709 
25-29 27.9 1.1 69.8 1.2 100.0 642 
30-34 25.1 0.7 72.2 1.9 100.0 541 
35-39 27.4 0.5 70.8 1.4 100.0 453 
40-44 21.6 1.4 75.0 1.9 100.0 323 
45-49 16.9 1.5 79.2 2.5 100.0 246 
50-54 15.5 1.6 80.6 2.3 100.0 214 
55-59 14.1 0.5 83.5 1.9 100.0 188 
60-64 15.1 4.8 78.1 2.0 100.0 176 
65+ 7.5 2.7 84.2 5.6 100.0 338 
20-39 28.3 0.7 69.7 1.3 100.0 2,345 
25+ 21.9 1.3 74.7 2.1 100.0 3,121 
Total 15-24 34.8 0.2 63.8 1.1 100.0 1,783 
Total 15-49 29.3 0.7 68.6 1.4 100.0 3,988 
Total 15+ 26.7 0.9 70.7 1.7 100.0 4,904 
1Relates to Global AIDS Monitoring indicator 3.16: Prevalence of male circumcision and PEPFAR VMMC_TOTALCIRC NAT / SUBNAT. 








▪ Although early sexual debut was uncommon among adults, half of women who had first sexual 
intercourse before 15 years of age were HIV positive. Sexual health programs among early 
adolescents can continue to reinforce the importance of delayed sexual debut, notably among 
females but also males, to maintain adolescent health and well-being. 
▪ Sexual activity with non-marital, non-cohabitating partners is frequent, especially among adults 
who are married or living with a partner and is accompanied by insufficient condom use at last 
sex. Condom promotion among adults practicing high risk behaviors remains an area in need of 
more effective strategies.   
▪ Medical circumcision uptake is substantially below the national target of 70% and risks new 
infections that are preventable among men aged 15 years and older. There is a critical need for 
culturally informed MC mobilization efforts. 
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Chapter 16   Intimate Partner Violence 
16.1 Key Findings 
 
16.2 Background 
Intimate partner violence (IPV) includes physical violence, sexual violence, stalking and psychological 
aggression (including coercive tactics) by a current or former intimate partner, such as a spouse, 
boyfriend, dating partner, or ongoing sexual partner.1 Exposure to IPV has been implicated in an 
increased risk of a woman contracting HIV, through mechanisms such as forced sex with an infected 
partner, an increase in risky sexual behaviors, and reduced ability to negotiate safe sex.2  
 
IPV is defined in this survey as physical or sexual violence by a current or former male intimate partner 
(i.e., a cohabitating partner, regardless of marital status). Violence questionnaires were administered to 
one randomly selected adult female (defined in this survey as those aged 15 years and older, unless 
otherwise noted) in each household. Physical violence was classified as being punched, kicked, whipped, 
beaten, slapped, pushed, shoved, choked, smothered, drowned or burned. It also included having an 
object thrown at oneself or being hurt or threatened with a knife, gun or other weapon. Sexual violence 
was specified as being physically forced to have sex. 
 
This chapter describes the occurrence of physical and sexual violence among adult females generally 
and among those who report having had a male intimate partner in their lifetime. Women reporting 
violence were offered referral to social services (Appendix I). 
 
16.3 Intimate Partner Violence in the Prior 12 Months 
Among ever married or partnered (i.e. having a cohabitating partner) adult females, 3.6% experienced 
IPV in the 12 months prior to the survey. Reported intimate partner violence mainly comprised physical 
violence (3.6%) compared with 0% sexual violence (Table 16.3.A).  
 
IPV among ever married or partnered adult females was higher in those not in polygynous unions (4.1%) 
and highest in those not reporting any type of union (9.4%). IPV was highest among ever married or 
partnered adult females who attended secondary education (5.8%), next highest in those who attended 
primary education (4%), and lowest in those with no education (0.4%). IPV among ever married or 
partnered adult females was lowest in Manzini region (2.9%; Table 16.3.A).   
16 INTIMATE PARTNER VIOLENCE     
  
▪ Among ever married or partnered (i.e. having a cohabitating partner) females aged 15 years and 
older, 3.6% reported intimate partner violence (IPV) in the 12 months prior to the survey. IPV 
peaked at 9.8% among those aged 20-24 years. 
▪ Among ever married or partnered females aged 15-24 years, over a tenth (11.2%) experienced IPV 
in the 12 months prior to the survey. 
▪ IPV was higher among ever married or partnered females aged 15 years and older testing HIV 
positive in the survey (5.9%) compared to those testing HIV negative in the survey (2.3%). 
▪ Among females aged 15 years and older, 5.2% had experienced physical violence in their lifetime. 
Lifetime physical violence was highest among those aged 20-24 years (9.2%). 
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IPV was highest among ever married or partnered adult females who tested HIV positive in the survey 
(5.9%), and next highest in those who did not receive HIV testing in the survey (4.2%; Table 16.3.A). 
 
Among ever married or partnered adult females aged 15-24 years, over a tenth (11.2%) reported IPV in 
the 12 months prior to the survey, all of whom (11.2%) reported intimate partner physical violence 
while none (0%) reported intimate partner sexual violence. Reported IPV was highest in ages 20-24 
years (9.8%), followed by ages 25-29 years (6.9%) and ages 30-34 years (4.1%). Few reports of IPV 
occurred in adult females aged 50 years and older (Table 16.3.A).   
 
The estimates of IPV are lower than findings from other nationally-representative surveys in Eswatini. 
IPV is likely under-reported in SHIMS2, and results should be interpreted with caution. 
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Table 16.3.A Intimate partner violence 
Among ever married or partnered women aged 15 years and older, percentage who experienced physical or sexual violence from a male 










Number of ever-married 
or partnered women 
Result of PHIA survey HIV test 
     
HIV positive 5.9 0.0 0.0 5.9 481 
HIV negative 2.3 0.1 0.1 2.3 895 
Not tested 4.2 0.0 0.0 4.2 58 
Residence 
     
Urban 3.7 0.0 0.0 3.7 317 
Rural 3.6 0.1 0.1 3.6 1,117 
Region 
     
Hhohho 4.2 0.0 0.0 4.2 430 
Lubombo 4.5 0.0 0.0 4.5 274 
Manzini 2.9 0.0 0.0 2.9 439 
Shiselweni 3.2 0.3 0.3 3.2 291 
Marital status 
     
Never married * * * * 0 
Married 3.4 0.0 0.0 3.4 861 
Living together 8.3 0.4 0.4 8.3 152 
Divorced/separated 2.2 0.0 0.0 2.2 94 
Widowed 1.4 0.0 0.0 1.4 320 
Type of union 
     
In polygynous union 2.2 0.0 0.0 2.2 87 
Not in polygynous union 4.1 0.1 0.1 4.1 865 
Not currently in union 1.6 0.0 0.0 1.6 414 
Don't know/missing 9.4 0.0 0.0 9.4 68 
Education 
     
No education 0.4 0.0 0.0 0.4 181 
Primary 4.0 0.0 0.0 4.0 500 
Secondary 5.8 0.0 0.0 5.8 347 
High school 2.7 0.0 0.0 2.7 255 
Tertiary 2.3 0.4 0.4 2.3 146 
Wealth quintile 
     
Lowest 3.6 0.0 0.0 3.6 356 
Second 3.4 0.0 0.0 3.4 308 
Middle 5.1 0.2 0.2 5.1 304 
Fourth  2.7 0.0 0.0 2.7 247 
Highest 3.2 0.0 0.0 3.2 219 
Age 
     
15-19 * * * * 7 
20-24 9.8 0.0 0.0 9.8 76 
25-29 6.9 0.0 0.0 6.9 174 
30-34 4.1 0.3 0.3 4.1 227 
35-39 2.3 0.0 0.0 2.3 175 
40-44 2.4 0.0 0.0 2.4 127 
45-49 2.7 0.0 0.0 2.7 124 
50-54 2.1 0.0 0.0 2.1 110 
55-59 0.0 0.0 0.0 0.0 81 
60-64 0.9 0.0 0.0 0.9 114 
65+ 0.5 0.0 0.0 0.5 219 
15-29 8.5 0.0 0.0 8.5 257 
25+ 3.0 0.1 0.1 3.0 1,351 
Total 15-24 11.2 0.0 0.0 11.2 83 
Total 15-49 4.6 0.1 0.1 4.6 910 
Total 15+ 3.6 0.0 0.0 3.6 1,434 
1 Physical violence was defined as being punched, kicked, whipped, beaten, slapped, pushed, shoved, choked, smothered, drowned or burned. It also 
included having an object thrown at oneself or being hurt or threatened with a knife, gun or other weapon; 2 Sexual violence was defined as being 
physically forced to have sex; 3 Relates to Global AIDS Monitoring indicator 4.3: Prevalence of recent intimate partner violence.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
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16.4 Physical and Sexual Violence in the Prior 12 Months 
Among adult females, 5.2% had experienced physical violence in the 12 months prior to the survey. 
Physical violence in adult females was higher in rural areas (5.6%) than in urban areas (4.1%). It was 
highest among adult females who lived with their partner (10.7%), completed primary education (6.0%), 
and lived in Shiselweni region (7.2%; Table 16.4.A).  
 
Among adult females aged 15-24 years, 5.8% had experienced physical violence in the 12 months prior 
to the survey. Among adult females aged 15-29 years, 6.4% had experienced physical violence: 2.1% in 
ages 15-19 years, 9.2% in ages 20-24 years, and 7.8% in ages 25-29 years. Physical violence among adult 
females peaked in ages 20-24 years at 9.2% (Table 16.4.A). 
 
Among adult females, 0.2% had experienced sexual violence in the 12 months prior to the survey. 
Among adult females aged 15-24 years, 0.1% had experienced sexual violence in the 12 months prior to 
the survey. There were no meaningful differences in reported sexual violence in the prior 12 months 
within demographic groups (Table 16.4.A). 
 
The estimates of physical and sexual violence are lower than results from other nationally-
representative surveys in Eswatini. Violence is likely under-reported in SHIMS2, and results should be 
interpreted with caution.  
 123 
Table 16.4.A Physical and sexual violence 
Among women aged 15 years and older, percentage who experienced physical violence or sexual violence in the past 12 months by selected 
demographic characteristics, SHIMS2 2016-2017 
 Characteristic 
Physical violence 1 Sexual violence 2 
Percentage Number Percentage Number 
Residence     
Urban 4.1 584 0.1 797 
Rural 5.6 1,835 0.2 2,596 
Region     
Hhohho 6.0 711 0.1 994 
Lubombo 4.5 453 0.1 671 
Manzini 3.7 788 0.1 1,092 
Shiselweni 7.2 467 0.3 636 
Marital status     
Never married 4.5 838 0.2 1,152 
Married 5.3 952 0.0 1,378 
Living together 10.7 161 0.3 195 
Divorced/separated 6.3 103 0.0 147 
Widowed 3.1 356 0.1 509 
Type of union     
In polygynous union 4.1 98 0.0 143 
Not in polygynous union 5.8 948 0.0 1,337 
Not currently in union 4.4 1,297 0.2 1,808 
Don't know/missing 12.8 76 1.5 105 
Education     
No education 3.1 223 0.1 317 
Primary 6.0 709 0.2 1,019 
Secondary 4.9 686 0.0 941 
High school 5.9 557 0.3 782 
Tertiary 3.3 239 0.2 327 
Age     
15-19 2.1 215 0.0 293 
20-24 9.2 300 0.3 399 
25-29 7.8 317 0.1 450 
30-34 6.0 343 0.4 474 
35-39 3.3 249 0.0 349 
40-44 3.8 167 0.0 254 
45-49 5.4 167 0.5 231 
50-54 5.0 139 0.0 188 
55-59 1.5 104 0.0 153 
60-64 2.2 153 0.0 209 
65+ 1.4 265 0.1 393 
15-29 6.4 832 0.1 1,142 
25+ 4.9 1,904 0.2 2,701 
Total 15-24 5.8 515 0.1 692 
Total 15-49 5.6 1,758 0.2 2,450 
Total 15+ 5.2 2,419 0.2 3,393 
1 Physical violence was defined as being punched, kicked, whipped, beaten, slapped, pushed, shoved, choked, smothered, drowned or burned. It also 
included having an object thrown at oneself or being hurt or threatened with a knife, gun or other weapon; 2 Sexual violence was defined as being 
physically forced to have sex. 
 
 
16.5 Gaps and Unmet Needs 
  
▪ Violence prevention interventions may benefit from more tailored strategies for the protection 
of young women, particularly among ages 20-24 years.   
▪ The prevalence of violence experienced by men is unknown and demonstrates a need for future 
violence assessments to be conducted among both women and men. 
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Chapter 17   Tuberculosis 
17.1 Key Findings 
 
17.2 Background 
TB remains the leading cause of HIV-associated morbidity and mortality, despite being preventable and 
curable. To reduce the burden of TB among people living with HIV, integration of HIV and TB services is 
emphasized in all MOH facilities in Eswatini. TB screening is routinely conducted among HIV-positive 
patients according to national health guidelines. TB diagnostic investigations are performed among 
those who present with TB signs or symptoms. This chapter describes the self-reported TB clinical care 
cascade for HIV-positive individuals: received care at a TB clinic, TB diagnosis among those receiving 
care, and treatment among those diagnosed with TB.   
 
17.3 Tuberculosis 
Among self-reported HIV-positive adults (defined in this survey as those aged 15 years and older, unless 
otherwise noted), one-third (34.8%) reported ever having visited a health facility for TB services: 41.1% 
of males and 32.0% of females. Among self-reported adults living with HIV who visited a facility for TB 
services, 60.1% were diagnosed with TB. TB diagnosis was higher in males (69.7%) than in females 
(54.6%). Among self-reported HIV-positive adults who were diagnosed with TB, a large majority (97.9%) 
received TB treatment (98.1% in males and 97.8% in females; Table 17.3.A). 
 
▪ One-third (34.8%) of self-reported adults living with HIV aged 15 years and older attended a 
health facility for tuberculosis (TB) services. 
▪ A large majority (97.9%) of self-reported HIV-positive adults aged 15 years and older, who report 
attending TB services and a TB diagnosis, reported receipt of TB treatment.  
▪  
17 TUBERCULOSIS  
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Table 17.3.A Tuberculosis clinic attendance and services among HIV-positive adults 
Among self-reported HIV-positive persons aged 15 years and older, percentage who ever visited a tuberculosis (TB) clinic; among those who had ever visited a TB clinic, percentage who were  
diagnosed for TB; and among those diagnosed with TB, percentage who were treated for TB, by sex, SHIMS2 2016-2017 
 Among HIV-positive persons  
Among HIV-positive persons who ever  
visited a TB clinic 
 
Among HIV-positive persons who were  
diagnosed with TB 
Characteristic 
Percentage who ever  
visited a TB clinic 
Number  
Percentage who were  
diagnosed with TB 
Number  
Percentage who were  
treated for TB 
Number 
Sex         
Male 41.1 809  69.7 337  98.1 237 
Female 32.0 1,885  54.6 604  97.8 327          
Total 15+ 34.8 2,694  60.1 941  97.9 564 
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17.4 Gaps and Unmet Needs 
 
  
▪ One-third of self-reported HIV-positive adults reported attending a clinic for TB services. 
Continued efforts to increase TB screening among all people living with HIV is necessary to 
ensure prevention and management of HIV/TB co-infection. 
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Chapter 18   Food and Water Security 
18.1 Key Findings 
 
18.2 Background 
Food and water insecurity have increased in severity and frequency in southern Africa and is associated 
with increased high-risk sexual behavior among women and increased HIV acquisition risk in rural 
areas.1, 2 Recent episodes of recurrent drought in 2015-2016, which caused some of the driest crop 
seasons in recent history, combined with high unemployment rates, resulted in increased risk for food 
and water insecurity in Eswatini.3   
 
18.3 Food and Water Security 
In the four weeks prior to the survey, almost a third (30.8%) of households in Eswatini reported a food 
shortage. A food shortage occurred at least 10 times in 2.4% of households in four weeks prior to the 
survey. Food shortages were higher in rural households (37.0%) than in urban households (17.9%) and in 
Shiselweni (39.6%) and Lubombo (35.5%) regions. Food shortages occurred in a third (34.7%) of female-
headed households compared with 26.2% of male-headed households (Table 18.3.A). 
  
In the four weeks prior to the survey, 16.9% of households lacked water for nutritional needs for at least 
24 hours. Nutritional water shortages were higher in rural households (19.9%) than in urban households 
(10.8%) and were slightly higher in female-headed households (18.0%) than in male-headed households 
(15.6%). More than a tenth (12.4%) of households lacked water for hygiene purposes for at least 24 
hours in the four weeks prior to the survey. Hygiene water shortages were more than twice as high in 
rural households than in urban households (15.5% and 6.1%, respectively; Table 18.3.A). 
 
▪ Across the four regions, food insecurity in the four weeks prior to the survey was higher in 
Shiselweni region (39.6%) and Lubombo region (35.5%). 
▪ The percentage of households experiencing water insecurity for hygiene was more than twice as 
high in rural areas (15.5%) than in urban areas (6.1%). 
▪ Food shortages occurred in more than a third (34.7%) of female-headed households compared 
with 26.2% of male-headed households. 
▪  
18 FOOD AND WATER SECURITY  
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Table 18.3.A Food and water security among households, SHIMS2 2016-2017 
Percent distribution of households by sex of head of household; median size of household and median (Q1, Q3) number of children below 18 years of age, by residence, SHIMS2 2016-2017 
 Food insecurity  Water insecurity (for nutrition)  Water insecurity (for hygiene) 
 
Household ever 
without any food in 
the past 4 weeks 
Household often 
(>10 times) without 




without water for 
nutritional needs for 
24 hours in the past 
4 weeks 
Household often 
(>10 times) without 
water for nutritional 
needs for 24 hours in 
the past 4 weeks 
 
Household ever 
without water for 
hygiene needs for 24 
hours in the past 4 
weeks 
Household often 
(>10 times) without 
water for hygiene 
needs for 24 hours 
in the past 4 weeks 
Characteristic Percent Number Percent Number  Percent Number Percent Number  Percent Number Percent Number 
Residence               
Urban 17.9 1,406 1.0 1,406  10.8 1,405 1.0 1,405  6.1 1,405 0.8 1,405 
Rural 37.0 3,773 3.1 3,773  19.9 3,775 2.5 3,775  15.5 3,774 2.1 3,774                
Region               
Hhohho 29.2 1,473 1.8 1,473  17.3 1,472 1.2 1,472  12.2 1,474 0.9 1,474 
Lubombo 35.5 1,063 3.3 1,063  21.2 1,064 3.9 1,064  16.9 1,063 3.4 1,063 
Manzini 25.6 1,702 1.8 1,702  12.4 1,702 1.5 1,702  8.4 1,701 1.2 1,701 
Shiselweni 39.6 941 3.9 941  21.5 942 2.5 942  16.6 941 2.1 941                
Household headship               
Male  26.2 2,353 2.2 2,353  15.6 2,354 2.1 2,354  10.9 2,355 1.7 2,355 
Female 34.7 2,826 2.6 2,826  18.0 2,826 2.0 2,826  13.7 2,824 1.7 2,824                
Total 30.8 5,179 2.4 5,179  16.9 5,180 2.0 5,180  12.4 5,179 1.7 5,179 
                
 Food insecurity  Water insecurity (for nutrition)  Water insecurity (for hygiene) 
 
Household ever 
without any food in 
the past 4 weeks 
Household often 
(>10 times) without 




without water for 
nutritional needs for 
24 hours in the past 
4 weeks 
Household often 
(>10 times) without 
water for nutritional 
needs for 24 hours in 
the past 4 weeks 
 
Household ever 
without water for 
hygiene needs for 24 
hours in the past 4 
weeks 
Household often 
(>10 times) without 
water for hygiene 
needs for 24 hours 
in the past 4 weeks 
Characteristic Median Q1, Q3 Median Q1, Q3   Median Q1, Q3 Median Q1, Q3  Median Q1, Q3 Median Q1, Q3 
Size of households 4 2, 6 5 3, 6  4 2, 6 5 3, 7  4 2, 6 5 2, 7 
Number of children under 18 years of age 2 0, 4 2 0, 4  2 0, 3 2 0, 4  2 0, 3 2 0, 4 
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18.4 Gaps and Unmet Needs 
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▪ HIV prevention efforts may benefit from targeting rural households and female-headed 
households with food and water supply interventions during drought, since food and water 




Conclusion and Recommendations 
SHIMS2 2016-2017 provided critical data on the primary outcomes of HIV incidence among adults, 
defined as those aged 15 years and older, and HIV prevalence among children, defined as those aged 0-
14 years. It allowed for measurement of progress since SHIMS 2011, demonstrating program impact and 
characterizing the current HIV epidemic in Eswatini. The SHIMS2 team encourages public health staff, 
programmers, epidemiologists and policy makers to examine the SHIMS2 data for their respective 
program areas and utilize the data to inform program planning. Overarching recommendations based on 
SHIMS2 findings are:  
 
HIV incidence: Approximately 6,000 new cases of HIV occurred annually among adults, with HIV 
incidence highest among women aged 35-49 years and men aged 25-34 years. These high incidence 
levels demonstrate the need for sustained HIV prevention efforts.  
Recommendations:  
▪ Continue to scale-up HIV prevention services, including pre-exposure prophylaxis (PrEP) for not only 
young but also older women and MC for men above 25 years of age.  
▪ Identify HIV-positive men and young people who are not aware of their status, initiate them on ART, 
and ensure a sustained high level of VLS among all people living with HIV to interrupt the 
transmission cycle. 
 
HIV prevalence: Close to half of households in Eswatini had at least one HIV-positive member. 
Approximately 197,000 adults are living with HIV, where nearly 1 in 2 women aged 30-44 years and 
men aged 45-49 years are HIV positive. HIV prevalence was significantly higher among adult women, 
with female youth aged 15-24 years having triple the HIV prevalence of their male peers.  
Recommendations:  
▪ HIV programs would benefit from continued scale-up to reach all people living with HIV in Eswatini.  
▪ Program design can better address an aging HIV population, addressing challenges of chronic HIV 
infection and ART use, as well as comorbidities associated with aging.  
▪ For the high proportion of young females living with HIV, services for prevention of sexual and 
vertical transmission would benefit from continued scale-up and strengthening of existing services, 
as well as cervical cancer screening and other reproductive health services.  
 
HIV testing: While the majority of the population had ever tested for HIV, testing in the prior 12 months 
was very low among older adolescents, aged 15-19 years. Lifetime testing was low among adult 
males.  
Recommendation:  
▪ Strengthen existing services to address the unique needs of youth and men and identify innovations 
to more effectively target these sub-populations.   
 
90-90-90 target: At population level, Eswatini had achieved the third 90, and was close to achieving the 
first and second 90’s. However, there were significant age and gender disparities, with youth 15-24 
years, particularly males in this age group, significantly lagging behind in the first and third 90’s.  
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Recommendations: 
▪ Different HIV testing modalities, such as index testing, community-based testing, self-testing, and 
couples testing, warrant expansion and strengthening. Innovations targeting youth are urgently 
needed.  
▪ ART retention programs that tailor to the unique circumstances of youth is key for continued 
progress toward epidemic control.   
▪ Continue ART adherence counseling and stigma reduction initiatives to maximize ART uptake.  
▪ Expedited scale-up of VL services is critical to support continuous monitoring of VLS by clinicians and 
their HIV-positive clients.  
 
Clinical characteristics and ARV resistance: Approximately 39% of adults unaware of their HIV status 
had significant immunosuppression. Among a small sample of recently infected HIV-positive adults, 
evidence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors 
may exceed the recommended WHO threshold of 10% for replacing a first-line regimen.  
Recommendations:  
▪ Efforts are needed to ensure earlier HIV diagnosis before significant immunosuppression occurs.   
▪ Exploring the value of revisions to national first-line regimens is warranted.  
▪ Implement continuous drug resistance surveillance, namely among those with new infections.  
▪ Regularly review the national treatment recommendations to make applicable adjustments. 
 
PMTCT: There was high maternal HIV testing and ART uptake, yet a number of infants aged 18 months 
and younger acquired HIV. About a tenth of HIV-positive women reported as not breastfeeding, in 
contrast to national guidelines.  
Recommendations:  
▪ The apparent gap between maternal ART uptake and infant HIV acquisition requires further 
investigation, followed by targeted action to fully realize the highly effective preventive benefits of 
maternal ART.   
 
Children: About a third of infants aged 0-5 months were not currently breastfed. HIV prevalence was 
highest among infants 0-17 months of age and young adolescents aged 10-14 years, both at more 
than 4%. Children living with HIV had not met the first 90 target (with less than three-quarters 
[71.2%] of children living with HIV diagnosed, based on parental/guardian report) or the third 90 
target (with less than three-quarters [73.9%] of children on ART having suppressed viral loads, based 
on presence of detectable ARVs).   
Recommendations:  
▪ Interventions encouraging age-appropriate exclusive breastfeeding and complementary feeding are 
essential to promote infant health, regardless of infant HIV status. 
▪ Greater efforts to address barriers to HIV testing among children and effective ART and adherence 
among children who are living with HIV is needed to remedy the low VLS prevalence.   
 
Intimate partner violence: IPV in the prior year occurred in close to 4 out of 100 ever married or 
partnered adult females. IPV was higher in HIV-positive women. IPV, lifetime physical violence, and 
lifetime sexual violence peaked among ages 20-24 years, with nearly 1 out of 10 reported as having 




▪ Greater understanding of the vulnerabilities to experiencing violence is warranted. Additional 
information on perpetrators of IPV and gender-based violence in general will be instructive.  
▪ The dearth of evidence on the extent of violence experienced by men limits a gendered approach to 
violence prevention programs. Opportunities to collect this information is needed.  
▪ Scale-up of interventions mitigating gender-based violence and IPV, particularly among young 
women, remains imperative.  
 
Food and water security: During times of drought, food and water insecurity is experienced more 
disproportionately by rural households and female-headed households.   
Recommendations: 
▪ Considerations for rural areas and female-headed households may enhance national emergency 
management plans to mitigate the impact of food and water insecurity on the risk of HIV and other 
health conditions.   
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Appendix A   Sample Design and Weighting 
Appendix A provides a high-level overview of sampling and weighting procedures for SHIMS2 2016-
2017. In-depth details are provided in the SHIMS2 2016-2017 Sampling and Weighting Technical Report, 
which may be found online at the PHIA Project website. 
 
A.1 Sample Design 
Overview 
The sample design for SHIMS2 is a stratified multistage probability sample design, with strata defined by 
region and urban/rural status, first-stage sampling units defined by enumeration areas (EAs) within 
strata, second-stage sampling units defined by households within EAs, and eligible persons within 
households. The first-stage sampling units (also referred to as “primary sampling units” or PSUs) were 
stratified by urban/rural status within each of the four regions of the country, and then within each 
stratum were selected with probabilities proportionate to the number of households in the PSU based 
on the 2007 census. The allocation of the sample PSUs to the eight sampling strata was made in a 
manner designed to achieve specified precision levels for a national estimate of HIV incidence rate, and 
four regional estimates of viral load suppression (VLS) rates. 
 
The second-stage sampling units were selected from lists of dwelling units/households compiled by 
trained staff for each of the sampled PSUs. Upon completion of the listing process, a random systematic 
sample of dwelling units/households was selected from each PSU at rates designed to yield a self-
weighting (i.e., equal probability) sample within each stratum to the extent feasible. 
 
Within the sampled households, all eligible adults (defined in this survey as those aged 15 years and 
older) were included in the study sample for data collection. All eligible children (defined in this survey 
as those aged 0-14 years) in a randomly designated subset of one-half of the selected households were 
included in the study for data collection. 
 
Population of Inference 
The population of inference for SHIMS2 is comprised of individuals who were present in households 
(i.e., “slept in the household”) on the night prior to the date of interview. This population is referred to 
as the de facto population. In contrast, those individuals who are usual residents of the household 
regardless of whether they were present in the household during the previous night comprise the de 
jure population. All individuals belonging to either the de facto or de jure populations were included for 
data collection; however, only members of the de facto population are included in the study population. 
 
Precision Specifications and Assumptions 
The following specifications were used to develop the sample design for SHIMS2. 
▪ The relative standard error of the national estimate of annual HIV incidence among persons aged 
15-49 years should be 20% or less. 
▪ 95% confidence bounds around the estimated VLS rate among HIV-positive persons aged 15-49 
years for each of the four regions of the country should be 10% or less. 
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The following assumptions were used to develop the sample design for SHIMS2: 
▪ An overall HIV prevalence rate of 0.2770 (27.7%) that varies by region and urban/rural status.  
Source: 2011 Swaziland HIV Incidence Measurement Survey (SHIMS1) conducted from December 
2010 to June 2011.1 
▪ An annual HIV incidence rate for adults aged 15-49 years of 𝑃𝑎 = 0.0189 (1.89%). Source: UNAIDS 
estimate for 2014. 
▪ A mean duration of recent infections (MDRI) of 130 days, yielding an annualization rate of 365/130= 
2.8077. Hence, the estimated incidence rate for MDRI = 130 days is 𝑃𝑚 = 0.0189/2.8077 = 0.0067 
(0.67%). 
▪ A VLS rate among HIV-positive adults aged 15-49 years in each region h of 50%.vhP = 50%.vhP =
This is a conservative assumption, because it will overstate the actual variance of the VLS rate. 
▪ An average of 20 occupied sampled households per sampled cluster (PSU). 
▪ An intra-cluster correlation (ICC) of   = 0.05 for prevalence and VLS rates. An intraclass of  
  = 0.022 was used for estimates of incidence. The ICC provides an average measure of the 
homogeneity of responses within the first-stage sampling units. 
▪ An occupancy rate of 89.4% for sampled dwellings. Note that this is not included in the calculation 
of the overall survey response rate but does determine the initial numbers of dwelling units to be 
sampled. Source: 2011 Swaziland HIV Incidence Measurement Survey (SHIMS1). 
▪ An overall household response rate of 94.4% among the occupied dwelling units. Source: 2011 
Swaziland HIV Incidence Measurement Survey (SHIMS1). 
▪ The average number of persons aged 15-49 years in a household is 2.33. Source: 2011 Swaziland HIV 
Incidence Measurement Survey (SHIMS1) and 2016 national population projections produced by the 
Eswatini Central Statistical Office (CSO). 
▪ The percentage of children in households is 37.9%. Source: 2016 national population projections for 
Swaziland. 
▪ The percentage of persons in households who are 18-49 years of age is 42.6%. Source: 2016 national 
population projections for Swaziland. 
▪ The percentage of persons in households who are ages 50 years and older is 12.4%. Source: 2016 
national population projections for Swaziland. 
▪ Among all adults, an overall biomarker response rate of 77.1% reflecting sample loss due to any of 
the following reasons: nonparticipation (refusal) of some sample households, nonresponse to the 
individual interview, refusal to provide a blood sample, or providing a unanalyzable blood sample. 
▪ Among children in the eligible responding households, an overall biomarker response rate of 72.1%. 
This value is the comparable response rate for adults minus 5.0%. 
 
Selection of the Primary Sampling Units 
The first-stage or PSUs for SHIMS2 are defined to be the EAs created for the 2007 Swaziland Census of 
Population and Housing. The 2007 sampling frame consisted of 2,064 EAs containing an estimated 
212,000 households and 1,005,000 persons, with an average number of households and persons per EA 
of 103 and 487, respectively. A stratified sample of 287 EAs was selected from the final EA sampling 
frame in accordance with the sample allocation. The eight strata specified for sampling were defined by 
crossing the four regions Hhohho, Manzini, Shiselweni, and Lubombo by urban/rural status. The EA 
samples were selected systematically and with probabilities proportionate to a measure of size (MOS) 
                                                 
 
1 SHIMS report:  https://www.k4health.org/sites/default/files/SHIMS_Report.pdf  
2 This estimate was derived from tabulations of the 2011 SHIMS data files. 
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within each stratum. The MOS used for sampling was equal to the number of households in the EA 
based on the 2007 Census of Population and Housing. 
 
The first step of the sampling process was to divide the sampling frame of EAs into the eight strata. 
Next, within each stratum, the EAs were sorted by the unique 5-digit EA identification code. The sorting 
of the EAs prior to sample selection induces an implicit stratification of the sampling frame designed to 
ensure that a representative mix of EAs with respect to geography are included in the sample. To select 
the sample from a particular stratum, the cumulative MOS was determined for each EA in the ordered 
list of EAs, and the sample selections were designated using a sampling interval equal to the total MOS 
of the EAs in the stratum divided by the number of EAs to be selected and a random starting point. The 
resulting sample has the property that the probability of selecting an EA within a particular stratum is 
proportional to the MOS of the EA in the stratum.  
 
Details regarding EA substitution and segmentation may be found in the SHIMS2 2016-2017 Sampling 
and Weighting Technical Report. 
 
Selection of Households 
For both sampling and analysis purposes, a household is defined to be a group of individuals who reside 
in a physical structure such as a house, apartment, compound, or homestead, and share in 
housekeeping arrangements. The physical structure in which people reside is referred to as the 
“dwelling unit” which may contain more than one household meeting the above definition. Households 
are eligible for participation in the study if they are located within the sampled EA. 
 
The selection of households for SHIMS2 involved the following steps: (1) listing the dwelling 
units/households within the sampled EAs, (2) assigning eligibility codes to the listed dwelling 
unit/household records, (3) selecting the samples of dwelling units/households, and (4) designating a 
subsample of households for child data collection. 
 
A description of the household listing process as well as a summary of household eligibility may be 
found in the SHIMS2 2016-2017 Sampling and Weighting Technical Report. 
 
Selection of households utilized an equal probability design. In order to achieve an equal probability 
sample of dwelling units within each of the four regions of the country, the sampling rates required to 
select dwelling units within an EA will depend on the difference between the size measure used in 
sampling (i.e., the number of households in the EA based on the 2007 census) and the actual number of 
dwelling units/households found at the time of listing in mid-2016. Thus, application of these within-EA 
sampling rates can yield more than the desired 20 households in EAs that have experienced growth in 
population since the 2007 census, and fewer than 20 households in EAs that have declined in 
population. The SHIMS2 2016-2017 Sampling and Weighting Technical Report provides an in-depth 
description of the equal probability sample design, as well as a detailed summary of the results of the 
household selection. 
 
Selection of Individuals 
The selection of individuals for SHIMS2 involved the following steps: (1) compiling a list of all individuals 
known to reside in the household or who slept in the household during the night prior to data collection; 
(2) identifying those rostered individuals who are eligible for data collection; and (3) selecting for the 
study those individuals meeting the age and residency requirements of the study. However, only those 
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individuals who were present in the household the night before the interview (i.e., the de facto 
population) are retained for subsequent weighting and analysis. 
 
The SHIMS2 2016-2017 Sampling and Weighting Technical Report provides a brief description of the 
process for listing and selecting individuals for participation in SHIMS2, and also presents detailed 
summaries of the distributions of eligible individuals and participants in individual interviews and HIV 




In general, the purpose of weighting survey data from a complex sample design is to (1) compensate for 
variable probabilities of selection, (2) account for differential nonresponse rates within relevant subsets 
of the sample, and (3) adjust for possible under coverage of certain population groups. Weighting is 
accomplished by assigning an appropriate sampling weight to each responding sampled unit (e.g., a 
household or person), and using that weight to calculate weighted estimates from the sample. The 
critical component of the sampling weight is the base weight which is defined to be the reciprocal of the 
probability of including a household or person in the sample. The base weights are used to inflate the 
responses of the sampled units to population levels and are generally unbiased (or consistent) if there is 
no nonresponse or noncoverage in the sample. When nonresponse or noncoverage occurs in the survey, 
weighting adjustments are applied to the base weights to compensate for both types of sample 
omissions. 
 
Nonresponse is unavoidable in virtually all surveys of human populations. For SHIMS2, nonresponse can 
occur at different stages of data collection, for example, (1) before the enumeration of individuals in the 
household, (2) after household enumeration and selection of persons but before completion of the 
individual interview, and (3) after completion of the interview but before collection of a usable blood 
sample. 
 
Noncoverage arises when some members of the survey population have no chance of being selected for 
the sample. For example, noncoverage can occur if the field operations fail to enumerate all dwelling 
units during the listing process, or if certain household members are omitted from the household 
rosters. To compensate for such omissions, the post stratification procedures are used to calibrate the 
weighted sample counts to available population projections. 
 
Methods 
The overall weighting approach for SHIMS2 includes several steps. Methods and results for each of the 
steps below are detailed in the SHIMS2 2016-2017 Sampling and Weighting Technical Report. 
 
▪ Initial checks: Checks of the data files are carried out as part of the survey and data quality control, 
and the probabilities of selection for PSUs and households are calculated and checked.  
 
▪ Creation of jackknife replicates: The variables needed to create the jackknife replicates for variance 
estimation are established at this point. This step can be implemented immediately after the PSU 
sample has been selected. All of the subsequent weighting steps described below are applied to the 
full sample, and to each of the jackknife replicates. 
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▪ Calculation of PSU base weights: The weighting process begins with the calculation and checking of 
the sample PSU (EA) base weights, which are computed as the reciprocals of the overall PSU 
probabilities of selection.  
 
▪ Calculation of household weights: The next step is to calculate household weights. The household 
base weights are calculated as the nonresponse adjusted EA weights times the reciprocal of the 
within-EA household selection probabilities. The household base weights are adjusted first to 
account for dwelling units for which it could not be determined whether the dwelling unit contained 
an eligible household (this only happened for 1.0% of the listings) and then the responding 
households have their weights adjusted to account for nonresponding eligible households. This 
adjustment is made based on the EA the households are in, and the resulting weight is the final 
household weight. 
 
▪ Calculation of person-level interview weights: Once the household weights are determined, they are 
used to calculate the individual base weights. The individual base weights are then adjusted for 
nonresponse among the eligible individuals, with a final adjustment for the individual weights to 
compensate for under coverage in the sampling process by weighting up to 2017 population 
projections produced by the Eswatini CSO.  
 
▪ Calculation of person-level HIV testing weights: The individual weights adjusted for nonresponse are 
in turn the base weights for the blood data sample, with a further adjustment for nonresponse to 
the blood draw, and a final post stratification adjustment to compensate for under coverage. 
 
▪ Application of weighting adjustments to jackknife replicates: All of the adjustment processes are 
applied to the full sample and the replicate samples so that the final set of full sample and replicate 
weights can be used for variance estimation that takes into account the complex sample design and 











Appendix B   HIV Testing Methodology 
 
B.1 Specimen Collection and Handling 
Blood was collected by qualified survey staff from consenting participants. Fourteen milliliters (mL) of 
venous blood was collected from adults (defined as persons aged 15 years and older), while six mL was 
collected from persons aged 2-14 years. One mL of capillary blood was collected from children aged 0-2 
years using finger-stick for children aged 6-24 months and heel-stick for children aged less than 6 
months. 
 
Blood samples were labeled with a unique barcoded participant ID and stored in temperature-controlled 
cooler boxes. Samples were transported to the national laboratory, the Eswatini Health Laboratory 
Services (EHLS), for registration in a laboratory data information system, processing into plasma and 
dried blood spots (DBS), and storage at -20C within 24 hours of blood collection. Samples for additional 
testing and long-term storage were stored at -80C. 
 
B.2 Household-Based Procedures 
HIV Rapid Testing 
HIV rapid testing was conducted in each household based on Eswatini’s national guidelines (Figure 
B.2.A). Specimens discordant between screening and confirmatory rapid testing underwent additional 
testing at EHLS, as described in section B.3. For participants who reported being HIV positive but tested 
HIV negative during the survey, additional testing was conducted at EHLS, as described in section B.3. 
For children aged less than 18 months, only the initial rapid test was performed. If the test was reactive, 
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All participants who tested HIV positive and a random sample of 2.0% of participants who tested HIV 
negative received a CD4 T-cell count measurement in the field by qualified survey staff. The 
measurement was performed using a Pima™ Analyzer and Pima™ CD4 Cartridge (Abbott Molecular Inc., 
Chicago, Illinois, United States, formerly Alere). 
 
Counseling, Referral to Care, and Active Linkage to Care 
Pre- and post-test counseling were conducted in each household in accordance with Eswatini’s national 
guidelines. For adults, results were communicated directly to the participant, while for children, aged 0-
14 years, results were communicated to the child’s parent or guardian. All participants who consented 
to HIV testing were asked to share contact information and to select a referral health facility. 
Participants with an HIV-positive test result were referred to HIV care and treatment at the health 
facility of their choice, while participants with HIV-negative test result by Clearview were advised to seek 
repeated testing at the health facility of their choice in two weeks. Further, HIV-positive participants 
were asked to consent to be contacted by qualified healthcare personnel, in order to facilitate active 
linkage to HIV care and treatment in Eswatini’s healthcare system. 
 
In rare cases where participants were provided an incorrect HIV test result, reported an HIV-positive 
status but tested HIV negative during the survey, or required additional collection of blood to complete 
testing, households were revisited by qualified personnel to provide participants with correct 
information and guidance on appropriate actions. 
 
Quality Assurance and Control 
To control the quality of the performance of HIV rapid tests, field staff conducted testing of a panel of 
HIV-positive and HIV-negative dried tube specimens on a weekly basis. To assure the quality of the 
performance of field staff conducting HIV testing, proficiency testing using a panel of blinded HIV-
positive and HIV-negative dried tube specimens was evaluated twice during the course of fieldwork. 
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Additionally, sample re-testing was conducted at a laboratory hub for the first 50 samples tested by 
each field staff member and a random sample of 5.0% of specimens, regardless of HIV status. 
 
A limitation of the survey is the potential limitation of rapid tests to detect HIV antibodies among people 
in the serological window of early infection, among persons with HIV infection who are on antiretroviral 
therapy (ART), and in infants aged 4 months and older. Participants in the first two categories are not 
expected to be a significant source of bias. The inability of rapid tests to reliably establish HIV-exposure 
status of an infant by detecting maternal HIV antibodies among infants aged 4 months and older and 
born to HIV-positive women, is another inherent limitation of the study. WHO currently recommends 
rapid tests to establish exposure status only in infants aged 4 months and younger.1 Further analysis will 
identify how many infants born to HIV-positive women were not identified by a rapid test. 
 
B.3 Laboratory-Based Procedures 
Four survey laboratory hubs were established in existing health facility laboratories across the country. 
One central laboratory was established at EHLS in Mbabane, Eswatini. 
 
Geenius Testing  
Samples with discrepant screening and confirmatory rapid test results were tested using the Geenius™ 
HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, California, United States) (Figure B.3.A). Testing was 
conducted at EHLS in accordance with the manufacturer-specified protocol. 
 
HIV TNA PCR 
HIV total nucleic acid (TNA) polymerase chain reaction (PCR) was conducted for children aged less than 
18 months who had a reactive HIV test result during household-based testing (Figure B.3.A). 
Additionally, HIV TNA PCR was evaluated for participants who reported being HIV positive but tested HIV 
negative during the survey, as well as for samples that were HIV positive by the rapid testing algorithm 
but were HIV negative by Geenius testing (Figure B.3.B). HIV TNA PCR was conducted using the Roche 
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 (Roche Molecular Diagnostics, 
Indianapolis, Indiana, United States) at EHLS in accordance with the manufacturer-specified protocol. 
 
Classification of Final HIV Status 
For participants aged 18 months or older, the algorithm for classification of final HIV status included 
results from HIV rapid testing, Geenius testing, and HIV TNA PCR (Figure B.3.A). For children aged less 
than 18 months, the algorithm for classification of final HIV status included results from HIV rapid testing 
and HIV TNA PCR (Figure B.3.B). Classification of final HIV status was used to determine estimates for 












Viral Load Testing 
The Roche COBAS Ampliprep/TaqMan HIV-1 Assay (Roche Molecular Diagnostics, Indianapolis, Indiana, 
United States) was used to prepare plasma samples from confirmed HIV-positive participants for reverse 
transcription polymerase chain reaction (RT-PCR), using the Roche COBAS Ampliprep. HIV-1 viral load 
(HIV ribonucleic acid (RNA) copies per mL) was then measured using the Roche TaqMan HIV-1 Assay. 
The Abbott RealTime HIV-1 Assay (Abbott Molecular Inc., Chicago, Illinois, United States) was used to 
measure viral load from DBS samples from children and from adults with insufficient volume of plasma. 
 
Viral load results were returned to the health facility chosen by each HIV-positive participant. 
Participants were provided with a referral form during home-based testing and counseling for 
subsequent retrieval of their results. Survey staff also contacted participants who provided contact 
information, informing them that their viral load results were available at the chosen facility and further 
advising them to seek care and treatment. 
 
HIV Recency Testing 
Estimation of HIV incidence was based on the classification of confirmed HIV-positive cases as recent or 
long-term infections. The survey used two laboratory-based testing algorithms to estimate incidence. 
The first estimate used an algorithm that employed a combination of the HIV-1 Limiting Antigen (LAg)-
Enzyme Immunoassay (EIA) (Sedia Biosciences Corporation, Portland, Oregon, United States) and viral 
load results (Figure B.3.C). Antiretroviral (ARV) detection results were added to that algorithm for the 
second estimate (Figure B.3.D). The HIV recent infection testing algorithms were applied to repository 
specimens from all confirmed HIV-positive participants 18 months and older. 
 
LAg testing was performed twice, with an initial screening test followed by a confirmatory process. 
Samples with a normalized optical density (ODn) > 2.0 during initial testing were classified as long-term 
infections, while those with ODn ≤ 2.0 underwent further testing of the specimen in triplicate. Samples 
with a median ODn > 1.5 during confirmatory testing were classified as long-term infections. Samples 
with a median ODn < 0.4 were retested using the HIV diagnostic testing algorithm to confirm HIV-1 
seropositivity, and samples identified as HIV-1 negative were excluded from the total number of HIV-
positives and incorporated into the total number of negative specimens for incidence estimation. 
 
Samples with a median ODn ≤ 1.5 were classified as potential HIV-recent infections, and their viral load 
results were assessed. For the first incidence testing algorithm, specimens with viral load < 1,000 
copies/mL were classified as long-term infections, while those with viral load ≥ 1,000 copies/mL were 
classified as recent infections. For the ARV-adjusted incidence algorithm, those classified as recent 
infections by the first algorithm were reclassified using ARV detection data. Those samples in which 
ARVs were detected (i.e., efavirenz, lopinavir, and nevirapine) were classified as long-term infections 
and those in which no ARVs were detected remained classified as recent infections. 
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Figure B.3.D HIV-1 Recent Infection Testing Algorithm (LAg/viral load/ARV), aged 18 months and 
older, SHIMS2 2016-2017 
 
 
HIV Incidence Estimation 
Incidence estimates were obtained using the formula recommended by the World Health Organization 
Incidence Working Group and Consortium for Evaluation and Performance of Incidence Assays. 
Weighted counts for HIV-negative persons (N); HIV-positive persons (P); numbers tested on the LAg 
assay (Q); and numbers HIV recent (R) are provided for use in incidence calculations or Joint United 
Nations Programme on HIV/AIDS Spectrum models (Tables B.3.A, B.3.B). Incidence estimates were 
calculated using the following parameters: Mean duration recent infection (MDRI) = 130 days (95.0% 
confidence interval: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year. In-
depth details are provided in the SHIMS2 2016-2017 Technical Report, which may be found online at the 
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Table B.3.A Annual HIV incidence auxiliary data: N, P, Q, R, MDRI, PFR, and T 
Annual incidence of  HIV among persons aged 15-49, and 15 years and older, by sex and age, SHIMS2 2016-2017 




















































15-24 1606.82 68.18 68.18 4.52  1657.53 268.47 268.47 11.17  3273.76 327.24 327.24 15.40 
25-34 839.27 206.73 206.73 4.51  876.42 678.58 677.53 5.79  1749.87 851.13 850.17 10.38 
35-49 522.31 411.69 411.69 1.27  692.65 704.35 704.35 6.01  1216.18 1114.82 1114.82 7.22 
15-49 2965.46 689.54 689.54 10.54  3203.61 1674.39 1673.34 22.87  6208.12 2324.88 2323.88 32.95 
15+ 3587.28 918.72 918.72 13.13  4338.12 2089.88 2088.72 26.48  7983.51 2950.49 2949.42 39.02 
1Weighted number 
Note: Mean duration recent infection (MDRI) = 130 days (95.0% CI: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year 
  
 
Table B.3.B Annual HIV incidence auxiliary data incorporating ARV detection into the recent infection algorithm: N, P, Q, R, MDRI, PFR, and T 
Annual incidence of HIV among persons aged 15-49 years and 15 years and older, by sex and age, using LAg/VL/ARVs algorithm, SHIMS2 2016-2017 


















































15-24 1606.82 68.18 68.18 2.96 1657.53 268.47 268.47 9.94 3273.76 327.24 327.24 12.58 
25-34 839.27 206.73 206.73 4.51 876.42 678.58 677.53 4.85 1749.87 851.13 850.17 9.53 
35-49 522.31 411.69 411.69 1.27 692.65 704.35 704.35 5.21 1216.18 1114.82 1114.82 6.44 
15-49 2965.46 689.54 689.54 9.05 3203.61 1674.39 1673.34 19.91 6208.12 2324.88 2323.88 28.56 
15+ 3587.28 918.72 918.72 10.85 4338.12 2089.88 2088.72 21.95 7983.51 2950.49 2949.42 32.31 
1Weighted number 





Detection of Antiretrovirals 
To understand recent exposure to ARVs and hence level of ART coverage, samples from all confirmed 
HIV-positive participants were evaluated for the presence of selected ARVs, using high-resolution liquid 
chromatography coupled with tandem mass spectrometry to detect ARVs from DBS specimens.2 Three 
ARVs, two non-nucleoside reverse transcriptase inhibitors, efavirenz and nevirapine, and one protease 
inhibitor, lopinavir, were used as markers for both first- and second-line regimens, based on Eswatini’s 
national treatment guidelines. The ARVs were selected based on their long half-lives, allowing for a 
longer window period from drug exposure to detection. 
 
To qualitatively detect ARVs, a single DBS was eluted, and chromatographic separation carried out on a 
Luna 5μm PFP column (110 Å, 50 x 2 mm) (Phenomonex, Torrance, California, United States). Each ARV 
was detected using an API 4000 LC/MS/MS instrument (Applied Biosystems, Foster City, California, 
United States). Internal standards and in-house quality control cut-off samples including negative 
controls were utilized in each run. This qualitative method used a limit of detection of 0.02 microgram 
(μg)/mL for each ARV, with a signal-to-noise ratio of at least 5:1 for all ARVs. Samples with 
concentrations above 0.02 μg/mL were considered positive for each ARV. Testing was conducted at 
University of Cape Town in Cape Town, South Africa. 
 
Genotyping for Detection of Antiretroviral Drug Resistance and HIV Subtyping 
To determine the extent of transmitted HIV-1 drug resistance mutations among participants, samples 
from confirmed HIV-positive children aged less than 18 months and HIV-positive participants aged 18 
months and older who were classified as recent infections as well as an equal or greater number of who 
were classified as long-term infections were evaluated using a TaqMan® SNP Genotyping Assay (Applied 
Biosystems) to identify mutations within the HIV-1 pol gene region, which encodes amino acid 
substitutions known to be responsible for resistance to specific ARVs. 
 
Viral RNA or TNA from plasma or DBS was extracted using the NucliSENS® easyMAG® (bioMérieux, 
Marcy-L’Etoile, France) platform. The HIV pol gene was amplified by one-step RT-PCR, which was 
followed by nested PCR. Sequencing of the approximately one-kilobase amplicons was performed on the 
ABI 3730 DNA Analyzer (Applied Biosystems).3,4,5  
 
The customized ReCALL software program was used to edit raw sequences and generate consensus 
sequences.6 Mutations in the protease and reverse transcriptase genes were classified as potentially 
associated with drug resistance, according to the Stanford University HIV Drug Resistance Database.7 
Sequences with greater than 98.0% homology were flagged for potential cross-contamination or 
possible epidemiological links. Internal quality assurance measures and in-house quality control 
standards were included in each run, to validate results. The assay’s sensitivity has been established at 
1000 copies/mL for plasma and DBS.8 Sequences were also analyzed for potential cross-contamination 
by phylogenetic analysis from code 6 of the protease gene to code 251 of the reverse transcriptase 
gene. 
 
Subtyping of each sample was performed using the REGA HIV-1 & 2 Automated Subtyping Tool.9,10 This 
BioAfrica viral subtyping tool is designed to use phylogenetic methods in order to identify the HIV-1 










1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection. Geneva: World Health Organization; 2016.  
https://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed December 17, 2018. 
 
2. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in 
dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid 
Commun Mass Spectrom. 2005;19(21):2995-3001. 
 
3. Loens K, Bergs K, Ursi D, Goossens H, Ieven M. Evaluation of NucliSens easyMAG for automated 
nucleic acid extraction from various clinical specimens. J Clin Microbiol. 2007 Feb;45(2):421-5. Epub 
2006 Dec 13. 
 
4. Perandin F, Pollara PC, Gargiulo F, Bonfanti C, Manca N. Performance evaluation of the automated 
NucliSens easyMAG nucleic acid extraction platform in comparison with QIAamp Mini kit from clinical 
specimens. Diagn Microbiol Infect Dis. 2009 Jun;64(2):158-65. doi: 10.1016/j.diagmicrobio.2009.02.013. 
 
5. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global 
AIDS epidemic 2010. Geneva, Switzerland: UNAIDS; 2010. 
http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 
February 19, 2019. 
 
6. Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, a freely 
accessible sequence analysis tool. J Clin Microbiol. 2012 Jun;50(6):1936-42. doi: 10.1128/JCM.06689-11. 
Epub 2012 Mar 7. 
 
7. Stanford University. HIV Drug Resistance Database. Stanford, California: Stanford University; 2019. 
http://hivdb.stanford.edu. Accessed February 19, 2019. 
 
8. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-
spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol. 
2010;48(9):3158-64. doi: 10.1128/JCM.00564-10. 
 
9. Alcantara LC, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput 
genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 2009;37(Web 
Server issue):W634-42. doi: 10.1093/nar/gkp455. 
 
10. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and 









Appendix C   Estimates of Sampling Errors 
Estimates from sample surveys are affected by two types of errors: non-sampling errors and sampling 
errors. Non-sampling errors result from mistakes made during data collection (e.g., misinterpretation of 
an HIV test result) and data management (e.g., transcription errors in data entry). While SHIMS2 
implemented numerous quality assurance and control measures to minimize non-sampling errors, these 
errors are impossible to avoid and difficult to evaluate statistically. 
 
In contrast, sampling errors can be evaluated statistically. The sample of respondents selected for 
SHIMS2 is only one of many samples that could have been selected from the same population, using the 
same design and expected size. Each of these samples would yield results that differ somewhat from the 
results of the actual sample selected. Sampling errors are a measure of the variability between all 
possible samples. Although the degree of variability is not known exactly, it can be estimated from the 
survey results. 
 
The standard error, which is the square root of the variance, is the usual measurement of sampling error 
for a particular statistic (e.g., proportion, mean, rate, count). In turn, the standard error can be used to 
calculate confidence intervals within which the true value for the population can reasonably be assumed 
to fall. For example, for any given statistic calculated from a sample survey, the value of that statistic will 
fall within a range of approximately plus or minus two times the standard error of that statistic in 95% of 
all possible samples of identical size and design. 
 
SHIMS2 utilized a multistage stratified sample design, which requires complex calculations to obtain 
sampling errors. Specifically, a variant of the jackknife replication method was implemented in SAS to 
estimate variance for proportions (e.g., HIV prevalence), rates (e.g., annual HIV incidence), and counts 
(e.g., numbers of people living with HIV). Each replication considers all but one cluster in the calculation 
of the estimates. Pseudo-independent replications are thus created. In SHIMS2, a jackknife replicate is 
created by randomly deleting one cluster from each variance-estimation stratum and retaining all of the 
clusters in the remaining strata. A total of 250 variance-estimation strata were created by pairing (or 
occasionally tripling) the sample clusters in the systematic order in which they had been selected. 
Hence, 250 replications were created. The variance of a sample-based statistic, y, is calculated as 
follows: 
 
var(y) = ∑  𝐾𝑘=1 (yk - y)
2 
 
where y is the full-sample estimate, and yk is the corresponding estimate for jackknife replicate k (k = 1, 
2, ..., K).  
 
In addition to the standard error, the design effect for each estimate is also calculated. The design effect 
is defined as the ratio of the standard error using the given sample design to the standard error that 
would result if a simple random sample had been used. A design effect of 1.0 indicates that the sample 





design is as efficient as a simple random sample, while a value greater than 1.0 indicates the increase in 
the sampling error due to the use of a more complex and less statistically efficient design. Confidence 
limits for the estimates, which are calculated as:  
 
y  ±  t(0.975; K) √𝑣𝑎𝑟(𝑦) , 
 
where t(0.975; K) is the 97.5th percentile of a t-distribution with K degrees of freedom, are also 
computed. 
 
Sampling errors for selected variables from SHIMS2 are presented in Tables C.1 through C.8, and 
sampling errors for all survey estimates may be found online at the PHIA Project website. For each 
variable, sampling error tables include the weighted estimate, unweighted denominator, standard error, 
design effect, and lower and upper 95% confidence limits. 
 














15-24 1.31 0.97 0.66 1.96 
25-34 1.65 1.32 0.65 2.65 
35-49 1.65 1.01 0.44 2.85 
15-49 1.48 1.12 0.96 1.99 
15+ 1.36 0.95 0.92 1.80 
MEN 
15-24 0.79 1.04 0.08 1.49 
25-34 1.50 1.33 0.12 2.85 
35-49 0.68 0.89 0.00 1.85 
15-49 0.99 1.25 0.39 1.59 
15+ 1.02 0.72 0.47 1.57 
WOMEN 
15-24 1.87 1.05 0.79 2.95 
25-34 1.84 1.23 0.34 3.32 
35-49 2.40 1.04 0.48 4.29 
15-49 1.99 1.19 1.16 2.80 























0-17 months 4.2 266 1.5 1.2 7.2 
18-59 months 0.8 765 0.3 0.1 1.4 
5-9 2.9 1,187 0.5 1.8 4.0 
10-14 4.1 1,154 0.6 2.9 5.2 
      
Total 0-4 1.7 1,031 0.5 0.7 2.7 
Total 0-14 2.8 3,372 0.3 2.2 3.4 
      
15-19 5.6 2,059 0.5 4.4 6.7 
20-24 12.8 1,542 0.9 11.0 14.6 
25-29 26.1 1,383 1.5 23.0 29.1 
30-34 40.8 1,218 1.4 37.9 43.6 
35-39 49.1 978 2.3 44.4 53.8 
40-44 48.4 722 2.6 43.2 53.7 
45-49 44.9 631 1.9 41.0 48.9 
50-54 38.5 552 2.3 33.7 43.3 
55-59 30.5 474 2.2 26.0 35.0 
60-64 26.8 457 2.1 22.5 31.1 
65+ 10.9 918 1.1 8.6 13.3 
      
Total 15-24 9.1 3,601 0.5 8.0 10.2 
Total 15-49 27.2 8,533 0.7 25.8 28.7 
Total 15+ 27.0 10,934 0.6 25.7 28.3 
MEN 
0-17 months 4.3 142 1.8 0.7 8.0 
18-59 months 0.5 377 0.4 0.0 1.2 
5-9 3.1 587 0.8 1.4 4.8 
10-14 4.7 576 0.9 2.8 6.5 
      
Total 0-4 1.6 519 0.6 0.3 2.9 
Total 0-14 3.0 1,682 0.5 2.1 4.0 
      
15-19 3.9 1,028 0.7 2.5 5.4 
20-24 4.2 647 0.8 2.5 6.0 
25-29 13.3 572 1.5 10.2 16.4 
30-34 28.1 474 2.3 23.4 32.9 
35-39 41.9 410 2.9 35.9 47.9 
40-44 43.3 292 3.4 36.4 50.2 
45-49 48.8 232 3.5 41.5 56.1 





      
















55-59 31.8 176 3.2 25.2 38.4 
60-64 31.9 163 3.7 24.3 39.5 
65+ 14.9 320 1.9 10.9 19.0 
      
Total 15-24 4.1 1,675 0.5 2.9 5.2 
Total 15-49 18.9 3,655 0.8 17.3 20.4 
Total 15+ 20.4 4,506 0.7 18.9 21.9 
WOMEN 
0-17 months 4.0 124 2.1 0.0 8.3 
18-59 months 1.0 388 0.5 0.0 2.1 
5-9 2.7 600 0.8 1.1 4.2 
10-14 3.4 578 0.8 1.8 5.1 
      
Total 0-4 1.8 512 0.6 0.5 3.1 
Total 0-14 2.6 1,690 0.4 1.8 3.4 
      
15-19 7.2 1,031 0.9 5.4 9.0 
20-24 20.9 895 1.5 17.8 24.0 
25-29 37.5 811 2.0 33.4 41.5 
30-34 50.7 744 2.0 46.5 54.9 
35-39 54.2 568 2.8 48.5 60.0 
40-44 51.9 430 3.2 45.4 58.5 
45-49 42.3 399 2.4 37.4 47.2 
50-54 36.1 360 2.7 30.6 41.6 
55-59 29.5 298 3.0 23.3 35.8 
60-64 22.3 294 2.5 17.2 27.3 
65+ 7.4 598 1.2 5.0 9.8 
      
Total 15-24 13.9 1,926 0.9 12.1 15.8 
Total 15-49 34.3 4,878 0.8 32.6 36.0 










Table C.3 Sampling errors: HIV prevalence by residence and region, among adults 
aged 15 years and older, SHIMS2 2016-2017 
Characteristic 
Weighted 












Residence      
Urban 29.8 2265 2.1 25.5 34.0 
Rural 26 8669 0.6 24.8 27.2 
      
Region      
Hhohho 25.7 3,284 1.2 23.2 28.2 
Lubombo 29.4 2,253 1.3 26.7 32.1 
Manzini 27.3 3,405 1.5 24.3 30.3 
Shiselweni 25.9 1,992 1.2 23.6 28.3 
MEN 
Residence      
Urban 23.5 970 2.3 18.7 28.2 
Rural 19.3 3,536 0.7 17.9 20.7 
      
Region      
Hhohho 19.7 1,402 1.2 17.2 22.2 
Lubombo 23.5 971 1.6 20.1 26.8 
Manzini 20.7 1,360 1.8 17.0 24.4 
Shiselweni 17.1 773 1.0 15.0 19.2 
WOMEN 
Residence      
Urban 34.9 1,295 2.2 30.5 39.4 
Rural 31.6 5,133 0.7 30.1 33.1 
      
Region      
Hhohho 31.0 1,882 1.6 27.8 34.2 
Lubombo 34.9 1,282 1.7 31.4 38.3 
Manzini 32.4 2,045 1.4 29.4 35.3 
























0–14 61.3 96 5.3 50.4 72.2 
15–24 50.6 338 2.6 45.2 55.9 
25–34 68.4 933 1.9 64.6 72.2 
35–44 78.3 860 1.5 75.1 81.5 
45–54 80.8 511 1.9 76.8 84.8 
55-64 88.3 269 1.9 84.3 92.3 
65+ 85.5 92 4.4 76.5 94.6 
      
Total 15-24 50.6 338 2.6 45.2 55.9 
Total 15-49 70.8 2,423 1.0 68.8 72.9 
Total 15+ 73.1 3,003 0.9 71.3 75.0 
MEN 
0–14 58.3 52 6.9 44.2 72.4 
15–24 32.9 69 5.5 21.5 44.3 
25–34 54.8 220 3.5 47.6 62.1 
35–44 69.2 317 2.8 63.3 75.0 
45–54 80.0 207 3.0 73.9 86.1 
55-64 89.3 111 3.2 82.8 95.9 
65+ 84.9 48 6.1 72.4 97.5 
      
Total 15-24 32.9 69 5.5 21.5 44.3 
Total 15-49 62.3 729 1.8 58.7 65.9 
Total 15+ 67.6 972 1.5 64.5 70.6 
WOMEN 
0–14 64.9 44 8.1 48.2 81.7 
15–24 55.5 269 2.9 49.5 61.5 
25–34 73.5 713 2.2 69.0 78.1 
35–44 83.4 543 1.7 79.9 86.8 
45–54 81.5 304 2.4 76.5 86.4 
55-64 87.3 158 2.4 82.3 92.3 
65+ 86.6 44 4.9 76.5 96.8 
      
Total 15-24 55.5 269 2.9 49.5 61.5 
Total 15-49 74.8 1,694 1.2 72.3 77.3 







Table C.5 Sampling errors: Viral load suppression by residence and region, among 
adults aged 15 years and older, SHIMS2 2016-2017 
Characteristic 
Weighted 












Residence      
Urban 70.4 725 1.9 66.6 74.2 
Rural 74.3 2,278 1.0 72.2 76.3 
      
Region      
Hhohho 72.1 874 1.7 68.5 75.7 
Lubombo 72.6 672 1.9 68.7 76.5 
Manzini 71.5 931 1.6 68.2 74.7 
Shiselweni 79.1 526 1.6 75.8 82.5 
MEN 
Residence      
Urban 62.1 257 2.6 56.8 67.4 
Rural 70.0 715 1.8 66.2 73.8 
      
Region      
Hhohho 65.6 295 3.0 59.4 71.9 
Lubombo 68.2 240 3.3 61.4 75.0 
Manzini 65.7 292 2.4 60.6 70.7 
Shiselweni 75.9 145 3.8 68.0 83.9 
WOMEN 
Residence      
Urban 75.0 468 2.3 70.3 79.6 
Rural 76.5 1,563 1.2 74.0 78.9 
      
Region      
Hhohho 75.8 579 2.1 71.6 80.1 
Lubombo 75.4 432 2.3 70.6 80.2 
Manzini 74.4 639 2.0 70.3 78.5 








Table C.6 Sampling errors: ARV-adjusted 90-90-90 by age (conditional percentages), among adults aged 15 years and older, SHIMS2 2016-2017 
 Diagnosed On Treatment Viral Load Suppression 
Age (years) 
Weighted 




































15-24 72.1 336 2.8 66.4 77.8 85.3 248 2.4 80.3 90.3 76.5 214 3.0 70.4 82.7 
25-34 85.0 930 1.4 82.1 87.9 85.2 807 1.4 82.3 88.2 89.9 690 1.2 87.3 92.4 
35-49 90.9 1,151 0.9 89.1 92.7 90.2 1,058 1.0 88.1 92.3 93.5 954 0.7 92.0 95.0 
15-49 86.1 2,417 0.7 84.7 87.6 87.8 2,113 0.9 86.0 89.6 90.3 1,858 0.6 89.0 91.6 
15+ 87.0 2,997 0.6 85.7 88.3 88.8 2,651 0.8 87.2 90.4 91.4 2,369 0.5 90.3 92.5 
MEN 
15-24 60.3 68 6.4 47.2 73.5 92.2 44 5.9 80.1 100.0 57.6 41 7.5 42.0 73.1 
25-34 69.2 220 3.5 62.0 76.4 84.3 156 3.3 77.4 91.1 85.0 133 3.4 78.0 92.0 
35-49 84.8 439 1.7 81.3 88.3 89.9 381 1.7 86.4 93.4 92.4 342 1.4 89.6 95.2 
15-49 77.3 727 1.6 74.0 80.6 88.4 581 1.6 85.2 91.6 87.6 516 1.6 84.4 90.9 
15+ 80.1 970 1.3 77.4 82.8 90.2 800 1.2 87.8 92.7 90.5 728 1.2 88.1 93.0 
WOMEN 
15-24 75.5 268 2.8 69.7 81.2 83.7 204 2.5 78.6 88.9 81.2 173 3.2 74.6 87.9 
25-34 91.1 710 1.2 88.5 93.6 85.5 651 1.6 82.2 88.8 91.2 557 1.4 88.4 94.1 
35-49 94.6 712 0.9 92.8 96.4 90.4 677 1.3 87.7 93.1 94.1 612 0.9 92.3 95.9 
15-49 90.2 1,690 0.8 88.6 91.8 87.5 1,532 1.0 85.4 89.6 91.4 1,342 0.7 89.9 92.8 
15+ 90.7 2,027 0.7 89.2 92.1 88.1 1,851 0.9 86.3 90.0 91.8 1,641 0.6 90.4 93.1 
 





Table C.7  Sampling errors: ARV-adjusted 90-90-90 by age (unconditional percentages), among adults aged 15 years and older, SHIMS2 2016-2017 










































                   TOTAL 
15-24 72.1 336 2.8 66.4 77.8 61.5 336 3.0 55.3 67.7 47.1 336 2.9 41.2 53.0 
25-34 85.0 930 1.4 82.1 87.9 72.5 930 1.8 68.8 76.1 65.1 930 1.9 61.1 69.1 
35-49 90.9 1,151 0.9 89.1 92.7 82.0 1,151 1.3 79.3 84.6 76.6 1,151 1.3 73.9 79.4 
15-49 86.1 2,417 0.7 84.7 87.6 75.6 2,417 1.0 73.6 77.5 68.2 2,417 1.0 66.1 70.4 
15+ 87.0 2,997 0.6 85.7 88.3 77.3 2,997 0.8 75.6 79.0 70.6 2,997 0.9 68.8 72.5 
                   MEN 
15-24 60.3 68 6.4 47.2 73.5 55.6 68 6.7 41.9 69.4 32.0 68 5.5 20.7 43.4 
25-34 69.2 220 3.5 62.0 76.4 58.3 220 3.5 51.1 65.5 49.6 220 3.7 42.0 57.2 
35-49 84.8 439 1.7 81.3 88.3 76.2 439 2.0 72.0 80.4 70.4 439 2.1 66.0 74.9 
15-49 77.3 727 1.6 74.0 80.6 68.3 727 1.8 64.7 72.0 59.9 727 1.9 56.1 63.7 
15+ 80.1 970 1.3 77.4 82.8 72.3 970 1.5 69.2 75.3 65.4 970 1.6 62.2 68.6 
                    WOMEN 
15-24 75.5 268 2.8 69.7 81.2 63.2 268 3.1 56.8 69.6 51.3 268 3.3 44.6 58.1 
25-34 91.1 710 1.2 88.5 93.6 77.9 710 1.8 74.2 81.5 71.1 710 2.1 66.8 75.3 
35-49 94.6 712 0.9 92.8 96.4 85.5 712 1.5 82.4 88.5 80.4 712 1.6 77.1 83.7 
15-49 90.2 1,690 0.8 88.6 91.8 78.9 1,690 1.0 76.8 81.1 72.1 1,690 1.2 69.7 74.5 
15+ 90.7 2,027 0.7 89.2 92.1 79.9 2,027 0.9 78.1 81.8 73.3 2,027 1.0 71.2 75.4 
 
ARV: antiretroviral  
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Table C.8 Sampling errors: Number of new infections annually and number of people living with 
HIV, among adults aged 15 years and older, SHIMS2 2016-2017 










Number of new infections annually 
(using LAg/VL algorithm) 
7,255 1,150 4,881 9,629 
Number of new infections annually 
(using LAg/VL/ARVs algorithm) 
6,015 1,041 3,866 8,163 
Number of people living with HIV 196,645 4,621 187,128 206,162 
 




Appendix D   Survey Personnel 

































































































Daniel Williams   
Drew Voetsch 
Hetal Patel 
































Theo Smart  
Yen Pottinger 
 
ICAP in South Africa 



































































































































































Muhle Dlamini  
Mpumelelo Mavimbela 
Mpumelelo Ndlangamandla 
Nhlanhla Magagula  
Nicholas Kisyeri 
Nsindiso Dlamini 
Sebentile Myeni  
Simangele Mthethwa-Hleta 
Tengetile Dlamini  
Thulani Maphosa  
Zandile Nhleko
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Appendix E   Household Questionnaire 
ENGLISH 
CONFIDENTIAL 
MINISTRY OF HEALTH 
SWAZILAND HIV INCIDENCE MEASUREMENT SURVEY  
(SHIMS2 2016-2017) 
HOUSEHOLD QUESTIONNAIRE 




[THIS PAGE AUTOPOPULATED WITH HOUSEHOLD LISTING INFORMATION]  
   
REGION CODE 
 






REGION NAME:  _____________________________________ 
INKHUNDLA  NAME:  _____________________________________ 
CHIEFDOM  NAME: _____________________________________ 


















LINE NO. OF RESPONDENT TO 
HOUSEHOLD 
QUESTIONNAIRE 
LANGUAGE OF INTERVIEW:  
NATIVE LANGUAGE OF RESPONDENT: 






SUPERVISOR:  ______________________________ 
 




OFFICE EDITOR: KEYED BY: 
* RESULTS CODES: 
(1) COMPLETED 
(2) NO HOUSEHOLD MEMBER AT HOME OR NO COMPETENT RESPONDENT AT 
HOME AT TIME OF VISIT 
(3) ENTIRE HOUSEHOLD ABSENT FOR EXTENDED PERIOD OF TIME 
(4) POSTPONED 
(5) REFUSED 
(6) DWELLING VACANT OR ADDRESS NOT A DWELLING 
(7) DWELLING DESTROYED 
(8) DWELLING NOT FOUND 
(9) PARTLY COMPLETED 
(96) OTHER (SPECIFY) 
START TIME 
START Look at the time on the tablet in the right top 
corner and record the start time.  
 
USE 24-HOUR TIME.  
 
IF START TIME IS 3:12 PM, RECORD 15 HOURS, 
12 MINUTES, NOT 03 HOURS, 12 MINUTES.  
HOUR:  
 
MINUTES:   
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NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 1: HOUSEHOLD ROSTER 
Interviewer says: “Please give me the names of the persons who usually live in your household or guests of the household who stayed here last 
night, starting with the head of the household.” 
1 
 
Add a new "HH MEMBER" group? Do not add 1 if item = 1 item 11 
2 personid Name [INSERT SERIAL NUMBER]   text     
3 relattohh* What is the relationship of  HEAD 1    




2    
    BIOLOGICAL SON OR 
DAUGHTER 
3    
    SON-IN-LAW / 
DAUGHTER-IN-LAW 
4    
    GRANDCHILD 5    
    PARENT 6    
    PARENT-IN-LAW 7    
    BROTHER/SISTER 8    
    CO-WIFE 9    
    OTHER RELATIVE 10    
    ADOPTED/FOSTER/STE
PCHILD 
11    
    NOT RELATED 12    
    DON'T KNOW -8    
4 householdhead
gender* 
Is [HHRNAME*] male or female? MALE 1     
     FEMALE 2     
5 livehere* Does [HHRNAME*] usually live here? YES 1     
     NO 2     
6 sleephere* Did [HHRNAME*] sleep here last night? YES 1    
    NO 2    
7 age* How old is [HHRNAME*] in years? AGE IN YEARS integer if age >=1 & age <=5 item 9 
   IF [HHRNAME*] IS LESS THAN 1 YEAR 
OLD, KEY 0 HERE AND KEY AGE IN 
MONTHS ON NEXT SCREEN. 
  if age >5 & age <12 HHRSCHLHL* 
      if age >=12 & age <18 empancipated* 
      if age <1 agem 
         if age >=18 hhrschlhl* 
8 agem* How old is [HHRNAME*] in months? AGE IN MONTHS integer ALL hhrschlhl* 
9  You said that [HHRNAME*] was [age*].  
How many months over [age*] is 
[HHRNAME*]? 
MONTHS OVER integer ALL hhrschlhl* 
10 emancipated* Is [HHRNAME*] a child with special 
circumstances? 
YES 1  hhrschlhl* 
   A child with special circumstances is a 
child 12-17 years of age who is married 
or has a child of their own and is not 
currently living with parents, or a child 
who is the decision maker in a 
household where there is no identified 
adult head of household. 
NO 2    
11 hhrschlhl* What was the highest level of school 
completed by [HHRNAME*]? 
NEVER COMPLETED 
ANY 
0     
    KINDERGARTEN/ 
NURSERY 
1    
    PRIMARY  2    
    SECONDARY  3    
    HIGH SCHOOL 4    
    TERTIARY 5    
    DON’T KNOW  -8    
     REFUSED  -9     
12 hhr12moaway* In the last 12 months, was 
[HHRNAME*] away from home for 
more than one month at a time? 
YES   1 if age*>=0 & age*<18  item 1 
    NO   2 if age*>=18 sick3mo* 
    DON’T KNOW   -8    




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
13 sick3mo* Has [HHRNAME*] been very sick for at 
least 3 months during the past 12 
months, that is [HHQNAME*] was too 
sick to work or do normal activities? 
YES 1     
    NO 2    
     DON'T KNOW -8     
Interviewer says: “Thank you for completing the Household Roster.  The next step will be to ask some confirmation questions.”  
14  Just to make sure I have complete 
listing, are there any other persons 
such as small children or infants that 
we have not listed? 
     
   IF NEW PERSONS ARE IDENTIFIED, 
SWIPE BACK TO THE ROSTER AND ADD 
THOSE NEW PEOPLE. 
     
15  Are there any other people who may 
not be members of your household 
such as domestic servants, lodgers, or 
friends who usually live here? 
      
   IF NEW PERSONS ARE IDENTIFIED, 
SWIPE BACK TO THE ROSTER AND ADD 
THOSE NEW PEOPLE. 
        
16  Are there any guests or temporary 
visitors staying here, or anyone else 
who stayed here last night who we 
have not seen? 
     
   IF NEW PERSONS ARE IDENTIFIED, 
SWIPE BACK TO THE ROSTER AND ADD 
THOSE NEW PEOPLE. 
     
Interviewer says: “Thank you for confirming the Household Roster is complete.  The next step will be to answer some additional questions for the 
Household Members who are 0-17 years old.” 
17  CONTINUE TO THE NEXT ITEM? YES 1 if item = 2 HH REFUSAL OR 
WITHDRAWAL 
FORM 
   SELECT 'NO' ONLY IF THE PARTICIPANT 
HAS EXPRESSED HE/SHE DOES NOT 
WISH TO CONTINUE ON WITH THE 
SURVEY. 





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 2: HOUSEHOLD ROSTER (FOR MINORS)     if emancipated* =1 
OR age >= 18 
  
  These questions are regarding 
[HHRNAME*] 
     
18 momalive* Is [HHRNAME*]'s natural mother alive? YES 1 if momalive*=2,-8 FEMGUARDHHM
* 
    NO 2    
     DON'T KNOW -8     
19 momhhm* Does [HHRNAME*] 's natural mother 
usually live in this household or was a 
guest last night? 
YES 1 if momhhm*=2 femguardhhm* 
    NO 2    
20 momfemname* PLEASE SELECT [HHRNAME*]'S 
NATURAL MOTHER FROM THE LIST OF 
HOUSEHOLD MEMBERS BELOW. 
[LIST OF ALL FEMALES 
FROM HOUSEHOLD] 
list     
21 femguardhhm* Does [HHRNAME*] have a female 
guardian who usually lives in this 
household or was a guest last night? 
YES 1 if femguardhhm*=2 dadalive* 
     NO 2     
22 momfemname* PLEASE SELECT [HHRNAME*]'S FEMALE 
GUARDIAN FROM THE LIST OF 
HOUSEHOLD MEMBERS BELOW. 
[LIST OF ALL FEMALES 
FROM HOUSEHOLD] 
list     
23 dadalive* Is [HHRNAME*]'s natural father alive? YES 1 if dadalive*=2,-8 maleguardhhm* 
    NO 2    
    DON'T KNOW -8    
24 dadhhm* Does [HHRNAME*] 's natural father 
usually live in this household or was a 
guest last night? 
YES 1 if dadhhm*=2 maleguardhhm* 
     NO 2     
25 dadmalename* PLEASE SELECT [HHRNAME*]'S 
NATURAL FATHER FROM THE LIST OF 
HOUSEHOLD MEMBERS BELOW. 
[LIST OF ALL MALES 
FROM HOUSEHOLD] 
list    
26 maleguardhhm
* 
Does [HHRNAME*] have a male 
guardian who usually lives in this 
household or was a guest last night? 
YES 1 if maleguardhhm*=2 item 28 
     NO 2     
27 dadmalename* PLEASE SELECT [HHRNAME*]'S MALE 
GUARDIAN FROM THE LIST OF 
HOUSEHOLD MEMBERS BELOW. 
[LIST OF ALL MALES 
FROM HOUSEHOLD] 
list    
28 parentguardqx SELECT AN ELIGIBLE ADULT WHO WILL 
FILL OUT CHILDREN'S MODULE FOR 
[HHRNAME*]. 






list SKIP if age*>14   
   THE CHILDREN'S MODULE WILL ASK 
QUESTIONS ABOUT [HHRNAME*] IN 
THE ADULT QUESTIONNAIRE.  THE 
SELECTED ADULT SHOULD BE 
SOMEONE WHO KNOWS 
[HHRNAME*]. 
        
29  SELECT AN ADULT WHO CAN PROVIDE 
CONSENT OR GIVE PERMISSION FOR 
[HHRNAME*] TO PARTICIPATE IN THE 
SURVEY. 






list SKIP if age*>14   
       NONE if item 28a ! = NONE 
if item 28a = NONE 
sick3mo* 
emancipated* 
30  You said that there is no adult in the 
household who can provide consent or 
permission for [HHRNAME*].  Is this 
correct? 
YES 1 if emancipated = 1 END OF SURVEY 
FOR 
[HHRNAME*] 






NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
Interviewer says: “Thank you for completing the questions regarding the Household members who are 0-[INSERT AGE OF LEGAL ADULTHOOD]  
years old.  The next step will be to answer some additional questions regarding the men who live in the household.”  
31 momsick* Has [HHRNAME*]'s natural mother 
been very sick for at least 3 months 
during the past 12 months, that is she 
was too sick to work or do normal  
YES 1     
   activities? NO 2    
     DON'T KNOW -8     
32  Does [HHRNAME*]'s natural mother 
have HIV/AIDS? 
YES 1    
    NO 2    
    DON'T KNOW -8    
    REFUSED  -9    
33 dadsick* Has [HHRNAME*]'s natural father been 
very sick for at least 3 months during 
the past 12 months, that is he was too 
sick to work or do normal activities? 
YES 1     
    NO 2    
    DON'T KNOW -8    
34  Does [HHRNAME*]'s natural father  YES 1     
   have HIV/AIDS? NO 2    
    DON'T KNOW -8    
     REFUSED  -9     
35  CONTINUE TO THE NEXT ITEM? YES 1 if item=2 HH REFUSAL OR 
WITHDRAWAL 
FORM 
   SELECT 'NO' ONLY IF THE PARTICIPANT 
HAS EXPRESSED HE/SHE DOES NOT 
WISH TO CONTINUE ON WITH THE 
SURVEY. 





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
 MODULE 3: HOUSEHOLD SPOUSES/LIVE-IN PARTNERS 
36  Does [HHRNAME*] have a spouse or 
co-habitating partner who usually lives 
in the household or was a guest last 
night? 
YES 1 SKIP IF FEMALE   
    NO 2 if item = 2 item 35 
37  How many spouses or co-habitating 
partners (those who usually live in the 
household or stayed here last night) 
does [HHRNAME*] have? 
NUMBER OF PARTNERS integer SKIP IF FEMALE   
38  SELECT [HHRNAME*]'S [# SPOUSE] OR 
PARTNER FROM THE LIST BELOW 




list SKIP IF FEMALE   
Interviewer says: “Thank you for completing the questions for the household's men.  The next step will be to complete some additional questions 
for the women of the household.” 
39  Does [HHRNAME*] have a spouse or 
co-habitating partner who usually lives 
in the household or was a guest last 
night? 
YES 1 SKIP IF MALE   
    NO 2 if item = 2 item 38 
40  SELECT [HHRNAME*]'S [# SPOUSE] OR 
PARTNER FROM THE LIST BELOW 




list SKIP IF MALE   
Interviewer says: “Thank you for completing the questions for the household's women.  The next step will be to complete some additional 
questions regarding the household itself.” 
41  CONTINUE TO THE NEXT ITEM? YES 1 if item = 2 HH REFUSAL OR 
WITHDRAWAL 
FORM 
   SELECT 'NO' ONLY IF THE PARTICIPANT 
HAS EXPRESSED HE/SHE DOES NOT 
WISH TO CONTINUE ON WITH THE 
SURVEY. 





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
 MODULE 4: ORPHANS AND VULNERABLE CHILDREN   
Interviewer says: “I would now like to ask you about any formal, organized help or support for children 
that your household may have received for which you did not have to pay.  By formal, organized 
support, I mean help provided by someone working for a program.  This program could be government, 
private, religious, charity, or community-based. I will ask you about help you have received for each 
child.”  
if momsick*!=2,-8 OR 
dadsick*!=2,-8 OR 
momalive*!=1 OR 
dadalive*!=1 OR  
age*>=18 
[NEXT MODULE] 
42 supportmed12 Now I would like to ask you about the 
support your household received for 
[HHRNAME*].  In the last 12 months, 
has your household received any 
medical support for [HHRNAME*], 
such as medical care, supplies or 
medicine, for which you did not have 
to pay? 
YES 1     
    NO 2    
     DON'T KNOW -8     
43 supportemot12 In the last 12 months, has your 
household received any emotional or 
psychological support for 
[HHRNAME*], such as companionship, 
counseling from a trained counselor, 
or spiritual support, which you 
received at home and for which you 
did not have to pay? 
YES 1 if supportemot12=2,-
8 
supportmater12 
    NO 2    
     DON'T KNOW -8     
44 supportemot3 Did your household receive any of this 
emotional or psychological support for 
[HHRNAME*] in the past 3 months? 
YES 1    
    NO 2    
    DON'T KNOW -8    
45 supportmater12 In the last 12 months, has your 
household received any material 
support for [HHRNAME*], such as 
clothing, food, or financial support, for 
which you did not have to pay? 
YES 1 if supportmater12=2,-
8 
supportsocial12 
    NO 2    
     DON'T KNOW -8     
46 supportmater3 Did your household receive any of this 
material support for [HHRNAME*] in 
the past 3 months? 
YES 1    
    NO 2    
    DON'T KNOW -8    
47 supportsocial12 In the last 12 months, has your 
household received any social support 
for [HHRNAME*] such as help in 
household work, training for a  
YES 1 if supportsocial12=2.-
8 
supportschol12 
   caregiver, or legal services, for which  NO 2    
   you did not have to pay? DON'T KNOW -8     
48 supportsocial3 Did your household receive any of this  YES 1    
   social support for [HHRNAME*] in the  NO 2    
   past 3 months? DON'T KNOW -8    
49 supportschol12 In the last 12 months, has your 
household received any support for 
[HHRNAME*]'s schooling, such as 
allowance, free admission, books, or  
YES 1     
   supplies, for which you did not have to  NO 2    




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 5: DEATHS IN THE HOUSEHOLD 
Interviewer says: “Now I would like to ask you some more questions about your household.” 
50 deaths Has any usual resident of your 
household died since January 1,  2014? 
YES 1 if deaths=2, -8 [NEXT MODULE] 
    NO 2    
    DON'T KNOW -8    
51 deathcount How many usual household residents 
died since January 1, 2014? 
NUMBER OF DEATHS integer if deathcount=-8 [NEXT MODULE] 
    DON'T KNOW -8    
52  What was the name of the person who 
died (most recently/before him/her)? 
        
53 dieddatey1-4* When did [HHQDTHNAM*] die? Please 
give your best guess. 
YEAR integer    
    DON'T KNOW YEAR -8    
    REFUSED YEAR -9    
  dieddatem1-4*  MONTH integer    
    DON'T KNOW MONTH -8    
    REFUSED MONTH -9    
  dieddated1-4*  DAY integer    
    DON'T KNOW DAY -8    
    REFUSED DAY -9    
54 diedgend1-4* Was [HHQDTHNAM*] male or female? MALE 1     
    FEMALE 2    
55 diedagey1-4* How old was [HHQDTHNAM*] when 
(he/she) died? 
YEARS integer if died1-4*!=0 [NEXT MODULE] 
    DON'T KNOW -8    
   ENTER '0' IF LESS THAN ONE YEAR REFUSED -9     
56 diedagem1-4* How many months was 
[HHQDTHNAM*] when (he/she) died? 
MONTHS       
    DON'T KNOW -8    
     REFUSED -9     
57 diedaged1-4* How many days was [HHQDTHNAM*] 
when (he/she) died? 
DAYS       
    DON'T KNOW -8    





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 6: HOUSEHOLD ASSETS 
Interviewer says: “Now I would like to ask you more questions about your household.”    
58 watersource What is the main source of drinking 
water for members of your household? 
PIPED INTO DWELLING 11 if watersource != 96 wtrsfr 
    PIPED TO COMPOUND, 
YARD, OR PLOT 
12    
    PUBLIC TAP/STANDPIPE 13    
    PIPED TO NEIGHBOUR 14    
    TUBE WELL OR 
BOREHOLE 
21    
    PROTECTED WELL 31    
    UNPROTECTED WELL 32    
    PROTECTED SPRING 41    
    UNPROTECTED SPRING 42    
    RAINWATER 
COLLECTION 
51    
    TANKER TRUCK 61    
    CART WITH SMALL 
TANK/DRUM 
71    
    SURFACE WATER 
(RIVER, STREAM, DAM, 
LAKE, POND, CANAL, 
IRRIGATION CHANNEL) 
81    
     OTHER (SPECIFY) 96     
59 wtrsfr Do you do anything to the water to 
make it safer to drink? 
YES 1 if wtrsfr=2,-8 hhq4wnwtn 
    NO 2    
    DON'T KNOW -8    
60 wtrtreat What do you do to make your water 
safe for drinking? 
BOIL 1     
   SELECT ONLY ONE RESPONSE. USE WATER FILTER 
(CERAMIC, SAND,      
COMPOSITE, ETC.) 
2    
    LET IT STAND AND 
SETTLE  
3    





4    
    STRAIN IT THROUGH A 
CLOTH 
6    
     OTHER (SPECIFY) 96     
61 hhq4wnwtn In the past four weeks, did your 
household go a whole day and night 
without water to meet your nutritional 
needs e.g. cooking or drinking? 
YES 1 if hhq4wnwtn = 2, -8 hhq4wnwth 
    NO 2    
    DON'T KNOW -8    
62 hhq4wnwtnfrq How often did this happen in the past 
4 weeks? 
RARELY (1-2 TIMES) 1     
    SOMETIMES (3-10 
TIMES) 
2    
    OFTEN (MORE THAN 10 
TIMES) 
3    
     DON'T KNOW -8     
63 hhq4wnwth In the past four weeks, did your 
household go a whole day and night 
without water to meet your hygiene 
needs e.g. bathing or washing utensils? 
YES 1 if hhq4wnwth = 2, -8 toilettype 
    NO 2    





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
64 hhq4wnwthfrq How often did this happen in the past 
4 weeks? 
RARELY (1-2 TIMES) 1     
    SOMETIMES (3-10 
TIMES) 
2    
    OFTEN (MORE THAN 10 
TIMES) 
3    
     DON'T KNOW -8     
65 toilettype What kind of toilet facility do members 
of your household usually use? 
FLUSH TO PIPED SEWER 
SYSTEM 
1 if toilettype=61 item 50 
    FLUSH TO SEPTIC TANK 2 if toiletttype != 96 toiletshare 
    FLUSH TO PIT (LATRINE) 3    
    FLUSH TO SOMEWHERE 
ELSE (SPECIFY) 
4    
    VENTILATED 
IMPROVED PIT LATRINE 
(VIP) 
22    
    PIT LATRINE WITH 
CONCRETE SLAB 
23    
    PIT LATRINE WITHOUT 
CONCRETE 
24    
    INCOMPLETE LATRINE 25    
    VIP LATRINE WITH 
HEALTH CARE WASTE 
COMPONENT 
26    
    COMPOSTING TOILET 31    
    BUCKET 32    
    FLYING TOILET 
(PLASTIC) 
33    
    NO FACILITY, BUSH, 
FIELD 
61    
     OTHER (SPECIFY) 96     
66 toiletshare Do you share this toilet facility with 
other households? 
YES 1 if toiletshare = 2 item 50 
     NO 2     
67 toiletsharenum How many households use this facility? NUMBER OF 
HOUSEHOLDS IF LESS 
THAN 10 
integer    
    10 OR MORE 
HOUSEHOLDS 
96    
    DON'T KNOW -8    
68 havelec Does your household have fuctional: ELECTRICITY? A     
  havrad READ ALL RESPONSES ALOUD.  SELECT 
ALL THAT APPLY. 
A RADIO? B    
  havtele  A TELEVISION? C    
  havmobl  A TELEPHONE/MOBILE 
TELEPHONE? 
D    
  havfrig   A REFRIGERATOR? E     
69 cookingfuel What type of fuel does your household 
mainly use for cooking? 
ELECTRICITY 1 if cookingfuel != 96 matfloor 
   SELECT ONLY ONE RESPONSE. LIQUEFIED PETROLEUM 
GAS (LPG)  
2    
    BIOGAS 3    
    PARAFFIN 4    
    COAL, LIGNITE 5    
    CHARCOAL 6    
    DUNG 8    
    WOOD 11    
    STRAW/SHRUBS/GRASS  12    
    AGRICULTURAL CROP 
RESIDUE 
13    
    NO FOOD COOKED IN 
HOUSEHOLD 
95    




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
70 matfloor MAIN MATERIAL OF FLOOR. EARTH/SAND 11 if matfloor != 96 matroof 
   RECORD OBSERVATION. DUNG 12    
    WOOD PLANKS 21    
    PALM/BAMBOO 22    
    PARQUET OR POLISHED 
WOOD 
31    
    VINYL OR ASPHALT 
STRIP 
32    
    CERAMIC TILES  33    
    CEMENT/TERAZO 34    
    CARPET 35    
    OTHER (SPECIFY) 96    
71 matroof MAIN MATERIAL OF THE ROOF NO ROOF 11 if matroof != 96 matexwalls 
   RECORD OBSERVATION. THATCH/GRASS 12    
    RUSTIC MAT 14    
    WOOD PLANKS 15    
    CARDBOARD 16    
    CORRUGATED IRON 21    
    WOOD 23    
    CALAMINE/CEMENT 
FIBRE 
24    
    ASBESTOS 31    
    CEMENT/ CONCRETE 32    
    CERAMIC TILES 33    
    OTHER (SPECIFY) 96    
72 matexwalls MAIN MATERIAL OF THE EXTERIOR 
WALLS 
NO WALLS 11 if matexwalls != 96 roomsleep 
   RECORD OBSERVATION. CANE/PALM/TRUNKS 12    
    STICK & MUD 14    
    GRASS 15    
    BAMBOO WITH MUD 21    
    STONE WITH MUD 22    
    REUSED WOOD 25    
    PLYWOOD (OFF CUTS) 26    
    CARDBOARD/CARTONS 27    
    CORRUGATED IRON 28    
    CEMENT 31    
    STONE WITH 
LIME/CEMENT 
32    
    BRICKS 33    
    CEMENT BLOCKS  34    
    WOOD 
PLANKS/SHINGLES 
35    
    OTHER (SPECIFY) 96    
73 roomsleep How many rooms are used for 
sleeping? 
NUMBER OF ROOMS integer     
74 ownbike Does any member of your household 
own: 
A BICYCLE? A     
  ownmoto READ ALL RESPONSES ALOUD.   A MOTORCYCLE OR 
MOTOR SCOOTER? 
B    
  owncar SELECT ALL THAT APPLY. A CAR OR TRUCK? C    
  ownboat  A BOAT WITH A 
MOTOR? 
D    
  owncows  COWS? E    
  owngtsh  GOATS/SHEEP? F    
  ownplry  POULTRY (E.G. DUCKS, 
CHICKEN)? 
G    
  ownanml   OTHER ANIMALS 
(CAMELS, HORSES, 
DONKEYS)? 
X     
75 mosnets Does your household have any 
mosquito nets that can be used while 
sleeping? 
YES 1     
    NO 2    




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
76 nofood4wkyn In the past 4 weeks, was there ever no 
food to eat of any kind in your 
household because of lack of resources 
to get food? 
YES 1 if nofood4wkyn=2,-8 hungry4wkyn 
    NO 2    
    DON'T KNOW -8    
77 nofood4wkfreq How often did this happen in the past 
4 weeks? 
RARELY (1-2 TIMES) 1     
    SOMETIMES (3-10 
TIMES) 
2    
    OFTEN (MORE THAN 10 
TIMES) 
3    
78 hungry4wkyn In the past 4 weeks, did you or any 
household member go to sleep at 
night hungry because there was not 
enough food? 
YES 1 if hungry4wkyn=2,-8 noeat4wkyn 
    NO 2    
    DON'T KNOW -8    
79 hungry4wkfreq How often did this happen in the past 
4 weeks? 
RARELY (1-2 TIMES) 1     
    SOMETIMES (3-10 
TIMES) 
2    
    OFTEN (MORE THAN 10 
TIMES) 
3    
80 noeat4wkyn In the past four weeks, did you or any 
household member go a whole day 
and night without eating anything 
because there was not enough food? 
YES 1 if noeat4wkyn=2,-8 [NEXT MODULE] 
    NO 2    
    DON'T KNOW -8    
81 noeat4wkfreq How often did this happen in the past 
4 weeks? 
RARELY (1-2 TIMES) 1     
    SOMETIMES (3-10 
TIMES) 
2    
    OFTEN (MORE THAN 10 
TIMES) 





NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 7: ECONOMIC SUPPORT 
Interviewer says: “Now I will ask you questions on the economic support you have received.” 
82 econsup3 Has your household received any of 
the following forms of external 
economic support in the last 3 
months? 
NOTHING A     
   READ THE RESPONSES ALOUD. CASH TRANSFER (E.G. 
PENSIONS, DISABILITY 
GRANTS, CHILD GRANT) 
B    
   SELECT ALL THAT APPLY. ASSISTANCE FOR 
SCHOOL FEE 
C    
    MATERIAL SUPPORT 





D    
    INCOME GENERATION 




E    
    FOOD ASSISTANCE 
PROVIDED AT THE 
HOUSEHOLD OR 
EXTERNAL INSTITUTION 
F    
    MATERIAL OR 
FINANCIAL SUPPORT 
FOR SHELTER 
G    
    SOCIAL PENSION H    
    OTHER X    
     DON'T KNOW Z     
Interviewer says:  “This is the end of the household survey.  Thank you very much for your time and for your responses.  Do you have any 







TO BE COMPLETED AFTER THE INTERVIEW: 
 
 






















Appendix F   Adult Questionnaire 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 1: RESPONDENT BACKGROUND 
Interviewer says: “Thank you for agreeing to participate in this survey. The first set of questions is about your life in general. Afterwards, we will 
move on to other topics.” 
101 gender DO NOT READ: IS THE RESPONDENT 





    
102 schlat Have you ever attended school? YES  1 IF schlat = 2,-8,-9 mont12away 
  
  










  REFUSED  -9     
103 schlcur Are you enrolled in school? YES  1     
  
  










  REFUSED  -9     
104 schlhi What is the highest level of school or  PRIMARY  1     
  
 




















  REFUSED  -9     
105 schcom What is the highest grade/form that  GRADE/FORM integer     
  
 
you have completed? MARK GRADE OR 























REFUSED  -9 
 
  
106 mont12away In the last 12 months, how many times 
have you been away from home for  










  REFUSED  -9     
107 mo12away In the last 12 months, have you been 
away from home for more than one 
month at a time? 
YES  1     
  
  










  REFUSED  -9     
108 work12mo Have you done any work in the last 12 
months for which you received a 
paycheck, cash or goods as payment? 














REFUSED  -9 
 
  
109 work30days Have you done any work in the last 
thirty days for which you received cash 
or goods as payment? 
YES  1     
  
  










  REFUSED  -9     
 
  
APPENDIX F ADULT QUESTIONNAIRE  
 178 
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 2: MARRIAGE 
Interviewer says: “Now I would like to ask you about your current and previous relationships and/or marriages.”  
201 evermar Have you ever been married or lived  YES  1 IF evermar = 2, -8, -9 [NEXT  
  
 










  REFUSED  -9     
202 curmar What is your marital status now: are 
you married, living together with 
someone as if married, widowed, 
divorced, or separated? 































REFUSED  -9     





If gender is Female 
and partner linked in 
roster 
 
If gender is Female 







203 numwif Altogether, how many wives or 
partners do you have?  
NUMBER OF WIVES OR 
PARTNERS 










  REFUSED  -9     
204 reviewwife The Household Schedule listed  YES  1 IF reviewwife = 1 npyn 
  
 
[INSERT NUMBER OF REPORTED 
PARTNERS] household members as 
your wives/partners.  Please review 
the list below.  Are all of the listed 
household members your 
wives/partners who live in the 
household? 
NO  2     
205 
 
Is [HHRNAME**] your wife/partner? YES  1 IF item = 2 npyn 
  
 
  NO  2     
206 livehere Does [HHRNAME**] live in the 
household? 
YES  1     
  
 
  NO  2     
207 npyn Do you have other wives/partner(s) 
that live with you in this household? 
YES  1 IF npyn = 2 npnyhstd 
  
 
  NO  2     
208 npnum How many other wives/partners(s) live 
with you in this household? 
NUMBER OF WIVES OR 
PARTNERS 
integer IF npnum = -8, -9 npnyhstd 
  
  





  REFUSED  -9     
209 
 
Please enter the name of your 
wife/partner that lives with you in this 
household. 
  text     
  
  





  REFUSED  -9     
210 npnyhstd Do you have other wives/partner(s)  YES  1 IF npnyhstd = 2 wifliveew 
  
 
that live with you in this homestead NO  2 
 
  
211 npnumhstd How many other wives/partners(s) live  YES  integer     
  
 





  REFUSED  -9     
212 wifliveew How many wives or live-in partners do  
 
integer ALL [NEXT  
  
 





homestead? REFUSED  -9 
 
  
213 huslivew Is your husband or partner living with 
you now or is he staying elsewhere? 
LIVING TOGETHER  1 IF huslivew = 2 and 
count of household 






STAYING ELSEWHERE  2 IF huslivew = -8, -9  husotwif 
  
  
DON’T KNOW  -8 and no partner linked   
  
  




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
214 
 
The household schedule listed [NAME] 
as your husband/partner who is living 
here.  Is that correct? 
YES  1 IF item = 1, -8, -9 husotwif 
  
  










  REFUSE TO ANSWER  -9     
215 husid Please select the husband/partner that 
lives with you. 
[LIST OF PERSONS on 
HH ROSTER] 
 
IF husid != 96 husotwif 
  
 
  NOT LISTED IN 
HOUSEHOLD 
96     
216 
 
Please enter the name of your 
husband/partner that lives with you. 
  text     
  
  





  REFUSED  -9     
217 husotwif Does your husband or partner have 
other wives or does he live with other 
women as if married? 














  REFUSE TO ANSWER  -9     
218 husnwif Including yourself, in total, how many 
wives or live-in partners does your 
husband or partner have? 
NUMBER OF WIVES OR 
LIVE-IN PARTNERS  
integer     
  
  





  REFUSE TO ANSWER  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 3: REPRODUCTION     IF (gender* = 1) item 342 
Interviewer says: “Now I would like to ask you questions about your pregnancies and your children.”   
301 pregnum How many times have you been 
pregnant including a current 
pregnancy? 
NUMBER OF TIME(S) integer     
  
 
CODE ‘0’ IF NONE. DON’T KNOW  -8 IF pregnum = 0 item 342 
  
 
  REFUSED  -9 IF pregnum = -8, -9  item 342 
302 liveb Have you ever had a pregnancy that 
resulted in a live birth? 
YES  1 IF liveb = 2, -8, -9 item 342 
  
 
A live birth is when the baby shows 
signs of life, such as breathing, beating 
of the heart or movement. 










REFUSED  -9 
 
  
303 childa2012 How many live births have you had 
since the 1st of January, 2013?  
NUMBER OF LIVE 
BIRTHS 










  REFUSED  -9     
Interviewer says: “Now I would like to ask you some questions about the last pregnancy that resulted in a live birth since the 1st of January, 2013.” 
304 prgtwin Did your last pregnancy result in birth 
to twins or more? 
YES  1 IF prgtwin = 2, -8, -9 childlast 
  
  
NO  2 IF prgtwin = 1  pregnm 
  
  





  REFUSED  -9     
  pregnm How many live children were born 
from your last pregnancy? 
Number of children integer     
305 
 
What is the name of the 
[BIRTHORDER*] born child from your 








A live birth is when the baby shows 
signs of life, such as breathing, beating 
of the heart or movement. 




DO NOT READ: IF THE CHILD WAS NOT 
NAMED BEFORE DEATH, INPUT BIRTH 
AND THE BIRTH ORDER NUMBER. FOR 
EXAMPLE, "BIRTH 1". 






NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
306 
 
What is the name of the child from 
your last pregnancy that resulted in a 






A live birth is when the baby shows 
signs of life, such as breathing, beating 
of the heart or movement. 




DO NOT READ: IF THE CHILD WAS NOT 
NAMED BEFORE DEATH, INPUT BIRTH 
1. 
   
  
307 prgcare When you were pregnant with 
[CHILDLAST/PRGTWINNAME*], did you 
visit a health facility for clinic visits for 
the pregnancy? 
YES  1 IF prgcare = 1 item 309 
  
  
NO  2 IF prgcare = -8, -9 brthwhr 
  
  





REFUSED  -9 
 
  
308 pregncr What is the main reason you did not 
visit a clinic for the pregnancy when 
you were pregnant with 
[CHILDLAST/PRGTWINNAME*]? 
CLINIC WAS TOO FAR 
AWAY 
1 IF pregncr != 96 brthwhr 
  
  
COULD NOT TAKE TIME 






COULD NOT AFFORD 






DID NOT TRUST THE 













DID NOT WANT AN HIV 










































  REFUSED  -9     
Interviewer says: “I will now be asking you questions on HIV testing.  Please remember that your responses will be kept confidential and will not 
be shared with anyone else.”   
309 hivtsbp Have you ever tested for HIV before 
your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
YES  1 IF hivtsbp = 2, -8, -9 hivtopg 
  
  










  REFUSED  -9     
310 hivpsbp Did you test positive for HIV before 
your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
YES  1 IF hivpsbp = 2, -8, -9 hivtopg 
  
  










  REFUSED  -9     
311 arvfvst At the time of your first clinic visit for 
the pregnancy when you were 
pregnant with 
[CHILDLAST/PRGTWINNAME*], were 
you taking ARVs, that is, antiretroviral 
medications, to treat HIV?  
YES  1 IF arvfvst = 1 brthwhr 
  
  
NO  2 IF arvfvst = 2, -8, -9 arvtkpg 
  
  









NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
306 
 
What is the name of the child from 
your last pregnancy that resulted in a 






A live birth is when the baby shows 
signs of life, such as breathing, beating 
of the heart or movement. 




DO NOT READ: IF THE CHILD WAS NOT 
NAMED BEFORE DEATH, INPUT BIRTH 
1. 
   
  
307 prgcare When you were pregnant with 
[CHILDLAST/PRGTWINNAME*], did you 
visit a health facility for clinic visits for 
the pregnancy? 
YES  1 IF prgcare = 1 item 309 
  
  
NO  2 IF prgcare = -8, -9 brthwhr 
  
  





REFUSED  -9 
 
  
308 pregncr What is the main reason you did not 
visit a clinic for the pregnancy when 
you were pregnant with 
[CHILDLAST/PRGTWINNAME*]? 
CLINIC WAS TOO FAR 
AWAY 
1 IF pregncr != 96 brthwhr 
  
  
COULD NOT TAKE TIME 






COULD NOT AFFORD 






DID NOT TRUST THE 













DID NOT WANT AN HIV 










































  REFUSED  -9     
Interviewer says: “I will now be asking you questions on HIV testing.  Please remember that your responses will be kept confidential and will not 
be shared with anyone else.”   
309 hivtsbp Have you ever tested for HIV before 
your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
YES  1 IF hivtsbp = 2, -8, -9 hivtopg 
  
  










  REFUSED  -9     
310 hivpsbp Did you test positive for HIV before 
your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
YES  1 IF hivpsbp = 2, -8, -9 hivtopg 
  
  










  REFUSED  -9     
311 arvfvst At the time of your first clinic visit for 
the pregnancy when you were 
pregnant with  
YES  1 IF arvfvst = 1 brthwhr 
  
 
[CHILDLAST/PRGTWINNAME*], were NO  2 IF arvfvst = 2, -8, -9 arvtkpg 
  
 





medications, to treat HIV? REFUSED  -9     
312 hivtopg During any of your clinic visits for the 
pregnancy when you were pregnant 
with [CHILDLAST/PRGTWINNAME*], 
were you offered an HIV test? 
YES  1     
  
  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
313 hivtprg Were you tested for HIV during any of 
your clinic visits for the pregnancy  
YES  1 IF hivtprg = 1 hivrtpg 
  
 
when you were pregnant with NO  2 IF hivtprg = -8, -9 brthwhr 
  
 





  REFUSED  -9 
 
  
314 hivtsnr What is the main reason you were not 
tested for HIV during clinic visits for 
the pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
DID NOT WANT AN HIV 
TEST DONE / DID NOT 
WANT TO KNOW MY 
STATUS  
1 hivtsnr != 96 brthwhr 
  
  









WOULD KNOW ABOUT 






DID NOT NEED 
















  REFUSED  -9     
315 hivrtpg What was the result of your last HIV 
test during your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 





























  REFUSED  -9     
316 arvtkpg Did you take ARVs during your 
pregnancy with [NAME] to stop 
[CHILDLAST/PRGTWINNAME*] from 
getting HIV? 
YES  1 IF arvtkpg = 1, -8, -9 brthwhr 
  
 
DO NOT READ: SHOW ARV GRAPHIC IF 
PARTICIPANT IS UNSURE. 










  REFUSED  -9     
317 arvnrpg What was the main reason you did not 
take ARVs while you were pregnant 
with [CHILDLAST/PRGTWINNAME*]? 
WAS NOT PRESCRIBED  1 IF arvnrpg !=96 brthwhr 
  
  





































DID NOT WANT PEOPLE 
























REFUSED  -9 
 
  
318 brthwhr Where did you give birth to 
[CHILDLAST/PRGTWINNAME*]? 





AT A HEALTH FACILITY  2 IF brthwhr = 2 hivtobr 
  
  



















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
319 hivtobr Were you offered an HIV test during 
labor? 















  REFUSED  -9     
320 hivttlb Did you test for HIV during labor? YES  1 SKIP IF hivpsbp = 1  




NO  2 IF hivttlb = 2, -8, -9 birthday 
  
  





  REFUSED  -9     
321 hivrslr What was the result of that test? POSITIVE  1 SKIP IF hivpsbp = 1  




























  REFUSED  -9     
322 offrarvs During labor, were you offered ARVs to 
protect [NAME] against HIV? 
YES  1 SKIP IF arvtkpg = 1   
  
 
DO NOT READ: SHOW ARV GRAPHIC IF 











REFUSED  -9 
 
  
323 arvtklb During labor, did you take ARVs to 
protect [CHILDLAST/PRGTWINNAME*] 
against HIV? 
YES  1 SKIP IF arvtkpg = 1   
  
 
DO NOT READ: SHOW ARV GRAPHIC IF 
PARTICIPANT IS UNSURE 
NO 2 IF arvtklb = 2, -8, -9 birthday 
  
  





REFUSED  -9 
 
  
324 arvcntn Did you continue to take the ARVs  YES  1     
  
 
after delivery? NO  2 SKIP IF arvtkpg = 1   
  
  





REFUSED  -9 
 
  
325 birthday1-2 When did you give birth to 
[CHILDLAST/PRGTWINNAME*]? Please 
give your best guess. 
DAY integer     
  
  



































REFUSED YEAR -9 
 
  
326 childlive1-2 Is [CHILDLAST/PRGTWINNAME*] still 
alive? 















  REFUSE  -9     
327 deathageyr1-2 How old 
was[CHILDLAST/PRGTWINNAME*] 
when he/she died? 
YEARS _____ 
 





DO NOT READ: KEY ‘0’ IF CHILD WAS 
LESS THAN ONE YEAR OLD.   





REFUSED  -9     
328 deathagemo1-2 How old was 
[CHILDLAST/PRGTWINNAME*] in 






DO NOT READ: KEY ‘0’ IF CHILD WAS 
LESS THAN ONE MONTH OLD.   





  REFUSED  -9     
329 childlivewith1-2 Is [CHILDLAST/PRGTWINNAME*] living 
with you? 
YES  1 IF childlivewith* = 2 childarv 
  
 




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
330 hhlnchild1-2 DO NOT READ: RECORD HOUSEHOLD 











    
331 childarv1-2 Did [CHILDLAST/PRGTWINNAME*] 
take any ARVs to stop [him/her] from 
getting HIV infection? This would be 
before [CHILDLAST/PRGTWINNAME*]’s 
first HIV test. 
YES  1 IF childarv* = 2, -8, -9 childbac* 
  
 
DO NOT READ: SHOW ARV GRAPHIC IF 
PARTICIPANT IS UNSURE. 










  REFUSE  -9     
332 childarvt1-2 For how long did 
[CHILDLAST/PRGTWINNAME*] take 
the ARVs to stop him/her from getting 
HIV? 
WEEKS integer     
  
 





ONLY ONE OPTION MAY BE SELECTED.  
FOR EXAMPLE, ANSWER ONLY IN 
WEEKS OR IN MONTHS. 















  REFUSED  -9     
333 childbac1-2 Did [CHILDLAST/PRGTWINNAME*] 
take Bactrim or cotrimoxazole? This 
would be before 
[CHILDLAST/PRGTWINNAME*]’s first 
HIV test. 





Bactrim or cotrimoxazole is a medicine 
recommended for people with HIV, 
even if they have not started 
treatment for HIV.  It helps prevent 
certain infections but it is not a 
treatment for HIV. 







DO NOT READ: SHOW 
COTRIMOXAZOLE GRAPHIC IF 
PARTICIPANT IS UNSURE. 










  REFUSED  -9     
334 childbact1-2 For how long did 
[CHILDLAST/PRGTWINNAME*] take 
Bactrim or cotrimoxazole? 
WEEKS integer     
  
 
ONLY ONE OPTION MAY BE SELECTED.  
FOR EXAMPLE, ANSWER ONLY IN 


















  REFUSED  -9     
335 childbrstfd1-2 Did you ever breastfeed 
[CHILDLAST/PRGTWINNAME*]? 

























For how long did you breastfeed 
[CHILDLAST/PRGTWINNAME*]? 
WEEKS integer     
  childbrstfddurn
um1-2 
DO NOT READ: ONLY ONE OPTION 
MAY BE SELECTED.  FOR EXAMPLE, 























NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
338 childbfcont1-2 Did you continue taking ARVs while 
you were breastfeeding 
[CHILDLAST/PRGTWINNAME*]? 





NO  2 SKIP IF arvfvst = 1  OR 









  REFUSED  -9     
339 
 




IF prgtwin = 1 RETURN TO 
childlive* FOR 
EACH VALUE OF 
prgtwinname* 
Interviewer says: “I will now ask about current pregnancies.” 
340 pregnant Are you pregnant now? YES  1 IF pregnant = 2,-8,-9 item 335 
  
  










  REFUSED  -9     




DO NOT READ: SHOW GRAPHIC OF 
PREGNANCY IF NOT SURE. 







  REFUSED  -9     
Interviewer says: “I will now ask you about family planning.”  
342 avoidpreg Are you or your partner currently 
doing something or using any method 
to delay or avoid getting pregnant? 
















  REFUSED  -9     
343 cmethod_a Which method are you or your partner 
using? 
FEMALE STERILIZATION  A IF cmethod_x != X [NEXT 
MODULE] 
  cmethod_b DO NOT READ: SELECT ALL THAT 
APPLY. 
MALE STERILIZATION  B 
 
  
  cmethod_c 
 
PILL  C 
 
  
  cmethod_d 
 
IUD/”COIL”  D 
 
  
  cmethod_e 
 
INJECTIONS  E 
 
  
  cmethod_f 
 
IMPLANT  F 
 
  
  cmethod_g 
 
CONDOM  G 
 
  
  cmethod_h 
 
FEMALE CONDOM  H 
 
  







  cmethod_j 
 
WITHDRAWAL  J 
 
  
  cmethod_k 
 
NOT HAVING SEX  K 
 
  
  cmethod_x 
 
OTHER (SPECIFY) X 
 
  
  cmethod_y 
 
DON’T KNOW  Y 
 
  
  cmethod_z   REFUSED  Z     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 4: CHILDREN 
Interviewer says: “I am going to ask you a number of questions about your children regarding their health and where they get their health 
services. We will ask you about these children.” 
  
 
LIST OF CHILDREN < 14 ASSIGNED TO 
[NAME]  




Now I am going to ask you questions 
for [CHILD*].  
  
 
    
402 age How old is [CHILD*] in years? AGE IN YEARS integer IF age>=1 & age<=5 item 403a 
  
 
IF [CHILD*] IS LESS THAN 1 YEAR OLD, 
KEY 0 HERE AND KEY AGE IN MONTHS. 
DON’T KNOW  -8 IF age > 5 gender 
  
 
ON NEXT SCREEN REFUSED  -9 IF age <1 agem 
403 agem How old is [CHILD*] in months? AGE IN MONTHS integer ALL gender 
403A 
 
You said that [CHILD*] was 
[KIDAGEY*].  How many months over 
[KIDAGEY*] is [CHILD*]? 
MONTHS OVER integer ALL gender 
404 gender Is [CHILD*] a boy or girl? BOY  1     
  
  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 












NO, TOO YOUNG TO BE 











  REFUSED  -9     
406 ch_kidhighlvl What is the highest level of school 
[CHILD*] has attended: primary, 
secondary, or high school? 





SECONDARY 2 IF ch_kidhighlvl = 96  ch_kidcrcm 
  
  

















  REFUSED  -9     
407 ch_kidclass What grade/form is [CHILD*] in now? GRADE/FORM integer SKIP IF ch_kidenroll = 
2 
  
























  REFUSED  -9     
408 ch_kidenrlstyr Was [CHILD*] enrolled in school during 
the previous school year? 















  REFUSED  -9     
409 ch_kidclasslstyr What grade/form was [CHILD*] during 





























  REFUSED  -9     
410 ch_kidcrcm Is [CHILD*] circumcised? YES  1 SKIP IF gender = 2   
  
 
Circumcision is the complete removal 
of the foreskin from the penis.  I have a 
picture to show you what a completely 
circumcised penis looks like. 











REFUSED  -9 
 
  
411 ch_kidcrcmprt Who circumcised [CHILD*]? DOCTOR, CLINICAL 
OFFICER, OR NURSE  
























































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
413 ch_kidhivwhyne
ver_a 
Why has [CHILD*] never been tested 
for HIV? 
DON'T KNOW WHERE 







DO NOT READ: SELECT ALL THAT 
APPLY. 






TRANSPORT  COSTS 













AFRAID OTHERS WILL 



































DON’T WANT TO 









































REFUSED  Z 
 
  
414 ch_kidhivtestm What month and year was [CHILD*]’s 
most recent HIV test done?  
MONTH date     
  
  





REFUSED MONTH -9 
 
  












  REFUSED  YEAR -9     
415 ch_kidhivlastres
ult 
What was [CHILD*]’s last HIV test 
result? 
POSITIVE  1 IF ch_kidhivlastresult 





























  REFUSED  -9     
416 ch_kidtldpos Has [CHILD*] been told (or know) that 
he/she is HIV positive? 





















Why has [CHILD*] not been told they 
are HIV positive? 





































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
418 ch_kidlposm What was the month and year of 
[CHILD*]’s first HIV positive test result? 
Please give your best guess. 
MONTH date     
  
 
This will be the very first HIV positive 
test result that you have received. 





DO NOT READ: PROBE TO VERIFY 
DATE. 
REFUSED MONTH -9 
 
  












  REFUSED  YEAR -9     
419 ch_kidhivcare Has [CHILD*] ever received HIV care 
and treatment from a doctor, clinical 
officer or nurse? 




















What is the main reason why [CHILD*] 
has never seen a doctor, clinical 
officer, or nurse for HIV care and 
treatment? 
FACILITY IS TOO FAR 
AWAY  





I DON’T KNOW WHERE 
TO GET HIV MEDICAL 
















I DON’T THINK CHILD 







I FEAR PEOPLE WILL 
KNOW THAT CHILD HAS 
HIV IF I TAKE HIM/HER 



















CHILD HAS NOT BEEN 






















What month and year did [CHILD*] 
first see a doctor, clinical officer or 
nurse for HIV care and treatment? 
MONTH date     
  
 
DO NOT READ: PROBE TO VERIFY 
DATE. 





















  REFUSED  -9     
422 ch_kidhivcarela
stm 
What month and year did [CHILD*] last 
see a doctor or nurse for HIV care and 
treatment? 
MONTH date IF CURRENT DATE - 
ch_kidhivcarelastm/c
































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
423 ch_kidhivnot6rsn What is the main reason for [CHILD*] 
not seeing a doctor, clinical officer or 
nurse for HIV care and treatment for  
FACILITY IS TOO FAR 
AWAY  





more than 6 months? I DON’T KNOW WHERE 
TO GET HIV MEDICAL 
















I DON’T THINK CHILD 







I FEAR PEOPLE WILL 
KNOW THAT CHILD HAS 
HIV IF I TAKE HIM/HER 






































  REFUSED  -9     
424 ch_kidcd4 Has [CHILD*] ever had a CD4 count 
test? 
YES  1 IF ch_kidcd4 = 2, -8, -





The CD4 count tells you how sick you 
are with HIV. 
NO  2 IF ch_kidcd4 = 2, -8, -




DON’T KNOW  -8 = 2, -8, -9   
  
 
  REFUSED  -9     
425 ch_kidcd4lastm What month and year was [CHILD*] 
last tested for his/her CD4 count? 











REFUSED MONTH  -9 
 
  












REFUSED YEAR  -9 
 
  
426 ch_kidarvs Has [CHILD*] ever taken ARVs, that is, 
antiretroviral medications, to treat 
his/her HIV infection? 









DO NOT READ: SHOW AID IF DON’T KNOW  -8 IF ch_kidarvs = -8, -9 ch_kidseptrin 
  
 
PARTICIPANT IS UNSURE. REFUSED  -9     
427 ch_kidarvsnvrrs
n 
What is the main reason  [CHILD*] has 
never taken ARVs? 
CHILD IS NOT ELIGIBLE 
FOR TREATMENT 




















DO NOT THINK CHILD 






























CHILD HAS NOT BEEN 






















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
428 ch_kidarvsfirst
m 
What month and year did [CHILD*] 
first start taking ARVs? 
MONTH  date     
  
 
[DO NOT READ]: FOR DO NOT KNOW: 
PROBE TO VERIFY DATE. 





REFUSED MONTH  -9 
 
  
  ch_kidarvsfirsty 
 










  REFUSED YEAR  -9     
429 ch_kidarvsnow Is [CHILD*] currently taking ARVs, that 
is, antiretroviral medications? 
YES  1     
  
 
By currently, I mean that [CHILD*] may 
have missed some doses but [CHILD*] 
is still taking ARVs. 










  REFUSED  -9     
430 ch_kidarvsnotrs
n 
Can you tell me the main reason why 
[CHILD*] is not currently taking ARVs? 
I HAVE TROUBLE 
GIVING CHILD A TABLET 
EVERYDAY 































CHILD IS HEALTHY, 




































  REFUSED  -9     
431 ch_kidseptrin Is [CHILD*] currently taking Bactrim, 
Septrin or cotrimoxazole?  





Bactrim, Septrin or cotrimoxazole is a 
medicine recommended for people 
with HIV, even if they have not started 
treatment for HIV.  It helps prevent 
certain infections but it is not 
treatment for HIV. 





By currently, I mean that [CHILD*] may 
have missed some doses but is still 
taking Bactrim, Septrin or 
cotrimoxazole. 
I DON’T KNOW WHAT 






DO NOT READ: SHOW AID IF 
PARTICIPANT IS UNSURE 
REFUSED  -9 
 
  
432 ch_kidvisttbclin Has [CHILD*] ever visited a health 
facility or TB clinic for TB diagnosis or 
treatment? 















  REFUSED  -9     
433 ch_kiddiagtb Have you ever been told by a doctor, 
clinical officer or nurse that [CHILD*]  















  REFUSED  -9     



















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
435 ch_kidtrttcurr Is [CHILD*] currently on treatment for 
TB? 




















The last time [CHILD*] was treated for 
TB, did [CHILD*] complete at least 6 
months of treatment?  
YES  1     
  
  
NO, THE MEDICINE 
WAS STOPPED IN LESS 


















  REFUSED  -9     
Interviewer says: “Thank you for the information about [CHILD*]. “ 
  






NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 5: MALE CIRCUMCISION 
Interviewer says: “I will be asking a few questions about circumcision. Circumcision is the complete removal of the foreskin from the penis.  I have 
a picture to show you what a completely circumcised penis looks like.”  
DO NOT READ: SHOW ILLUSTRATION  
501 mcriskr Does male circumcision alone reduce 
the  risk, or chance, of a man getting 




1     
  
  















  REFUSED  -9     
502 mccndms Do you agree or disagree with the 
following statement: Men who are 
circumcised do not need to use 
condoms to protect themselves from 
HIV. 

























REFUSED  -9 
 
  
503 mchiv Do you agree or disagree with the 
following statement: Men who are 
circumcised can have multiple sexual 
partners and not be at risk for HIV. 























  REFUSED  -9     
504 mcstatus Some men are uncomfortable talking 
about circumcision but it is important 
for us to have this information.  Some 
men are circumcised and others are  
YES  1 IF mcstatus = 1 mcage 
  
 









  REFUSED -9     




















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
506 mcnorsn_a There may be different reasons why 
some men are circumcised and others 
are not.  What are your reasons for not 
getting circumcised?  
RESPONDENT OPPOSED A IF mcnorsn != 96 [NEXT 
MODULE] 
  mcnorsn_b SELECT ALL THAT APPLY. PARTNER OPPOSED B 
 
  
  mcnorsn_c 
 
OTHERS OPPOSED C 
 
  















  mcnorsn_f 
 






  mcnorsn_g 
 
HEALTH CONCERNS G 
 
  
  mcnorsn_h 
 
FEAR OF SIDE EFFECTS H 
 
  
  mcnorsn_i 
 





  mcnorsn_j 
 
COSTS TOO MUCH J 
 
  













  mcnorsn_x 
 
OTHER (SPECIFY) X 
 
  
  mcnorsn_y 
 
DON’T KNOW  Y 
 
  
  mcnorsn_z   REFUSED  Z     
507 mcage How old were you when you were 
circumcised? Please give your best 
guess. 
AGE IN YEARS integer     
  
 
DO NOT READ: IF LESS THAN ONE 
YEAR, CODE '0' 





  REFUSED -9     
508 mcwho Who did the circumcision? DOCTOR, CLINICAL 
OFFICER, OR NURSE  





























509 mcyesrn_a There may be different reasons why 
some men are circumcised and others 
are not.  What are your reasons for 
getting circumcised?  
RELIGION A IF mcyesrn_x != X [NEXT 
MODULE] 
  mcyesrn_b 
 
PREVENT HIV B 
 
  
  mcyesrn_c DO NOT READ: SELECT ALL THAT 
APPLY. 










  mcyesrn_e 
 





  mcyesrn_x 
 
OTHER (SPECIFY) X 
 
  
  mcyesrn_y 
 
DON’T KNOW  Y 
 
  
  mcyesrn_z   REFUSED  Z     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 6: SEXUAL ACTIVITY         
Interviewer says: “In this part of the interview, I will be asking questions about your sexual relationships and practices.  These questions will help 
us have a better understanding of how they may affect your life and risk for HIV. Let me assure you again that your answers are completely 
confidential and will not be shared with anyone.  If there are questions that you do not want to answer, we can go to the next question.”     
601 firstsxage How old were you when you had 
vaginal sex for the very first time? 




Vaginal sex is when a penis enters a 
vagina 


















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
602 analsxever People have sex in different ways.  
Some have vaginal sex.  Some have 
anal sex.  Anal sex is when a penis 
enters a person’s anus.  Have you ever 
had anal sex? 
YES  1     
  
  










  REFUSED  -9     
603 lifetimesex People often have sex with different 
people over their lifetime.  In total, 
with how many different people have 
you had sex in your lifetime?  Please 
give your best guess. 
NUMBER OF SEXUAL 
PARTNERS IN LIFETIME 
integer     
  
 
IF NUMBER OF SEXUAL PARTNERS IS 
GREATER THAN 100, ENTER '100' 





  REFUSED  -9     
604 firstsexcndm The first time you had vaginal or anal 
sex, was a condom used? 
YES  1     
  
  










  REFUSED  -9     
605 condomget If you wanted a condom, would it be 
easy for you to get one? 
















REFUSED  -9 
 
  
606 cmezrsn_a Why is it not easy for you to get a 
condom? 
CONDOMS NOT 
AVAILABLE/TOO FAR  
A SKIP IF condomget != 
2 
  
  cmezrsn_b DO NOT READ: SELECT ALL THAT 
APPLY. 
NOT CONVENIENT  B 
 
  
  cmezrsn_c 
 
COSTS TOO MUCH  C 
 
  
  cmezrsn_d 
 
EMBARASSED TO GET 
CONDOMS  
D IF cmezrsn_x !=X part12monu
m 
  cmezrsn_e 
 
DO NOT WANT OTHERS 




  cmezrsn_f 
 
DO NOT KNOW WHERE 




  cmezrsn_x 
 
OTHER (SPECIFY) X 
 
  
  cmezrsn_y 
 
DON’T KNOW  Y 
 
  
  cmezrsn_z   REFUSED  Z     
607 part12monum People often have sex with different 
partners over their lifetime.  In total, 
with how many different people have 
you had sex in the last 12 months? 
NUMBER OF SEXUAL 
PARTNERS IN LAST 12 
MONTHS 










IF NUMBER OF SEXUAL PARTNERS IS 
GREATER THAN 100, ENTER '100' 
REFUSED  -9     
Interviewer says: “Now I would like to ask you some questions about the partners you have had sex with in the last 12 months. Let me assure you 
again that your answers are completely confidential and will not be told to anyone. I will first ask you about your most recent partner.” 
 
DO NOT READ ALOUD: ASK ONLY ABOUT THE LAST 3 PERSONS THE PARTICIPANT HAD SEX WITH. 
608 partlivew1-3 Does the person you had sex with live 
in this household? 
YES  1 IF partlivew = 2 partid1-3 
  
  
NO  2 
 
  
609 partid1-3 Please select the name below from the 
household membership list.  Please 
identify the person you had sex with. 
LINE NO integer     
610 
 
I would like to ask you for the initials of 
your partner so I can keep track.   They 
do not have to be the actual initials of 
your partner. 






NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
611 partrelation1-3 What is your relationship with 
[INITIALS]? 
HUSBAND/WIFE  1 IF partrelation != 96 partgend1-3 
  
  





PARTNER, NOT LIVING 











































  REFUSED  -9     
612 partgend1-3 Is [INITIALS] male or female? MALE  1 SKIP IF partlivew = 1   
  
  










REFUSED  -9 
 
  
613 partage1-3 How old is [INITIALS]? Please give your  AGE IN YEARS integer     
  
 





  REFUSED  -9     
614 partfirstsxtime1
-3 
How long has it been since you first 




integer     
  partfirstsxunits1
-3 
DO NOT READ: IF LESS THAN ONE 


























  REFUSED  -9     
615 partlastsxtime1-
3 
How long has it been since you last had 
sex with (INITIALS)? 
Number of 
DAYS/WEEKS/MONTHS 
integer     
  partlastsxunits1
-3 
DO NOT READ: IF LESS THAN ONE 





















  REFUSED  -9     
616 partlastcndm1-
3 
The last time you had sex with 
[INITIALS] was a condom used? 




















In the last 4 weeks, what is the total 
number of times you had sex with 
[INITIALS]? By “times” we mean 
number of sex acts.  For example, you 
could have sex 5 times with the same 
partner.  
NUMBER OF TIMES integer     
  parttimes4wksd DO NOT READ: ENTER '0' IF NONE. DON’T KNOW  -8 
 
  
  k1-3   REFUSED  -9     
618 partcondfreqva
g1-3 
In the last 12 months, how often did 
you use condoms with [INITIALS] when 
having vaginal sex? Was it always, 
most of the time, sometimes, rarely or 
never? 





(Note: Due to a skip pattern error, this 
question was asked to very few 
participants.) 




















NO VAGINAL SEX IN 

















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
619 partcondfreqan
al1-3 
In the last 12 months, how often did 
you use condoms with (INITIAL) when 
having anal sex? Was it always, most of 
the time, sometimes, rarely or never? 
ALWAYS  1 SKIP IF analsxever != 1   
  
  




















NO ANAL SEX IN THE 











  REFUSED  -9     
620 partlube1-3  In the last 12 months, how often did 
you use lubricant with (INITIAL) when 
having anal sex? Was it always, most of 
the time, sometimes, rarely or never? 
ALWAYS  1 SKIP IF analsxever != 1   
  
  




















NO ANAL SEX IN THE 











  REFUSED  -9     
621 partlastsup1-3 Did you enter into a sexual relationship 
with (INITIALS) because (INITIALS) 
provided you with gifts, help you to 
pay for things, or help you in other 
ways? 
YES  1 SKIP IF partrelation1-














  REFUSED  -9     
622 partlastsup21-3 Did you enter into a sexual relationship 
with (INITIALS) because you expected 
that (INITIALS) would provide you gifts, 
help you to pay for things, or help you 
in other ways? 
YES  1 SKIP IF partrelation1-














  REFUSED  -9     
623 partlastsupwhat
_a1-3 
In the last 12 months, what have you 
received from [INITIALS]?  














SELECT ALL THAT APPLY. FOOD  C SKIP IF partrelation1-










































OTHER (SPECIFY) X 
 
  
  no one selected 
 












NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
624 partagain1-3 Do you expect to have sex with 
[INITIALS] again? 
YES  1     
  
  










  REFUSED  -9     
625 partknowhiv1-3 Does [INITIALS] know your HIV status? 
HIV status could mean you are HIV 
negative or HIV positive. 
YES  1     
  
  










  REFUSED  -9     







DO NOT READ: READ RESPONSES 
ALOUD. 
(INTIALS) TOLD ME 




















(INITIALS) TOLD ME 


















REFUSED  -9 
 
   
  I will now ask you about the person 




    
627 sellsxever Have you ever sold sex for money? YES  1 IF sellsxever = 2, -8, -9 buysxever 
  
  










  REFUSED  -9     
628 sellsx12mo In the last 12 months, have you sold 
sex for money? 
YES  1 SKIP IF sellsxever != 1   
  
  










REFUSED  -9 
 
  
629 sellsxcndm The last time you sold sex for money, 
was a condom used?  
YES  1 SKIP IF sellsxever != 1   
  
  










  REFUSED  -9     
















REFUSED  -9 
 
  
631 buysx12mo In the last 12-months, have you paid 
money for sex? 
YES  1 SKIP IF buysxever != 1   
  
  










  REFUSED  -9     
632 buysxcndm The last time you paid money for sex, 
was a condom used?  
YES  1 SKIP IF buysxever != 1   
  
  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 7: HIV TESTING 
Interviewer says: “I would now like to ask you some questions about HIV testing.”  




NO  2 IF hivtstever = -8, -9 hivelikely 
  
  









NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
702 hivtstnors_a Why have you never been tested for 
HIV? 
DON'T KNOW WHERE 
TO TEST   
A IF hivtstnors_x != X hivelikely 
  hivtstnors_b 
 
TEST COSTS TOO MUCH  B 
 
  
  hivtstnors_c DO NOT READ: SELECT ALL THAT 
APPLY. 
TRANSPORT  COSTS 




  hivtstnors_d 
 
TOO FAR AWAY  D 
 
  
  hivtstnors_e 
 
AFRAID OTHERS WILL 





  hivtstnors_f 
 





  hivtstnors_g 
 















  hivtstnors_i 
 
DON’T WANT TO 




  hivtstnors_j 
 
CANNOT GET 




  hivtstnors_k 
 





  hivtstnors_l 
 
RELIGIOUS REASONS  L 
 
  
  hivtstnors_x 
 
OTHER (SPECIFY) X 
 
  
  hivtstnors_y 
 
DON’T KNOW  Y 
 
  
  hivtstnors_z 
 
REFUSED  Z 
 
  
703 lifetimehivtest In your lifetime, how many times have  NUMBER OF TIMES integer SKIP IF hivtstever != 1   
  
 





  REFUSED  -9     

























REFUSED YEAR  -9 
 
  
705 hivtstlocation Where was the last test done? VCT FACILITY  1 IF hivtstlocation != 96 hivtstrslt 
  
  































































  REFUSED  -9     
































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
707 hivlikely How likely do you think it is that you  VERY LIKELY 1     
  
 















  REFUSED -9     
Interviewer says: “Please tell me if you strongly agree, agree, disagree or strongly disagree with the following statements.”  [ASKED OF ALL 
PARTICIPANTS]  
708 allowwork A person with HIV/AIDS should be  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     
709 compassion People who have HIV/AIDS deserve  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     
710 loserespect People who are suspected of having  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     























  REFUSED  -9     
712 hivonly Only persons who think they might be  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     
713 startimm I would be willing to start treatment  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     
714 startsck I would not want to start treatment  STRONGLY AGREE 1     
  
 




















  REFUSED  -9     
715 hivtfposm What was the month and year of your 
first HIV positive test result? Please 
give your best guess. 





This will be the very first HIV positive 
test result that you have received 
DON’T KNOW MONTH  -8 SKIP IF hivtstever !=1   
  
 
DO NOT READ: PROBE TO VERIFY 
DATE. 
REFUSED MONTH  -9 
 
  












  REFUSED YEAR  -9     
716 hivpostell_a Who have you told that you are HIV 
positive?   
NO ONE  A IF hivpostold != X next item 
  hivpostell_b DO NOT READ: CHECK ALL THAT APPLY. SPOUSE/SEX PARTNER  B 
 
  
  hivpostell_c 
 
DOCTOR  C SKIP IF hivtstrslt! =1   
  hivpostell_d 
 
FRIEND  D 
 
  
  hivpostell_e 
 
FAMILY MEMBER  E 
 
  
  hivpostell_x 
 
OTHER (SPECIFY) X 
 
  
  hivpostell_y 
 
DON’T KNOW  Y 
 
  




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
Interviewer says: “Now I would like to ask you questions about your experiences with health care 
providers.” 
SKIP IF hivtstrslt! =1   
717 hivstathide In the last 12 months, when you 
sought health care in a facility where 
your HIV status is not known, did you 
feel you needed to hide your HIV 
status? 
YES  1 SKIP IF hivtstrslt! =1   
  
  





NO, DID NOT ATTEND 
HEALTH FACILITY IN 
















In the last 12 months, have you been 
denied health services including dental 
care, because of your HIV status? 
YES  1 SKIP IF hivtstrslt! =1   
  
  

















  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 8: HIV STATUS, CARE AND TREATMENT  
Interviewer says: “Now I’m going to ask you more about your experience with HIV support, care and 
treatment.” 
SKIP MODULE IF 
hivtstrslt = 2, 3, 4, -8, 
-9 
  
801 hivcare After learning you had HIV, have you 
ever received HIV medical care and  
YES  1 IF hivcare = 1  hivcfm/hivcfy 
  
 
treatment from a doctor, clinical  NO  2 IF hivcare = -8, -9 cd4testever 
  
 





  REFUSED -9     
802  hivcnotrsn What is the main reason why you have 
never received HIV medical care and 
treatment from a doctor, clinical 
officer or nurse? 
FACILITY IS TOO FAR 
AWAY  
1 IF hivcnotrsn != 96 cd4testever 
   
I DON’T KNOW WHERE 

















I DO NOT NEED IT/I 
FEEL HEALTHY/NOT 






I FEAR PEOPLE WILL 
KNOW THAT I HAVE HIV 





































REFUSED  -9 
 
  
803 hivcfm What month and year did you first see 
a doctor, clinical officer or nurse for 
HIV medical care and treatment? 
MONTH date     
  
 
DO NOT READ: PROBE TO VERIFY 
DATE. 





REFUSED MONTH  -9 
 
  


















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
804 hivclm What month and year did you last see 
a doctor, clinical officer or nurse for 
HIV medical care? 
MONTH date IF [CURRENT DATE] - 
hivclm/hivcly <= 7 
MONTHS OR 









REFUSED MONTH -9 
 
  












  REFUSED  -9     
805  hivcnot6mo What is the main reason for not seeing 
a doctor, clinical officer or nurse for  
FACILITY IS TOO FAR 
AWAY  
1 IF hivcnot6mo != 96 cd4testever 
  
 
HIV medical care in the past 6 months? I DON’T KNOW WHERE 

















I DO NOT NEED IT/I 
FEEL HEALTHY/NOT 






I FEAR PEOPLE WILL 
KNOW THAT I HAVE HIV 






































  REFUSED  -9     
806 cd4testever Have you ever had a CD4 count test?  YES  1 IF cd4testever = 2, -8, 




The CD4 count tells you how sick you  NO  2 IF cd4testever = 2, -8,  [NEXT  
  
 
are with HIV and if you need to take DON’T KNOW  -8 -9 AND HIVCARE = 2,- MODULE] 
  
 
ARVs or other HIV medications. REFUSED  -9 -8, -9   
807 cd4ttm What month and year were you last  MONTH date     
  
 





REFUSED MONTH  -9 
 
  












  REFUSED YEAR  -9     
808 arvstakenev Have you ever taken ARVs, that is,  YES  1 IF arvstakenev = 1 arvftm/arvfty 
  
 
antiretroviral medications to treat HIV  NO  2 IF arvstakenev = -8, -9 [NEXT  
  
 





REFUSED  -9 
 
  
809 arvsnottake What is the main reason you have 
never taken ARVs? 
NOT ELIGIBLE FOR 
TREATMENT 





































































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
810 arvftm What month and year did you first 






DO NOT READ: PROBE TO VERIFY 
DATE. 





REFUSED MONTH  -9 
 
  












REFUSED YEAR  -9 
 
  
811 arvscurrent Are you currently taking ARVs, that is, 
antiretroviral medications? 
YES  1 IF arvscurrent = 1 arvsmissdays  
  
 
By currently, I mean that you may have 
missed some doses but you are still 
taking ARVs. 









  REFUSED  -9     
812 arvsnotcurrsn Can you tell me the main reason why 
you are not currently taking ARVs? 
I HAVE TROUBLE 
TAKING A TABLET 
EVERYDAY  











FACILITY TOO FAR 
AWAY FOR ME TO GET 




















































  REFUSED  -9     
813 arvsmissdays People sometimes forget to take all of 
their ARVs every day.  In the past 30 
days, how many days have you missed 
taking any of your ARV pills ? 










REFUSED  -9 
 
  
814 hivcdistance At your last HIV care visit, 
approximately how long did it take you 
to travel from your home (or 
workplace) one way? 
LESS THAN ONE HOUR  1     
  
  

















REFUSED  -9 
 
  
815 hivccost At your last HIV care visit, 
approximately how much did it cost to 
travel from your home (or workplace) 
one way?  
COST integer     





  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 9: TUBERCULOSIS AND OTHER HEALTH ISSUES  
Interviewer says: “Now I will ask you about tuberculosis or TB.” 
901  tbclinvisit Have you ever visited a TB clinic (or 
health facility) for TB diagnosis or 
treatment? 
















  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
902 tbdiagn Have you ever been told by a doctor, 
clinical officer or nurse that you had 
TB? 














  REFUSED  -9     














REFUSED  -9 
 
  
904 tbttretcurr Are you currently on treatment for TB? YES  1     
  
  










  REFUSED  -9     
905 tbtreat6mofull The last time you were treated for TB, 
did you complete at least 6 months of 
treatment? 





NO, MEDICINE WAS 
STOPPED IN LESS THAN 


















  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 10: ALCOHOL USE 
Interviewer says: “The next few questions will be on your use of alcohol.  Remember, all the answers you provide will be kept  confidential.” 
1001 alcfreq How often do you have a drink 
containing alcohol? 































REFUSED  -9 
 
  
1002 alcnumday How many drinks containing alcohol do 
you have on a typical day? 



































  REFUSED  -9     
1003 alcsixmore How often do you have six or more 
drinks on one occasion? 






































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 11: GENDER NORMS SKIP IF curmar = 3, 4, 
5, -8, -9 
  
Interviewer says: “Now I would like to ask you question on attitudes and decision-making in your home.”  
1101 healthc Who usually makes decisions about 
health care for yourself: you, your 
(spouse/partner), you and your 
(spouse/partner) together, or 
someone else? 

























REFUSED  -9 
 
  
1102 money Who generally decides about how the 
money you receive is spent: you, your 
(spouse/partner), you and your 
(spouse/partner) together, or 
someone else?  
I DO  1     
  
  




















  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 12: VIOLENCE IF gender = 1 OR IF 
gender = 2 AND NOT 
SELECTED 
REFER 
Interviewer says: “You have been selected to be asked questions on other important aspects of a person’s life.  I know that some of these 
questions are very personal.  However, your answers are important for helping to understand the condition of men and women in Swaziland. Let 
me assure you that your answers are completely confidential and will not be told to anyone and no one in your household will know that you 
were asked these questions. 
 
By sex, we mean vaginal, anal, oral sex or the insertion of an object into your vagina or anus.  Vaginal sex is when a penis enters a vagina.  Anal sex 
is when a penis enters an anus (butt).  Oral sex is when a partner puts his/her mouth on his/her partner’s penis or vagina.”   
1201 touchever Have you ever  been touched by 
someone in a sexual way without your 
permission? 





Touching in a sexual way without 
permission includes fondling, pinching, 
grabbing, or touching you on or around 
your sexual body parts. 










  REFUSED  -9     
1202 touchtimes How many times has anyone ever 
touched you in a sexual way without 
your permission, but did not try and 
force you to have sex? 
NUMBER OF TIMES integer IF touchtimes = -8, -9 frcsxtimes 
  
 
Touching in a sexual way without 
permission includes fondling, pinching, 
grabbing, or touching you on or around  





your sexual body parts.  REFUSED  -9 
 
  
1203 touchage How old were you the first time this 
happened? 
AGE IN YEARS integer     
  
  





  REFUSED  -9     
1204 frcsxtimes How many times in your life have you 
been physically forced to have sex? 










REFUSED  -9 
 
  
1205 frcsxage How old were you the first time 
someone physically forced you to have 
sex? 
AGE IN YEARS integer     
  
  









NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
1206 frcsx12mo In the past 12 months, did someone 
physically force you to have sex?  















REFUSED  -9 
 
  
1207 frcsx12mowho In the last 12 months, who physically 
forced you to have sex?  








By partner, I mean a sexual partner 
whether or not you were married at 
the time.   















  REFUSED Z     
1208 uwntsxhelp_a After any of these unwanted sexual 
experiences, did you try to seek 
professional help or services from any 
of the following? 
I DID NOT TRY TO SEEK 
HELP  
A SKIP IF (touchtimes = 
0, -8, -9) AND 
(frcsxtimes = 0, -8, -9) 
  
  uwntsxhelp_b DO NOT READ: READ RESPONSES 
ALOUD. 
HEALTHCARE 
PROFESSIONAL   
B IF unwntseek = A unwntsxnohlp 
  uwntsxhelp_c SELECT ALL THAT APPLY. POLICE OR OTHER 
SECURITY PERSONNEL   
C IF unwntseek = B, C, 
D, E, Y, Z 
vlnc12motim
es 





ORGANIZATION   
D IF unwntseek = X unwntseekot
h 
  uwntsxhelp_e 
 
RELIGIOUS LEADER    E 
 
  
  uwntsxhelp_x 
 
OTHER (SPECIFY) X 
 
  
  uwntsxhelp_y 
 
DON’T KNOW  Y 
 
  
  uwntsxhelp_z   REFUSED  Z     
1209 unwntsxnohlp What was the main reason that you 
did not try to seek help or services? 
DID NOT KNOW 
SERVICES WERE 
AVAILABLE  
































DID NOT THINK IT WAS 

























AFRAID OF MAKING 
















  REFUSED  -9     
1210 vlnc12motimes In the past 12 months, how many 
times did someone: 
NOT IN LAST 12 
MONTHS  





-       Punched, kicked, whipped, or beat 
you with an object 





-       Slapped you, threw something at 
you that could hurt you, pushed you or 
shoved you 





-       Choked, smothered, tried to 
drown you, or burned you intentionally 





-       Used or threatened you with a 
knife, gun or other weapon? 











NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
1211 vlnc12mowho In the last 12 months, who did any of 
these things to you? 








By partner, I mean a sexual partner 
whether or not you were married at 
the time.   















  REFUSED Z     
1212 seekhelp_a Thinking about all these experiences 
that we just discussed, whether 
someone has done the following: 
I DID NOT TRY TO SEEK 
HELP  
A IF seekhelp = A seekhelpwhy
not 
  seekhelp_b -       Punched, kicked, whipped, or beat 
you with an object 
HEALTHCARE 
PROFESSIONAL   
B IF seekhelp = B, C, D, 
E, Y, Z 
END 
  seekhelp_c -       Slapped you, threw something at 
you that could hurt you, pushed you or 
shoved you 
POLICE OR OTHER 




  seekhelp_d -       Choked, smothered, tried to 








  seekhelp_e -       Used or threatened you with a 
knife, gun or other weapon 
RELIGIOUS LEADER    E 
 
  
  seekhelp_x Did you try to seek professional help or 
services for any of these incidents from 
any of the following? 
OTHER (SPECIFY) X 
 
  
  seekhelp_y DO NOT READ: READ RESPONSES 
ALOUD. 
DON’T KNOW  Y 
 
  
  seekhelp_z SELECT ALL THAT APPLY. REFUSED  Z     
1213 seekhelpwhynot What was the main reason that you 
did not try to seek help or services? 
 DID NOT KNOW 
SERVICES WERE  
AVAILABLE  

































DID NOT THINK IT WAS 

























AFRAID OF MAKING 
















REFUSED  -9 
 
  
Interviewer says: “Thank you for taking the time to participate in this survey.  Your responses will be very helpful to the Ministry of Health to 
better understand how to improve health programs in the country.” 
 
 206 
Appendix G  Young Adolescent Questionnaire 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS 
101 gender Gender was previously given as 
(Male/Female). If this is not correct, 
please review previously given answer 
in the eligibility form and update as 
needed. 
  





    
102 age Age was previously given as (insert 
age). If this is not correct, please review 
previously given answer in the 
eligibility form and update as needed. 
  
    
103 adensch Are you enrolled in school? YES 1 IF adensch = 2, -8, -9 adnoschreas 
  
  










  REFUSED  -9     
104 admisch During the last school week, did you 
miss any school days for any reason? 
YES  1 IF admisch = 2, -8, -9 adcurgrd 
  
  










  REFUSED  -9     
105 admischreas Why did you miss school? I HAVE BEEN SICK 1 IF admischreas != 96 adcurgrd 
  
  








I DON'T FEEL SAFE 













I HAVE TO LOOK 



























I HAVE A CHILD OR 






I MISSED TOO 
MUCH SCHOOL 
BECAUSE OF MY 
PERIOD 
















  REFUSED  -9     
106 adcurgrd What grade/form are you in now? GRADE/FORM integer     

















  REFUSED  -9     
107 adlstyrgd What grade/form were you in last 
year? 
GRADE/FORM integer ALL admedia_a - z  

















  REFUSED  -9     




NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
108 adnoschreas Why do you NOT go to school? I HAVE BEEN SICK 1 IF adnoschreas != 96 adatndsch 
  
  








I DON'T FEEL SAFE 













I HAVE TO LOOK 



























I HAVE A CHILD OR 






I MISSED TOO 
MUCH SCHOOL 
BECAUSE OF MY 
PERIOD 
















  REFUSED  -9     
109 adatndsch Have you ever attended school? YES  1 IF adatndsch = 2, -8, -
9 
admedia_a - z  
  
  










  REFUSED  -9     
110 adlstregsch When was the last time you regularly 
attended school? Would you say it was 
less than a year ago or more than a 
year ago? 
LESS THAN 1 YEAR  1     
  
  










  REFUSED  -9     
111 adhigrade What is the highest grade/form that 
you have completed? 
GRADE/FORM integer     
























  REFUSED  -9     
112 admedia_a In the past 30 days, have you used any 





A     
  admedia_b READ RESPONSES ALOUD. INTERNET B 
 
  
  admedia_c SELECT ALL THAT APPLY. TEXTING C 
 
  
  admedia_y 
 
DON’T KNOW  Y 
 
  
  admedia_z   REFUSED  Z     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 2: HIV KNOWLEDGE  
Interviewer says: “Now I would like to ask you some questions about what you know about some things related to HIV.”  
201 adhrdhiv Have you ever heard of HIV?  YES  1 IF adhrdhiv = 2, -8, -9 adykwcon 
  
  















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 




A IF adhiv_x != X addishiv 
  adhiv_b PROBE: "Anywhere else?" PARENTS / 
GUARDIAN / 




  adhiv_c RECORD ALL MENTIONED FRIENDS C 
 
  












  adhiv_f 
 
MOBILE PHONE F 
 
  










  adhiv_h 
 
TELEVISION / FILM  H 
 
  












  adhiv_x 
 
OTHER (SPECIFY) X 
 
  
  adhiv_y 
 
DON’T KNOW Y 
 
  
  adhiv_z 
 
REFUSED  Z 
 
  
203 addishiv Have you ever discussed HIV with your 
parents or guardian? 
YES  1     
  
  










  REFUSED  -9     
204 adhip_a Have you taken part in any of the 
following HIV prevention programs? 
NONE A if adhip_x != X adykwcon 
  adhip_b SHOW CHILD LOGO FOR EACH 
PROGRAM 
STEPPING STONES B 
 
  















  adhip_e 
 
SUPPER BUDDIES E 
 
  















  adhip_h 
 
TEEN CLUB H 
 
  
  adhip_i 
 
GLOW CLUB I 
 
  
  adhip_j 
 
BRO CLUB J 
 
  
  adhip_x 
 
OTHER (SPECIFY) X 
 
  
  adhip_y 
 
DON’T KNOW Y 
 
  














  REFUSED -9     
207 adclc_a Where can a person go to get a male 
condom? 
CLINIC / HOSPITAL A IF adclc_x != X adcldcon 
  adclc_b SELECT ALL THAT APPLY KIOSK / SHOP B 
 
  












  adclc_e 
 
FRIENDS / PEERS E 
 
  







  adclc_x 
 
OTHER (SPECIFY) X 
 
  
  adclc_y 
 
DON’T KNOW Y 
 
  








NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
208 adcldcon If you wanted to, could you yourself get  YES  1 IF adcldcon = 1, -8, -9 adcondem 
  
 










REFUSED  -9 
 
  
209 adnez_a Why is it not easy for you to get a male  TOO FAR A IF adnez_x != X adcondem 
  adnez_b condom? COSTS TOO MUCH B 
 
  
  adnez_c SELECT ALL THAT APPLY DO NOT WANT 




  adnez_x 
 
OTHER (SPECIFY) X 
 
  
  adnez_y 
 
DON’T KNOW Y 
 
  
  adnez_z   REFUSED Z     
210 adcondem Have you ever seen a male condom 
demonstration? 





By a condom demonstration, I mean 
someone like a nurse or health  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 3: SEXUAL BEHAVIOR 
Interviewer says: “The next questions ask about sexual behavior. There is no right or wrong answer. Your responses will not be linked to you in  
any way or shared with anyone, including your parents. You can choose not to answer any of the questions.” 
 
DO NOT READ: PLEASE LOOK OUT FOR SIGNS OF DISTRESS IN CHILD WHEN ASKING THE FOLLOWING SEXUAL BEHAVIOR QUESTIONS.  IF THE CHILD 
SEEMS DISTRESSED, ASK CHILD IF HE/SHE WANTS TO STOP THE INTERVIEW. 
301 adknsx Do you know what sex is? YES  1 (IF (age <13) &  adlghiv 
  
  
NO  2 (adknsx = 2, -8, -9))   
  
  





  REFUSED  -9     













REFUSED  -9 
 
  
303 adsxage How old were you when you had sex 
for the first time? 
AGE IN YEARS integer     
  
 
IF CHILD IS UNSURE OF AGE, PROBE BY 
ASKING WHEN THEY FIRST HAD SEX  





AND HELPING THEM CALCULATE. REFUSED  -9     
304 adwhysx The first time you had sex, was it  WANTED TO 1 IF adwhysx = 1, -8, -9 adsxfrsn 
  
 
because you wanted to or because you  FORCED 2 IF adwhysx = 1 adfpsxage 
  
 





REFUSED  -9 
 
  
305 adsxfrc The first time you had sex, were you 
physically forced or were you  
PHYSICALLY 
FORCED 
1 ALL adfpsxage 
  
 










  REFUSED  -9     
306 adsxfrsn What was the main reason that you  IT JUST HAPPENED 1 IF adsxfrsn != 96 adfpsxage 
  
 
had sex for the first time? MY FRIENDS 







TO SHOW MY LOVE 













MY BOYFRIEND / 
GIRLFRIEND 














I WANTED TO 




















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
307 adfpsxage How old was the person you first had  AGE IN YEARS integer     
  
 





  REFUSED  -9     
308 adfsxcon The first time you had sex, was a  YES  1 SKIP IF adykwcon = 2   
  
 










REFUSED  -9 
 
  
309 addifpsx In total, how many different people 
have you had sex with? Please give  
NUMBER OF 
PARTNERS 
integer     
  
 





  REFUSED  -9     
310 adsex30dy In the last 30 days, how many times  NUMBER OF TIMES integer     
  
 





  REFUSED  -9     
311 adltsxcon The last time you had sex was a  YES  1 SKIP IF adykwcon = 2   
  
 










  REFUSED  -9     
312 admatsup Sometimes people have sex to get 
material support. Material support 
means someone providing you gifts, 
helping to pay for things or helping you 
in other ways.   
YES  1     
  
 










support? REFUSED  -9     
313 adpsup12_a In the last 12 months, what material 
support have you received from any of 
your sexual partners?  
DID NOT RECEIVE 
ANYTHING  
A ALL adcmth_a-z 
  adpsup12_b SELECT ALL THAT APPLY. MONEY  B 
 
  
  adpsup12_c 
 
FOOD  C 
 
  
  adpsup12_d 
 
SCHOOL FEES  D 
 
  
  adpsup12_e 
 
EMPLOYMENT  E 
 
  
  adpsup12_f 
 
GIFTS/FAVORS  F 
 
  
  adpsup12_g 
 
TRANSPORT  G 
 
  
  adpsup12_h 
 
SHELTER/RENT  H 
 
  
  adpsup12_i 
 
PROTECTION  I 
 
  
  adpsup12_x 
 
OTHER (SPECIFY) X 
 
  
  adpsup12_y 
 
DON’T KNOW  Y 
 
  
  adpsup12_z   REFUSED  Z     
314 adpreg Have you ever been pregnant?  YES  1 SKIP IF gender=1   
  
  










REFUSED  -9 
 
  
315 adcmth_a What are you or your sexual partner 
currently doing to prevent pregnancy?  
NOTHING A if adcmth_x != X adtpsx 
  adcmth_b SELECT ALL THAT APPLY. PILL  B 
 
  
  adcmth_c 
 
IUD/”COIL”  C 
 
  
  adcmth_d 
 
INJECTIONS  D 
 
  
  adcmth_e 
 
IMPLANT  E 
 
  
  adcmth_f 
 
CONDOM  F 
 
  
  adcmth_g 
 
FEMALE CONDOM  G 
 
  







  adcmth_i 
 
WITHDRAWAL  I 
 
  
  adcmth_j 
 
ANAL SEX J 
 
  
  adcmth_k 
 
ORAL SEX K 
 
  
  adcmth_x 
 
OTHER (SPECIFY) X 
 
  
  adcmth_y 
 
DON’T KNOW  Y 
 
  
  adcmth_z 
 
REFUSED  Z 
 
  
316 adtpsx Have you ever talked with a parent or 
guardian about sex?    
YES  1     
  
  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 4: HIV RISK PERCEPTIONS 
  
SKIP MODULE IF 
adhrdhiv = 2, -8, -9 
  
401 adlghiv How likely do you think it is for you to 
get HIV? 




SOMEWHAT LIKELY 2 IF adlghiv = 3 admrnlhiv 
  
  

















  REFUSED  -9     
402 admrlhiv What is the main reason you think you 
are likely to get HIV? 
I HAVE HAD SEX 
WITHOUT A 
CONDOM 
















































I DESERVE IT / I AM 
















REFUSED  -9 
 
  
403 admrnlhiv What is the main reason you think you 
are not likely to get HIV? 















































  REFUSED  -8     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 5: HIV KNOWLEDGE 
  
SKIP MODULE IF 
adhrdhiv = 2, -8, -9 
  
501 adghiv_a How do people acquire HIV? SEX A IF adghiv_x != X adrednosx 







  adghiv_x 
 
OTHER (SPECIFY) X 
 
  
  adghiv_y 
 
DON’T KNOW Y 
 
  
  adghiv_z 
 
REFUSED  Z 
 
  
502 adrednosx Can a person reduce their chance of 
getting HIV by not having sex?    
YES  1     
  
  










  REFUSED  -9     
503 adredcon Can a person reduce their chance of  YES  1     
  
 














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
504 adlkshiv Can a healthy-looking person have HIV 
or AIDS? 
YES  1     
  
  










  REFUSED  -9     
505 admhivubb Can a mother with HIV or AIDS pass HIV 
to her unborn baby? 
YES  1     
  
  










  REFUSED  -9     
506 admedll Are there medicines that people with 
HIV or AIDS can take to help them live 
longer? 
YES  1     
  
  










  REFUSED  -9     
507 adcirhiv Can male circumcision help prevent HIV 
infection? 
YES  1     
  
 
Circumcision is the removal of the 
foreskin from a penis. 










  REFUSED  -9     
508 adarvless Can ARVs make people with HIV less 
likely to spread the virus? 
YES  1     
  
  










  REFUSED  -9     
509 admosquito Can a person get HIV from a mosquito 
bite? 
YES  1     
  
  










  REFUSED  -9     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 6: HIV TESTING  SKIP MODULE IF 
adhrdhiv = 2, -8, -9 
  
Interviewer says: “I would now like to ask you some questions about HIV testing.”  
601 adcldtest If you wanted to, could you get an HIV 
test? 
YES  1 IF adcldtest = 1, -8, -9 adevtestalt 
  
  










  REFUSED  -9     
602 adnttst_a What are the reasons why you could 
not get an HIV test if you wanted to? 
CLINIC TOO FAR A IF adnttst_x=! X adevtestalt 





  adnttst_c 
 
DO NOT WANT 




  adnttst_x 
 
OTHER (SPECIFY) X 
 
  
  adnttst_y 
 
DON'T KNOW Y 
 
  
  adnttst_z   REFUSED Z     
603 adevtestalt Should everyone get tested for HIV? YES  1     
  
  










  REFUSED  -9     














  REFUSED  -9     
605 adrcrshiv Did you receive the results of any of 
your HIV tests? 


















NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 














REFUSED  -9 
 
  
607 adtxhiv Are you currently on treatment for 
HIV? 
YES  1     
  
  










  REFUSED  -9     
608 adwkhv_a Aside from a health care worker, who 
knows about your HIV status? 
NO ONE A IF adwknhv_x != X [NEXT 
MODULE] 
  adwkhv_b SELECT ALL THAT APPLY. PARENT B 
 
  
  adwkhv_c 
 
GRAND PARENT C 
 
  



















  adwkhv_x 
 
OTHER (SPECIFY) X 
 
  
  adwkhv_y 
 
DON'T KNOW Y 
 
  
  adwkhv_i   REFUSED Z     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 7: HIV STIGMA  
  
SKIP IF (adhrdhiv = 2, -
8, -9) OR (adrshiv  =  
1) OR (adlghiv  = 3) 
  
Interviewer says: “Now I would like to ask you some more question about HIV.”  
701 adshfdhiv  Would you be willing to share food 
with someone who has HIV? 
YES  1     
  
  










  REFUSED  -9     
702 adteachhiv Would you be comfortable to have a 
teacher who has HIV? 















REFUSED  -9 
 
  
703 adplhiv Would you be friends with someone 
who has HIV? 
YES  1     
  
  














NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 8: ALCOHOL AND DRUGS  
Interviewer says: “I would like to ask you some questions about alcohol and drugs or substances that you may have taken that were not given to 
you by doctor. Your answers will not be told to anyone, even your parents. You can choose not to answer any of these questions.”  
801 adhdalc Have you ever had more than a few 
sips of alcohol, for example beer, cider, 
wine, liquor, or traditional brew? 
YES  1 IF adhdalc = 2, -8, -9 item 904 
  
 
SHOW GRAPHIC IF HE OR SHE IS 
UNSURE 










  REFUSED  -9     
802 admnondrk During the past 1 month, on how many 
days did you have at least one drink 
containing alcohol? 
NUMBER OF DAYS integer     
  
 
We count one drink of alcohol as one 
can or bottle of beer, one glass of wine, 
or one shot of liquor, or a cup of 
traditional brew. 









NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
803 adalcsixmore How often do you have six or more 
drinks on one occasion? 


































  REFUSED  -9     
804 addtr_a What drugs have you ever tried? NONE A if addttr_x != X [NEXT 
MODULE] 












  addtr_d RECORD ALL MENTIONED NYAOPE/UNGA D 
 
  
  addtr_e 
 
ECSTASY  E 
 
  
  addtr_x 
 
OTHER (SPECIFY) X 
 
  
  addtr_y 
 
DON’T KNOW Y 
 
  
  addtr_z   REFUSED  Z     
 
NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 9: PARENTAL SUPPORT   
901 adparprb If you have a problem, can you freely 
go to your parents/guardians for help? 













  REFUSED  -9     
902 adparfrtm Do your parents/guardians really know 
what you were doing with your free 
time when you were not at school or 
work? 
ALWAYS 1     
  
  































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
MODULE 10: VIOLENCE 
Interviewer says: “Now I would like to ask you questions about some other important aspects of a person’s life.  I know that some of these 
questions are very personal.  However, your answers are important for helping to understand the condition of children in Swaziland. Let me 
assure you that your answers are completely confidential and will not be told to anyone. You can choose not to answer any of these questions.” 
1001 adattck Has anyone ever done any of these 
things to you: 
YES  1 IF (age >=13 OR 
adknsx = 1)  AND 




-       Punched, kicked, whipped, or beat 
you with an object such as a stick 
NO  2 IF (age <13 AND 




-       Choked smothered, tried to drown 
you, or burned you intentionally 
DON’T KNOW -8 AND adattck = 2,-8,-9   
  
 
 -      Used or threatened you with a 
knife, gun or other weapon? 
REFUSED  -9     
1002 adattkrel The first time this happened, what was 
your relationship to the person who did 




1 IF (age >=13 OR 
adknsx = 1) AND 




what was your relationship with the 
person you knew the best? 
RELATIVE / FAMILY 
MEMBER 
2 IF age <13 AND 
















POLICE / SECURITY 












































REFUSED  -9 
 
  
1003 adsxltch Has anyone ever touched your [penis 
or buttock, vagina, buttock, or breast] 
when you did not want them to?  This 
could be pinching, grabbing, or  
YES  1 SKIP IF age > 12 adtchwopm 
  
 
touching you on or around your [penis  NO  2 ALL REFER 
  
 





breast]. REFUSED  -9     
1004 adtchwopm Has anyone ever touched you in a 
sexual way without your permission, 
but did not try and force you to have 
sex? 





Touching in a sexual way without 
permission includes fondling, pinching,  










your sexual body parts. REFUSED  -9     
1005 adftrel The first time this happened, what was 
your relationship to the person who did 




1 IF adftrel != 96 adprsxscc 
  
 
what was your relationship with the 
person you knew the best? 



















POLICE / SECURITY 
















































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
Interviewer says: “You said before that you had been pressured or forced to have sex. I'm going to ask 
you again about these topics.” 
SKIP IF adwhysx != 2   















  REFUSED  -9     
1007 adfrcscc Has anyone ever physically forced you  YES  1     
  
 










REFUSED  -9 
 
  
1008 adfrcrel The first time you were pressured or 
forced to have sex, what was your 




1 SKIP Q IF (adprsxscc = 
2, -8, -9 ) AND 

































































  REFUSED  -9     
1009 adprsv_a After any of these unwanted sexual 
experiences, did you try to seek help or 
services from any of the following? 
I DID NOT TRY TO 
SEEK HELP 
A SKIP Q IF (adtchwopm = 
2, -8, -9) AND 
(adprsxscc = 2, -8, -9)  
  




B AND (adfrcscc = 2, -8, -
9) 
 
  adprsv_c READ RESPONSES ALOUD. POLICE C 
  









F IF adprosvc = B, C, D,F, 
G, Y, Z 
adsxtell 
  adprsv_g 
 
LAWYER’S OFFICE  G IF adprosvc = A adrsprsvc  
  adprsv_x 
 
OTHER (SPECIFY) X 
 
  
  adprsv_y 
 
DON’T KNOW Y 
 
  
  adprsv_z   REFUSED  Z     
1010 adrsprsvc What was the main reason that you did 
not try to seek help or services? 
DID NOT KNOW 
SERVICES WERE 
AVAILABLE 
































DID NOT THINK IT 









































NO. VARIABLE QUESTIONS CODING LABELS CODING 
VALUES 
SKIP PATTERNS SKIP TO 
1011 adsxtell After any of these unwanted sexual 
experiences, did you tell anyone about 
it?  
YES  1 if adsxtell =  2, -8, -9 REFER 
  
  










  REFUSED  -9     
1012 adsdsc_a Which of the following describes who 




A if adsdsc_x != X REFER 
  adsdsc_b DO NOT READ: SELECT ALL THAT APPLY  SIBLING B 
 
  



















  adsdsc_f 
 
RELIGIOUS LEADER  F 
 
  
  adsdsc_x 
 
OTHER (SPECIFY) X 
 
  
  adsdsc_y 
 
DON’T KNOW Y 
 
  
  adsdsc_z 
 
REFUSED  Z 
 
  
Interviewer says: “Thank you for sharing your personal experiences with me. I know it may have been 
difficult for you to talk about your experiences with me. If you would like to talk further about these 
experiences, I can refer you to a place that can provide you with help.”  
  
SKIP IF (adattck = 2, -
8, -9) AND (adsxltch = 
2, -8, -9) AND 
adprsxscc = 2, -8, -9) 





DO NOT READ: PROVIDE PARTICIPANT 
WITH LIST OF ORGANIZATIONS. 
  
 
    
Interviewer says: “This is the end of the survey.  Thank you very much for your time and for your 
responses.” 
  
   






Appendix H  Survey Consent Forms 




Hello. My name is___________. I would like to invite you to take part in this survey about HIV in Swaziland. 
The Government of Swaziland is leading this survey in partnership with the United States Centers for 
Disease Control and Prevention and ICAP at Columbia University.  
 
What language do you prefer for our discussion today? 
 
___siSwati     ___ English  
 
Title of Survey: This survey is called the Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016) 
  
Purpose of survey 
This survey will help us to know how many people in Swaziland are living with HIV and need health 
services. It will also tell us about people’s risk for HIV and who has been infected recently. About 6,000 
households will join this survey. We would like your household to join the survey too, even if people in 
the household are already aware of their HIV status. What you tell us will help the Ministry of Health 
make health services better in the country. 
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
 
Survey Procedures 
If you join this survey, we will ask you questions and your answers will be kept between us. There are 
two parts to this survey– a household interview and individual interviews.  In the household interview, 
we would like to ask you some questions about the people living in your household.  We will ask how 
many people live here, their relationship to you and to each other, their gender, and age. We will ask 
you about people who are ill or recently died in your household.  We will also ask you about some of the 
things you have in your household. The household interview will take up to 45 minutes.    
 
After completing the household interview, we would begin the individual interviews. We would like to 
invite you and others living in your household to take part in the second part of this survey. We will ask 
each person to give his or her written permission to take part before joining the survey. 
 
Costs for being in the survey:  There is no cost to you for being in the household interview, except for 
your time.  
  
APPENDIX H SURVEY CONSENT FORMS  
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Right to refuse or withdraw 
Your taking part in this household interview is entirely voluntary. If you choose to take part in the 
interview, you may change your mind at any time and stop taking part.  If you decide not to take part, it 
will not affect your healthcare in any way.   
 
Risks 
The risks to taking part in the household interview are small.  You may feel uncomfortable about some of 
the questions we will ask.  You can refuse to answer any question.   
 
Benefits  
The benefit in taking part is that the information you provide to us will be used to improve health care 
services in the country.  
 
Alternatives to taking part 
You have a choice not to take part in this survey. 
 
Confidentiality 
We will do everything we can to keep your answers private. The information we collect from you will be 
identified by a number and not by your name. Your name will not appear when we share survey 
findings. Only survey staff will have access to the information we collect during the survey.   
 
The following individuals and/or agencies will be able to look at your interview records to help oversee 
the conduct of this survey: 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your rights as a person taking part, 
including:  
▪ Swaziland Scientific and Ethics Committee (SEC) 
▪ The Centers for Disease Control and Prevention (CDC; Atlanta, USA)  
▪ Columbia University Medical Center 
▪ Westat (a statistical survey research organization). 
▪ The U.S. Office of Human Research Protections may examine the study records to ensure we are 
protecting your rights as a person taking part in this survey. 
▪ Selected survey staff and survey monitors. 
 
This survey has received approval from the Swaziland Scientific and Ethics Committee (SEC), The Centers 
for Disease Control and Prevention, and the Institutional Review Board of Columbia University Medical 
Center, and of Westat. 
 
If you have any questions about the survey or feel that you have been harmed by taking part, you can 
contact:  
Zandile Mnisi 
Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 





Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 
Do you want to ask me anything about the survey? 
 
Consent Statement 
I have read this form or someone has read it to me.  I was encouraged to ask questions and given time 
to ask questions.  Any questions that I had have been answered satisfactorily.  I agree to take part in the 
household interview.  I know that after choosing to be in the interview, I may withdraw at any time.   My 
taking part is voluntary.  I have been offered a copy of this consent form. 
 
Make your signature or mark if you agree to do the household interview 
Head of household signature or mark________________________________ Date: ___/___/___            
Printed name of head of household_________________________________ 
Household Listing ID number ____________________________    
 
[For participants who cannot read and/or write] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________   








Hello. My name is___________. I would like to invite you to take part in this survey about HIV in Swaziland. 
The Government of Swaziland is leading this survey in partnership with the United States Centers for 
Disease Control and Prevention and ICAP at Columbia University.  
 
What language do you prefer for our discussion today? 
 
___siSwati                 ___ English 
 
Title of Survey: This survey is called the Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016) 
 
Purpose of the survey 
This survey will help us to know how many people in Swaziland are living with HIV and need health 
services. It will also tell us about people’s risk for HIV and who has been infected recently. We will 
approach about 20,000 men, women, and children from about 6,000 households throughout Swaziland 
to take part in this survey. We would like to invite you to join the survey too, even if you already know 
your HIV status. Your taking part will help the Ministry of Health make health services better in the 
country. 
 
This form might have some words in it that are not familiar to you.  Please ask me to explain anything that 
you do not understand. 
 
Survey Procedures 
If you join this survey, we will ask you questions and your answers will be kept between us. The questions 
will be about your age, what kind of work you do, whether you have had any experience with health 
services, and your social and sexual behavior. The interview will take about 45 minutes. 
 
The information is collected on this tablet. The information is stored securely and can only be accessed by 
selected survey staff. The interview will take place in private here in your house or an area around your 
house.   
 
Survey procedures also include blood draw, HIV test, and storage of that blood for future testing if you 
agree to this. The testing and counseling will take about 45 minutes. 
 
If you agree to the HIV testing, a survey staff member who has been trained to draw blood, will take 
about 14 millilitres (less than 1 tablespoon) of blood from your arm into two tubes.  If it is not possible 
to take blood from your arm, then we will try to take a few drops of blood from your finger.  We will give 




For adults who test positive for HIV and some randomly selected adults without HIV, we will measure the 
amount of CD4 cells in your blood. CD4 cells help your body fight HIV infection and other diseases. If you 
are HIV positive, we will give you a referral form and information so that you can consult with a doctor or 
nurse to learn more about the test result and your health. 
  
Consent for Interview and Blood Testing: Adults 
If you test positive for HIV, we will send your blood to a laboratory to measure your viral load. Viral load 
is the amount of HIV in your blood. The results will be sent to a health facility of your choosing in about 
6-8 weeks from now.  You will be able to talk to a nurse or doctor at that facility about your viral load. 
Some of your blood will be sent to a laboratory out of the country for some additional tests related to 
HIV because there are no laboratories in Swaziland that can do the tests. If we have test results that 
might help guide your treatment, and if you have given us your contact information, we will contact you 
to tell you how you and your doctor or nurse may get these results. 
 
Additionally, we will ask you to take part in possible future research if you want to. If you agree, your 
contact information will be retained by approved researchers and you may be contacted for a period of 
up to 5 years and invited to take part in future research, if you still want to. If you do not agree to take 
part in future research you can still continue to take part in the research today.   
 
We would also like your consent to store your leftover blood for future research tests.  These tests may 
be about HIV, or other health issues important for the health of people living in Swaziland. This sample 
will be stored for 5-10 years. The sample will not have your name on it and so we will not be able to tell 
you the results of the future research tests. Your leftover blood will not be sold or used for commercial 
reasons. If you do not agree to long-term storage of your blood samples, you can still take part in the 
survey today and we will destroy your blood samples after survey-related testing has been completed.  
 
Conditions of the study: Taking part in the survey is voluntary and you will not be given money or gifts 
for your taking part. You can leave the survey at any time for any reason. If you decide to leave the 
survey, no more information will be collected from you.  However, we will not be able to take back the 
information that has already been collected and used within the survey. 
  
Costs for being in the survey: There is no cost to you for being in the survey, apart from your time. 
 
Use of survey findings 
The overall survey findings, which will not contain any personal information that would identify you, will 
be shared with the Government of the Kingdom of Swaziland and the Ministry of Health. This information 
will be used to improve the health care for the people of Swaziland. Finally, the findings will be shared 
with international partners to assist in the delivery of health services all over the world. 
 
Right to refuse or withdraw 
You do not have to take part in the survey interview or give blood and you are free to change your mind 
even after you have started the interview and/or the blood draw. If some of the questions make you feel 
 223 
 
uncomfortable you may decide not to answer or you may skip them and move to the next question. You 
may agree to let us test your blood for HIV, CD4 counts, and other lab testing but not agree to have your 
blood stored for future research tests. Your taking part is voluntary. If you decide not to take part, it will 
not affect your healthcare in any way. 
 
Risks 
The risks involved with taking part in the survey are small. We will do everything we can to keep your 
information private. However, we cannot promise complete confidentiality.  You may feel 
uncomfortable about some of the questions we will ask. You can refuse to answer any question.  
 
The risks to you from having your blood drawn are very small. They include brief pain from the needle 
stick, bruising, lightheadedness, bleeding and rarely, infection where the needle enters the skin.  The 
survey staff member who will take your blood has received training on how to draw blood.  If you 
experience any discomfort or any of the symptoms mentioned above, please let us know, and especially 
if there is any bleeding or swelling. 
 
Learning that you have HIV may cause some emotional distress. You will receive counseling on how to 
cope with learning that you have HIV.  If you test HIV positive, we will help you identify where to go and 
explain the options available for care and treatment. Care and treatment is available at government 
facilities free of charge. 
 
Benefits 
The main benefit for you to be in the survey is the chance to learn more about your health today. Some 
people who take part will test HIV positive.  If you test HIV positive, the benefit is that you will learn your 
HIV-positive status and where to go for HIV services. HIV care and treatment provided by the Ministry of 
Health is free. If you already know you have HIV and are not on treatment, you will get information to 
help your doctor or nurse determine if you are ready to start treatment. If you already know that you are 
HIV positive and you are on HIV treatment, the CD4 and viral load tests can help your nurse or doctor 
judge how well your treatment is working. If you test HIV negative, you will learn about what you can do 
to stay HIV negative.  Your taking part in this research could help us learn more about HIV in Swaziland. It 
can also help us learn about how HIV prevention and treatment programs are working in the country. 
Your taking part is important, and you are invited to participate even if you already know that you are HIV 
negative or positive. 
 
Confidentiality 
We will do everything we can to keep your taking part in the survey and your answers private. The 
information we collect from you will be identified by a number and not by your name. The information 
entered into the tablet will be identified only by the number.  Your name will not appear when we share 
survey results. Only survey staff will have access to the data during the survey.   
 
The following individuals and/or agencies will be able to look at your interview records to help oversee 
the conduct of this survey: 
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▪ Staff members from the Institutional Review Boards or Ethics Committees which oversee the 
conduct of this survey to ensure that we are protecting your rights as a person taking part, the 
staff members include:  
▪ Swaziland Scientific and Ethics Committee (SEC) 
▪ The Centers for Disease Control and Prevention (CDC; Atlanta, USA)  
▪ Columbia University Medical Center 
▪ Westat (a statistical survey research organization). 
▪ The U.S. Office of Human Research Protections may examine the study records to 
ensure we are protecting your rights as a person taking part in this survey. 
▪ Selected survey staff and survey monitors. 
 
This survey has received approval from the Swaziland Scientific and Ethics Committee (SEC), The Centers 
for Disease Control and Prevention, and the Institutional Review Boards of Columbia University Medical 
Center, and of Westat.  
 
The information we collect during the survey will not be released outside of the survey groups listed 
above unless there is an issue of safety. Your permission to allow us to use and share your name and 
contact information with the groups above will expire five years after the end of the survey. You can 
leave the survey at any time for any reason. If you want to leave the survey or if you have any questions 
about the survey or feel that you have been harmed by taking part, you can contact:  
 
Zandile Mnisi 
Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 
If you have any questions about your rights as a person taking part in this survey you can contact: 
 
Babazile Shongwe 
Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 
Do you want to ask me anything about the survey? 
 
Consent Statement 
I have read this form and/or someone has read it to me.  I was encouraged to ask questions and given 
time to ask questions.  Any questions that I had were answered satisfactorily.   I agree to be in this 
survey.  I know that after choosing to be in this survey, I may withdraw at any time.   My taking part is 




1. Make your initial or mark if you agree to take part in the survey interview, ‘YES’ means that you 
agree to participate in the survey interview. ‘NO’ means that you will NOT take part in the 
survey interview.  
        ______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. Make your initial or mark if you agree to give blood for testing, ‘YES’ means that you agree to 
give blood for testing. ‘NO’ means that you will NOT give blood for testing. 
        ______Yes              ______No 
(If “Yes” proceed to the next question) 
 
3. Make your initial or mark if you agree to be contacted for future research, ‘YES’ means that you 
agree to be contacted for future research. ‘NO’ means that you won’t be contacted for future 
research. 
______Yes              ______No 
 
4. Make your initial or mark if you agree to have your leftover blood stored, ‘YES’ means that you 
agree to have these blood samples stored. ‘NO’ means that these blood samples will NOT be 
stored. 
______Yes              ______No 
 
[Tablet summary statement] 
To confirm, you have agreed to <INSERT ALL OPTIONS MARKED YES: INTERVIEW, BLOOD TESTING, FUTURE 
RESEARCH, BLOOD STORAGE>, is this correct? ______Yes              ______No 
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
Printed name of participant________________________________________    
 
[For participants who cannot read and/or write] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
Signature of person obtaining consent________________________________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________    
 
Survey staff SHIMS ID number _________________________________    
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Parent Permission to Interview and Blood Draw 
 
Interviewer reads: 
Now I would like to ask you to let <INSERT NAME OF CHILD 0-17 YEARS FROM HOUSEHOLD LISTING> take 
part in the survey. 
 




___ English  
 
Title of Survey: This survey is called the Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016) 
 
Purpose of the survey 
This survey will help us learn more about the health of children in Swaziland. We plan to ask about four 
thousand children like him/her to join this survey. We would like to invite him/her to join the survey too, 
even if his/her HIV status is already known. His/her taking part will help the Ministry of Health make health 
services better in the country.    
 
Survey Procedures 
[For children ages <18 months old] 
We would like to test your child for HIV. We are doing this for all children in the survey regardless of 
their parent or guardian’s HIV status. A survey staff member, who has been trained to draw blood, will 
take about 5 to 10 drops of blood from your child’s heel into a small tube. The blood will be used to 
perform a test here today to assess whether your child has been exposed to HIV. We will also place a 
few drops of blood onto a card which will be sent to the National Laboratory in Mbabane. If your child 
has been exposed to HIV, the National Laboratory in Mbabane will do a special test appropriate for 
children younger than 18 months old, to confirm if he/she has the HIV infection. If you provide us with 
the name of a health facility, we can send the result there in about 6-8 weeks from now. We will also 
contact you to inform you that the results have been sent to the facility, if you provide us with your 
contact information. You will be able to talk to a doctor or nurse at the facility about the test result.  
If your child tests positive for HIV, we will also send his/her blood to a laboratory for more tests. One of 
these tests will be to measure his/her viral load. Viral load is the amount of HIV in the blood.  If you 
provide us with the name of a health facility, we can send your child’s viral load results there in about 6-
8 weeks from now. Some of your child’s blood will be sent to a laboratory out of the country for some 
additional tests related to HIV because there are no laboratories in Swaziland that can do the tests. If we 
have test results that might guide your child’s care or treatment, we will contact you to tell you how you 
and your child’s doctor or nurse may get these results. 
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We would like to ask your permission to store your child’s leftover blood for future research tests.  
These tests may be about HIV, or other health issues important for the health of people living in 
Swaziland. This sample will be stored for 5-10 years. The sample will not have your child’s name on it 
and so we will not be able to tell you the results of the future research tests. Your child’s leftover blood 
samples will not be sold or used for commercial reasons. If you do not agree to long-term storage of 
your child’s blood samples, your child can still take part in the survey. We will destroy your child’s blood 
samples after survey-related testing has been completed.  
 
Additionally, we would like to ask your permission for your child to take part in possible future research if 
you want to. If you agree, your child’s contact information will be retained by approved researchers and 
you may be contacted for a period of up to 5 years and invited to take part in future research, if you still 
want to. If you do not agree to take part in future research you can still continue to take part in the 
research today.   
 
[For children ages 18 months – 24 months old] 
We would like to test your child for HIV. We are doing this for all children in the survey regardless of 
their parent or guardian’s HIV status. A survey staff member, who has been trained to draw blood, will 
take about 5 to 10 drops of blood from your child’s heel into a small tube and perform an HIV test here 
in your home. We will give you the results and provide counseling about the results on the same day as 
the test.  We will also discuss with you how to share the results with your child if you decide to discuss 
the results with him/her.  The entire testing and counseling session will take about 45 minutes. 
 
For all children who test positive for HIV and some randomly selected children without HIV, we will also 
test the amount of CD4 cells in his/her blood and give you the result on the same day as the test.  CD4 
cells are the part of your immune system that fights HIV infection and other diseases. We will give you a 
referral form and information so that you can consult with a doctor or nurse to learn more about your 
child’s HIV test, CD4 counts, and health. 
 
We will also send his/her blood to a laboratory for more tests. One of these tests will be to measure 
his/her viral load. Viral load is the amount of HIV in the blood.  If you provide us with the name of a 
health facility, we can send your child’s viral load results there in about 6-8 weeks from now. Some of 
your child’s blood will be sent to a laboratory out of the country for some additional tests related to HIV 
because there are no laboratories in Swaziland that can do the tests. If we have test results that might 
guide your child’s care or treatment, we will contact you to tell you how you and your child’s doctor or 
nurse may get these results. 
We would like to ask your permission to store your child’s leftover blood for future research tests.  
These tests may be about HIV, or other health issues important for the health of people living in 
Swaziland. This sample will be stored for 5-10 years. The sample will not have your child’s name on it 
and so we will not be able to tell you the results of the future research tests. Your child’s leftover blood 
samples will not be sold or used for commercial reasons. If you do not agree to long-term storage of 
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your child’s blood samples, your child can still take part in the survey. We will destroy your child’s blood 
samples after survey-related testing has been completed.  
 
Additionally, we would like to ask your permission for your child to take part in possible future research if 
you want to. If you agree, your child’s contact information will be retained by approved researchers and 
you may be contacted for a period of up to 5 years and invited to take part in future research, if you still 
want to. If you do not agree to take part in future research you can still continue to take part in the 
research today.   
 
 
[For children ages 25 months -9 years old] 
We would like to test your child for HIV. We are doing this for all children in the survey regardless of 
their parent or guardian’s HIV status. A survey staff member, who has been trained to draw blood, will 
take about 6 millilitres of blood (a little over a teaspoonful) from your child’s arm into two tubes and 
perform an HIV test here in your home. If it is not possible to take blood from your child’s arm, then we 
will take a few drops of blood from your child’s finger and then perform the HIV test here in your home.  
We will give you the results and provide counseling about the results on the same day as the test.  We 
will also discuss with you how to share the results with your child if you decide to discuss the results 
with him/her.  If you would like, we can discuss the test results together with your child.  The entire 
testing and counseling session will take about 45 minutes. 
 
For all children who test positive for HIV and some randomly selected children without HIV, we will also 
test the amount of CD4 cells in his/her blood and give you the result on the same day as the test.  CD4 
cells are the part of your immune system that fights HIV infection and other diseases. We will give you a 
referral form and information so that you can consult with a doctor or nurse to learn more about your 
child’s HIV test, CD4 counts, and health. 
  
We will also send his/her blood to a laboratory for more tests. One of these tests will be to measure 
his/her viral load. Viral load is the amount of HIV in the blood.  If you provide us with the name of a 
health facility, we can send your child’s viral load results there in about 6-8 weeks from now. Some of 
your child’s blood may be sent to a laboratory out of the country for some additional tests related to HIV 
because there are no laboratories in Swaziland that can do the tests. If we have test results that might 
guide your child’s care or treatment, we will contact you to tell you how you and your child’s doctor or 
nurse may get these results. 
We would like to ask your permission to store your child’s leftover blood for future research tests.  
These tests may be about HIV, or other health issues important for the health of people living in 
Swaziland. This sample will be stored for 5-10 years. The sample will not have your child’s name on it 
and so we will not be able to tell you the results of the future research tests. Your child’s leftover blood 
samples will not be sold or used for commercial reasons. If you do not agree to long term storage of 
your child’s blood samples, your child can still take part in the survey. We will destroy your child’s blood 




Additionally, we would like to ask your permission for your child to take part in possible future research if 
you want to. If you agree, your child’s contact information will be retained by approved researchers and 
you may be contacted for a period of up to 5 years and invited to take part in future research, if you still 
want to. If you do not agree to take part in future research you can still continue to take part in the 
research today.   
 
[For children ages 10-14 years old] 
If both you and your child agree for him/her to join the survey, we will ask your child some questions. The 
interview will be conducted in private with only the child and a survey staff member. The interview will 
include questions about education, HIV prevention and treatment, social behavior, and his/her 
experiences in the household. It will take about 45 minutes.    
 
We would like to test your child for HIV. We are doing this for all children in the survey, whether they 
are sexually active or not. We will test all children regardless of their parent or guardian’s HIV status. A 
survey staff member, who has been trained to draw blood, will take about 6 millilitres of blood (a little 
over a teaspoonful) from your child’s arm into two tubes and perform an HIV test here in your home. If 
it is not possible to take blood from your child’s arm, then we will try to take a few drops of blood from 
your child’s finger and then perform the HIV test here in your home.  We will give you the results and 
provide counseling about the results on the same day as the test.  We will also discuss with you how to 
share the results with your child if you decide to discuss the results with him/her.  If you would like, we 
can discuss the test results together with your child.  The entire testing and counseling session will take 
about 45 minutes. 
For all children who test positive for HIV and some randomly selected children without HIV, we will also 
test the amount of CD4 cells in his/her blood and give you the result on the same day as the test.  CD4 
cells are the part of your immune system that fights HIV infection and other diseases. We will give you a 
referral form and information so that you can consult with a doctor or nurse to learn more about your 
child’s HIV test, CD4 counts, and health. 
  
We will also send his/her blood to a laboratory for other tests. One of these tests will be to measure 
his/her viral load. Viral load is the amount of HIV in the blood.  If you provide us with the name of a 
health facility, we can send your child’s viral load results there in about 6-8 weeks from now. Some of 
your child’s blood may be sent to a laboratory out of the country for some additional tests related to HIV 
because there are no laboratories in Swaziland that can do the tests. If we have test results that might 
guide your child’s care or treatment, we will contact you to tell you how you and your child’s doctor or 
nurse may get these results. 
We would like to ask you and your child’s permission to store your child’s leftover blood for future 
research tests.  These tests may be about HIV, or other health issues important for the health of people 
living in Swaziland. This sample will be stored for 5-10 years. The sample will not have your child’s name 
on it and so we will not be able to tell you the results of the future research tests. Your child’s leftover 
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blood samples will not be sold or used for commercial reasons. If you do not agree to long term storage 
of your child’s blood samples, your child can still take part in the survey. We will destroy your child’s 
blood samples after survey-related testing has been completed.  
 
Additionally, we would like to ask your permission for your child to take part in possible future research if 
you want to. If both you and your child agree, your child’s contact information will be retained by 
approved researchers and you may be contacted for a period of up to 5 years and invited to take part in 
future research, if you still want to. If you do not agree to take part in future research you can still continue 
to take part in the research today.   
  
[Children 15-17 years old] 
If both you and your child agree for him/her to join the survey, we will ask your child some questions. The 
interview will be conducted in private with only the child and a survey staff member. The interview 
questions will be the same as the ones that we ask adults who agree to take part in the survey. The 
questions will be about what kind of work they do, whether they have had any experience with health 
services, and their social and sexual behaviors. It will take about 45 minutes.    
 
We would like to test your child for HIV. We are doing this for all children in the survey, whether they 
are sexually active or not. We will test all children regardless of their parent or guardian’s HIV status. A 
survey staff member, who has been trained to draw blood, will take about 14 millilitres of blood (less 
than 1 tablespoonful) from your child’s arm into two tubes and perform an HIV test here in your home. 
If it is not possible to take blood from your child’s arm, then we will try to take a few drops of blood 
from your child’s finger and then perform the HIV test here in your home.  We will give the results to 
your child and provide counseling about the results on the same day as the test.  We will also discuss 
with him/her how to share the results with you if he/she decides to discuss the results with you. The 
entire testing and counseling session will take about 45 minutes.  
For all children who test positive for HIV and some randomly selected children without HIV, we will also 
test the amount of CD4 cells in his/her blood and give your child the result on the same day as the test.  
CD4 cells are the part of his/her immune system that fights HIV infection and other diseases. We will give 
him/her a referral form and information so that he/she can consult with a doctor or nurse to learn more 
about his/her HIV test, CD4 counts, and health. 
  
We will also send his/her blood to a laboratory for additional tests. One of these tests is to measure 
his/her viral load. Viral load is the amount of HIV in the blood.  If he/she provides us with the name of a 
health facility, we can send his/her viral load results there in about 6-8 weeks from now. Some of your 
child’s blood will be sent to a laboratory out of the country for some additional tests related to HIV 
because there are no laboratories in Swaziland that can do the tests. If we have test results that might 
guide your child’s care or treatment, we will contact him/her to tell him/her how he/she and a doctor or 
nurse at the preferred health facility may get these results. 
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We would like to ask you and your child’s permission to store your child’s leftover blood for future 
research tests.  These tests may be about HIV, or other health issues important for the health of people 
living in Swaziland. This sample will be stored for 5-10 years. The sample will not have your child’s name 
on it and so we will not be able to tell you the results of the future research tests. Your child’s leftover 
blood samples will not be sold or used for commercial reasons. If you do not agree to long term storage 
of your child’s blood samples, your child can still take part in the survey. We will destroy your child’s 
blood samples after survey-related testing has been completed.   
 
Additionally, we would like to ask you and your child’s permission for your child to take part in possible 
future research if you want to. If you agree, your child’s contact information will be retained by approved 
researchers and you may be contacted for a period of up to 5 years and invited to take part in future 
research, if you still want to. If you do not agree to take part in future research you can still continue to 
take part in the research today.   
 
Conditions of the study: Taking part in the survey is voluntary and you or your child will not be given 
money or gifts for taking part. Your child can leave the survey at any time for any reason. If you or your 
child decides to leave the survey, no more information will be collected from you.  However, we will not 
be able to take back the information that has already been collected and shared. 
 
Costs for being in the survey: There is no cost to you or your child for being in the survey, apart from 
your time. 
 
Use of survey findings 
The overall survey findings, which will not contain any personal information that would identify you or 
your child, will be shared with the Government of the Kingdom of Swaziland and Ministry of Health. This 
information will be used to improve health care for the people of Swaziland. Finally, the findings will be 
shared with international partners to assist in the delivery of health services all over the world. 
 
Right to refuse and to withdraw 
It is your decision about whether you will allow us to invite your child to join the survey. Your child does 
not have to be in the survey or give blood. You or your child may stop taking part at any time. If your 
child is in the age group interviewed and does not want to answer some of the questions he/she may 
skip them and move to the next question. If your child does not take part, it will not affect your child’s 
healthcare in any way.   
 
You may agree for your child’s blood to be tested in relation to this survey, but not agree for the blood 
to be stored for future research tests. Your child’s taking part is voluntary. If you or your child decide not 






[For children 10-17] During the interview, your child may feel uncomfortable answering some of the 
questions. We do not wish this to happen, and your child does not have to answer questions he/she 
feels are too personal or that make them feel uncomfortable. 
 
[For all children 0-17] The risks to your child from having his/her blood drawn are very small. They include 
brief pain from the needle stick, bruising, lightheadedness, bleeding and rarely, infection where the 
needle enters the skin.  The survey staff member who will take his/her blood has received training on how 
to draw blood. If he/she has any discomfort or any of the symptoms we’ve mentioned above, please let 
us know, and especially if there is any bleeding or swelling. 
 
[For children 15-17] Your child may learn that he/she is HIV positive. Learning that he/she has HIV may 
cause some emotional and/or psychological distress. He/she will receive counseling on how to cope with 
learning that he/she has HIV.  If he/she tests HIV positive, we will help identify where to go and explain 
the options available for care and treatment. Care and treatment is available at government facilities free 
of charge.  
 
[For children 18 months -14 years] You may learn that your child is HIV positive. Learning that your child 
has HIV may cause you some emotional and/or psychological distress. You will decide when and where 
to give your child the test results. We will provide you with counseling on how to cope with learning that 
your child has HIV. If your child tests HIV positive, we will help you identify where to go and explain the 




[For children 0-14] The main benefit for your child to be in the survey is the chance to learn more about 
his/her health today. If your child tests as part of the survey you will learn his/her HIV status. Some 
children who take part will test HIV positive.  If this happens to your child, the benefit is that you will 
learn his/her HIV-positive status and you will learn where to take your child for HIV services. HIV care 
and treatment provided by government facilities is free of charge.  If you already know that your child is 
HIV positive and he/she is on treatment, the CD4 and viral load tests can help your doctor or nurse judge 
how well the treatment is working.  If your child tests HIV negative, you will learn about what you can do 
to keep your child HIV negative. Your child’s taking part in this research could help us learn more about 
children and HIV in Swaziland. It can also help us learn about how HIV prevention and treatment 
programs are working in the country. You and your child’s taking part is important, even if you already 
know that your child is HIV negative or positive. 
 
[For children 15-17] The main benefit for your child to be in the survey is the chance for your child to 
learn more about his/her health today. If your child tests as part of the survey he/she will learn his/her 
HIV status. Some children who take part will test HIV positive.  If this happens to your child, the benefit 
is that he/she will learn about his/her HIV-positive status and he/she will learn where to go for HIV 
services. HIV care and treatment provided by government facilities is free of charge.  If you or your child 
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already knows that he/she is HIV positive and he/she is on treatment, the CD4 and viral load tests can 
help his/her doctor or nurse judge how well the treatment is working.  If your child tests HIV negative, 
your child will learn about what he/she can do to keep himself/herself HIV negative. Your child’s taking 
part in this research could help us learn more about children and HIV in Swaziland. It can also help us 
learn about how HIV prevention and treatment programs are working in the country. You and your 
child’s taking part is important, even if you already know that your child is HIV negative or positive. 
 
Confidentiality 
We will do everything we can to keep your child’s taking part in the survey confidential. The information 
we collect from you and your child in this computer will be identified by a number and not by your name 
or your child’s name.  Your child’s name and other personal information will be stored in a confidential 
manner, accessible only by survey staff. Your name and your child’s name will not appear when we 
share survey results. Only survey staff will have access to the data during the survey. However, in 
accordance with the Children’s Protection and Welfare Act, we are required to report any instances of 
children in imminent danger to the appropriate authority. 
 
[For children 10-17] Your child may choose to tell you about the interview but he/she does not have to 
do this. We will not be sharing with you responses given by your child.  
 
The following individuals and/or agencies will be able to look at your interview records to help oversee 
the conduct of this survey: 
▪ Staff members from the Institutional Review Boards or Ethics Committees which oversee the 
conduct of this survey to ensure that we are protecting your rights as a person taking part, the 
staff members include:  
▪ Swaziland Scientific and Ethics Committee (SEC) 
▪ The Centers for Disease Control and Prevention (CDC; Atlanta, USA)  
▪ Columbia University Medical Center 
▪ Westat (a statistical survey research organization). 
▪ The U.S. Office of Human Research Protections may examine the study records to ensure we are 
protecting your rights as a person taking part in this survey. 
▪ Selected survey staff and survey monitors. 
 
This survey has received approval from the Swaziland Scientific and Ethics Committee (SEC), The Centers 
for Disease Control and Prevention, and the Institutional Review Boards of Columbia University Medical 
Center, and of Westat.  
 
The information we collect during the survey will not be released outside of the survey groups listed 
above unless there is an issue of safety. Your permission to allow us to use and share your name and 
contact information with the groups above will expire five years after the end of the survey. You can 
leave the survey at any time for any reason. If you want to leave the survey or if you have any questions 





Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 
If you have any questions about your rights as a person taking part in this survey you can contact: 
 
Babazile Shongwe 
Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 
Do you want to ask me anything about the survey? 
 
Consent Statement 
I have read this form, and someone has read it to me.  I was encouraged to ask questions and given time 
to ask questions.  Any questions that I had were answered satisfactorily.  I agree for my child to take part 
in this survey.  I know that after allowing my child to take part I may change my mind and withdraw 
him/her from taking part in this survey at any time. I have been offered a copy of this consent form. 
 
 
[For children 10-17] I agree to allow you to ask my child to be in this survey.  I know that after allowing 
my child to decide whether he/she wants to be in this survey, he/she may withdraw at any time. His/her 
taking part is voluntary. 
 
[For children 0-10] I agree for my child to be in this survey.  I know that after allowing my child to be in 
this survey, I may withdraw him/her at any time. Taking part is voluntary. 
 
 
1. [For children 10-17] Make your initial or mark if you agree that we can approach your child to ask 
that he/she do the interview, ‘YES’ means that you give your permission to have the survey staff 
ask your child to take part in the interview, and to participate if the child agrees. ‘NO’ means that 
you will NOT give permission for your child to be interviewed.  
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. [For children 10-17 years] Make your initial or mark if you agree that we can approach your child 
to give blood for HIV testing and related testing, ‘YES’ means that you give your permission to 
have the trained survey staff to ask your child to collect a sample of your child’s blood for HIV and 
related testing, and to collect the blood and perform the tests if the child agrees. ‘NO’ means that 
your child will NOT give blood for HIV testing and related testing.  
______Yes              ______No 




3. [For children 0-9 years] Make your initial or mark if you agree that your child give blood for HIV 
testing and related testing, ‘YES’ means that you give your permission to have the trained survey 
staff collect a sample of your child’s blood for HIV and related testing. ‘NO’ means that your 
child will NOT give blood for HIV testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
4. [For children 10-17 years] Make your initial or mark if you agree to allow us to ask your child to 
have his/her leftover blood stored for future research, ‘YES’ means that you give permission for 
us to ask your child to allow us store leftover blood samples for future research, and to store it 
if the child agrees. ‘NO’ means that your child’s blood samples will NOT be stored for future 
research.  
______Yes              ______No 
 
5. [For children 0-9 years] Make your initial or mark if you agree to have your child’s leftover blood 
stored for future research, ‘YES’ means that you give permission for your child’s leftover blood 
samples to be stored for future research. ‘NO’ means that your child’s blood samples will NOT 
be stored for future research.  
______Yes              ______No 
 
Parent Permission to Interview and Blood Draw 
 
6. [For children 10-17 years] Make your initial or mark if you agree to allow us to ask your child to 
retain his/her contact information for future research, ‘YES’ means that you give permission for 
us to ask your child to allow us to retain his/her contact information for future research, and to 
retain the information if the child agrees. ‘NO’ means that your child’s contact information will 
NOT be retained for future research.  
______Yes              ______No 
 
7. [For children 0-9 years] Make your initial or mark if you agree to have your child’s contact 
information retained for future research, ‘YES’ means that you give permission for your child’s 
contact information to be retained for future research. ‘NO’ means that your child’s contact 
information will NOT be retained for future research. 
______Yes              ______No 
 
To confirm, you have agreed to <INSERT ALL OPTIONS MARKED YES: APPROACH CHILD FOR INTERVIEW, 
APPROACH CHILD FOR BLOOD TESTING, CHILD INTERVIEW, CHILD BLOOD TEST, APPROACH CHILD FOR 
BLOOD STORAGE, CHILD BLOOD STORAGE, APPROACH CHILD FOR STORAGE CONTACT INFORMATION, 




Parent/guardian signature or mark_____________________________________ Date: ___/___/___            
Printed name of parent/guardian________________________________________    
 
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
Signature of person obtaining consent_______________________________ Date: ___/___/___          
Printed name of person obtaining consent____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 





Adolescent Assent for Interview and Blood Draw 
 
What language do you prefer for our discussion today?    ___siSwati     ___ English  
 




Hello. My name is___________. I would like to invite you to take part in a research survey. Surveys help 
us learn new things. As a part of this research survey, we are asking people questions about themselves 
and also giving people a chance to learn if they have HIV.  We are inviting people to participate even if 
they already know they have HIV or they don’t. We are also asking people if we can keep some of their 
blood for future testing.  
 
This form talks about our survey and the choice that you have to take part in it. We want you to ask us 
any questions that you have.  You can ask questions any time.  
 
Why are we doing this survey?  
We are doing this survey to help us learn more about the health of children in Swaziland. We plan to ask 
thousands of children like you to join this survey.  A survey is a way to learn about something by 
interviewing and testing many people. We would like to invite you to join this survey.  
 
[Exclude for child with special circumstances] 
Your parent/guardian said it was okay for us to ask you to join. 
 
This form might have some words that you may not have heard before. Please ask me to explain 
anything that you do not understand. 
 
What would happen if you join this survey? 
If you decide to join the survey, here is what would happen: 
 
• We will ask you questions about your age, what you know about HIV, and whether you have 
experience with behavior that may put you at risk of HIV.  
• The interview will take place in private here in your house or an area around your house.   
• The interview will take about 45 minutes. 
• After we ask you the questions, if you have agreed, we will take some of your blood to test 
for HIV and to store for future research tests. 
• [Children 10-14] We will use a needle to take about 6 millilitres of blood (a little over a 
teaspoonful) from your arm into two tubes. If it’s not possible to take blood from your arm, 
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then we will try to take a few drops of blood from your finger. Then we will test your blood 
for HIV here in your home. 
• [Children 15-17] We will use a needle to take about 14 millilitres of blood (less than a 
tablespoonful) from your arm into two tubes. If it’s not possible to take blood from your 
arm, then we will try to take a few drops of blood from your finger. Then we will test your 
blood for HIV here in your home.  
• It will take about 45 minutes to do the test and to talk to you about the results.  
• If you have HIV, we will measure how well your body can fight HIV and other infections. We 
can do this test here in your home. We will also measure this in the blood of some people 
without HIV. This is known as CD4+. 
• If you test positive for HIV, we will send your blood to the National Laboratory in Mbabane 
to measure the amount of HIV in your blood. Some of your blood will be sent to a laboratory 
out of the country for some additional tests related to HIV because there are no laboratories 
in Swaziland that can do these tests. 
• You may be eligible to take part in future studies related to health in Swaziland. We are 
asking for your permission to contact you in the next five years if such an opportunity 
occurs. To do this, approved researchers will be able to request access to your contact 
information.  If we contact you, we will give you details about the new study and ask you to 
sign a separate assent/consent form at that time. You may decide at that time that you do 
not want to take part in that study. If you do not wish to be contacted about future studies, 
it does not affect your taking part in this survey.  
• We will ask you if we can store some of your blood for future testing. These tests will help us 
learn about the health of people in Swaziland. This sample will be stored for 5-10 years. 
Your leftover blood will not be used for anything other than these tests. Your blood will not 
be sold. If you do not agree to future storage and testing of your blood, we will destroy your 
blood after survey related testing has finished and you can still receive your test results and 
conduct the survey interview.  
 
Could bad things happen if you join this survey?  
You may feel uncomfortable answering some of the questions we will ask. You can refuse to answer any 
question at any time and we will stop.   
 
The needle may hurt when it is put into and taken out of your arm. This pain will go away quickly.  
Sometimes the needle can leave a bruise on the skin.  You might bleed a little or feel a little dizzy 
afterwards.  Rarely, an infection might occur where the needle enters the skin.  We may have to try 
more than one time in order to get the right amount of blood.  We will do our best to make it as painless 




We will test for HIV and you may learn that you have HIV. Learning that you have HIV may cause you to 
feel worried. We will talk to you to support you through this situation. What we talk about we will not 
tell anyone else but there is a small chance other people might find out. 
 
Could the survey help me? 
You may not get anything yourself by being in the survey. But you may help us figure out ways to help 
other children and learn more about HIV in Swaziland. Your taking part is important, even if you already 
know that you have HIV or you don’t have HIV. 
 
[For children 10-14 years] 
Being in the survey may help you by learning whether or not you have HIV.  We would give your results 
to your parent/guardian and you can talk to him/her about your test result.  If your parent wants us to 
tell you about your test results, we would talk with you about any questions that you might have about 
the results.  If you are HIV positive, we will tell your parent/guardian where to take you for your medical 
care and the Government of Swaziland will pay for your care. We hope to learn about HIV health care 
needs in this survey. And we hope it will help other children in Swaziland in the future.  
[For children with special circumstances 12-14] 
Being in the survey may help you by learning whether or not you have HIV.  We would give your results 
to you and help you to share them with a person of your choice who can support you. We would talk 
with you about any questions that you might have about the results.  If you are HIV positive, we will tell 
you where you can go for your medical care and the Government of Swaziland will pay for your care. We 
hope to learn about HIV health care needs in this survey. And we hope it will help other children in 
Swaziland in the future.  
[For children 15-17 years] 
Being in the survey may help you by learning whether or not you have HIV. We will give you your results 
of your HIV test and provide counseling to you and discuss with you how to share these results with your 
parent/guardian, if you decide to. If you test positive for HIV, you will learn about it and you will learn 
where to go for care and treatment of HIV. Care and treatment provided by the Government of 
Swaziland is free. If you already know you have HIV and are not on treatment, you will get information 
to help your doctor/nurse determine if you are ready to start treatment.  If you already know that you 
have HIV and you are on HIV treatment, the tests may help your doctor/nurse judge how well your 
treatment is working. If you test negative for HIV, you will learn about what you can do to stay that way.  
Your taking part in this survey is important, even if you already know your HIV status as it will help us 
learn more about HIV in Swaziland. 
Conditions of the study: Taking part in the survey is voluntary and you will not be given money or gifts 
for your taking part. You can leave the survey at any time for any reason. If you decide to leave the 
survey, no more information will be collected from you.  However, we will not be able to take back the 
information that has already been collected and shared. 
  




Use of survey findings 
The overall survey findings, which will not contain any personal information that would identify you, will 
be shared with the Government of the Kingdom of Swaziland and the Ministry of Health. This information 
will be used to improve the health care for the people of Swaziland. The findings will also be shared with 
international partners to assist in the delivery of health services all over the world. 
 
What else should you know about this survey? 
If you don’t want to be in the survey study, you don’t have to be. Nobody will get upset with you if you 
do not want to join the survey. 
It is also OK to say ‘Yes’ and change your mind later.  You can stop being in the survey at any time.  If you 
want to stop, please tell us.  
 
Confidentiality  
[For children 15-17, children with special circumstances 12-14] We will do everything we can to keep 
your test results confidential. The blood we collect from you will be identified by a number, not by your 
name. Besides you, no one else will know your test results except the people working on the survey and 
people you decide to tell. 
 
[For children 10-14] We will do everything we can to keep your test results confidential. The blood we 
collect from you will be identified by a number, not by your name. Besides you and your 
guardian/parent, no one else will know your test results except the people working on the survey. 
 
We will not tell other people that you are in this survey and will not share information about you to anyone 
who does not work in the survey. Any information about you will have a number on it instead of your 
name. Only selected survey staff will have access to the information we collect during the survey.   
 
  The following individuals and/or agencies will be able to look at your research records: 
▪ Survey staff collecting data and monitoring data quality. 
▪ Staff members analyzing data within Swaziland and internationally. 
▪ Staff members from groups that protect your rights as a person taking part in a survey who 
check that we are protecting your rights like the Swaziland Scientific and Ethics Committee (SEC) 
and similar agencies in the United States of America.  
 
This survey has been approved by committees that protect your rights in Swaziland and internationally. 
 
Is there anything else? 
If you want to be to take part in the survey after we finish talking now, please write your name below.  
We will write our name too. This shows we talked about the survey and that you want to take part. 
 






Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 
 
If you have any questions about your rights as a person taking part in this survey you can contact: 
 
Babazile Shongwe 
Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 
Do you want to ask me anything about: 
• The interview? 
• Taking your blood for HIV testing? 
• Testing in the laboratory? 
• Storage of blood for future research testing? 
 
Assent statement 
I have read this form, or someone has read it to me.  I was encouraged to ask questions and given time 
to ask questions.  Any questions that I had were answered satisfactorily.  I agree to be in this survey.  I 
know that after choosing to be in this survey, I may withdraw at any time.   My taking part is voluntary. I 
have been offered a copy of this consent form. 
 
1. Do you agree to do the interview? ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. [For children 10-14] Make your initial or mark if you agree to give blood for testing and have 
your parent/guardian receive your result, ‘YES’ means that you agree to give blood for testing. 
‘NO’ means that you will NOT give blood for testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
3. [For children 15-17, children with special circumstances 12-14] Make your initial or mark if you 
agree to give blood for testing, ‘YES’ means that you agree to give blood for testing and receive 
your results. ‘NO’ means that you will NOT give blood for testing. 
______Yes              ______No 




4. Make your initial or mark if you agree to have your leftover blood stored, ‘YES’ means that you 
agree to have these blood samples stored. ‘NO’ means that these blood samples will NOT be 
stored. 
______Yes              ______No 
 
5. Do you agree to be contacted in the future? ‘YES’ means that you agree to be contacted in the 
future if a study opportunity arises. ‘NO’ means that you will NOT be contacted about future 
studies.  
________YES  ________NO 
 
[Tablet summary statement] 
To confirm, you have agreed to <INSERT ALL OPTIONS MARKED YES: INTERVIEW, BLOOD TESTING AND 
RESULT TO PARENT (10-14YEARS), BLOOD TESTING AND RESULT TO YOU (15-17 YEARS, CHILDREN WITH 
SPECIAL CIRCUMSTANCES 12-14), CHILD INTERVIEW, FUTURE RESEARCH, BLOOD STORAGE>, is this 
correct? ______Yes              ______No 
 
 
Child signature or mark_______________________________ Date: ___/___/___            
Printed name of child ________________________________________    
Printed name of parent/guardian_____________________________ 
[For illiterate participants or parents/guardians] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining consent_____________________ __________ Date: ___/___/___          
Printed name of person obtaining consent____________________________    
 







Household Interview Consent: Child with Special Circumstances 
 




Hello. My name is___________. I would like to invite you to take part in a research survey. Surveys help 
us learn new things. As a part of this research survey, we are asking people questions about themselves 
and also giving people a chance to learn if they have HIV. We are inviting people to participate even if they 
already know they have HIV or they don’t. The Government of the Kingdom of Swaziland is leading this 
survey, in partnership with the United States government.  
 
What language do you prefer for our discussion today? 
 
___siSwati         ___ English  
 
Title of Survey: Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016) 
  
Purpose of survey 
This survey will help us to know how many people in Swaziland are living with HIV and need health 
services. About 6,000 households will join this survey. We would like your household to join the survey 
too, even if people in the household already know their HIV status. What you tell us will help make 
health services better in the country. 
 
This form might have some words that you may not have heard before. Please ask me to explain 
anything that you do not understand. You can ask questions at any time.  
 
Survey Procedures 
If you join this survey, we will ask you questions and your answers will be kept between us. There are two 
parts to this survey– a household interview and individual interviews.  In the household interview, we 
would like to ask you some questions about the people living in your household.  We will ask how many 
people live here, their relationship to you and to each other, their gender, and age. We will ask you about 
people who are ill or recently died in your household.  We will also ask you about some of the things you 
have in your household. The household interview will take up to 45 minutes.    
After completing the household interview, we would begin the individual interviews. We would like to 
invite you and others living in your household to take part in the second part of this survey. We will ask 
each person to give his or her written permission to take part before joining the survey. 
Costs for being in the survey:  There is no cost to you for being in the household interview, except for 




Right to refuse or withdraw 
If you don’t want to be in the survey study, you don’t have to be. Nobody will get upset with you if you 
do not want to join the survey. 
It is also OK to say ‘Yes’ and change your mind later.  You can stop being in the survey at any time.  If you 
want to stop, please tell us.   
 
Risks 
The risks to taking part in the household interview are small.  You may feel uncomfortable about some of 
the questions we will ask.  You can refuse to answer any question you do not want to answer.   
 
Benefits  
The benefit in taking part is that the information you provide to us will be used to improve health care 
services in the country.  
 
Alternatives to taking part  
You have a choice not to take part in this survey. 
 
Confidentiality 
We will not tell other people that you are in this survey and will not share information about you to anyone 
who does not work in the survey. Any information about you will have a number on it instead of your 
name. Only selected survey staff will have access to the information we collect during the survey.   
 
  The following individuals and/or agencies will be able to look at your research records: 
▪ Survey staff collecting data and monitoring data quality. 
▪ Staff members analyzing data within Swaziland and internationally. 
▪ Staff members from groups that protect your rights as a person taking part in a survey who 
check that we are protecting your rights like the Swaziland Scientific and Ethics Committee (SEC) 
and similar agencies in the United States of America.  
 
This survey has been approved by committees that protect your rights in Swaziland and internationally. 
 




Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 
If you have any questions about your rights as a person taking part in this survey you can contact: 
 
Babazile Shongwe 
Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 





I have read this form or someone has read it to me.  I was encouraged to ask questions and given time 
to ask questions.  Any questions that I had were answered satisfactorily.  I agree to take part in the 
household  
 
Household Interview Consent: Child with Special Circumstances 
 
interview.  I know that after choosing to be in the interview, I may withdraw at any time.   My taking 
part is voluntary.  I have been offered a copy of this consent form. 
 
Make your signature or mark if you agree to do the household interview 
Head of household signature or mark________________________________ Date: ___/___/___            
Printed name of head of household_________________________________ 
Household Listing ID number ____________________________    
 
[For participants who cannot read and/or write] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________   




Permission to Interview and Blood Draw Children: Child with Special Circumstances 
 
What language do you prefer for our discussion today?    ___siSwati     ___ English  
 
Title of Survey: This survey is called the Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016) 
 
Interviewer reads: 
Now I would like to ask you to let <INSERT NAME OF CHILD 0-17 YEARS FROM HOUSEHOLD LISTING> take 
part in the survey. 
 
Purpose of the survey 
This survey will help us learn more about the health of children in Swaziland. We plan to ask thousands of 
children like him/her to join this survey. We would like to invite him/her to join the survey too, even if 
you already know that <INSERT NAME OF CHILD 0-17 YEARS FROM HOUSEHOLD LISTING> is HIV positive 
or negative. His/her taking part will help the Ministry of Health make health services better in the country.   
 
Why are we doing this survey?  
We are doing this survey to help us learn more about the health of children in Swaziland.  A survey is a 
way to learn about something by interviewing and testing many people. We would like to invite your 
child to join this survey.  
 
This form might have some words that you may not have heard before. Please ask me to explain 
anything that you do not understand. 
 
What would happen if <INSERT NAME OF CHILD UNDER 18 months> joins this survey? 
If you decide to let this child join the survey, here is what would happen: 
 
• We will take about 5 to 10 drops of blood from his/her heel into a small tube. We shall 
perform a test here today to check if your child has been exposed to HIV.  
• A few drops of blood from the tube will be placed on a card and sent to the National 
Laboratory in Mbabane for a special test to determine if your child has an HIV infection. 
• If he/she tests positive for HIV, we will measure the amount of HIV in his/her blood. Some of 
his/her blood will be sent to a laboratory out of the country for some additional tests 
related to HIV because there are no laboratories in Swaziland that can do these tests.  
• We will ask you if we can store some of his/her blood for future testing. These tests will help 
us learn about the health of people in Swaziland. This sample will be stored for 5-10 years. 
His/her leftover blood will not be used for anything other than these tests. This blood will 
not be sold. If you do not agree to future storage and testing of his/her blood, your child can 
still take part in the survey today.  After survey related testing and informing you of the 





• He/she may be eligible to take part in future studies related to health in Swaziland. We are 
asking for your permission to contact you in the next five years if such an opportunity 
occurs. In order to do this, approved researchers will be able to request access to your 
contact information.  If we contact  
you, we will provide details about the new study and ask you to sign a separate consent 
form at that time. You may decide at that time not to take part in that study. If you do not 
wish to be contacted about future studies, it does not affect your taking part in this survey. 
 
What would happen if <INSERT NAME OF CHILD 18-24 months> joins this survey? 
If you decide to let this child join the survey, here is what would happen: 
 
• We will take about 5 to 10 drops of blood from his/her heel into a small tube. Then we will 
test his/her blood for HIV here in your home.     
• It will take about 30 minutes to do the test and to talk to you about the results.  
• If he/she has HIV, we will measure how well his/her body can fight HIV and other infections. 
We can do this test here in your home. We will also measure this in the blood of some 
children without HIV. This is known as CD4+.  
• If he/she tests positive for HIV, we will send his/her blood to the National Laboratory in 
Mbabane to measure the amount of HIV in his/her blood. Some of his/her blood will be sent 
to a laboratory out of the country for some additional tests related to HIV because there are 
no laboratories in Swaziland that can do these tests. 
• We will ask you if we can store some of his/her blood for future testing. These tests will help 
us learn about the health of people in Swaziland. This sample will be stored for 5-10 years. 
His/her leftover blood will not be used for anything other than these tests. This blood will 
not be sold. If you do not agree to future storage and testing of his/her blood, your child can 
still take part in the survey today. After survey related testing and informing you of the 
result, we will destroy his/her blood sample. 
• He/she may be eligible to take part in future studies related to health in Swaziland. We are 
asking for your permission to contact you in the next five years if such an opportunity 
occurs. In order to do this, approved researchers will be able to request access to your 
contact information.  If we contact you, we will provide details about the new study and ask 
you to sign a separate assent/consent form at that time. You may decide at that time not to 
take part in that study. If you do not wish to be contacted about future studies, it does not 
affect your taking part in this survey. 
 
What would happen if <INSERT NAME OF CHILD 25 months -9 YEARS> joins this survey? 
If you decide to let this child join the survey, here is what would happen: 
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• We will use a needle to take about 6 millilitres of blood (a little over a teaspoonful) from 
his/her arm into two tubes. If it’s not possible to take blood from his/her arm, then we will 
try to take a few drops of blood from his/her finger. Then we will test his/her blood for HIV 
here in your home.     
• It will take about 30 minutes to do the test and to talk to you about the results.  
• If he/she has HIV, we will measure how well his/her body can fight HIV and other infections. 
We can do this test here in your home. We will also measure this in the blood of some 
children without HIV. This is known as CD4+.  
• If he/she tests positive for HIV, we will send his/her blood to the National Laboratory in 
Mbabane to measure the amount of HIV in his/her blood. Some of his/her blood will be sent 
to a laboratory out of the country for some additional tests related to HIV because there are 
no laboratories in Swaziland that can do these tests. 
• We will ask you if we can store some of his/her blood for future testing. These tests will help 
us learn about the health of people in Swaziland. This sample will be stored for 5-10 years. 
His/her leftover blood will not be used for anything other than these tests. This blood will 
not be sold. If you do not agree to future storage and testing of his/her blood, your child can 
still take part in the survey today. After survey related testing and informing you of the 
result, we will destroy his/her blood sample. 
• He/she may be eligible to take part in future studies related to health in Swaziland. We are 
asking for your permission to contact you in the next five years if such an opportunity 
occurs. In order to do this, approved researchers will be able to request access to your 
contact information.  If we contact you, we will provide details about the new study and ask 
you to sign a separate assent/consent form at that time. You may decide at that time not to 
take part in that study. If you do not wish to be contacted about future studies, it does not 
affect your taking part in this survey. 
 
What would happen if <INSERT NAME OF CHILD 10-17 YEARS> joins this survey? 
If you decide to let this child join the survey, here is what would happen: 
• We will ask him/her questions about his/her age, what he/she knows about HIV, and 
whether he/she has experience with behavior that may put them at risk of HIV.  
• The interview will take place in private here in your house or an area around your house.   
• The interview will take about 30 minutes. 
• After we ask him/her the questions, if he/she has agreed, we will take some of his/her blood 
to test for HIV and to store for future research surveys. 
• [Children 10-14 years] We will use a needle to take about 6 millilitres of blood (less than a 
tablespoonful) from his/her arm into two tubes. If it’s not possible to take blood from 
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his/her arm, then we will try to take a few drops of blood from his/her finger. Then we will 
test his/her blood for HIV here in your home.     
• [Children 15-17 years] We will use a needle to take about 14 millilitres of blood (less than a 
tablespoonful) from his/her arm into two tubes. If it’s not possible to take blood from 
his/her arm, then we will try to take a few drops of blood from his/her finger. Then we will 
test his/her blood for HIV here in your home.     
• [Children 10-14 years] It will take about 30 minutes to do the test and to talk to you about 
the results.  
• [Children 15-17 years] It will take about 30 minutes to do the test and to talk to him/her 
about the results.  
• If he/she has HIV, we will measure how well his/her body can fight HIV and other infections. 
We can do this test here in your home. We will also measure this in the blood of some 
people without HIV. This is known as CD4+.  
• If he/she tests positive for HIV, we will send his/her blood to the National Laboratory in 
Mbabane to measure the amount of HIV in his/her blood. Some of his/her blood will be sent 
to a laboratory out of the country for some additional tests related to HIV because there are 
no laboratories in Swaziland that can do these tests. 
• We will ask him/her if we can store some of his/her blood for future testing. These tests will 
help us learn about the health of people in Swaziland. This sample will be stored for 5-10 
years. His/her leftover blood will not be used for anything other than these tests. This blood 
will not be sold. If you or your child do not agree to future storage and testing of his/her 
blood, your child can still take part in the survey today. After survey related testing and 
informing you of the result, we will destroy his/her blood sample. 
• He/she may be eligible to take part in future studies related to health in Swaziland. We are 
asking for both your permission and his/her permission to contact you or him/her in the 
next five years if such an opportunity occurs. In order to do this, approved researchers will 
be able to request access to your contact information.  If we contact you or him/her, we will 
provide details about the new study and ask you or him/her to sign a separate 
assent/consent form at that time. You or he/she may decide at that time not to take part in 
that study. If you or he/she do not wish to be contacted about future studies, it does not 
affect your taking part in this survey. 
 
Could bad things happen if he/she joins this survey?  
[For children 0 to 24 months] The needle may hurt when it is put into and taken out of his/her finger or 
heel and the child may cry. This pain will go away quickly.  Sometimes the needle can leave a bruise on 
the skin.  Very rarely, an infection might occur where the needle enters the skin.  We may have to try 
more than one time in order to get the right amount of blood.  We will do our best to make it as painless 




Learning that this child has HIV may cause you to feel worried. We will talk to you to support you 
through this situation. We will not tell anyone else what we talk about but there is a small chance other 
people might find out. 
 
 [For children 25 months-9 years] The needle may hurt when it is put into and taken out of his/her arm 
or finger and the child may cry. This pain will go away quickly.  Sometimes the needle can leave a bruise 
on the skin.  Rarely, an infection might occur where the needle enters the skin.  We may have to try 
more than one time in order to get the right amount of blood.  We will do our best to make it as painless 
as possible.    
 
Learning that this child has HIV may cause you to feel worried. We will talk to you to support you 
through this situation. We will not tell anyone else what we talk about but there is a small chance other 
people might find out. 
 
[For children 10-17] He/she may feel uncomfortable answering some of the questions we will ask. 
He/she can refuse to answer any question and we will skip that question.    
 
The needle may hurt when it is put into and taken out of his/her arm. This pain will go away quickly.  
Sometimes the needle can leave a bruise on the skin.  He/she might bleed a little or feel a little dizzy 
afterwards.  Rarely, an infection might occur where the needle enters the skin.  We may have to try 
more than one time in order to get the right amount of blood.  We will do our best to make it as painless 
as possible.    
 
We will test for HIV and you and he/she may learn that he/she has HIV. Learning that he/she has HIV 
may cause you and him/her to feel worried. We will talk to you and him/her and try to make you and 
him/her understand the situation and how to handle it. We will not tell anyone else what we talk about 
but there is a small chance other people might find out. 
 
Could the survey help him/her? 
He/she may not get anything himself/herself by being in the survey. But he/she may help us figure out 
ways to help other children and learn more about HIV in Swaziland. His/her taking part is important. 
 
[For children 0-14 years] 
Being in the survey may help you by learning whether or not this child has HIV.  We would give his/her 
results to you and you can talk to him/her about his/her test result.  If you want to tell him/her about 
his/her test results, we would talk with you and/or him/her about any questions that you and/or he/she 
might have about the results.  If he/she is HIV positive, we will tell you where to take him/her for his/her 
medical care and the Government of Swaziland will pay for his/her care. Children can participate in the 
survey whether it is known that they have HIV or not. We hope to learn about HIV health care needs in 




[For children 15-17 years] 
Being in the survey may help him/her by learning whether or not he/she has HIV. We will give him/her 
the results of his/her HIV test and provide counseling to him/her and discuss with him/her how to share 
these results with you, if he/she decides to. If he/she tests positive for HIV, he/she will learn about it 
and he/she will learn where to go for care and treatment of HIV. Care and treatment provided by the 
Government of Swaziland is free. If he/she already knows he/she has HIV and are not on treatment, 
he/she will get information to help his/her doctor/nurse determine if he/she is ready to start treatment.  
If he/she already knows that he/she has HIV and he/she is on HIV treatment, the tests may help his/her 
doctor/nurse judge how well his/her treatment is working. If he/she test negative for HIV, he/she will 
learn about what he/she can do to stay that way.  Children can participate in the survey whether it is 
known that they have HIV or not. His/her taking part in this survey will help us learn more about HIV in 
Swaziland.  
Conditions of the study: Taking part in the survey is voluntary and he/she will not be given money or 
gifts for his/her taking part. He/she can leave the survey at any time for any reason. If he/she decides to 
leave the survey, no more information will be collected from him/her.  However, we will not be able to 
take back the information that has already been collected and shared.   
  
Costs for being in the survey: There is no cost to you or to him/her for being in the survey, apart from 
your and his/her time. 
 
Use of survey findings 
The overall survey findings, which will not contain any personal information that would identify him/her, 
will be shared with the Government of the Kingdom of Swaziland and the Ministry of Health. This 
information will be used to improve the health care for the people of Swaziland. The findings will also be 
shared with international partners to assist in the delivery of health services all over the world. 
 
What else should you know about this survey? 
If you don’t want this child to be in the survey, he/she doesn’t have to be. Also, if he/she doesn’t want 
to be in the survey, he/she doesn’t have to be. Nobody will get upset with you or him/her if he/she 
doesn’t join the survey. 
It is also OK to say ‘Yes’ and change your mind later.  You can stop him/her being in the survey at any 
time.  If you want to stop, please tell us.  
Confidentiality  
[For children 15-17] We will do everything we can to keep his/her test results confidential. The blood we 
collect from him/her will be identified by a number, not by his/her name. Besides him/her, no one else 
will know his/her test results except the people working on the survey and people he/she decides to tell. 
 
[For children 0-14] We will do everything we can to keep his/her test results confidential. The blood we 
collect from him/her will be identified by a number, not by his/her name. Besides you and him/her, no 




We will not tell other people that he/she is in this survey and will not share information about him/her 
with anyone who does not work in the survey. Any information about him/her will have a number on it 
instead of his/her name. Only selected survey staff will have access to the information we collect during 
the survey.  However, in accordance with the Children’s Protection and Welfare Act, we are required to 
report any instances of children in imminent danger to the appropriate authority. 
 
  The following individuals and/or agencies will be able to look at his/her research records: 
▪ Survey staff collecting data and monitoring data quality. 
▪ Staff members analyzing data within Swaziland and internationally. 
▪ Staff members from groups that protect your rights as a person taking part in a survey who 
check that we are protecting your rights like the Swaziland Scientific and Ethics Committee (SEC) 
and similar agencies in the United States of America.  
 
This survey has been approved by committees that protect your rights in Swaziland and internationally. 
 
Is there anything else? 
 
If you want this child to take part in this survey after we finish talking now, please write your name 
below.  We will write our name too. This shows we talked about the survey and that you allow <INSERT 
NAME OF CHILD 0-17 YEARS FROM HOUSEHOLD LISTING> to take part. 
 
If you have any questions about the survey or feel that you or this child have been harmed by taking 
part, you can contact:  
 
Zandile Mnisi 
Address: Ministry of Health, PO Box 5, Mbabane, Swaziland. 
Office Phone: +268 2404 4905  Mobile Phone: +268 7872 1846 
Email: zandimnisi@gmail.com  
 
If you have any questions about your rights as a person taking part in this survey you can contact: 
 
Babazile Shongwe 
Address: Swaziland Scientific and Ethics Committee, P.O Box 5, Mbabane, Swaziland 
Office Phone: +268 2404 0865   Mobile Phone: +268 7872 1863 
Email: babazileshongwe@gmail.com  
 
Do you want to ask me anything about: 
• [Children 10-17 years] The interview?  
• Drawing blood for HIV testing? 
• Testing in the laboratory? 






I have read this form, or someone has read it to me.  I was encouraged to ask questions and given time 
to ask questions.  Any questions that I had were answered satisfactorily.  I agree for this child to be in 
this survey.  I know that after allowing this child to be in this survey, I may withdraw this child at any 
time.   This child’s taking part is voluntary. I have been offered a copy of this consent form. 
 
1. [For children 10-17] Make your initial or mark if you agree that we can approach your child to ask 
that he/she do the interview, ‘YES’ means that you give your permission to have the survey staff 
ask your child to take part in the interview, and to participate if the child agrees. ‘NO’ means that 
you will NOT give permission for your child to be interviewed.  
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. [For children 10-17 years] Make your initial or mark if you agree that we can approach your child 
to give blood for HIV testing and related testing, ‘YES’ means that you give your permission to 
have the trained survey staff to ask your child to collect a sample of your child’s blood for HIV and 
related testing, and to collect the blood and perform the tests if the child agrees. ‘NO’ means that 
your child will NOT give blood for HIV testing and related testing.  
______Yes              ______No 
 
(If “Yes” proceed to the next question) 
 
3. [For children 0-9 years] Make your initial or mark if you agree that your child give blood for HIV 
testing and related testing, ‘YES’ means that you give your permission to have the trained survey 
staff collect a sample of your child’s blood for HIV and related testing. ‘NO’ means that your child 
will NOT give blood for HIV testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
4. [For children 10-17 years] Make your initial or mark if you agree to allow us to ask your child to 
have his/her leftover blood stored for future research, ‘YES’ means that you give permission for 
us to ask your child to allow us store leftover blood samples for future research, and to store it if 
the child agrees. ‘NO’ means that your child’s blood samples will NOT be stored for future 
research.  
______Yes              ______No 
 
5. [For children 0-9 years] Make your initial or mark if you agree to have your child’s leftover blood 
stored for future research, ‘YES’ means that you give permission for your child’s leftover blood 
samples to be stored for future research. ‘NO’ means that your child’s blood samples will NOT be 
stored for future research.  




6. [For children 10-17 years] Make your initial or mark if you agree to allow us to ask your child to 
retain his/her contact information for future research, ‘YES’ means that you give permission for 
us to ask your child to allow us to retain his/her contact information for future research, and to 
retain the information if the child agrees. ‘NO’ means that your child’s contact information will 
NOT be retained for future research.  
______Yes              ______No 
 
7. [For children 0-9 years] Make your initial or mark if you agree to have your child’s contact 
information retained for future research, ‘YES’ means that you give permission for your child’s 
contact information to be retained for future research. ‘NO’ means that your child’s contact 
information will NOT be retained for future research. 
______Yes              ______No 
 
To confirm, you have agreed to <INSERT ALL OPTIONS MARKED YES: APPROACH CHILD FOR INTERVIEW, 
APPROACH CHILD FOR BLOOD TESTING, CHILD INTERVIEW, CHILD BLOOD TEST, APPROACH CHILD FOR 
BLOOD STORAGE, CHILD BLOOD STORAGE>, is this correct? ______Yes              ______No 
 
Child with special circumstances signature or mark________________________ Date: ___/___/___            
Printed name of child with special circumstances ________________________________________ 
   
 [For illiterate participants or parents/guardians] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
Signature of person obtaining consent_____________________ __________ Date: ___/___/___          
Printed name of person obtaining consent____________________________    
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